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Preface to ”Asthma: Current Perspectives on
Phenotypes, Endotypes, and Treatable Traits”
Asthma is a complex heterogeneous disease with different phenotypes and clinical expressions
that greatly affects patients’ quality of life. Some aspects of the natural history of the disease are
incompletely understood. New insights into the mechanisms that drive the natural history of asthma
and the evolution of airway inflammation in preschool age children are discussed. The role of lung
microbiome in asthma pathogenesis and its possible manipulation has recently emerged. Likewise,
the role of the NLRP3 inflammasome and its targeting as a potential therapeutic approach is of
great importance. Particular endotypes of severe asthma such as eosinophilic asthma have gained
interest due to the major advances of the novel targeted biological therapies that have changed
the treatment landscape of severe asthma. Particular comorbidities such as OSAS in adults and
chronic rhinitis in children greatly affect the clinical expression of asthma. In addition to these
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Abstract: Asthma is a heterogeneous condition characterized by reversible airflow limitation, with
different phenotypes and clinical expressions. Although it is known that asthma is influenced by
age, gender, genetic background, and environmental exposure, the natural history of the disease is
still incompletely understood. Our current knowledge of the factors determining the evolution from
wheezing in early childhood to persistent asthma later in life originates mainly from epidemiological
studies. The underlying pathophysiological mechanisms are still poorly understood. The aim of
this review is to converge epidemiological and pathological evidence early in the natural history of
asthma to gain insight into the mechanisms of disease and their clinical expression.
Keywords: wheezing; bronchial biopsies; symptom persistence; clinical remission
1. Introduction
Asthma is a heterogeneous condition characterized by reversible airflow limitation with different
phenotypes and clinical expressions [1,2]. Several studies on lung specimens from adult asthmatic
patients have established that asthma is a process involving both the central and peripheral airways.
The process includes chronic activation of the inflammatory response as well as structural changes of the
airway wall—the latter is collectively called airway remodeling. The inflammatory response in asthma
has been demonstrated to have a large heterogeneity and to involve both the innate (i.e., eosinophils,
mast cells, innate lymphoid cells) and the acquired immunity (i.e., T-lymphocytes). Airway remodeling
consists of shedding of the bronchial epithelium, thickening of the subepithelial reticular basement
membrane (RBM) and of the smooth muscle mass, as well as proliferation of bronchial vessels or
angiogenesis [3,4]. Although chronic inflammation in asthma is associated with airway remodeling,
the mutual relation between the two is still a point of substantial debate.
Although the histopathological features characteristic of asthma have been extensively described
since the early 20th century, the molecular mechanisms responsible for the recruitment and activation
of inflammatory cells and establishment of the architectural changes typical of airway remodeling
are still only partially understood. The majority of studies in this field have considered adult and
childhood asthma separately, almost as if they were different disease entities. At present, the evidence
on asthma histopathology has been gathered exclusively from studies on adult cohorts, while
there is a scarcity of studies on the histopathology of asthma in children. This is due essentially
to the difficulty of obtaining bronchial biological samples from children and to the diagnostic
dilemma—particularly in infants and preschool children—of discerning true asthma from other
wheezing disorders. We suggest that a thorough comprehension of the histopathology of wheezing
in children (i.e., at the beginning of the natural history of asthma) and of its interrelationship with
J. Clin. Med. 2019, 8, 1180; doi:10.3390/jcm8081180 www.mdpi.com/journal/jcm1
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the spectrum of clinical phenotypes should be the compass for guiding research into the jungle of
inflammatory cells, mediators, and cytokines underlying asthma pathogenesis. Therefore, this review
focuses on the major cellular and structural changes present in the airways of children with asthma in
relation with the most important clinical phenotypes, in an attempt to integrate these data with those
emerging from the longitudinal investigation of outcomes from early childhood to adulthood.
2. Wheezing Disorders and Their Evolution across Developmental Ages
Wheezing is very common in the first 3 years of life. Yet, most preschool children with wheeze will
be symptom-free by the time they reach school age, whereas only a minority will remain symptomatic,
develop persistent wheeze, and ultimately be diagnosed as asthmatics. The identification of the factors
which may predict the future development of asthma in early wheezing children has mainly been
addressed by epidemiological studies [5], and is still a matter of vivid debate.
While the great majority of wheezers do not usually progress to asthma in childhood and
adolescence, some of them may have relapsing symptoms and be at increased risk of asthma in
adulthood, and even of chronic obstructive pulmonary disease (COPD) later on [6]. Furthermore,
the adult onset of asthma symptoms may occur in a considerable proportion of asthmatics, especially
in women [7]. However, many patients do not completely remember their childhood symptoms, so it
is unclear which cases might reflect relapse rather than true new onset.
Phenotypes with documented clinical importance in childhood asthma have been defined in
several ways: (i) on the basis of concomitant traits, such as atopy; (ii) on the basis of the temporal pattern
of symptoms appearance; (iii) on the basis of the longitudinal evolution of wheezing symptoms. As such,
specific wheezing phenotypes that have been investigated in preschool children include: non-atopic
and atopic wheezing; episodic and multiple-trigger wheezing; transient, persistent, and late-onset
wheezing [2].
Prospective birth cohort studies such as the pioneering Tucson cohort have determined
the longitudinal outcome of wheezing and defined specific categories, such as: (i) transient
wheeze—children who wheeze during the first years of life, but not after the age of 3; (ii) persistent
wheeze—children who start to wheeze before the age of 3 and maintain their symptoms even beyond
school age; and (iii) late-onset wheeze—children who start to wheeze after the age of 3 [8]. However,
these categories can only be recognized retrospectively, and are of little value in clinical practice [9].
The presence of atopy, and particularly an early sensitization to multiple allergens, is generally
considered a fundamental risk factor for the future development of persistent asthma [8,10–13],
although the relationship between wheezing and allergic sensitization in the first years of life is still
controversial [14]. The predominant role of atopy was so generally accepted that often wheezing
was considered by many pediatricians to truly represent asthma only when associated to atopy.
Conversely, non-atopic wheezing was thought to be a transient phenotype, mostly triggered by viral
infections [1,10–12,14–16]. On the same line, pediatricians proposed a clinical distinction between
episodic and multiple-trigger (multitrigger) wheezing. Episodic wheezing is thought to be triggered
by viral infections, manifests only in association with coryzal symptoms, and affected children are
symptom-free between viral episodes, while multitrigger wheeze is triggered by multiple stimuli
(including allergens, viruses, exercise, laughing) and is characterized by the presence of symptoms in
between discrete episodes [2]. Multitrigger wheezing is usually considered as the phenotype associated
with wheezing persistence over time [8,17]. However, some reports suggest that there is a wide overlap
between the two phenotypes, with the wheezing pattern varying over time in many children [9],
and that severe viral wheeze is equally associated with a high risk of asthma at school age [18].
Further important determinants of persistent symptoms include prenatal features (preterm birth
and low birth weight), pulmonary function deficits and reduced breast feeding in early infancy, as well
as indoor and outdoor exposures—particularly to environmental pollutants and cigarette smoking [19].
In the present review we focus mainly on the role of atopy and viral infections, the pathogenetic
mechanisms of which are better known.
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3. Pathological Changes in Childhood Asthma
Endobronchial biopsy is the main diagnostic technique for evaluating the pathological processes
in the bronchial mucosa directly [20,21]: it allows evaluation of the grade and type of inflammation,
and provides evidence of the structural changes that may occur during the process of airway remodeling.
Eosinophilic inflammatory infiltrate associated with thickening of the RBM, epithelial shedding,
neo-angiogenesis, and smooth muscle enlargement are characteristic changes of asthma that have been
widely described in adults [22,23], but scarcely investigated in children.
The first pioneering study that investigated the bronchial histopathology in asthmatic children was
by Cutz et al. in 1978, who described a prominent eosinophilic infiltrate and airway remodeling in the
specimens of four asthmatic children [24]. After 20 years, Cokuğraş et al. [25] qualitatively examined
bronchial biopsy specimens from 10 children with moderate asthma. They described a thickened RBM
associated to an inflammatory infiltrate characterized by lymphocytic predominance, and only in one
case they identified a prominent eosinophilic infiltrate. Subsequently, Jenkins and colleagues [26]
reported a qualitative histopathological analysis of six children with severe asthma. They confirmed a
thickened RBM and the presence of lymphocytes in lamina propria, but also recognized eosinophils in
the inflammatory infiltrate and smooth muscle enlargement. These studies only performed qualitative
analyses on a limited number of cases, and without a proper control group they can be considered
as isolated observations. Payne and co-workers were the first to perform a quantitative evaluation
of inflammatory and structural changes in a cohort of severe therapy-resistant asthmatic children.
In two controlled studies [27,28], they demonstrated that asthmatic children had a thickened RBM
in the absence of a prominent eosinophilia, suggesting that structural alterations can even precede
inflammation in the natural history of the disease. However, the children examined in these two
studies were severe asthmatics, most of them in treatment with maximal inhaled steroid therapy
or even oral corticosteroids, which could have influenced the inflammatory process—particularly
eosinophils. Conversely, our group has demonstrated in two consecutive studies that eosinophilic
inflammation was definitely present in children with milder forms of the disease. Only a minority of
children in our cohort were on inhaled corticosteroids (at low dose); the great majority of individuals
were on as-needed salbutamol, and therefore free from the potential bias of steroid therapy [29,30].
Of importance, while earlier studies examined populations of school-aged children, our group was the
first to assess histopathological changes typical of asthma in preschool children [30]. It is of interest
that the early detection of airway eosinophilia in these children was associated with important features
of airway remodeling—not only a thickened RBM, but also epithelial shedding and neo-angiogenesis
(Figure 1) [30].
The presence of RBM thickening and eosinophilic inflammation was subsequently confirmed in
an even younger cohort of children [31] (median age 2.4 years), and was further investigated in several
cohorts whose results are summarized in Table 1 [32–38]. Taken together, these studies showed that
most of the structural and inflammatory changes typical of asthma are present in asthmatic children,
and also in preschool wheezing children, that is, at the beginning of the natural history of the disease.
In particular, almost all reports converged on showing a thickened basement membrane, indicating
that this is an early event present from 2–3 years of life. Whether RBM thickening is already present
in younger infants (1 year of age) is actually a matter of debate, since it was not found in a cohort
of 16 infants by Saglani et al. [36], but has been recently reported in a larger cohort of 30 infants by
Berankova and coworkers [34]. Some incongruities regarding eosinophilic airway inflammation have
been reported, but these could reflect the different treatment levels in different cohorts, rather than
true pathogenetic differences as also suggested by other authors [39]. Finally, other aspects of airway
remodeling (epithelial loss, angiogenesis, and smooth muscle enlargement have been examined in
limited reports [30,33,37,38], and deserve further investigation.
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Figure 1. Biopsy sections from a child with asthma (A,C), and a control child (B,D). An increased
number of subepithelial vessels (A, brown) and eosinophils (C, red) are demonstrated in the child
with asthma. The arrows indicate loss of epithelial cells (A,C), while the arrowheads indicate reticular
basement membrane thickening (A). Immunostaining with monoclonal antibody anti-CD31 (A,B) and
anti-EG2 (C,D). Original magnification ×630. Reprinted with permission of the American Thoracic
Society from [30].














Cutz 1978 [24] 4 12 (11–12) + 0 + Eos /
Cokuğraş 2001 [25] 10 9.3 ± 3.8 + / / Ly /
Jenkins 2003 [26] 6 13.5 (6–17) + / + EosLy /
Payne 2003 [27] 19 13 (6–16) + / / 0 /
Barbato 2003 [29] 9 8 (4–12) + / / Eos /
Payne 2004 [28] 36 13 (6–16) + / / 0 /
Saglani 2005 [36] 16 1 (0.3–2) 0 / / 0 /
Barbato 2006 [30] 17 5 (2–15) + + / Eos +
Saglani 2007 [31] 16 2.4 (0.6–4.75) + / / Eos /
Kim 2007 [32] 18 13 ± 1 + / / / /
Regamey 2008 [37] 24 12.5 (6.7–15.8) / / + / /
Zhou 2011 [33] 13 7.2 (1.5–15) + + + LyEos /
Bossley 2012 [38] 53 12 (9–14) + / + Eos /
Berankova 2014 [34] 30 1 (0.3–3.3) + / / / /
Van Mastrigt 2015 [35] 107 9.5 ± 4.6 + / / / /
Age is reported as median (range) or mean ± SD. Definition of abbreviations: Eos: eosinophils; Ly: lymphocytes;
RBM: reticular basement membrane; SM: smooth muscle. Presence of the histological feature (+), absence (0), feature
not evaluated in the study (/).
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In conclusion, these studies conducted in the last twenty years, despite their unquestionable
limitations (small cohorts, influence of steroid treatment, and diagnostic wheezing dilemma in
preschool children) provide evidence that both inflammation and remodeling are present early in
the natural history of the disease, challenging the “classic theory” of asthma pathogenesis which
views remodeling as a consequence of a long-lasting chronic inflammation. These observations
support the hypothesis that the epithelial–mesenchymal signaling may play a fundamental role in
the development of bronchial asthma and its clinical phenotypes. In fact, the chronic damage to
the airway epithelium due to a variety of stimuli could activate inflammatory pathways, with the
release of damage-related cytokines—especially IL-33, which is hyperexpressed in children and directly
correlated to RBM thickness [40], but also IL-25, TSLP, and mitotic/fibrogenic growth factors, thereby
promoting angiogenesis as well as thickening of the RBM and smooth muscle [41–43]. The stimuli
which have been more extensively investigated are allergens and viral pathogens, and we will now
review the evidence in the literature on the activation of these pathogenetic mechanisms in relation to
airway histopathological changes in childhood asthma.
4. Atopy and Related Pathological Changes
Atopy is generally considered to be a crucial feature characterizing asthma either in children or in
adults, and early onset allergic asthma is considered to be the archetypal phenotype of the disease.
The term atopy (from the Greek “atopos”, meaning “out of place”) describes the tendency to be
hyperallergic, the genetic propensity to mount an IgE response to triggers including pollens, animal
dander, and food-based allergens. Allergens are well known triggers of type 2 immunity characterized
by the differentiation of naïve T CD4+ cells towards Th2 effector cells, which is typically associated
with IgE production, eosinophilia, and mast cell activation. The keystone cytokines in type 2 immune
response include IL-4, IL-5, IL-9, and IL-13. IL-4 is crucial for the differentiation of naïve Th0 cells to
Th2 cells, which in turn induces isotype switching to IgE production. Specific IgE antibodies bind to
their high-affinity FceRI receptors on the surface of basophils or mast cells, leading to the sensitization
of those cells. IL-5 and IL-9 are responsible for the activation and recruitment of eosinophils and mast
cells, respectively, while IL-13 induces goblet cell hyperplasia, mucus hyper-secretion, and airway
hyper-responsiveness [44].
Atopic sensitization, with the resulting activation of the Th2 cascade, has long been considered
a key determinant of wheezing persistence and asthma development in childhood. Indeed, it has
been reported in several cohorts that children who have either a family history of allergies or who will
become sensitized to local aeroallergens are more likely to have wheezing that persists into adulthood,
whereas wheezing appears to resolve in adolescence in those children who do not develop atopic
sensitization [15]. Based on this evidence, we investigated the hypothesis that a different airway
pathology could be present in atopic and non-atopic wheezing children. In a well-characterized cohort
of children in whom symptoms of wheezing were those typical of asthma (multitrigger, responsive to
bronchodilators), we reported that all the histopathological traits of asthma were observed in both
atopic and non-atopic children [45]. These traits included RBM thickening, epithelial desquamation,
angiogenesis, and even an eosinophilic inflammatory infiltrate with upregulation of Th2 cytokines IL-4
and IL-5. Further work from our group demonstrated that atopic and non-atopic wheezing children
have a similar degree of eosinophilic inflammation even in bronchoalveolar lavage (i.e., eosinophils and
eosinophil cationic protein levels) [46]. These data in children complemented the seminal observations
by Humbert and co-workers, who showed more similarities than differences in the immunopathology
of atopic and non-atopic asthma in adults [47]. In conclusion, studies on bronchial biopsies and BAL
demonstrated the similar nature of the histopathological substrate of these two crucial wheezing
phenotypes from the beginning of the disease.
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5. Viral Infections and Related Pathological Changes
Rhinovirus infections are among the most frequent cause of asthma exacerbations in adults, but
even more so in children [48–50]. Indeed, cold-related wheezing is the most common respiratory
symptom in preschool children, with up to 40%–50% of children experiencing at least one wheezing
episode before the age of three. However, recurrent wheeze in early childhood is not always asthma.
Recent techniques with the molecular detection of viral pathogens brought significant advances to
understand the relationship between viral infections and asthma inception. Not only viruses are
frequently isolated in exacerbations of asthma, but respiratory viral infections in early life—particularly
rhinovirus and respiratory syncytial virus (RSV)—are associated with increased risk of asthma later in
life [18,51–56].
Defective production of type I and type III interferons (IFNs) upon rhinovirus infection has been
documented in adults with asthma, which can lead to impaired viral clearance, thus aggravating the
impact of infections on the lung [57,58]. We demonstrated that such impaired immune response by
epithelial cells was already present in preschool children with asthma [59]. Of importance, we found
that impaired innate lung immunity was associated with structural changes in the airway biopsies
(epithelial loss) and to markers of type 2 immunity [59]. We then investigated whether such deranged
antiviral response can be considered as a risk for future asthma persistence. After an 8-year follow-up,
we showed that children with asthma persisting at adolescence already had deficient IFN production
and higher viral replication at preschool age [60]. These findings suggested the hypothesis that the
immunologic interactions between viral infections and type 2 immunity predisposes to more severe
acute responses to the virus, resulting in chronic insults to the epithelium, and eventually leading
to the development of asthma. These observations are also in agreement with findings from the
follow-up of large cohorts of children in the Tucson and the COPSAC studies, where children with
asthma at school age already exhibited aberrant immune responses in infancy, not only to viruses but
also to bacteria [61,62]. Altogether, these observations would support the concept that an aberrant
response to infectious pathogens very early in life—mainly driven by the airway epithelium—is a
crucial determinant of the evolution toward asthma.
6. Evolution of Asthma Symptoms in Relation to Pathological Changes
The last decades have seen a rapid growth of information on the evolution of asthma-like
symptoms in childhood and their determinants. Most infants and young children with wheezing will
outgrow their symptoms as their lungs develop, but some will persist in their symptoms over time
toward confirmed asthma (Figure 2) [5,63]. Those transient wheezers who do not usually progress
to asthma in childhood and adolescence can still have symptoms remittance in adulthood, and can
be at increased risk of COPD [6]. Emerging evidence from clinical and epidemiological studies that
followed-up children from the care of their pediatrician into adolescence and then into adulthood
has helped us to understand the main determinants of symptoms persistence [5]. Early aeroallergen
sensitization, respiratory infections in infancy, and cigarette smoking exposure have all been associated
with persistent symptoms [19]. Reduced lung function in early infancy (as soon as 1 month of age)
is another factor that has been associated with persistent wheezing at 11 years [3]. This has been
confirmed by the results of a number of studies [4,10,11,14,15], which have demonstrated that poor
airway function shortly after birth (at 2–3 months of age) is a risk factor for asthma in teenagers
and young adults (at 11, 16, and 22 years of age). This effect may reflect the variation in genes
regulating normal lung growth and airway structure during lung development [64,65]. Furthermore,
the association between lung function and symptoms persistence is independent of the effect of airway
hyperresponsiveness, atopy, and type 2 allergic inflammation (as measured by blood eosinophil
levels) [66]. These findings indirectly suggest that airway structural changes, which start early in life,
are crucial determinants of the persistence of asthma symptoms and therefore highlight the need for a
better understanding of the pathogenetic mechanisms underlining symptom persistence.
6
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Figure 2. Determinants of disease course across asthma transition and ages. The figure displays
putative determinants that affect the disease course of different asthma phenotypes by course and time
of onset of symptoms. AHR: airway hyper-responsiveness. Reprinted with permission from Elsevier
from [5].
To our knowledge, only four longitudinal studies have investigated the pathological changes able
to predict the presence of asthma at follow-up. The first two, by Malmström and co-workers, evaluated
a cohort of 53 infants with pathological changes and airway conductance measured at baseline and
then re-evaluated them at 3 and 8 years of age. While there was a correlation between RBM thickening
and mucosal mast cells with corticosteroid purchase at 3 years (as an indirect index of asthma) [67],
the correlations were not present when children were comprehensively reassessed for asthma at 8 years
of age [68]. Indeed, no pathologic features at baseline correlated with the presence of confirmed asthma
at school age [68]. Then, O’Reilly and co-workers reported a follow-up of a cohort of 47 preschool
children with severe recurrent wheezing [69]. RBM thickening and the eosinophilic infiltrate, despite
being distinctive features of wheezing children at baseline, were not able to distinguish children who
did or did not develop asthma at follow-up. Conversely, airway smooth muscle mass, which was not
enlarged at baseline in symptomatic children, was the only histological feature to be associated to the
development of asthma at school age. More recently, our group has also completed a clinical follow-up
of a cohort of 80 preschool wheezing children (and non-wheezing controls) that had histological
parameters assessed at baseline. At variance with previous studies, a thicker RBM and an eosinophilic
inflammation in the lamina propria were clearly associated to the persistence of asthma from preschool
to school age. When we performed a multivariate analysis, only RBM thickening remained a significant
predictor of asthma persistence. Even when we limited our analysis to toddlers only (children under
3 years), RBM thickening at this early age remained a significant predictor of asthma later in life [70].
While the persistence of wheezing from early life to school age is associated with abnormal
histological traits, it is also important to know what happens to these traits with the remission of
symptoms. Marshall and co-workers compared the lung function and sputum cellularity of children
with persistent or transient wheezing after following them through adolescence [71]. They found
that airway eosinophilic inflammation and lung function impairment were seen not only in persistent
wheezers, but also in children with a transient wheezing phenotype. Similarly, Dutch cohorts that
examined young adults in clinical remission from childhood asthma reported persistent airway
remodeling despite symptoms disappearance [72,73], suggesting that symptoms remission does not
equate remission of the underlying pathology. In support of this hypothesis is the observation that,
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when assessed with functional tests, the majority of patients in apparent clinical remission still retain
impaired lung function and airway hyperresponsiveness [74].
This topic now becomes truly fascinating, since pathological changes in children that predispose
them to symptoms persistence are also present in subjects in clinical remission during adolescence/early
adulthood. To disentangle this issue, we have created a number of different wheezing phenotypes
(atopic/non-atopic, multitrigger/episodic, transient/persistent/late onset, etc.). However, there is
no doubt that we are forcing an extensive variety of clinical phenotypes into artificially simple
categories—all of them unable to fully capture the real complexity of a disease that is variable by
definition. Instead of being distinct pathogenetic entities, these wheezing phenotypes may rather
represent different clinical expressions of the same underlying pathology (i.e., different levels of disease
severity). Let us imagine the process as a continuum: wheezing children develop airway structural
changes very early in life and keep all the pathological hallmarks of asthma also in adolescence,
and maybe for their entire life, independently from the clinical “activity” of the disease. To elicit
symptoms, a certain threshold of trigger is needed at a given time point; with lower burdens, individuals
will remain asymptomatic and this will occur mostly during adolescence/early adulthood when they
achieve their maximal levels of pulmonary function. Nonetheless, these subjects, even if in clinical
remission, have all the pathological hallmarks of asthma in their airways and will be prone to relapse
whenever exposed to a high burden of inflammatory stimuli. The most harmful factor in adolescence
is cigarette smoking, against which they should be strongly advised. With the recent widespread use
of e-cigarettes in adolescents, whose effects on the lungs are a cause of strong concern, we also need to
look carefully at the possible effects of e-cigarette use in these vulnerable children.
The description of the clinical course of asthma and pulmonary function trajectories during the
entire human life in relation to airway histopathology is crucial for matching the wide spectrum of
asthma phenotypes—from early wheezing in infancy to the late-onset adult forms—with specific
pathological traits. We have reviewed here the available data focusing on the early stages of the disease
to address the pathology at the onset of asthma symptoms and then investigated its relation with the
evolution of symptoms during childhood and adolescence. With the upcoming follow-up of existing
cohorts across the whole natural history of asthma, further into adulthood and elder age, we will have
a unique opportunity to unravel the mechanisms behind this multifaceted disease.
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Abstract: Fractional exhaled nitric oxide (FeNO) is a non-invasive marker for eosinophilic airway
inflammation and has been used for monitoring asthma. Here, we assess the characteristics of FeNO
from preschool to school age, in parallel with asthma activity. A total of 167 asthmatic children and
66 healthy, age-matched controls were included in the 2-year prospective PreDicta study evaluating
wheeze/asthma persistence in preschool-aged children. Information on asthma/rhinitis activity,
infections and atopy was recorded at baseline. Follow-up visits were performed at 6-month intervals,
as well as upon exacerbation/cold and 4–6 weeks later in the asthmatic group. We obtained 539 FeNO
measurements from asthmatics and 42 from controls. At baseline, FeNO values did not differ between
the two groups (median: 3.0 ppb vs. 2.0 ppb, respectively). FeNO values at 6, 12, 18 and 24 months
(4.0, CI: 0.0–8.6; 6.0, CI: 2.8–12.0; 8.0, CI: 4.0–14.0; 8.5, CI: 4.4–14.5 ppb, respectively) increased with
age (correlation p ≤ 0.001) and atopy (p = 0.03). FeNO was non-significantly increased from baseline
to the symptomatic visit, while it decreased after convalescence (p = 0.007). Markers of disease
activity, such as wheezing episodes and days with asthma were associated with increased FeNO
values during the study (p < 0.05 for all). Age, atopy and disease activity were found to be important
FeNO determinants in preschool children. Longitudinal and individualized FeNO assessment may
be valuable in monitoring asthmatic children with recurrent wheezing or mild asthma.
Keywords: asthma; PreDicta; preschool; FeNO; spirometry
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1. Introduction
The use of objective measurements, including the measurement of lung function and airway
inflammation by means of fractional exhaled nitric oxide (FeNO) is currently becoming reinforced
in most official recommendations for children with asthma, even though there are not always
clear correlations between the two. Moreover, associations between disease activity and airway
inflammation are frequently inconclusive or negative, probably because they have mostly been
assessed cross-sectionally or for limited time periods [1,2].
As defined by the Global Initiative for Asthma (GINA), FeNO measurements are associated with
clinical asthma control indices in school-aged children and adults [3]. However, the preschool-age
group is of particular interest because preschool age is often a milestone whereby wheezing disease is
expected to transform by either resolving or becoming persistent in a significant number of patients.
Few studies, however, have evaluated how inflammation progresses or correlates with symptoms in
asthmatic preschoolers [4–6]. A limited number of cross-sectional studies have shown that preschool
children with increased wheezing morbidity, as assessed by symptom frequency and persistence,
present higher levels of FeNO, which suggests that FeNO levels might correlate with current and/or
subsequent asthma diagnosis [7,8]. Moreover, fluctuations in airway inflammation have not been
extensively studied in young children with asthma-associated symptoms, either due to difficulties in
obtaining acceptable and repeatable maneuvers or to the potential impact of viral respiratory infections,
use of inhaled corticosteroids and atopy per se [9].
In order to understand wheeze/asthma in preschoolers and how it relates to asthma later in life,
we need to understand the main characteristics of obstructive airway disease over time, particularly
bronchoconstriction, inflammation and hyper-responsiveness. The PreDicta pediatric longitudinal
cohort, within “PreDicta”, a European Commission-funded project under the 7th Framework Program
for Research and Technological Development (FP7), was designed as a 2-year prospective study
with the aim of evaluating wheeze/asthma persistence in preschool- to school-age children [10].




The PreDicta cohort study was conducted across five major cultural and climatic regions of
Europe: Greece, Germany, Belgium, Poland and Finland. Children 4–6 years of age with an asthma
diagnosis of mild to moderate severity according to GINA [11] confirmed by a doctor from one of
the participating study centers within the last 2 years were invited to participate as cases. Moreover,
healthy, age-matched children with no reported history of wheeze/asthma served as cross-sectional
controls at the beginning of the 2-year follow-up period. The eligibility and exclusion criteria, study
design and baseline characteristics of the cohort have been described previously [10]. The study
was approved by all participants’ institutional ethics committees and written informed consent was
obtained from parents.
2.2. Study Design
At baseline, children were required to be asymptomatic, without a cold or an exacerbation for
at least 4 weeks. A questionnaire including detailed information on asthma and rhinitis activity and
severity and infection history was filled in by all participants, while the presence of atopy was assessed
by skin prick tests (SPTs) to common aeroallergens [10].
Follow-up visits were performed at 6-month intervals for two years in the asthmatic group.
At regular follow-up visits, a questionnaire with information regarding asthma and rhinitis activity
and infections during the previous period was obtained. Moreover, children were assessed in the clinic
during symptomatic periods on the basis of their daily symptom score or their parent’s perception and
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were reassessed 4–6 weeks later at convalescence, through a questionnaire and clinical examination.
At all of the time points, airway inflammation was determined with FeNO measurements in parts per
billion (ppb), using the Bedfont NObreath equipment (Bedfont Ltd., UK) [12]. Data were available
from the four follow-up visits for 146, 125, 121 and 140 subjects, respectively. Measurements were also
performed during 75 symptomatic visits and 56 of the respective convalescent visits.
2.3. FeNO Measurements
FeNO values were measured at visits using the Bedfont NObreath equipment (Bedfont Ltd.,
Maidstone, UK), in parts per billion (ppb). According to the 2005 American Thoracic and European
Respiratory Society’s guidelines [12] and the Bedfont NObreath specifications, for a correct FeNO
measurement, a single breath sample was instantly analyzed after the subject inhaled to total lung
capacity through a NO-scrubbing filter to avoid contamination with ambient NO. All exhalations
were performed with an exhalation pressure of 10 to 20 cm H2O to maintain a fixed flow rate of
50 ± 5 mL/s (<6 attempts per visit). The pressure is necessary to ensure closure of the soft palate, to
avoid contamination of the FeNO with gas from the nasopharynx where NO concentrations are very
high. In addition, the targeted constant-flow exhalation rate consists of a washout phase followed by a
2-s NO plateau. It is generally considered that this plateau represents NO derived primarily from the
lower respiratory tract. A ball moving within frames was used to help young children blow at the
right pressure during the exhalation. Whenever possible, the two most consistent attempts (i.e., lasting
6–10 s and/or agree within 10%) were recorded. Children had not eaten or drunk anything for at
least 2 h before and avoided nitrate-rich meals for at least 20 h before the measurements. Directions
were given according to these dietary recommendations for regular visits. Exacerbation visits were
arranged according to the last meal or snack. FeNO analysis was performed before spirometry because
spirometric maneuvers have been shown to transiently reduce airway inflammation measurements.
The following algorithm was used in order to calculate FeNO values at different time points: (a) if
at least one value was 0 or 1 ppb, the maximum value was recorded; (b) if both values were greater
than 1, then (b.1) if the absolute difference was ≤10 ppb, we calculated the average value, or (b.2) in
case the absolute difference was >10 ppb, the maximum value was recorded. Personal best FeNO was
defined as the minimum value recorded in all visits, baseline and follow-up for all cases.
2.4. Predictors of FeNO Measurements
Disease activity markers were derived from the questionnaires obtained at baseline and during
symptomatic/convalescent periods. These were selected from the following guidelines (a) the GINA
guidelines for determining asthma control and severity level, on the basis of criteria such as frequency
of day and night asthma symptoms, night-time awakenings due to asthma, limitation of activities,
need for reliever and controller medication and hospitalizations for asthma; (b) the PRACTALL
consensus for asthma phenotyping [13]; and (c) the Allergic Rhinitis and its Impact on Asthma (ARIA)
initiative for assessing the frequency and severity of rhinitis symptoms [14]. Moreover, history of
infections including the frequency and duration of upper and lower respiratory infections, the use of
antibiotics and family history of atopy-associated diseases were included as predictors. Symptoms
recorded in diary cards during symptomatic and convalescent visits were used for comparisons. All
the predictors that were assessed are depicted in the Supplementary Materials, Table S1.
2.5. Statistical Analysis
All variables assessed were non-parametric, according to the Shapiro-Wilk test for composite
normality; thus, descriptive statistics are presented as medians (25–75 percentiles—IQRs). In order
to identify dependencies between FeNO and other variables, non-parametric tests were applied: the
Wilcoxon rank-sum test was used for qualitative variables and Kendall’s correlation was used for
quantitative variables (such as the subjects’ age).
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The Friedman test was used in order to compare values at three consecutive visits (baseline or
follow-up, symptomatic and convalescent) for each patient. Post-hoc analysis was carried out using
the Wilcoxon paired signed-rank test, along with the Bonferroni correction.
All tests were considered two-sided and statistical significance was defined as p < 0.05.
Statistical analysis was performed with the R software for statistical computing, along with the
RStudio interface (both open-source products).
3. Results
A total of 167 cases (102 males, 61%, mean age: 5.2 ± 0.7) and 66 controls (30 males, 45%, mean
age: 5.1 ± 0.8) were recruited from the five participating centers. The demographic characteristics of
the two groups at inclusion have been reported elsewhere [10]. FeNO measurements were available for
131 (79.6%) asthmatic children (median: 3.0, CI: 0.0–6.7 ppb) and 35 (53%) healthy controls (median:
2.0, CI: 0.0–7.2 ppb, p = 0.37).
Baseline characteristics regarding disease activity and atopic history of the asthmatic children are
depicted in Table 1.





Family history of atopic disease (yes), n (%) 94 (91)
Family history of asthma/rhinitis (yes), n (%) 89 (86)
Any positive skin prick test (yes), n (%) 70 (56)
Upper Respiratory Symptoms
Rhinitis symptoms are present
<4 days/week, n (%) 61 (47)
Rhinitis duration
<4 consecutive weeks, n (%) 67 (51)
Are rhinitis symptoms associated with . . . ?
Sleep disturbance (yes), n (%) 65 (89)
School impairment (yes), n (%) 17 (24)
Leisure—sport (yes), n (%) 35 (49)
Visual analogue scale, median (CIs) 5 (3–6)
Number of medication courses for rhinitis in the
last 12 months, median (CIs) 1 (0–5)
Lower Respiratory Symptoms
Days with symptoms in the last 3 months
<1/week, n (%) 83 (64)
>1/week but <1/day, n (%) 37 (28)
daily, n (%) 11 (8)
Nights with symptoms in the last 3 months
≤2 times/month, n (%) 81 (62)
>2 times/month, n (%) 15 (12)
>1/week, n (%) 24 (18)
daily, n (%) 11 (8)
Cough, wheeze or difficulty in breathing during or
after exercise in the last 12 months (yes), n (%) 84 (64)
Limitation of activities limited by asthma
symptoms (yes), n (%) 46 (35)
Child completely well between symptomatic
periods (yes), n (%) 92 (70)
Number of episodes of wheezing/asthma/cough in
the last 3 months, median (25–75 percentiles) 1 (1–2)
Number of episodes of wheezing/asthma/cough in
the last 12 months, median (CIs) 5 (3–8)
Inhaled corticosteroids as prophylactic treatment
(yes), n (%) 107 (82%)
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Atopic asthmatics presented increased FeNO levels compared to non-atopic asthmatics, however,
the results were not statistically significant either when assessed in terms of the occurrence of any
positive SPT (median: 3.0, CI: 0.0–6.9 vs. 2.0, CI: 0.0–5.2, respectively, p = 0.47) or by quantifying,
i.e., by summation of positive SPTs (descriptive: 4.8, p = 0.48). Reported personal and family history of
atopy-related diseases was not associated with increased FeNO levels at baseline.
3.1. FeNO Evolution during the Two-Year Follow-Up
During the visits we obtained a total of 42 FeNO measurements from controls (35 at baseline) and
539 from cases. FeNO was measured in 67.8% of children at 6 months of follow-up (median: 4, CI:
0.0–8.6 ppb), 74.4% at 12 months (median: 6.0, CI: 2.8–12.0 ppb), 83.5% at month 18 (median: 8.0, CI:
4.0–14.0 ppb) and 72.1% at the final visit (median: 8.5, CI: 4.4–14.5 ppb), suggesting an increasing trend
with time/age in asthmatics.
Kendall’s correlation reveals a correlation of 16.4% between FeNO value and age in controls
(p = 0.14) and a correlation of 19.3% (p < 0.001) in children with asthma (Figure 1a). Post-hoc power
analysis yielded powers of 18% and 99%, respectively, for the above outcomes at the significance
level of 0.05; however, the slopes of the corresponding linear fits do not differ significantly between
cases and controls (p = 0.8). With regards to atopy, children with at least one positive SPT presented a
significantly increased FeNO trajectory compared to non-atopics (p = 0.03, Figure 1b).
Figure 1. (a) Non-parametric correlation between subjects’ fractional exhaled nitric oxide (FeNO)
and age, separately assessed in controls and cases. “P slopes” denote the p-value of the comparison
between the slopes of the two separate trend lines, i.e., controls (black line) vs. cases (gray line).
(b) FeNO progression slopes in preschool asthmatics for atopics (black line) and non-atopics (gray line),
at baseline and during the 2-year follow-up.
At all time points, no differences were noted in FeNO values in respect to sex when assessed
cross-sectionally in asthmatics.
3.2. FeNO and Seasonality
The FeNO values, either as absolute or % change from baseline values, were independent of
the season when they were assessed, at all visits; nevertheless, the number of symptomatic visits
(either due to a cold or an exacerbation) significantly increased during “cold months” (autumn = 26,
winter = 27, spring = 16, summer = 8).
3.3. Variation in FeNO Values from Healthy State (Asymptomatic) to Exacerbation and Convalescent Visit
In order to evaluate the variation in FeNO levels in asthmatic children during periods of different
health status, a comparison was performed at three distinct time points: (a) either at baseline or during
the last follow-up visit before a symptomatic visit, when the child was still asymptomatic; (b) at the
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subsequent symptomatic visit; and (c) at the respective convalescent visit. Forty-nine children (65.3%)
were able to perform FeNO measurements upon exacerbation and forty-two (75%) at convalescence.
In total, 28 measurements were available for comparison for all three time points. A post-hoc power
analysis yielded a power of 66% for the following outcomes at the significance level of 0.05. There was
an increase in absolute FeNO values from the baseline to the symptomatic visit, although there was no
significant difference (baseline median: 3.5, CI: 0.7–9.1 ppb vs. symptomatic median: 4.5, CI: 1.7–13.2,
respectively, p = 0.32).A significant drop was observed between the symptomatic and the convalescent
visit (median: 2.0, CI: 0.0–5.0, p = 0.007), (Figure 2A). The % FeNO differences were also significant from
symptomatic and convalescent visits (symptomatic visits: median 100, CI: −38.6–504.1, convalescent:
median 0.0, CI: −62.8–87.5, p = 0.005) (Figure 2B). The differences from symptomatic to convalescent
visits in absolute (p = 0.007) and % FeNO values (p = 0.005) are depicted in Figure 3A,B. The effect of
inhaled corticosteroids (ICS) could not be assessed since most asthmatic children were on prophylactic
treatment at all three time points (baseline: 80.7, symptomatic: 76.7, convalescent: 81.6).
Figure 2. Variations in FeNO measurements from healthy state (baseline/follow-up) to the subsequent
exacerbation and convalescence periods in preschool-aged children with recurrent wheeze/asthma.
(A) Comparison of absolute FeNO values, (B) Comparison of FeNO % change.
Figure 3. Difference in FeNO values of preschoolers with asthma during exacerbations and at their
respective convalescent visits (A) in absolute values, (B) in FeNO % change (from baseline).
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3.4. Predictors of FeNO Measurements at Baseline and during the Two-Year Follow-Up
Predictors derived from the questionnaires obtained at all-time points were assessed in respect
to FeNO values (Supplementary Materials, Table S1). FeNO measurements at baseline were
significantly correlated with the number of reported asthma episodes in the preceding 12 months
(correlation coefficient: 13.7, p = 0.03), while wheezing episodes and the number of days with asthma
symptoms were positively associated with increased FeNO values at the end of the 2-year follow-up
(median: 19.5, IQR: 15.75–46.25 and correlation coefficient: 16.1, p = 0.04, respectively).
4. Discussion
In our cohort, FeNO levels did not differ significantly between “asthmatic”/recurrent wheezers
when asymptomatic (at baseline) and healthy preschool children. A gradual and significant
increase in airway inflammation was noted in asthmatics in respect to time/age when prospectively
assessed; however, slopes between asthmatics and controls did not differ. In the presence of atopy,
as assessed by SPTs, asthmatics presented significant increases in airway inflammation during the
study. Moreover, FeNO values were significantly associated with markers of asthma activity such as
the number of days with asthma symptoms reported in the preceding 12 months and the number of
asthma exacerbations during the 2-year follow-up period.
FeNO levels, in both asthmatic and healthy children, were within normal limits, as indicated
by international guidelines [12] and in line with previous studies, suggesting that FeNO values
in preschoolers are less than 10 ppb [15]. Increased FeNO values have been reported previously
in preschoolers with recurrent or persistent asthma-associated symptoms compared to healthy
controls [16]; however, this was not the case in our cohort, which is probably due to mild to moderate
disease severity [10] or to the fact that measurements were performed during asymptomatic periods at
baseline. The lack of difference between the groups with regard to the increase in the FeNO slopes
in the 2-year follow-up might suggest that, potentially, FeNO increases are age-dependent, as noted
in previous studies [15], and independent of disease activity in this age group, although the impact
of small size on controls cannot be excluded. Nevertheless, atopy per se was a significant risk factor
for the increased FeNO trajectory in asthmatics, which is in line with reports supporting a strong
association between FeNO and allergic sensitization [17].
During episodic periods, FeNO levels significantly increased, while 4–6 weeks later, the values
recorded were even lower than their respective “baseline” ones. High levels of FeNO are typically
considered a marker of airway eosinophilic inflammation and are associated with deterioration in
asthma control [18]. FeNO levels increase during virus-induced asthma exacerbations, which are
mainly attributed to rhinoviruses, and reflect epithelial host-defense responses [19]. In our cohort, viral
respiratory infections, mostly by rhinoviruses, were the most commonly identified triggers for asthma
worsening (manuscript in preparation). It is plausible that the intermittent inflammatory airway
response that follows an episode accounts for the brief increase in FeNO levels. It is well-established
that FeNO levels are affected by the intake of corticosteroids, either oral or inhaled, to the extent that the
use of FeNO has been proposed as a marker for glucocorticoid response, or alternatively for adjusting
ICS dosing. The vast majority of asthmatic preschoolers in our cohort (95%) were on prophylactic
treatment at baseline, as described elsewhere [10]; thus, this may account for the low FeNO values
noted at inclusion. Moreover, treatment with increased doses of inhaled corticosteroids, which is
frequently recommended as an add-on therapy to b2-agonists during exacerbations [20], may explain
the lower FeNO levels noted at convalescence [21]. This further suggests that treatment may improve
airway inflammation, even if children appear asymptomatic.
We recorded FeNO values in 75.5% of all scheduled visits on average, and in 65% of visits during
episodes in asthmatics, indicating that FeNO determination is feasible in most, but not all preschoolers,
following proper training. Reliable FeNO measurements can be obtained in a standardized way
from the age of 4 years. Reports have shown that the NObreath equipment provides results that are
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comparable with other techniques [22]. In addition, FeNO measurements were performed during
morning hours, thus excluding the possibility of bias due to circadian fluctuations [23].
Our data support the monitoring of asthma with objective measurements, even in preschoolers.
FeNO personalized monitoring (±bronchodilator reversibility) was reported to be dominate over
other diagnostic tests, while an economic analysis indicated that FeNO monitoring could have
value as such a strategy [24]; thus, most recent guidelines suggest the incorporation of FeNO into
the asthma management algorithm [25]. Recently, an increasing number of reports have emerged
that utilize the measurement of FeNO at multiple expiratory flows and mathematical modeling of
pulmonary NO dynamics in order to estimate different components of FeNO, i.e., alveolar or acinar;
nevertheless, only a few publications have reported values in children with asthma and no data are
available for preschoolers. [26–28]. Future research is needed in order to establish the usefulness of the
aforementioned FeNO technique in clinical practice, especially in the pediatric population.
All in all, we were able to demonstrate significant fluctuations in airway inflammation, depending
on the activity and severity of the disease, which indicates that an individualized approach, i.e., using
the personal best as a reference value, may be preferable for this age group. Nevertheless, the age- and
atopy-dependent increase needs to be taken into account, suggesting that regular baseline measurement
may be necessary. FeNO changes, at least in preschoolers, should be longitudinally and individually
assessed, in order to efficiently aid disease management.
The major strength of our study is its multinational character and longitudinal design. Diagnosis
and disease assessment were made by specialists, while airway inflammation and atopy were
quantified via objective standardized measures. We have previously shown that our cohort is powered
to prospectively evaluate the role of infection on asthma persistence and it is representative of preschool
asthma, with well-balanced demographic and atopy-related characteristics [10]. Children were assessed
for an extended time period at regular follow-up visits and during symptomatic and convalescence
periods. We obtained a significant number of FeNO measurements at baseline and regular follow-up
visits (561) in the cohort. Although the available number of measurements for comparison during
symptomatic periods and convalescence was small, the statistical power obtained was moderate, due to
the moderate effect size (significant differences in the compared distributions’ median values) that
was present.
However, a weakness of this study is that several parameters, including asthma activity, severity
and medication use were assessed based on parental reports, which are subject to recall bias, although
previous studies have proven that short-term parental reports can be accurate.
5. Conclusions
This study clearly shows that indices of asthma and rhinitis activity and the presence of atopy
in preschool-aged children with asthma are significantly correlated with airway inflammation as
assessed by longitudinal follow-up. Airway inflammation increases during acute events, then values
return to better than the “personal normal” values 4–6 weeks later, suggesting a treatment effect.
Thus, longitudinal assessment of FeNO measurements can be valuable for monitoring preschool
children with recurrent wheeze/asthma. However, estimations can only be based on personalized,
rather than reference values.
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Abstract: Several researchers have assessed the utility of Impulse Oscillometry System (IOS)
in diagnosing and evaluating the severity of respiratory diseases in childhood, but none has
investigated the impact of the fluctuations of IOS parameters in an individualized manner. In this
two-year prospective study, we aimed to longitudinally evaluate changes in airflow limitation and
bronchodilator responsiveness in steroid-naïve four- to six-year-old children during a virus-induced
wheezing episode, with IOS pulmonary resistance parameters set at 5 (R5) and 20 (R20) Hz. Moreover,
feasibility and reproducibility, in addition to the diagnostic properties of these parameters were
examined. Lung function was assessed every six weeks (baseline), within the first 48 h following
an acute wheezing episode (Day 0), after 10, and after 30 days. Forty-three out of 93 recruited
children (4.5 ± 0.4 years old) experienced a wheezing episode during the study period. All children
were able to perform the IOS effort in an acceptable and highly reproducible manner. R5 and R20
fluctuated independently of atopy, age, height, and weight. On Day 0, R5 values were significantly
lower than the respective baseline values and returned to individual baseline levels within 10 days.
Post-bronchodilation R5 values were similar to the baseline ones, reflecting a reversible airway
obstruction on Day 0. Response to bronchodilation (ΔR5) was significantly more pronounced on
Day 0. ΔR5 values lower than −20.5% had a sensitivity of 70% and a specificity of 76% and could
accurately identify up to 75% of the examined preschoolers. This study provides evidence in favor of
the objective utility of IOS as an easy, highly reproducible, and sensitive technique to assess clinically
significant fluctuations and bronchodilation responses suggestive of airflow limitation. Reference
values although necessary are suboptimal, utilizing the personal best values as personal reference is
useful and reliable.
Keywords: lung function; bronchodilation; resistance; obstruction; reproducible; inflammation; spirometry
1. Introduction
Asthma is the most common chronic lower respiratory disease in childhood throughout the world.
Current guidelines are highly in favor of documenting reversible airflow obstruction as a cardinal
characteristic of asthma, both for the diagnosis and the subsequent monitoring of asthma, preferably
prior to controller treatment, in all age groups [1]. The most widely used pulmonary function test is
spirometry, which estimates lung volumes by rapid and maximal inspiratory and expiratory maneuvers
that are often difficult to perform even in older children.
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In contrast, the Forced Oscillation Technique (FOT) superimposes small air pressure perturbations
on the natural breathing of a subject to measure the mechanical properties of the lungs [2]. The
Impulse Oscillometry System (IOS), based on the aforementioned technique, measures the resistance
and reactance of the respiratory system, thus providing an indirect analysis of lung function through
the use of short pulses (impulses) of acoustic waves—most commonly over a range of frequencies
(5Hz to 20Hz)—applied at the mouth, during spontaneous, quiet breathing [3]. IOS has been used to
distinctively quantify the airflow limitation in the central and peripheral airways [4,5]. Low oscillation
frequencies like 5 Hz can penetrate the periphery of the bronchial tree (diameter <2 mm) and, therefore,
resistance of the respiratory system at 5 Hz (R5) reflects obstruction in both the peripheral and the
central airways. On the contrary, higher frequencies cannot be transmitted distally. Thus, resistance of
the respiratory system at 20 Hz (R20) reflects the proximal airways resistance. The change in resistance
from low to high-frequency ranges (e.g., R5 minus R20, R(5−20)) has been identified as an index of
the peripheral airways resistance only, and has been used as a potential marker of small airways
obstruction [6].
IOS has been developed as a patient-friendly lung function test that minimizes demands on the
patient and requires only passive cooperation with normal breathing through the mouth. It has been
successfully used for assessing lung function and asthma control in healthy and asthmatic children [5,6],
including preschoolers, and in patients who recently underwent surgery or are unable to perform
spirometry, both as an adjunct or even alternative to standard spirometry [4,7,8].
Pediatric reference values and positive bronchodilation responses indicating peripheral air
trapping have been standardized and published [9]. R5 is the main parameter to assess bronchodilation.
However, no consensus has been reached on the optimal cutoff values that could discriminate patients
from healthy individuals. These values vary between 20 and 50% and have been used to diagnose and
evaluate the severity of chronic respiratory diseases in childhood or compare to a number of techniques
routinely used to assess lung function [10–14]. Nevertheless, none of the studies has prospectively
followed either baseline fluctuations of IOS parameters or fluctuations in the course of virus-induced
wheeze episodes in preschool children.
In this prospective study, we aimed to longitudinally evaluate changes in airflow limitation
and bronchodilator responsiveness by means of the main IOS resistance parameters, in steroid-naïve
four- to six-year-old children during the course of a virus-induced wheezing episode. Moreover, IOS




Children four to six years of age from the outpatient clinics of the Allergy Department in the
Second Pediatric Clinic of the National and Kapodistrian University of Athens with a previous
diagnosis of “episodic viral wheeze” according to the European Respiratory Society Task Force [15]
or “virus-induced asthma” according to the Practical Allergy (PRACTALL) Consensus Report [16]
were invited to participate. Patients were eligible if they (1) had been given this diagnosis within
the 12 months preceding the index visit, (2) had at least one mild wheezing episode (based on
reference [16]) in the 12 months preceding the index visit, and (3) if—according to their medical
records—there were prescribed inhaled β-agonists, inhaled corticosteroids or montelukast, but did
not require hospitalization. Patients receiving inhaled corticosteroids or montelukast on a regular
or episodic basis were recruited after a minimum 14-week wash-out period. For the present study,
children were required to be able to perform acceptable and repeatable IOS maneuvers after proper
training. Since the protocol per se included both spirometric and IOS pulmonary function testing,
children were required to be able to perform a technically acceptable maximal expiratory flow/volume
effort with a forced expiratory time (FET) of 0.5 s or greater [17]. The study was approved by the
24
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institutional ethics committee, and written informed consent was obtained from all parents. The
outcomes of additional methods and the baseline characteristics of the study population recruited have
been previously described [18].
2.2. Study Design
Upper and lower airway symptoms and medication use were recorded daily by the parents on
diary cards. Parents were advised to contact the study physicians to arrange an appointment within
48 h after the child started wheezing or coughing, had difficulty breathing or nighttime awakening
due to breathing difficulties. The children were followed up at regular six-week intervals, until either
they had a wheezing episode or reached their sixth birthday. Study physicians were responsible to
evaluate the diary cards and to perform all IOS maneuvers at baseline, during the first 48 h following
a physician-diagnosed wheezing exacerbation (day 0), and then 10 (day 10) and 30 (day 30) days
following the initiation of the episode. During the episodes, children were added as a study observation
if they could be controlled with 200–400 μg of salbutamol, 3–4 times a day and as needed.
2.3. Allergic Sensitization
Levels of serum-specific IgE (ImmunoCAP; Phadia AB, Uppsala, Sweden) to a panel of locally
relevant common aeroallergens (Dermatophagoides pteronyssinus, Dermatophagoides farinae, cat dander,
dog epithelium, grass pollen, Cladosporium species, Aspergillus species, Alternaria species, olive, cypress,
and wall pellitory pollen), and food allergens (hen’s egg, cow’s milk, nuts, and peanut) were measured
either after the wheezing episode or at the age of six years for those children without a wheezing
episode during the study. A patient was classified as atopic if at least one allergen-specific IgE was
greater than 0.7 IU/mL.
2.4. Lung Function Test Maneuvers
IOS was performed using MasterScreen IOS (Jaeger, Würzburg, Germany), applying a standardized
protocol based on manufacturer’s instructions. The system was calibrated through several full strokes
of a single volume (3 L) of air at different flow rates, which were verified with a reference resistance
device (2.0 cm H2O/L/sec) supplied by the manufacturer. Children withheld the use of short-acting
bronchodilators at least 6–8 h prior to testing, which was performed and analyzed in accordance with
European Respiratory Society (ERS)/American Thoracic Society (ATS) guidelines [17,19]. IOS testing
was performed before the spirometry in order to prevent potential bronchoconstriction [7]. Prior to
testing, the child was familiarized with the procedure and was placed in a relaxed standing position,
with the head in a neutral or slightly extended position. Subsequently, the patient was instructed
to breathe normally during the test, making a tight seal with their lips around the mouthpiece. A
nasal clip was also used, while the cheeks were firmly supported. After a short sampling period to
ensure compliance, three to five efforts lasting 20–60 s were recorded. The 20–60 s period provides
the min-max limits of an effort to record an artifact-free maneuver. In case there was no evidence of
coughing, swallowing, vocalization or breath-holding causing artifacts during this period, the trial was
saved. Pulmonary resistance (R) at frequencies of 5 Hz (R5) and 20 Hz (R20) were calculated with the
pre-installed software and assessed by researchers. Each visit-observation consisted of an optimum
of three reproducible maneuvers. Reproducibility was defined as R5 within 10% of highest obtained
value. R5 and R20 measurements from the three saved reproducible efforts for each IOS parameter
were averaged. Calculations of the R(5−20) were assessed with an algorithm based on the equation R5
− R20.
Spirometry was performed with the children in the standing position by using a nose clip and
an incentive animation. Results were reported only if at least two technically acceptable curves (<8
maneuvers per visit), as determined according to standard criteria [17], with a FET≥0.5 s, were obtained.
In order to assess airway reversibility, a short-acting bronchodilator was administered (four puffs
of albuterol, 100 μg each) using a spacer. After 15 min, IOS was repeated. Predicted values for R5 and
25
J. Clin. Med. 2019, 8, 1475
R20 were based on gender and height according to the equipment’s default normal reference values, as
recommended by the manufacturer, based on existing reference values [20,21].
2.5. Statistical Analysis
Since all the analyzed parameters were normally distributed, descriptive statistics for continuous
variables are presented as means ± standard deviation (SD). Student’s t-tests were used to compare
binary outcomes at the same time point. Student’s paired t-tests were used for between-time point
comparisons of the same variable. Associations between categorical data were assessed using the
Pearson χ2 test. Analyses across these time points were performed with generalized estimating
equations (GEE) after adjusting for known confounders, such as height, age, and atopy. For the period
from day 0 to day 30, all variables were treated as time-dependent, except age, sex, atopy, and height.
A logistic regression analysis was performed among the binary outcome “having” or “not having”
a symptomatic wheezing episode, the resistance parameter of interest, and the above-mentioned
potential confounders. The same analysis was performed either by using the data from the cohort
of patients with a wheezing episode alone or after pooling data from both the children with and
without a wheezing episode. Between and within individuals, variability was taken into account in
the analysis of the pooled data. Predictor levels corresponding to “having a wheezing episode” with a
probability of ≥95% (95% predictive decision points) were identified, and so were their performance
characteristics (sensitivity, specificity, positive and negative predictive values calculated). Receiver
operating characteristic (ROC) analyses and curves were fitted to identify “optimal decision points,”
and the area under the curve (AUC) was calculated to compare the accuracy of each analyzed resistance
parameter. Additional information can be found in this article’s supplementary data.
3. Results
All 98 consecutively examined children were able to perform an acceptable IOS effort and consent
to be included in the study. Five of them were unable to achieve an acceptable spirometric maneuver
with FET ≥0.5 s, even after three visits of continuous training efforts, and were excluded. All 93 finally
recruited children (mean age 4.5 ± 0.4 years) were able to perform an IOS effort both at baseline and
during the wheezing episodes. None of the children needed more than three demonstrations and an
equal number of efforts during their initial visit to accomplish a technically correct IOS maneuver.
Among them, 49 (52.7%) were able to perform a correct spirometric maneuver during the first visit, 32
(34.4%) needed two visits, and the remaining 12 (12.9%) needed three visits to be trained well enough
to perform an acceptable and repeatable spirometric maneuver. Two out of these 12 were not able to
perform spirometry and an acceptable IOS effort during their first wheezing episode.
Regular follow-up visits occurred every 40 ± 4 days. Four children were lost to follow-up. Among
the remaining 89 children, 43 had at least one wheezing episode 0.6 ± 0.3 years after recruitment. This
corresponds to a median of five visits for each patient. According to the study protocol, among these
regular visits, the very last one was considered the baseline.
Following initial assessment at the beginning of an episode (day 0), the children were re-evaluated
10 ± 1 days (day 10) and 30 ± 3 days (day 30) later. None of the children reported wheezing unrelated
to an apparent respiratory tract infection.
There was no significant seasonality for the wheezing episodes except the period from early May
until late September (fewer episodes).
The variability of R5 and R20 among different visits was also estimated. Measurements at regular
visits and during the course of a wheezing episode were examined. Pre- and post-bronchodilation
R5 variability ranged from 2.9% to 33.7% (median: 15%, upper 95% percentile: 32.3%) and 1% to
27.7% (median 10.2%, upper 95% percentile 23.4%), respectively. Pre- and post-bronchodilation R20
variability ranged from 3% to 19.2% (median 8%, upper 95% percentile: 18.5%) and 1.7% to 25%
(median 7%, upper 95% percentile: 16.5%).
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The baseline demographic and somatometric characteristics and IOS measurements were similar
between atopic children, non-atopic children, and children completing the study without any wheezing
episode. Bronchodilation responses assessed by R5 and R20 did not differ either (Table 1 and
Supplementary Table S1).
Table 1. Baseline characteristics of children experiencing a wheezing episode during the study period,
and children without a wheezing episode during the study period.
Children with Wheezing Episode *
(n = 43)
Children with no Episode †
(n = 46)
Age (years) 5 ± 0.5 5 ± 0.7
Male, n (%) 23 (54%) 20 (44%)
Height (m) 1.15 ± 0.08 1.14 ± 0.08
Weight (kg) 22.9 ± 3.9 21.9 ± 4.3
Atopic 25 (58%) 21 (46%)
Baseline pre-bronchodilation R5Hz
(kPa/lt/sec) 0.943 ± 0.269 0.980 ± 0.222
Baseline post-bronchodilation R5Hz
(kPa/lt/sec) 0.817 ± 0.227 0.809 ± 0.186
ΔR5Hz −12% ± 13.5% −15.8% ± 15.4%
Baseline pre-bronchodilation R20Hz
(kPa/lt/sec) 0.757 ± 0.191 0.764 ± 0.173
Baseline post-bronchodilation R20Hz
(kPa/lt/sec) 0.669 ± 0.157 0.675 ± 0.153
ΔR20Hz −10.1% ± 13.9% −11.5% ± 17.2%
Previously treated with
Bronchodilators alone §
32 (74.4%) 32 (69.6%)
Values presented as mean ± (standard deviation) SD. All comparisons are non-significantly different. * baseline
values obtained eight weeks prior to the recorded wheezing episode; † baseline values obtained at recruitment and
atopic status at the age of six years old; § the rest of the children had been treated prior to enrolment with inhaled
corticosteroids and/or montelukast; Pulmonary resistance (R) at 5 Hz (R5) and 20 Hz (R20); ΔRx= (Rxpost-bronchodilation
− Rxpre-bronchodilation)/Rxpre-bronchodilation.
During the first 48 h from the beginning of a wheezing episode (day 0), pre-bronchodilation
R5 values were significantly higher than their respective baseline values (1.114 ± 0.280 kPa/lt/sec vs
0.943 ± 0.269 kPa/lt/sec, p < 0.001). The aforementioned measurements returned to baseline levels
within 10 days from the initiation of the episode (Figure 1). There were no significant differences in
respect to the atopic status at all time points (Supplementary Table S2).
A similar fluctuation pattern, independent of the atopic status, was recorded for R(5−20) values,
namely day 0 vs baseline: 0.314 ± 0.163 kPa/lt/sec vs 0.186 ± 0.115 kPa/lt/sec, respectively, p < 0.001. In
respect to the R20, a small but significant increase was noted on day 0 compared to baseline, namely
0.801 ± 0.162 kPa/lt/sec vs 0.757 ± 0.191 kPa/lt/sec, respectively, p = 0.048.
R5 and R20 were not found to be significantly related to age, gender, and somatometric measures
(cross-sectional logistic regression models at each time point and longitudinal GEE models). Gender
and height, however, are used by the predicted equations to estimate the equipment’s default normal
reference values. Pairwise correlation coefficients, although statistically significant, did not indicate
strong correlations between reference/predicted values and actual values for both pre-bronchodilation
R5 and R20 with Pearson’s correlation coefficients 0.522 vs 0.415 respectively, p < 0.001 (Supplementary
Figures S1 and S2). The same applied for the post-bronchodilation values with Pearson’s correlation
coefficients 0.496 and 0.308, respectively, p < 0.001 (Supplementary Figures S3 and S4). Independence
of age, height and weight and suboptimal reference/predicted values suggested that, at least for the
examined ages (four to six years of age), the personal best baseline measurement (lowest values) should
be the reference values for each individual. Therefore, the reference/predicted values were not taken
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into consideration in any of the performed calculations. Additional information can be found in this
article’s supplementary data.
 
Figure 1. Pairwise comparisons of R5Hz values at baseline, on day 0 (beginning of the wheezing
episode), and 10 and 30 days after. The bars and in-between lines represent the mean and standard
deviation (SD). All pairwise comparisons are presented with p-values that have been estimated with
paired Student’s t-test.; Pulmonary resistance (R) at 5 Hz (R5).
All post-bronchodilation values were significantly different in relation to the respective
pre-bronchodilation at all time points for both R5 and R20 (Table 2). Post-bronchodilation R5
values on day 0 were similar to the baseline pre-bronchodilation values, reflecting the reversible airway
obstruction occurring at the beginning of a wheezing episode both in atopic and non-atopic children
(Table 2).
Table 2. Mean R5Hz pre- and post-bronchodilation in atopic and non-atopic children and percentage of
response to bronchodilation: baseline and day 0, 10, and 30 from the beginning of the wheezing episode.
Atopics Non-Atopics
R5Hz Bronchodilation (kPa/lt/sec) Mean ΔR5Hz%* R5Hz Bronchodilation (kPa/lt/sec) Mean ΔR5Hz%*
Time Pre Post Pre Post
Baseline 0.930 ± 0.273 0.798 ± 0.230 −12.8% ± 14.9% 0.961 ± 0.271 0.844 ± 0.227 −10.8% ± 11.6%
Day 0 1.106 ± 0.279 0.847 ± 0.218 † −22.5 ± 12.8% ‡ 1.125 ± 0.289 0.818 ± 0.171 † −25.8% ± 11.1% ‡
Day 10 0.959 ± 0.225 † 0.831 ± 0.218 † −12.9% ± 13.5% 0.914 ± 0.192 0.803 ± 0.155 † −11.2% ± 11.3%
Day 30 0.905 ± 0.248 † 0.792 ± 0.159 † 18.6% ± 10.7% 0.947 ± 0.179 0.772 ± 0.191 † −10.3% ± 12.6%
All bronchodilation responses are significantly different at all time points. ΔR5 = (R5post-bronchodilation −
R5pre-bronchodilation) / R5pre-bronchodilation; † non-significant results compared with the respective (atopics, non-atopics)
baseline pre-bronchodilation values; ‡ Significant bronchodilation differences when compared with the respective
(atopics, non-atopics) baseline ΔR5Hz (p-value= 0.008 and p-value <0.001 respectively). All other comparisons with
baseline ΔR5Hz are not significant, irrespectively of atopic status.
In particular, bronchodilation responses assessed by ΔR5 were significantly more pronounced
only during the first 48 h from the initiation of the wheezing episode (day 0: −23.9% ± 12.1% versus
baseline: −12% ± 13.5%, p < 0.001), irrespectively of atopic status (Table 2 and Figure 2). The same
applied for the ΔR(5−20), as depicted in Figure 3. Bronchodilation responses measured with ΔR20
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values on day 0 did not differ from the responses recorded at baseline or on days 10 and 30 (Figure 4),
therefore excluding any potential diagnostic value of ΔR20 to classify wheezing episodes correctly.
 
Figure 2. Pairwise comparisons of ΔR5Hz values at baseline, on day 0 (beginning of the wheezing
episode), and 10 and 30 days after. The bars and in-between lines represent the mean and SD. All
pairwise comparisons are presented with p-values that have been estimated with paired Student’s t-test.;
Pulmonary resistance (R) at 5 Hz (R5); ΔR5Hz = (R5Hz post-bronchodilation – R5Hz pre-bronchodilation) /
R5Hz pre-bronchodilation
Figure 3. Pairwise comparisons of Δ(R5Hz−R20Hz) values at baseline, on day 0 (beginning of
the wheezing episode), and 10 and 30 days after. The bars and in-between lines represent the
mean and SD. All pairwise comparisons are presented with p-values that have been estimated with
paired Student’s t-test. Pulmonary resistance (R) at 5 Hz (R5) and 20 Hz (R20); ΔR(5−20)Hz =
((R5Hz−R20Hz)post-bronchodilation − (R5Hz−R20Hz)pre-bronchodilation) / (R5Hz−R20Hz)pre-bronchodilation.
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Figure 4. Pairwise comparisons of ΔR20Hz values at baseline, on day 0 (beginning of the wheezing
episode), and 10 and 30 days after. The bars and in-between lines represent the mean and SD. All
pairwise comparisons are presented with p-values that have been estimated with paired Student’s t-test.
Pulmonary resistance (R) at 20 Hz (R20); ΔR20Hz = (R20Hzpost-bronchodilation – R20Hzpre-bronchodilation)
/ R20Hzpre-bronchodilation.
ΔR5 and ΔR(5−20) were additionally examined as potential diagnostic markers of clinically
significant increase in peripheral resistance (assessed during a wheezing episode) in comparison with
measures during asymptomatic periods (baseline, day 10, and day 30). For this reason, a ROC analysis
was performed. The models examined were unadjusted since none of the other parameters was found
to be significant.
The AUCs were 0.725 and 0.671 for ΔR5 and ΔR(5–20) (p = 0.118). Although the AUCs were not
significantly different, the higher number for the ΔR5Hz and the simplicity of its calculation render
it preferable.
In the ROC analysis, a value of ΔR5 ≤−46.4% accurately classified 80.6% of the wheezing episodes,
while values ≤−35.1% correctly identified 77.3% of them (Supplementary Figure S5). Selected cutoff
values for ΔR5 and their respective sensitivity, specificity, positive predictive value (PPV) and negative
predictive value (NPV), are presented in Table 3.
Table 3. Positive and negative predicted values, sensitivity and specificity between selected ΔR5Hz
values, and their ability to correctly classify wheezing episodes (or increase in peripheral resistance as
it is assessed during a wheezing episode).
ΔR5Hz (%) PPV NPV Sensitivity Specificity Accuracy
−46.4% 100.00% 80.38% 4.65% 100.00% 80.57%
−35.1% 30.77% 80.30% 9.30% 94.64% 77.25%
−31.3% 32.00% 81.18% 18.60% 89.88% 75.36%
−20.5% 42.25% 90.71% 69.77% 75.60% 74.41%
−12.4% 28.57% 90.22% 79.07% 49.40% 55.45%
−8.3% 26.03% 92.31% 88.37% 35.71% 46.45%
−7.1% 25.16% 94.23% 93.02% 29.17% 42.18%
Data are given as percentages. PPV = Positive predictive value of having a wheezing episode if ΔR5Hz is lower than
or equal to that specified in the first column; NPV = negative predictive value of not having a wheezing episode if
ΔR5Hz is higher than or equal to that specified in the first column.
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4. Discussion
To our knowledge, this is the first study to prospectively assess IOS indices in virus-induced
wheezing illnesses, suggesting that this method could be used in this age group, where spirometry
might not be feasible for a substantial proportion of the children.
The IOS technique is easy to perform in preschoolers. All recruited children were trained
within a few minutes, and more importantly, none of them experienced difficulties in cooperating
during the episode. On the contrary, during the recruitment period, 44 out of 93 children (47.3%)
needed more than a regular (according to the study protocol) visit to be properly trained in order
to perform a correct spirometric effort, while two of them did not achieve a technically acceptable
spirometric maneuver during the episode. Taking into consideration the fact that measurements
were performed in a research setting, it is rather self-explanatory that, in everyday clinical practice,
spirometry might be quite time-consuming for the medical personnel, thus indisputably supporting the
IOS’s superiority in this age group. Since there is an unmet need for objective measures in preschoolers
with asthma-related symptoms, seeing that the documentation of reversibility using spirometry is
often problematic due to effort dependency, IOS merits the consideration of being included in the
diagnostic and therapeutic algorithm.
In particular, we showed that, in preschool children with virus-induced wheeze, IOS indices
mainly reflecting peripheral airways, such as R5, are indicative of airflow limitation during an
asthma-associated episode. R5 values increased significantly, while bronchodilation responses were
more pronounced upon the initiation of the wheezing illness than at baseline. Fluctuations of the
IOS resistance parameters resemble the correspondent fluctuations of symptoms (noisy breathing,
cough, and shortness of breath), airway inflammation (FeNO) and spirometric parameters (such as
FEV0.5)—as shown in our previously published study, indicating that these episodes share common
characteristics with the well-defined asthma exacerbations in older children [18].
In general, the within- and between-visit variability of R5 and R20 is estimated to be up to 10%.
This variability indicates acceptable repeatability among multiple efforts performed by the same
subject [22]. In children, this variability is expected to be higher and has been estimated to be up to
16% for measurements within the same day or up to 30% among several weeks [7,10,19,23,24]. When
assessing post-bronchodilation values, their variability is expected to vary even more, with coefficients
of variation twice the amount of these reported for measurements before bronchodilation [19]. This
was also the case in our cohort. The median variability ranged from 7% to 15% after taking into
consideration pre- and post- bronchodilation measurements for R5 and R20 at regular visits and
during the course of a wheezing episode. The variability did not differ significantly before and after
bronchodilation and, on both occasions, it was within the acceptable extent, suggesting excellent
repeatability and reliability in recorded measurements at different time points.
In our cohort, moderate to low correlations (ranging from 0.308 to 0.522) were found between
predicted and recorded values for both R5 and R20, before and after bronchodilation. Moreover,
neither pre- nor post-bronchodilation R5 and R20 values were found to be correlated with either age,
gender, or somatometric parameters. Predicted values for R5 and R20 were based on gender- and
height-adjusted existing reference values from a Swedish and a Polish study, as recommended by the
manufacturer [20,21]. In the Swedish study by Denker et al. [20], 350 children, 2.1 to 11.1 years old
with height 90–160 cm were examined. The investigators found significant correlations with height
but weak with weight for both R5 and R20. No significant gender-related difference was found for
respiratory resistance. The investigators stated that there were more observations in the height interval
130–145 cm (vs. 107–121 cm in our study population). They do not provide information about the
number of children between the 4–6 year of age but based on the height information, it is clear that
the predicted equations are weighted for older and higher children and are not representative for
preschoolers. In the Polish study by Nowowiejska et al. [21], 626 children, 3.1–18.9 years old (mean age
for boys 10.6 years and for girls 10.9 years), with height 95–193 cm (mean height for boys 144.8 cm and
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for girls 141.9 cm) were examined. Similar correlations with the Swedish study were found for both R5
and R20. Again, the predicted equations were weighted over older and higher children.
In general, young children exhibit higher pulmonary resistance than older children and adults,
and, therefore, airway resistance is inversely proportional to age, especially at lower frequencies [25].
In a recent meta-analysis, a correlation with anthropometric variables has been suggested too [26].
The lack of similar correlations in our study could be explained by the narrow range of height and
weight in the sample of 4- to 6-year-old children examined. The Polish and Swedish studies provide
predicted equations with anthropometric data based mainly on older and higher children, with values
over a wide spectrum. Thus, extrapolating data in younger and smaller children appears to provide
suboptimal reference values. Additionally, it should be underscored that the differences in ethnicity
might also influence the estimated reference values which do not seem to be appropriate at least for
the Greek children.
Nevertheless, based on the low variability and excellent repeatability in our study, measures
up to six months apart (based on this study average observational period until a wheezing episode
occurred), even during different seasons, could be considered stable and independent of known
confounders like gender, height or weight. For these reasons, at least in this age-group, reference
values are not recommended, until appropriate studies are conducted. An individualized approach
using the personal best value, recorded either when the child is asymptomatic or at least 10 days after
a mild wheezing episode occurs, is recommended. These values can be used up to at least six months
apart to follow-up mild wheezers.
Atopy does not seem to affect the resistance baseline measurements or the bronchodilation
responses either when these parameters are assessed cross-sectionally or longitudinally. This finding
has also been shown in spirometry and FENO in preschoolers [18]. This independence could be
explained by the intermittent, short-lasting inflammatory responses during mild wheezing episodes in
our cases. It remains to be shown [27] whether the probably new, atopy-related inflammation could
predispose patients to a more chronic inflammatory process since multiple relapses could lead to
alterations in the peripheral resistance measures and bronchodilation responses in atopics.
R5 and R(5−20) values, as indicators of bronchial obstruction, increased significantly during
wheezing episodes and spontaneously returned to baseline within 10 days. Post-bronchodilation R5
values on day 0 were similar to the pre-bronchodilation baseline values, reflecting a reversible airway
obstruction at the beginning of a wheezing episode, independently of atopic status as has previously
been shown for FEV0.5 [18].
Mean bronchodilation responses were significantly higher at the beginning of the episode
compared to the respective changes at baseline or on day 10 and 30 for ΔR5 (representing the total
airway resistance) and ΔR(5−20) (representing peripheral resistance) but not for ΔR20 (representing
the resistance of the large airways). Considering the resistance that each of these variables reflects, this
is to be expected. In particular, the bronchodilation responses assessed by ΔR5 were more pronounced
within the first 48 h from the initiation of the wheezing episode than the responses assessed by ΔR(5−20).
When both ΔR5 and ΔR(5−20) were examined for their potential diagnostic value in discriminating
clinically significant increase in peripheral resistance during the first days of a wheezing episode
(day 0, day 10 and day 30), compared to measurements during asymptomatic periods (baseline) their
AUCs were not significantly different (0.725 vs 0.671, respectively). Nevertheless, the higher absolute
magnitude of AUCΔR5 renders this parameter preferable for analyzing performance characteristics
with a ROC analysis.
Indeed, the ROC analysis provided specific diagnostic cutoff values. Based on the analysis of
this cohort, the optimal cutoff point with the highest sensitivity and specificity was found to be
−20.5% (Table 3). Taking into account that the cutoff values have been calculated in patients using
measurements even during a wheezing episode, the bronchodilation magnitude is expected to be
overestimated in healthy individuals of similar age, and, hence, the proposed cutoff values are expected
to be of greater diagnostic value.
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The major strength of this study is the steroid-naïve cohort that has been longitudinally examined,
providing robust data. To our knowledge, this is the first study to assess airflow limitation in preschool
children experiencing wheezing episodes with such study design, that is, by utilizing the IOS technique,
and it is also the first time cutoff values have been calculated based on longitudinal measures during and
outside an episode for a short period, to adjust for intra- and inter-variability. Considering the fact that
the two most likely sources to rely on for the calculation of cutoffs are either population surveys—using
only non-wheezers—or studies comparing wheezers with non-wheezers during asymptomatic periods,
the data of this study are expected to be more reliable.
A weakness of the study is the lack of a healthy control group because of ethical considerations
regarding salbutamol administration to healthy children [28]. This issue has been overcome by
assessing the value of a personalized approach and proving that the personal best value is reliable
enough to follow up with such patients. Moreover, the sample was small, although the multiple
measurements per studied child provided robust longitudinal analyses. Last but not least, it is not
known if the inferences could be applied in children with severe viral-induced wheezing episodes.
In summary, we have shown that IOS is an easy, highly reproducible, and sensitive technique
that can be successfully performed to assess airflow limitation objectively in preschool children with
virus-induced wheezing illnesses. The study design supports the superiority of the longitudinal
approach of such data, suggesting, that reference or predicted values, although necessary, are
suboptimal, and that an individualized approach utilizing the personal best values as the personal
reference is useful and reliable. Among the commonly measured parameters, the R5 seems to be
the best to assess clinically significant fluctuations and bronchodilation responses suggestive of
airflow limitation. Cutoff values do have diagnostic properties that can help identify significant
bronchodilation responses. Considering the difficulties in examining preschoolers using spirometry
and the time required to train them and perform an acceptable spirometric maneuver, IOS could be
suggested as the future gold standard to examine airflow limitation in children even in everyday clinical
practice. Further studies with similar design are needed for children with persistent or moderate to
severe symptoms.
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Abstract: Chronic asthma is associated with progressive airway remodeling, which may contribute
to declining lung function. An increase in matrix metalloproteinases-9 (MMP-9)/tissue inhibitor
metalloproteinase-1 (TIMP-1) may indicate airway inflammation and bronchial injury. Bronchial
biopsy specimens and alveolar macrophages (AMs) were obtained from patients with asthma under
regular treatment with inhaled corticosteroids or combination therapy and normal subjects (n = 10).
Asthmatics included those with a slow forced expiratory volume in one second (FEV1) decline
(<30 mL/year, n = 13) and those with a fast FEV1 decline (≥30 mL/year, n = 8) in 5-year follow-up.
Immunostaining expression of MMP-9 and TIMP-1 was detected in airway tissues. MMP-9 and
TIMP-1 was measured from AMs cultured for 24 h. After the 5-year treatment, the methacholine
airway hyperresponsiveness of the slow FEV1 decline group was decreased, but that of the fast
FEV1 decline group was increased (PC20, provocative concentration causing a 20% decrease in FEV1,
3.12 ± 1.10 to 1.14 ± 0.34 mg/dL, p < 0.05). AMs of asthma with a fast FEV1 decline released a higher
level of MMP-9 (8.52 ± 3.53 pg/mL, p < 0.05) than those of a slow FEV1 decline (0.99 ± 0.20 pg/mL).
The MMP-9/TIMP ratio in the fast FEV1 decline group (0.089 ± 0.032) was higher than that of the slow
FEV1 decline group (0.007 ± 0.001, p < 0.01). The annual FEV1 decline in 5 years was proportional
to the level of MMP-9 (r = 57, p < 0.01) and MMP-9/TIMP-1 ratio (r = 0.58, p < 0.01). The airways
of asthma with greater yearly decline in FEV1 showed an increased thickness of submucosa and
strong expression of MMP-9. An increase in MMP-9 and MMP-9/TIMP-1 in airways or AMs could
be indicators of chronic airway inflammation and contribute to a greater decline in lung function of
patients with chronic asthma.
Keywords: asthma; airway remodeling; matrix metalloproteinases-9; tissue inhibitor of
metalloproteinase-1; alveolar macrophages
1. Introduction
Asthma is a chronic respiratory disease of airway inflammation that manifests as variable airflow
limitation [1]. Patients with asthmatic airway inflammation develop tissue injury with subsequent
J. Clin. Med. 2019, 8, 1451; doi:10.3390/jcm8091451 www.mdpi.com/journal/jcm37
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structural changes, which is termed airway wall remodeling [2,3]. Elderly or longer duration of asthma
is correlated to airway wall remodeling and contributes to a decline in lung function [4]. The features of
airway remodeling include smooth muscle hypertrophy, goblet-cell hyperplasia, subepithelial fibrosis,
inflammatory cell infiltration, as well as epithelial shedding [5].
Matrix metalloproteinases (MMPs) are a family of enzymes that can break down proteins of
the extracellular matrix (ECM), thus contributing to pathological processes of inflammation, wound
healing, and fibrosis [6]. The MMPs also play an important role in several lung or airway diseases,
or even lung cancer [7–10]. Additionally, increased levels of MMP-9 in serum, sputum, or lavage
fluid were observed in patients with asthma [11–13]. MMP-9-deficient animals could inhibit airway
inflammation and the immunoreactivity of MMP-9 has also been reported to be correlated with
asthma severity [14]. Nevertheless, a defensive function of MMP-9 in asthma was reported through a
heightened inflammation in MMP9-deficient mice [15,16]. Taken together, MMP-9 may be an important
factor involved in asthma, but the production of MMP-9 in chronic asthma with persistent airway
obstruction is still undetermined.
The tissue inhibitors of matrix metalloproteinase (TIMPs) inhibit enzymatic activity of MMPs
through binding to the MMPs [17,18]. The secretion of TIMP-1 is associated with MMP-9. TIMP-1 may
possibly result in the thickening process of the basement membrane in asthma [19]. Therefore, MMP
and TIMP imbalance may cause clinical differences in chronic airway diseases [20,21]. The ratio of
MMP-9/TIMP-1 in the sputum of asthmatic patients has been shown to decrease after recovery from
an acute exacerbation of asthma, which may imply that MMP9/TIMP has a negative correlation [22].
Through increasing the thickness of the airway wall by collagen deposition, a decreased ratio of
MMP-9/TIMP-1 in chronic asthma may result in airway obstruction [4]. Vignola et al. [21] reported
that the ratio of sputum MMP-9/TIMP-1 has a positive correlation with the forced expiratory volume
in one second (FEV1) of asthmatic patients. Additionally, a previous report [23] showed that a low
serum MMP-9/TIMP-1 ratio was found in asthmatic patients who show little FEV1 improvement
with the treatment of corticosteroids. Despite some reports [22,23], which revealed the possibly
negative correlation of MMP9, TIMP, and lung function in asthmatic patients, the relation among these
parameters remains controversial. Some reports also presented no correlation between MMP9, TIMP,
and lung functions [24], or positive correlations among MMP9, TIMP, and lung functions [25,26].
Our aim was to evaluate whether the ratio of MMP-9/TIMP-1 released from cultured alveolar
macrophages was higher in chronic asthmatic patients who had a fast, yearly decline in FEV1. We also
investigate whether the ratio of MMP-9/TIMP-1 was correlated to the magnitude of yearly FEV1 decline.
2. Materials and Methods
2.1. Patient Population
Non-smoking asthmatic patients, aged 18 to 65 years, were recruited from outpatient clinics of the
Chang Gung Memorial Hospital. Asthma was defined according to the American Thoracic Society
criteria [27]. All asthmatic subjects had a >12% improvement in forced expiratory volume in one second
(FEV1) with inhaled albuterol (400 μg) and bronchial hyperreactivity to methacholine (provocative
concentration (PC) causing a 20% decrease in FEV1, PC20 < 8 mg/L). These patients received anti-asthma
medications, which included inhaled and/or oral corticosteroids, inhaled long-acting β2-agonist, or a
combination of these, and had been followed up at our clinics for more than 5 years. All of the patients
with asthma had used inhaled corticosteroids all the time. All patients had been stable for at least 3
months and were taking their usual medications before entry into the study. Inhaled β2-agonists were
withheld for 12 hours before methacholine testing.
The asthmatic subjects were divided into 2 groups: 13 asthmatic subjects (7 women and 6 men, aged
49.2 ± 3.4 years) with a slow FEV1 decline (< 30 mL/year) in the 5-year follow-up, and 8 asthmatic subjects
(3 women and 5 men, aged 49.4 ± 3.7 years) with a fast FEV1 (≥ 30 mL/year) in the 5-year follow-up,
as previously described [28]. During the following years, one of the asthmatics with a slow FEV1 decline
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and 4 asthmatics with a fast FEV1 decline experienced difficulty in controlling their asthma symptoms
despite taking the maximum recommended dose of inhaled corticosteroids and inhaled long-acting
β2-agonist. These patients needed additional therapy with long-term oral corticosteroids or a long-acting
muscarinic antagonist. The calculation of annual FEV1 decline (mL/year) was determined by subtracting
FEV1 at the first year by the second measurement 5 years later, then dividing this by 5 [28].
Ten normal non-smoking subjects (6 women and 4 men, aged 47.3 ± 2.8 years), who had normal
pulmonary function and no evidence of bronchial hyperresponsiveness, allergic rhinitis, or asthma,
were recruited. Their total IgE levels and eosinophil counts were normal and their serum-specific IgE
was negative.
2.2. Study Protocol
All patients who satisfied the enrollment criteria performed routine pulmonary function tests
and methacholine provocation testing after abstaining from short-acting oral or metered-dose inhaler
bronchodilator use for 6 h, and long-acting β2 agonist for 24–48 hours. Asthmatic subjects underwent
the procedure of fiberoptic bronchoscopy with bronchial biopsy and bronchoalveolar lavage. Informed
consent was obtained from all patients before entry into the study. The study was approved by the
Chang Gung Memorial Hospital Ethics Committee (IRB number: 90-13).
2.3. Fiberoptic Bronchoscopy
All study patients received fiberoptic bronchoscopy under sedation. The procedure of
bronchoscopy under sedation and administering of local anesthesia was performed in the study
institution. Sedation with intravenous midazolam (5–10 mg), and local anesthesia with 2%
xylocaine solution was performed during bronchoscopy. Oxygen saturation, blood pressure, and
electrocardiography (ECG) were monitored during bronchoscopy. The bronchoscope was advanced
through the nose and larynx, and then into the tracheal and bronchial lumen; bronchial biopsies were
taken from the 4th or 5th subsegmental bronchus. The specimens were fixed by 4% paraformaldehyde
for immunocytochemistry.
2.4. Preparation of BAL Cells
Bronchoalveolar lavage (BAL) was completed in subjects using 300 mL of 0.9% saline solution [29].
Sterile saline solution was instilled into the right fourth or fifth subsegmental bronchus. The lavage
fluid was retrieved by gentle aspiration, collected, and filtered through two layers of sterile gauze.
BAL fluid was kept on ice throughout processing. The collected BAL fluid was centrifuged at 600× g
for 20 min at 4 ◦C. The cell pellet was obtained after centrifugation followed by consecutive washes
and finally resuspended at 106 cells per mL in RPMI-1640 (GIBCO, Grand Island, New York, NY,
USA) containing 5% heat-inactivated fetal calf serum (FCS, Flow Laboratories, Paisley, Scotland, UK).
Trypan blue exclusion was used to determine cell viability. Differential cell counts were determined by
counting 500 cells on cytocentrifuge preparations using a modified Wright–Giemsa stain. BAL fluids
were stored at −70 ◦C until analysis. The purified alveolar macrophages were placed in 6-well plates at
106 cells/mL for 24 h at 37 ◦C and 5% CO2. The culture supernatant was collected and frozen at −70 ◦C
until use.
2.5. Immunocytochemistry
Immunoreactivity for tissues was performed with the use of the avidin–biotin peroxidase complex
method. Tissue sections (5 μm) from asthmatic subjects were incubated overnight at 4 ◦C with a
variety of primary antibodies, including anti-human MMP-9 (Oncogen Science Inc, Cambridge, MA,
USA) and TIMP-1 antibodies (Fuji Pharmaceutical Co, Toyama, Japan) [30]. Mouse immunoglobulin
G1 (Dako, Kyoto, Japan) was used for negative controls. After washing in PBS/Tween 20 twice,
the slides were counterstained by hematoxylin. Positive immunostaining was visualized as brown
granules contained in the cytoplasm. The scores corresponding to MMP-9 and TIMP-1 immunostaining
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expression were evaluated by a semi-quantitative assessment using the intensity and percentage of
positively stained cells, such as epithelial cells, inflammatory cells, and mucus gland or smooth muscle.
The intensity of MMP-9 and TIMP-1 staining was scored as follows: 1, weak; 2, moderate; and 3,
strong (Figures 1 and 2). The percentage scores were determined by the following definition: 1, ≤25%;
2, 26–50%; 3, 51–75%; and 4, >75%. These scores were multiplied by the intensity and the percentage
score. The range was between 1 and 12.
Figure 1. Immunohistochemical expression levels of MMP-9. An avidin–biotin complex
immunohistochemical study for MMP-9 labeling was performed in airway tissues obtained from
asthmatic patients with a slow FEV1 decline (A) and a fast FEV1 decline (B and C). Positive staining
was defined as brown–yellow particles or tan–brown particles in the cytoplasm (magnification, 200×).
(A) Airway tissue with weak staining (score 1); (B) airway tissue with moderate staining (score 6);
(C) airway tissue with strong staining (score 12); (D) the immunohistochemistry score of MMP-9
was determined through a semi-quantitative assessment by calculating the intensity and percentage
of positive cells. The central horizontal lines indicate the median, and the error bars (upper and
lower horizontal lines) are the 75th percentile and 25th percentile, respectively, *** p < 0.0001. IHC,
immunohistochemistry; MMP-9, matrix metalloproteinase-9.
40
J. Clin. Med. 2019, 8, 1451
Figure 2. Immunohistochemical expression levels of TIMP-1. An avidin–biotin complex
immunohistochemical study for TIMP-1 expression was performed in airway tissues derived from
asthmatic patients with a slow FEV1 decline (A and B) and a rapid FEV1 decline (C). Positive staining
was defined as brown–yellow particles or tan–brown particles in the cytoplasm (magnification, 200×).
(A) airway tissue with weak staining (score 1); (B) airway tissue with moderate staining (score 6);
(C) airway tissue with strong staining (score 12); (D) immunostaining of TIMP-1 was scored through a
semi-quantitative assessment by calculating the intensity and percentage of positive cells. The central
horizontal lines indicate the median, and the error bars (upper and lower horizontal lines) are the 75th
percentile and 25th percentile, respectively. IHC, immunohistochemistry; TIMP-1, tissue inhibitor of
matrix metalloproteinase-1.
2.6. Hematoxylin and Eosin Staining (H and E)
The thickness of the epithelium, basement membrane, and subepithelial layer was investigated by
H and E staining for 20 min at room temperature. The results were visualized using an Olympus BX51
microscope (Olympus Corporation, Tokyo, Japan).
2.7. MMP-9 and TIMP-1 ELISA
Quantitative sandwich-type enzyme-linked immunoassay techniques (ELISA) were used to
assay the secretory products in macrophage supernatants [26]. MMP-9 and TIMP-1 kits were used
(Amersham Life Sciences, Arlington Heights, IL, USA) according to the manufacturer’s instructions.
The optical density was measured with a spectrophotometer set to 450 mM for all assays. Quantification
was performed by interpolation from a standard curve.
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2.8. Statistical Analysis
Data were presented as mean ± SEM. The data were analyzed using a Student’s t-test for paired
or unpaired data. For data with even or uneven or variation, a Mann–Whitney U test or Wilcoxon
signed rank test was used for unpaired or paired data, respectively. ANOVA with post hoc analysis
was used when comparing data from three groups; p < 0.05 was considered significant.
3. Results
3.1. Demographic Features of Patients
Table 1 summarizes pulmonary function tests on asthmatic patients and normal subjects. The FVC,
FEV1, and levels of PC20 in methacholine tests demonstrated no difference between the two groups
of asthmatics. Initially, the PC20 was similar in both asthmatic groups. After 5 years, airway
hyperresponsiveness of patients with a slow FEV1 decline was significantly decreased (PC20 from
1.87 ± 0.52 to 3.52 ± 0.81 mg/dL, n = 13, p < 0.05), while that of asthmatics with a fast FEV1 decline
demonstrated an increased airway hyperresponsiveness (PC20 from 3.46 ± 1.02 to 1.14 ± 0.34 mg/dL,
n = 8, p < 0.05) (Figure 3).
Table 1. Baseline characteristics of the normal subjects and asthmatics.
Clinical Features Normal Subjects (n = 10) Asthma (n = 13)
Slow FEV1 Decline
Asthma (n = 8)
Fast FEV1 Decline
Age, year 47.6 ± 2.8 49.2 ± 3.4 49.4 ± 3.7
Gender, F/M 5/5 5/8 4/4
FVC, L 3.4 ± 0.3 3.0 ± 0.3 3.3 ± 0.2
FVC, % pred. 95.2 ± 4.7 88.8 ± 5.7 94.0 ± 5.0
FEV1, L 2.6 ± 0.3 2.1 ± 0.3 2.4 ± 0.2
FEV1, % pred. 82.4 ± 4.5 72.2 ± 6.3 77.6 ± 4.8
FEV1/FVC 83.3 ± 2.7 68.7 ± 3.6 73.8 ± 4.0
Annual FEV1 decline, mL/year −18.2 ± 9.7 135.8 ± 14.0 ***
PC20, mg/dL > 25 1.9 ± 0.5 3.5 ± 1.0
Values are mean ± SEM; F/M, female/male; FEV1: forced expiratory volume in one second; FVC: forced vital capacity;
% pred., percent of predicted value; L: liter; PC20: value of methacholine provocative concentration causing a 20%
decrease in FEV1. *** p < 0.0001 compared with group A.
Figure 3. The individual concentration of methacholine provocation in asthmatic patients who had a
slow FEV1 decline (open circle, n = 13) or a fast FEV1 decline (solid circle, n = 8) after receiving 5 years
of inhaled anti-asthma medicine, compared with the initial values (initial). The significance is indicated.
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3.2. Cellular Profile Analysis of Bronchoalveolar Lavage
The cellularity of lavage fluid was similar between the asthmatic groups but was significantly
lower in normal subjects. Compared to normal subjects, there was an increase in the percentage of
eosinophils and lymphocytes and a corresponding decrease in the proportion of alveolar macrophages
in asthmatics with either a fast or a slow decline in FEV1 (Table 2). The cellularity of different cell types
in normal subjects and asthmatics is presented in Figure 4 and had the same result as the percentage
of cell types. The asthmatic patients with a fast FEV1 decline over 5 years had a marked rise in the
proportion of neutrophils compared with those who exhibited a slow decline in FEV1 or normal
subjects (Table 2). In addition, the magnitude of the annual FEV1 decline in asthmatics was highly
correlated with the cellularity of neutrophils in BAL (r = 0.718, n = 21, p = 0.0002).
Table 2. Characteristics of bronchoalveolar lavage.
Cell Profile Normal (n = 10) Asthma (n = 13)
Slow FEV1 Decline
Asthma (n = 8)
Fast FEV1 Decline
Total cell count, ×106 cells 11.9 ± 1.7 21.2 ± 6.6 ** 34.2 ± 10.1 **
Recovered volume, % 62.9 ± 3.7 44.6 ± 5.0 47.5 ± 5.8
Cell viability, % 94.4 ± 1.4 94.1 ± 1.3 91.6 ± 2.5
AMs, % 97.5 ± 0.6 87.9 ± 2.3 ** 84.3 ± 5.3 **
Lymphocytes, % 1.5 ± 0.5 8.2 ± 1.8 ** 8.0 ± 3.6 **
Neutrophils, % 0.7 ± 0.2 1.4 ± 0.3 5.0 ± 1.5 **#
Eosinophils, % 0.2 ± 0.1 2.4 ± 1.1 * 2.6 ± 1.1 *
Abbreviation: AMs = alveolar macrophages; Values present as mean ± SEM; * p < 0.05, ** p < 0.01 compared with
normal subjects. # p < 0.05 compared with normal subjects or asthma with a slow FEV1 decline.
Figure 4. The concentration of different cell types in bronchoalveolar lavage fluid derived from normal
subjects (Normal, n = 10), and asthmatic patients with a slow FEV1 decline (Slow FEV1 decline, n = 13)
or a fast FEV1 decline (Fast FEV1 decline, n = 8); ** p < 0.01 is indicated.
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3.3. Expression of MMP-9 and TIMP-1 in Bronchial Biopsies
MMP-9 was expressed in airway tissue obtained from asthmatics, especially in epithelial cells,
inflammatory cells, or gland cells (Figure 1A–C). Furthermore, asthmatic patients with a rapid FEV1
decline had a significantly higher immunohistochemistry (IHC) score of MMP-9 (median, 8.5; IQR,
6.5–9.0), when compared with asthmatic patients with a slow FEV1 decline (median, 2.0; IQR, 1.0–4.0)
(p < 0.0001, Figure 1D). The IHC score of TIMP-1 expression in the airway showed no significant
difference between the two groups (Figure 2D). The thickness of the basement membrane (15.5 ± 2.2 μm,
n = 8, p = 0.0002) and subepithelial layer (138.3 ± 12.2 μm, n = 8, p < 0.0001) in asthmatics with a fast
FEV1 decline was significantly increased (Table 3). However, the asthmatics with a slow FEV1 decline
had a thinner basement membrane and subepithelial layer.
Table 3. The thickness of airway structure in patients with asthma.
Airway Structure Asthma (n = 13) Slow FEV1 Decline Asthma (n = 8) Fast FEV1 Decline p Value
Epithelium, μm 27.2 ± 6.3 23.8 ± 7.4 0.733
Basement membrane, μm 7.0 ± 0.6 15.5 ± 2.2 0.0002
Subepithelium, μm 37.8 ± 4.2 138.3 ± 12.2 <0.0001
Data expressed as mean ± SEM.
3.4. Generation of MMP-9 and TIMP-1 From Macrophages
Most importantly, alveolar macrophages (AMs) from chronic asthma with a fast FEV1 decline
spontaneously released a higher amount of MMP-9 (8.52 ± 3.53 ng/mL, n = 8, p < 0.05) than those of
asthma with a slow FEV1 decline (0.99 ± 0.20 ng/mL, n = 13) or normal subjects (0.47 ± 0.20 ng/mL,
n = 10). The level of MMP-9 was significantly higher in asthma with a slow FEV1 decline compared to
normal subjects (Figure 5A). Compared with MMP-9, concentrations of the inhibitor, TIMP-1, were
higher in supernatants from normal subjects and asthmatic groups (Figure 5B). A significantly higher
level of TIMP-1 released from AMs into the culture medium in asthmatics with a slow FEV1 decline
over 5 years was observed when compared to that of asthmatics with a fast decline in FEV1 or normal
subjects (Figure 5B). When data are expressed as the molar ratio of enzyme to inhibitor, chronic
asthmatics with a fast FEV1 decline in 5 years had a significant increase in this ratio in AMs (Figure 6).
The ratio of MMP-9/TIMP-1 showed no difference between the normal subjects and those suffering
from chronic asthma with a slow FEV1 decline at the 5-year follow-up (Figure 6).
Figure 5. Individual concentration of (A) MMP-9 and (B) TIMP-1 spontaneously released from alveolar
macrophages after 24 h culture in normal subjects (open square, n = 10), chronic asthma with a slow
FEV1 decline (open circle, n = 13), and chronic asthma with a fast FEV1 decline in (solid circle, n = 8).
The significance is indicated.
44
J. Clin. Med. 2019, 8, 1451
Figure 6. Ratio of MMP-9 to TIMP-1. Data are expressed as the individual value of MMP-9 to TIMP-1
ratio in normal subjects (open square, n = 10), chronic asthma with a slow FEV1 decline (open circle,
n = 13), and chronic asthma with a fast FEV1 decline (solid circle, n = 8). The p values are presented.
The generation of MMP-9 released from AMs was positively associated with the annual decline
in FEV1 (r = 570, n = 21, p < 0.01) (Figure 7A). However, there was no correlation between the level
of TIMP-1 and the annual decline in FEV1 (Figure 6B). When the MMP-9/TIMP-1 ratios were plotted
against the magnitude of FEV1 change, the annual decline in FEV1 was significantly proportional to
the ratio of MMP-9/TIMP-1 (r = 0.584, n = 21, p < 0.01) (Figure 7C).
Figure 7. Correlation of the level of (A) MMP-9 and (B) TIMP-1 released from alveolar macrophages
(AMs) cultured for 24 h with the magnitude of FEV1 decline per year (mL/year) from patients with
chronic asthma receiving inhaled corticosteroids. (C) Correlation of the MMP-9/TIMP-1 ratio in 24 h
AM culture with the magnitude of FEV1 decline per year over 5 years from patients with chronic
asthma receiving inhaled corticosteroids.
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4. Discussion
We demonstrated that the levels of MMP-9 expression in the epithelium, inflammatory cells, and
submucosa as determined from immunostaining showed upregulation in asthmatic patients who
regularly received inhaled corticosteroids and who had a rapid decline in pulmonary function at 5-year
follow-up. The alveolar macrophages from these unstable asthmatics also spontaneously released
higher amounts of MMP-9. Most importantly, the MMP-9 level and MMP-9/TIMP-1 ratio produced
from AMs were significantly decreased in chronic asthma with a slow FEV1 decline. The higher levels
of TIMP-1 released from cultured AM were observed in clinically stable asthmatics. The magnitude of
annual FEV1 decline was proportional to the MMP-9 generation and the ratio of MMP-9/TIMP-1 released
from alveolar macrophages, even though the patients had regularly received inhaled corticosteroids.
An increased thickness of the basement membrane and subepithelial layer was observed in asthmatics
with a fast FEV1 decline. Taken together, MMPs (mainly MMP-9) and TIMP-1 may contribute to
progressive loss of lung function and increased cellular matrix fibrosis of the airway wall in chronic
asthmatics who demonstrated a poor response to anti-asthma treatments.
We reported that the generation of MMP-9 from alveolar macrophages and the ratio of
MMP-9/TIMP-1 are strongly associated with the magnitude of FEV1 decline in chronic asthma,
which is in agreement with the data of Vignola et al. [21]. The same authors have stressed the potential
importance of MMP-9 and TIMP-1 imbalance in asthma by showing that the basal airway caliber was
related to the ratio of MMP-9 to TIMP-1. It was reported that concentrations of MMP-9 in airway
neutrophils and BAL fluid revealed a significant correlation after allergen challenge [31]. We also
observed that the BAL fluid of asthmatics with a rapid decline in FEV1 exhibited a higher amount
of neutrophils, while that of stable asthmatics did not show an increased amount of neutrophils.
The cellularity of neutrophils in BAL was highly correlated to the annual FEV1 decline in asthmatics.
These observations raise the possibility that neutrophils may cause injury to the airway and result in
further remodeling of chronic unstable asthma, as has been suggested by studies showing persistent
bronchial neutrophilia in severe asthma and status asthmatics [32]. Our results strongly suggest
that alveolar macrophages and neutrophils may be important sources of MMP-9 release, leading
some asthmatic patients—who are poorly responsive to inhaled corticosteroid treatment—to develop
progressive irreversible airway scarring and fibrosis. Accordingly, an excess of MMP-9 release in the
airway was associated with impairment in the lung function of FEV1.
It is thought that the imbalance between MMPs and TIMPs may play an important role in the
process of the degradation and synthesis of the extracellular matrix of the airway. Hoshino et al. [33]
reported that deposition of the basement membrane matrix components—including collagen III,
collagen V, and tenascin—in asthma correlated to the upregulated expression of MMP-9 and, therefore,
airway remodeling in asthma could cause airflow obstruction and airway hyperresponsiveness.
As well as the consuming mechanisms of the extracellular matrix, MMP-9 may modulate cytokines
and other proteases [34]. MMP-9 may degrade alpha1-antitrypsin and preserve neutrophil elastase
activity [35], thus activating the function of fibroblasts [36]. In addition, the binding of MMP-9 to
CD44 can result in the release of TGF-β1 and, therefore, regulate extracellular matrix remodeling via
fibroblast activation [37]. MMP-9 may also potentiate angiogenesis by vascular endothelial growth
factor activation [34,38] and increase the production of angiostatin [39]. Our results showed increased
thickness in the submucosa and basement membrane, as well as higher expression of MMP-9 in chronic
asthma with rapid pulmonary function decline. The asthmatics with a fast FEV1 decline presented
with higher airway hyperresponsiveness. Therefore, macrophages from these unstable asthmatics may
release more MMP-9, leading to collagen deposition or neovascularization in the basement membrane
of airways and contributing to airway hyperresponsiveness.
The TIMPs could bind to MMPs and inhibit their enzymatic activity. In our study, alveolar
macrophages from chronic stable asthma patients responsive to inhaled corticosteroids released higher
amounts of TIMP-1 than those of chronic unstable asthma patients who do not respond to inhaled
corticosteroids or healthy subjects. Hoshino and colleagues [27] found that corticosteroid treatment can
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decrease the deposition of subepithelial collagen through downregulation of MMP-9 and upregulation
of TIMP-1 in asthma. In addition, a higher level of TIMP in stable asthma potentially helps the airways
to mitigate the degrading activities of MMPs [40]. Nevertheless, this process may restrict cell trafficking
and tissue repair, and may cause increased deposition of the extracellular matrix through in vivo
inhibition of MMP-9 or other MMPs. Russell et al. reported that the release and activity of MMP-9 and
TIMP-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease might
be important in the development of COPD because these cells exhibit increased levels of MMP-9
elastolytic activity [41]. Meanwhile, Russell et al. also reported that dexamethasone prevented the
increase in MMP-9 release, and increased TIMP-1 release. Similarly, alveolar macrophages released a
higher amount of MMP-9 in chronic unstable asthma patients than those with stable asthma or normal
subjects in our study (Figures 5 and 6). Asthmatic patients had higher cell counts of BAL, including
total cell counts, macrophage, lymphocytes, neutrophils, and eosinophils than those observed in
normal subjects in Table 2 and Figure 4. MMP-9 is known to be produced by several inflammatory or
structural cells, including bronchial epithelial cells, eosinophils, mast cells, and alveolar macrophages,
and these may have a greater contribution relative to neutrophils in chronic asthma. This means
that persistent airway or lung inflammation of chronic unstable asthmatics may be less responsive to
anti-asthma treatment, which may contribute to higher cellularity of inflammatory cells, thus leading
to the increased amount of MMP-9.
Although our patients have received inhaled corticosteroids for more than 5 years, some of these
patients still demonstrated a progressive decline in pulmonary function and persistent airway structure
change. A report showed that a high dose of inhaled corticosteroids did not change the levels of MMP-1,
MMP-9, and TIMP-1 in induced sputum [42], although other authors have described a significant
decrease in MMP-9 in the bronchial biopsies of asthmatics treated with inhaled corticosteroids [27].
Our results revealed that inhaled corticosteroids do not modify the expression of MMP-9 and TIMP-1 in
AMs in patients with chronic asthma exhibiting a rapid decline in FEV1. Thus, inhaled corticosteroids
cannot inhibit the airway remodeling of chronic asthma. Several reports have shown that neutrophil
levels may increase in the airways in severe asthmatics or in patients with chronic asthma who exhibit
a poor response to inhaled steroids [32,43]. Persistent generation of inflammatory products and their
inhibitors in chronic asthma may cause airway injury and remodeling. The mechanisms should be
further studied.
Previous reports revealed that MMP-9 increases in severe asthma [40,44], and that it may be the
cause of airflow obstruction through the induction of airway structural changes [45]. The persistently
high levels of MMP-9 indicate that the remodeling of airways may be initiated at the beginning of
asthma development and may be expressed as severe asthma.
Extensive studies have revealed the role of MMPs in the pathogenesis of asthma, airway
hyperresponsiveness (AHR), and asthma-associated airway remodeling [45,46]. MMP-9 was the first
MMP to be investigated in depth for its role in the development of asthmatic pathology and was also
the most highly expressed MMP in the BAL fluid and sputum of asthma patients [21,47]. Moreover,
the high level of MMP-9 expression in bronchial biopsies from asthmatic patients [48] was associated
with asthma severity [49] as well as the number of macrophages and neutrophils [50]. MMP-9 can
degrade elastin and type IV collagen [51], an important component of the basement membrane and,
thus, MMP-9 plays a role in the disruption of the basement membrane and contributes to increased
ECM deposition, subepithelial fibrosis, and airway wall thickness [52]. Airway remodeling related
to the thickness of the sub-basement membrane [45] has been linked to airway AHR and leads to
the subsequent development of fixed airflow limitation and to a long-term decline in lung function
in asthmatics [53]. Our recent study revealed that AMs produced excessive MMP-9 over TIMP-1,
which was associated with increased AHR and was a predictor of the development of accelerated
lung function decline [20]. Other MMPs, including MMP-1, -2, -3, or -12, are also studied as being
involved in asthma [6]. MMP-1 is activated by mast cell tryptase, leading to a proproliferative
extracellular matrix. The interactions of airway smooth muscle/mast cell contribute to asthma severity
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by transiently increasing MMP activation, thus inducing airway smooth muscle hyperplasia and
AHR [54]. The potentially pro-remodeling roles for MMP-1 are involved in the promotion of airway
smooth muscle proliferation. In stable mild-to-moderate asthma, MMP-2 in association with MMP-3 is
released from bronchial fibroblasts and may have a negative effect on lung function and AHR [55].
However, studies on MMP-9 and MMP-2 double-knockout mice revealed that MMP-9, and not MMP-2,
is the dominant airway MMP controlling inflammatory cell egression [56]. Although MMP-12 is
suggested to be involved in asthma, this conclusion is based on studies in which mostly animal models
are used [6]. In humans, the MMP-12-mediated pathological degradation of the ECM is associated
with COPD patients [57]. Our study aimed to investigate whether the MMP released from AM was
associated with AHR and increased expression in airways, thus contributing to subepithelial thickness
and accelerated lung function decline. Therefore, our study focused on MMP-9. Nevertheless, a greater
understanding of the involvement of MMPs in airway remodeling in asthma is indispensable and,
thus, further studies are needed to examine the expression of other MMPs in airways and BAL fluid as
well as their release from AMs.
Limitations
Alveolar macrophages are the predominant immune cells in the lung and are represented by
the classically activated (or M1) and the alternatively activated (or M2) phenotypes according to
their function [58]. Increased polarization and activation of M2 macrophages, which was induced
by interleukin (IL)-4 and IL-13, are found in asthma and are suggested to be involved in asthma
pathogenesis [59,60]. A previous study has shown that activation of M1 or M2 macrophages may
upregulate a distinct group of MMPs and TIMP-3 [61]. A group of matrix metalloproteinases also
influences M1/M2 polarization of macrophages [62]. However, our study did not investigate the
association of MMP-9 with M1/M2 polarization in the asthma with accelerated lung function decline.
Therefore, to understand the causal relationship of MMP-9 and M1/M2 macrophage activation in the
development of airway remodeling in asthma, the macrophage polarization in BAL and airway tissue
should be addressed in future studies.
5. Conclusions
We concluded that there was an increase in MMP-9 and MMP-9/TIMP-1 in airways and alveolar
macrophages from chronic asthmatics with a rapid FEV1 decline, despite having been regularly treated
with inhaled corticosteroids. An increase in MMP-9 and MMP-9/TIMP-1 in airways or AMs could
contribute to a greater decline in lung function in cases of chronic asthma and could therefore be used
as an indicator of chronic airway inflammation.
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Abstract: A growing body of evidence implicates the human microbiome as a potentially influential
player actively engaged in shaping the pathogenetic processes underlying the endotypes and
phenotypes of chronic respiratory diseases, particularly of the airways. In this article, we specifically
review current evidence on the characteristics of lung microbiome, and specifically the bacteriome,
the modes of interaction between lung microbiota and host immune system, the role of the “lung–gut
axis”, and the functional effects thereof on asthma pathogenesis. We also attempt to explore the
possibilities of therapeutic manipulation of the microbiome, aiming at the establishment of asthma
prevention strategies and the optimization of asthma treatment.
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1. Introduction
Asthma is the most common chronic respiratory disease, affecting more than 300 million people of
all ages worldwide and killing about 250,000 of them each year [1], posing a substantial socioeconomic
burden, especially in low- and middle-income countries. Asthma is a multifactorial and heterogeneous
disease, comprising several different disease “phenotypes” and “endotypes” [2–4]. The current
approach acknowledging that different phenotypes may share a common endotype and vice versa and,
more important, that the disease phenotype may change over time has boosted our understanding on
asthma pathogenesis and facilitated the development of novel targeted biological therapies, especially
where they are most needed—that is severe corticosteroid-insensitive asthma [5]. However, while highly
effective biologics are now available, and several more are in the pipeline for severe uncontrolled
asthmatics with the Th2-high endotype [6], an almost-empty therapeutic arsenal is the case for those
with the Th2-low endotype. Moreover, given the fact that Th2 inflammatory markers are absent in up
to 50% of asthmatic patients (although an even higher corresponding percentage of 76% was reported
in a very recent randomized controlled trial of patients with mild persistent asthma) [7,8], it is clear that
further research is urgently needed to shed light on the biological pathways leading to non-eosinophilic
asthma and, thus, promote the discovery of new treatment strategies for this large group of patients.
A growing body of evidence implicates the human microbiome as a potentially influential player
that is actively engaged in shaping the pathogenetic processes underlying the aforementioned and
other unresolved issues both in asthma [9,10] and in the other chronic respiratory diseases, particularly
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of the airways [11–13]. In contrast to earlier beliefs, a well-developed metabolically active microbial
community, termed lung microbiota, resides in the lower respiratory tract of healthy humans. The entire
habitat, including the microorganisms (bacteria, archaea, lower and higher eukaryotes, and viruses),
their genomes (i.e., genes), and the surrounding environmental conditions are defined as the lung
microbiome [14]. The latter is involved in a constant cross-talk with the host, and the same applies for
the other bacterial communities residing in and on the human body, as well, with the most prominent
being the gut microbiota, forming the “gut–lung axis” [15]. The diverse mechanisms mediating this
cross-talk are now being gradually recognized. Under normal conditions; the interaction between the
microbiota and the host confers mutual benefits for both (“symbiosis”). However, we are becoming
increasingly cognizant of the fact that lung microbiota composition and diversity are affected in
disease (including asthma) and that these changes can be translated in altered host immune responses,
influencing asthma susceptibility, phenotype, exacerbation pattern, and treatment responsiveness
(“dysbiosis” instead of “symbiosis”).
In this article, we review current evidence on the characteristics of lung microbiome, the modes of
interaction between lung microbiota and host immune system, the role of the “lung–gut axis” and
the functional effects thereof on asthma pathogenesis. We also attempt to explore the possibilities
of therapeutic manipulation of the microbiome, aiming at the establishment of asthma prevention
strategies and the optimization of asthma treatment.
2. Microbiome
2.1. Historical Perspectives
The perception of the existence of bacteria inhabiting certain parts of the human body without
causing disease is not new. For decades, diverse microbial genera were isolated after in vitro cultivation
of biological samples collected from healthy individuals. However, the sensitivity of these traditional
culture-dependent microbiological methods was severely limited. For instance, in an early study,
it was estimated that only 24% of the entire microbiota present in an adult male fecal sample could be
recovered by cultivation [16]. Using a variety of media and incubation methods, the corresponding
sensitivity of in vitro cultivation for bacterial species identification in bronchoalveolar lavage samples
of healthy individuals was substantially higher (61%), but it was still limited [17]. However, the exact
role and teleology of this “normal (micro) flora” remained largely unknown, although it was postulated
that changes in its composition could be detrimental, as in the case of antibiotic-induced Clostridium
difficile overgrowth in the large intestine of patients with pseudomembranous colitis [18]. The advent
of novel molecular techniques for microbiological profiling, with the most important being the
implementation of polymerase chain reaction (PCR) amplification and sequencing of the highly specific
and ubiquitous among bacteria 16S-rRNA gene, led to a tremendous progress in our understanding of
the extent, diversity, composition, and location of the sum of microbial communities living inside or
on the human organism (now termed microbiota instead of normal flora) [19]. Large-scale research
collaborations, such as the two phases of the Human Microbiome Program (HMP), funded by the US
National Institutes of Health (NIH), and the Metagenomics of the Human Intestinal Tract (MetaHIT)
project, funded by the European Community, established enormous reference databases of human
microbiota genomes and metagenomes, after analyzing dozens of thousands of samples derived from
48 primary sites (mostly feces) in hundreds of healthy individuals and patients with specific conditions
or disorders [20–24]. Based on these advances, it is now estimated that human microbiome consists of
approximately 3.8 × 1013 bacteria, probably marginally outnumbering human cells (3 × 1013 for the
standard age and somatotype) [25,26]. As expected, the microbial community residing in the gut is
the most abundant, comprising slightly more than 1000 bacterial species [24,27]. These commensal
bacteria harbor about 3.3 million genes, surpassing in number the genes contained in the host genome
by approximately 150 times [24]. It soon became evident that this incredibly rich microbial ecosystem
could not be uninvolved in the biological processes underlying health and disease. Further evolution
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in molecular biology, namely the emergence of “-omics” technologies (genomics, transcriptomics,
proteomics, and metabolomics), have now enabled the investigation of the functional effects of human
microbiome by detecting and studying the functional genes encoded by the microbial community and
their products (proteins, metabolites etc.) [19].
Amplicon-based sequencing of marker genes, such as 16S rRNA, is a powerful tool for assessing
and comparing the structure of microbial communities at a high phylogenetic resolution. Because
16S rRNA sequencing is more cost-effective than whole-metagenome shotgun sequencing, marker
gene analysis is frequently used for broad studies that involve a large number of different samples.
With the expanded use of 16S rRNA sequencing for resident microbiota recognition on different human
surfaces, organs such as the lungs, the stomach, and the uterus, previously considered sterile based on
culture-dependent studies, were shown to host a substantial microbial burden under normal conditions.
These findings gave birth to the notion of lung microbiome and primed tenacious research endeavors
for its characterization.
2.2. The Lung Microbiome in Health
2.2.1. The Early Life Shaping
Although not specifically studied in humans, the development of the lung microbiome probably
adheres to that of the rest of the human body microbial ecosystem. The exact starting time point for
the bacterial colonization of the human body cannot be accurately determined. Until recently, amniotic
fluid, which fills fetal lungs prenatally, was considered sterile. This historical belief was challenged by
the discovery of bacterial DNA in amniotic fluid and placental samples [28], which may be suggestive
of a prenatal initiation of lung microbial colonization and development, although the actual existence of
an amniotic fluid microbiome remains controversial [29] and its potential significance vastly unknown.
Detectable microbial communities in multiple body sites have been identified in newborns as early as
<5 min after delivery, and their synthesis initially resembles the maternal vagina or skin microbiota
composition, depending on the mode of delivery (vaginal or caesarian section) [30]. This premature
microbiome has been shown to change in composition and diversity and mature functionally during
the first two to three years of life, after which it gradually stabilizes to a pattern closely matching
that of adults [31–33]. This early life microbiota instability, probably in parallel with the concurrent
immune system immaturity, is believed to render microbiome particularly susceptible to the influence
of diverse environmental factors, including diet (e.g., breastfeeding), day care, crowding, and antibiotic
use [34,35], which ultimately shape the structure of the adult human microbiome and, presumably,
confer predisposition or resistance to disease (“window of opportunity” theory) [36] (see Figure 1).
A similar trajectory of diversity and composition changes with increasing age has recently been
described in the lung microbiota of mice [37].
2.2.2. The Immigration/Elimination Balance
The synthesis of any bacterial (or other living organism) community at any given time is dictated
by the interaction between three factors: (1) immigration, (2) elimination, and (3) local reproduction of
community members (see Figure 2).
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Figure 1. The natural history of microbiome development.
Figure 2. Factors determining the immigration/elimination balance.
With regard to lung microbiome, immigration mostly originates from subclinical micro-aspiration
from the upper respiratory tract (URT), although other sources, including the inspired air (which carries
approximately 105–106 bacteria/m3) [38], and the upper gastrointestinal tract via aspiration of gastric
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contents [39], may also make minor contributions. The elimination of lung microbial community
members can be assumed to be mediated by the complete armory of lung defense mechanisms,
including cough reflex, mucociliary clearance, and innate and adaptive immunity [40], and, thus,
to depend on its effectiveness. In health, the balance between dispersal of microbes from the URT
and eradication of lung microbial community members via local defense mechanisms is considered
the major determinant of lung microbiome characteristics, whereas local bacterial reproduction most
probably plays a rather minor role. The URT as the major source of lung microbiome is strongly
supported by data showing a close resemblance between upper and lower respiratory tract (LRT)
microbiome composition in healthy individuals [41–43]. Further corroboration of these results comes
from the study of Venkataraman et al., demonstrating that lung microbiome composition in healthy
individuals could be best attributed to neutral dispersal of microbes from the oropharynx rather than
active local bacterial selection in the lungs [16]. Even more so, in a study investigating the possibility of
spatially determined intrapulmonary discrepancies in the characteristics of lung microbiome, Dickson
et al. showed that microbial richness and Firmicutes phylum abundance in the right upper lobe
was more similar to those of the supraglottic region compared with the other lung lobes sampled,
in which microbiome is practically identical [44]. Given the closer vicinity of the right upper lobe to
the URT, these findings suggest that not only is the LRT microbiome directly related to that of the
URT, but also this association is probably inversely proportional to the distance from the oropharynx
(i.e., the more proximal to the oropharynx, the closer the microbiome resemblance). Conversely,
if intrapulmonary bacterial growth was a major determinant of lung microbiome synthesis, significant
intra-subject variations in the microbiome characteristics of different lobes should have been expected,
given the well-established between-lobes disparities in local growth conditions (e.g., oxygen tension,
pH, temperature) [45]. This was not the case in the study of Dickson et al, in which all parts of the lung
located distally from the URT, irrespective of exact lobe, had practically identical microbiome [44].
2.2.3. Composition and Structural Features
In contrast with the microbial communities residing in other parts of the human body,
our knowledge on normal lung microbiome features, in terms of its development, composition
(particularly at the genus and species levels), functional effects, and their determinants remains largely
incomplete. To some extent, this reflects sampling difficulties, resulting in most relevant studies
suffering from small-size limitations and lack of longitudinal data [13].
Lung microbiota is a relatively small bacterial community. Based on the findings of studies
applying 16S rRNA sequencing in endobronchial brushing (EB) samples from healthy and diseased
individuals, it is estimated that there are on average 103–105 bacterial genomes (or 16S copies) per cm2
of bronchial tissue sampled, although with significant inter-subject variability [41,46]. Comparatively,
colon microbiota, which is the most abundant microbial ecosystem in the human body, comprises up
to 1011 CFU/gr of luminal content [47]. In a study evaluating the associations between the diverse
microbial communities of the aero-digestive tract, bacterial density in bronchoalveolar lavage (BAL)
fluid was found to be 100- to 1000-fold and 10- to 100-fold lower than in oral washes and gastric
aspirates, respectively, of the same healthy subjects [43]. Sequencing of these 16S rRNA genes
and comparison with established microbial genomic databases have led to the identification of 38
bacteria phyla, with 303 [48], or even more [49], genera residing in the human lung. However,
these are far from equally represented with the top six phyla and the top 25 genera accounting for
86% and 65%, respectively, of all sequences identified [48]. Specifically, Bacteroidetes and Firmicutes are
the most abundant phyla in the lung microbiota of healthy humans, followed by Proteobacteria and,
to a lesser extent, Actinobacteria and Fusobacteria [41,43,46,48,50]. At the genus level, Prevotella, Veillonella,
and Streptococcus are generally considered the most dominant taxa [41,42,46,51], although there is
substantial variation in the relevant abundance of lung commensal microbes between studies and
Neisseria, Haemophilus, Fusobacterium, or other genera (e.g., Actinomyces, Porphyromonas, and Lactobacillus)
are occasionally found in comparable counts [42,46–49,52]. Although these discrepancies are probably,
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at least in part, due to the small sizes of the relevant studies, the presence of considerable inter-subject
variability in lung microbiota composition has been documented in healthy individuals [44,52], so that,
to date, it is not possible to define a typical (“normal”) lung microbiome.
2.3. Potential Effects of Sampling Methods on the Assessment of Lung Microbiome Structure
The study of lung microbiota parameters requires bronchoscopy for BAL or EB samples acquisition.
Induced sputum analysis may be a less invasive alternative, although differences in bacterial
composition of sputum samples compared with those retrieved by bronchoscopic techniques, as a result
of contamination by the rich oral/oropharyngeal microbiota, have been well documented [49]. Moreover,
there is a certain degree of uncertainty surrounding putative effects of the specific bronchoscopic
technique used for sampling on the characteristics of the derived microbiota. Denner et al. reported
significant discrepancies in the extent, diversity, and relative affluence of the retrieved microbial
communities between BAL and EB bronchoscopic sampling, the latter being associated with a denser
and more diverse microbiome [48]. An earlier study comparing the microbial communities sampled by
multiple respiratory tract sites of healthy individuals, demonstrated that the bacterial population of the
left lower lobar bronchus retrieved by EB was generally larger than the populations of the right middle
lobe segmental bronchi, which were sampled by consecutive BALs, although no differences were
found in the corresponding bacterial communities’ composition [41]. Other researchers have ruled out
bronchoscopic-technique-specific effects on the lung microbiota synthesis after applying both BAL
and EB in contralateral lobes of healthy volunteers [44]. Although the reported discrepancies could be
merely the result of differences in the nature of the samples (and in the modes of their acquisition),
along with small study sizes, they might also represent a shift in the microbiota characteristics of
the small peripheral airways and the lung parenchyma (sampled by BAL) compared with the more
proximal bronchi (sampled by EB). Until further research addresses these issues and establishes
a standardized technique for lung microbiota derivation, sampling methods should be taken into
account when designing or evaluating the results of human lung microbiome studies.
2.4. Spatial Discrepancies in the Structure of Lung Microbiome
Some degree of spatially dependent intra-subject variability in lung microbiota features has been
demonstrated, although this is substantially more limited than the aforementioned between-subjects
variability [44]. Specifically, it has been shown that the right upper lobe microbial community richness,
composition, and variation are all significantly different from those of more distal parts of the lungs (left
upper lobe, right middle lobe, and lingula) of the same healthy individuals and more closely resemble
the upper respiratory tract microbiota [44]. Finally, it should be mentioned that, in contrast with the gut
microbiome which has been shown to present significant geographical variation possibly associated
with the regional lifestyle [32], there are no data suggesting a similar trend in lung microbiome. Despite
the lack of direct comparisons between populations from different parts of the world, no dissimilarities
have been found in the lung microbiome of HMP initiative participants from eight different US
cities [42] and, to date, the relatively few studies conducted in non-Western populations do not seem
to yield different results from the majority of lung microbiome studies, which have generally been
confined to the Western world [53,54].
Cross-Talk between Lung Microbiota and the Host
The host immune system is primarily responsible for the conduct of most of the host–microbiome
interplay, and there is now a growing body of evidence establishing the presence of an active
and multiform cross-talk between the lung microbiome and the host immune system [11]. Invading
pathogens activate the inflammasomes (multi-meric protein complexes) both directly and indirectly [55],
to produce inflammasome associated pro-cytokines (IL-18, IL-1β), after the recognition of the pathogens
by a family of receptors through pathogen-associated molecular patterns (PAMPs) [56]. Structural
components of the bacterial cells and LPS (a ubiquitous structural component of Gram-negative
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bacteria outer membrane) are ligands for the pattern recognition receptors (PRRs) expressed by the
host antigen-presenting cells. Upon stimulation, PRRs (with Toll-like receptors (TLRs)-2 and -4 being
the principle representatives) may trigger diverse cellular processes regulating immune responses in
the lung. Importantly, these responses appear to be bacterial species- or genus-specific, underscoring
the potentially significant effects of lung microbiome composition alterations on the host immune
regulation (see Figure 3).
Figure 3. Respiratory microbiota produce metabolites (SCFAs, NO, or nitrite, aromatic amino acids),
which influence host immune activity. Inflammasome-associated pro-cytokines can be produced and
activated by a family of receptors which detect the presence of pathogens through PAMPs. SCFA: short
chain fatty acids; NO: nitric oxide; AAs: aromatic amino acids; TLR: Toll-like receptors; ROS: reactive
oxygen species; PAMP: pathogen associated molecular patterns; MMP: matrix metalloproteinase; MDC:
macrophage-derived chemokine; MIP1α: macrophage inflammatory protein 1α.
Interspecies differences in LPS structure are thought to account for the corresponding variations
in TLR subtype specificity and lung inflammatory capacity [57,58]. The Bacteroides Prevotella, one of
the most abundant genera in the healthy lung microbiome, appears to exhibit a TLR2-dependent low
inflammatory potential, whereas the Proteobacteria Haemophilus influenzae and Moraxella catarrhalis,
linked with lung microbiome alterations in asthma and COPD, induce severe TLR2 independent (and
probably TLR4-dependent) lung inflammation and injury in mice [57]. Other potentially pathogenic
Proteobacteria residing in the lung, such as Pseudomonas aeruginosa, Stenotrophomonas maltophilia,
and Burkholderia spp, possess flagella, the major structural component of which flagellin is recognized
by host TLR5, leading to the induction of pro-inflammatory mediators’ secretion [59]. Bacterial DNA
may also stimulate host immune responses. This effect is mediated by the abundant in bacterial DNA
sequences unmethylated CpG dinucleotides, which bind to the host TLR9, inducing an inflammatory
response of the T-helper-1 (Th1) type [60]. Furthermore, all four major phyla of the lung microbiome
(Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria) have been shown to stimulate NOD2
receptors in vitro, and this effect is mediated by the bacterial cell wall component peptidoglycan [61].
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Beyond structural microbial components, resident microbes-derived metabolites are also believed
to be actively involved in the interplay between lung microbiome and the host immune system.
Short-chain fatty acids (SCFAs) and amino acids metabolism products are the most extensively studied
metabolites generated by human microbiota. SCFAs, such as butyrate, propionate, and acetate, are the
main end-product of dietary fiber fermentation undertaken by the gastrointestinal tract microbiota.
However, there are also data implying SCFAs production from lung microbiota, since active expression
of bacterial genes associated with SCFAs metabolism has been described in bronchial brushings [62].
SCFAs have been implicated in numerous mechanisms promoting maintenance of homeostasis in health,
including preservation of gut barrier integrity, control of appetite and energy intake, protection against
autoimmunity and tumorigenesis in colon, and regulation of blood–brain barrier permeability, among
others [63,64]. Importantly, they have also been shown to possess immunomodulatory properties [64,65].
The latter are mediated by G protein coupled receptors, particularly GPR41, GPR43, and GPR109a,
which are all expressed on the surface of most types of inflammatory cells (macrophages/monocytes,
dendritic cells, and neutrophils), as well as by direct inhibition of histone deacetylases (HDACs) [63–65],
i.e., enzymes actively participating in post-translational modifications of the histones-DNA interaction
inside the chromatin structure that regulates cell transcriptional activity and gene expression [66].
The principal immunomodulating effect of SCFAs appears to be the induction of differentiation and
proliferation of extra-thymic regulatory T cells (Tregs) [67–69], a lymphocyte subset with established
anti-inflammatory and anti-allergic effects [70,71]. Apart from the SCFAs, indole-3-acetate, a metabolite
of the amino acid tryptophan produced by gut microbiota, was recently shown to attenuate LPS-induced
pro-inflammatory cytokine and chemokine secretion in alveolar macrophages derived from smokers,
and this observed anti-inflammatory action of indole-3-acetate was hypothesized to potentially mediate
the effect of azithromycin on lowering exacerbation rates in COPD patients [72]. Indole-3-acetate
and the other tryptophan metabolites are activators of the aryl hydrocarbon receptor [73], another
well-known modulator of inflammation and immunity, with a proposed role in Treg generation [74].
We previously focused on microbiota-derived mediators engaged in shaping diverse aspects of
host immune response. It must be realized that the opposite is most probably also valid. This means
that numerous signaling molecules originating from host cells can be sensed by resident microbes
and are capable of modifying the composition and diversity of lung microbiome. Indeed, there are
data from several in vitro studies demonstrating potential influences of catecholamines and cytokines
on the growth and virulence of various bacterial strains, perhaps with a species- or genus-specific
manner [75–79]. This host-to-microbiome signaling pathway may be implicated in respiratory disease
pathogenesis by contributing to lung microbiome alterations favoring the dominance of specific
potentially pathogenic species. In this context, it has been shown that increased intra-alveolar levels of
the catecholamines epinephrine and norepinephrine in BAL samples from lung-transplant recipients
are significantly associated with both indices of acute infection and reduced lung microbiome diversity,
characterized by the predominance of a single bacterial species, notably Pseudomonas aeruginosa [80].
2.5. Microbiome and Asthma Susceptibility
The “Gut–Lung Axis” and the Hygiene Hypothesis
Accumulated evidence arising from both human and animal studies suggests that the development
of allergic diseases, including asthma, may, in fact, be dependent on the bacterial communities residing
in the gut. Gut microbiota actively interact with the host immune system via bacterial structural
components and secreted metabolites, and these interactions possess the ability to modulate immune
responses both locally in the gastrointestinal tract and systemically, influencing various distal sites,
including the lungs. The term “gut–lung axis” has been coined to account for these effects of gut
microbiota on lung immunity, both in health and in disease [81] (see Figure 4).
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Figure 4. The “lung–gut” axis interactions with host immunity. TLR: Toll-like receptors; Treg:
T regulatory cell; MDC: macrophage-derived chemokine; MIP1α: macrophage inflammatory protein 1α.
The presumable involvement of resident microbiota in allergic asthma development is primarily
supported by data showing an exaggerated Th2 immunity-driven airway inflammation in germ-free
(GF) mice sensitized with ovalbumin compared with specific pathogen-free (SPF) counterparts,
which can be abrogated when GF mice are recolonized by the commensal flora of the SPF animals prior to
sensitization [82]. Likewise, gut microbiota disruption as a result of antibiotics administration promotes
allergic airway disease in experimental murine asthma [83,84]. Importantly, antibiotic-induced
long-term alterations in gut microbiota diversity and composition have also been observed in
humans [85–87] and both early life and maternal antibiotic use have been associated with an increased
risk for recurrent wheeze and asthma development in childhood [88,89]. Aside from antibiotic
exposure, formula feeding [90,91] and Caesarian-section delivery [92,93] have been correlated both
with differences in infant gut microbiota composition and with a heightened childhood asthma
susceptibility compared with breastfeeding and vaginal delivery. Other exposures operating in early
life, when the microbiome and the host immune system are both in the process of maturation, might also
be relevant (see Figures 1 and 5). For instance, living with dogs or cats as pets during the first year
of life has been linked to a decreased prevalence of atopy at age six to seven [94], and dust from
households with dogs has been shown to enrich cecal microbiota, together with downregulating
Th2-mediated airway inflammation in a murine model of allergic sensitization [95]. Fujimura et al. [95]
elegantly showed that exposure to pets may be associated with distinct gut microbiota composition
characteristics conferring protection against airway allergen challenge [95]. Specifically, the cecal
microbiome of mice exposed to dust derived from households with dogs was significantly enriched
in Firmicutes compared with mice exposed to dust from residencies without pets, with Lactobacillus
johnsonii being the most dominant taxon.
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Figure 5. Early life exposures that may affect the symbiosis/dysbiosis balance and predispose to asthma.
The relative microbial diversity of the environment and the level of exposure during the first
years of life have also been highlighted as important factors influencing subsequent allergy and
asthma susceptibility. Several studies from around the world have consistently demonstrated that
children growing up in rural settings with high-level exposure to bacterially enriched farming
environments presented significantly lower rates of atopic asthma compared with their non-farm
peers [96]. In a landmark study published in 2016, 60 schoolchildren from two reproductively isolated
US agricultural communities, the Amish and the Hutterites, sharing strong similarities in terms of
genetic background and lifestyle, but with diametrically opposite farming practices, were examined [97].
The children of the Amish, who practice a traditional type of farming, presented a significantly lower
rate of allergic sensitization compared to those of Hutterites, who use highly industrialized farming
infrastructure, and no asthma cases were identified among Amish, in contrast to the six asthmatic
Hutterite children.
Short-chain fatty acids (SCFAs) have been proposed as pivotal mediators of the gut–lung interplay.
Knockout mice lacking the gpr43 receptor gene have been shown to present an exaggerated allergic
airway inflammatory response upon ovalbumin challenge [98]. In a landmark study, Trompette et
al. demonstrated that the dietary fiber content may influence the extent of allergic inflammatory
changes in the lungs via SCFAs-mediated defects in DC activation, leading to an impaired Th2
cell differentiation [99]. Interestingly, they showed that high-fiber diet attenuated Th2-driven lung
inflammation, as assessed by total and differential cell count in BAL fluid, Th2 cytokines mRNA
levels in lung tissue, serum total IgE, metacholine challenge, and lung histological analysis. On the
contrary, low-fiber diet aggravated allergic inflammation in the lungs. Furthermore, the administration
of SCFAs to mice through drinking water led to an acceleration of Th2 inflammation resolution in
propionate-supplemented wild-type mice compared with un-supplemented controls, which was
abrogated in a separate group of GPR41-dedicient mice. These results indicate that circulating SCFAs
(propionate in particular) produced by gut resident bacteria in direct proportion to the dietary fiber
content may reduce susceptibility to allergic airway disease through the activation of the GRP41 receptor.
2.6. The Lung Microbiome in Asthma
During the last decade, an ever-growing number of studies have attempted to shed light on the
features of lung microbiome in patients with asthma [46,48,50,62,100–108]; however, the small sample
sizes, the lack of uniformity and standardization in the selection and processing of respiratory samples
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used for microbiome characterization in asthma, the scarcity of data on potential longitudinal changes
in lung microbiome composition during the course of the disease and in association with treatment
implementation, and finally, the absence of a clearly described ‘normal’ lung microbiome with which
comparisons can be safely made pose limitations to the complete delineation and interpretation of lung
microbiome in asthmatic patients. Despite these caveats, studies investigating the lung microbiome
in asthma have been relatively successful in capturing microbiome alterations in a large part of the
spectrum of disease severity and phenotypes, thus providing an initial premature understanding of
a potential association between features of lung microbiome and specific disease characteristics.
Alterations of Lung Microbiome Structure in Asthma
The most constant finding of lung microbiome studies in asthma is probably an observed
increase in the relative abundance of the Proteobacteria phylum in asthmatic lungs [9,46,62,106–109].
At the genus level, this change is seemingly driven by a corresponding increase in the prevalence
of Haemophilus and/or Neisseria [46,62,103,105–107], although other potentially pathogenic genera
belonging to the Proteobacteria phylum, such as Moraxella, Pseudomonas, and members of the
Enterobacteriaceae family, might also be involved [48,103,106,108]. It appears, though, that this
Proteobacteria expansion is rather specific to non-severe asthma, as studies directly comparing
non-severe with severe asthmatics have demonstrated distinct patterns of lung microbiome composition
in these two groups, with Proteobacteria dominating in the lung microbiome of non-severe asthmatics,
while other phyla, possibly Actinobacteria [108] or Firmicutes (mainly Streptococci) [106], are more
prevalent in severe asthma. However, an increased relative abundance of certain Proteobacteria,
such as the Pseudomonadaceae and Enterobacteriaceae (most notably Klebsiella spp), has also been reported
in severe asthma patients [104,108].
Other taxa, e.g., the common respiratory commensals Prevotella and Veillonella, have generally
been shown to be less common in the lung microbiome of patients with both severe and non-severe
asthma [46,48,50,106], although these findings are not universal [62]. Overall, asthma-associated
alterations in lung microbiome composition are significantly less firmly determined at the genus level
compared with the phylum level, possibly reflecting, at least in part, the corresponding variations
described in the lung microbiome composition of healthy individuals.
The relationship between asthma and lung microbial community diversity is even more
controversial. Earlier studies in patients with mild asthma have reported an increased bacterial
burden and diversity in induced sputa and EBs compared with healthy individuals [101,102]. In line
with these observations, Durack et al. found a marginally increased phylogenetic diversity in EB
samples retrieved from 42 asthmatic patients compared with 21 healthy controls [62]. Likewise,
Sverrild et al. showed bacterial diversity augmentation in BAL fluid specimens from 23 patients with
non-eosinophilic asthma [107]. On the contrary, other studies having included patients with more
severe or corticosteroids refractory disease failed to replicate these findings and occasionally came up
with opposite results [50,105,106,108].
2.7. The Potential Role of Lung Microbiome in Shaping Asthma Phenotypes and Endotypes
Several clinical, physiological, and inflammatory characteristics involved in the definition of
asthma phenotypes (and, to a lesser extent, endotypes) [3] have been linked with features of lung
microbiome (see Figure 6).
63
J. Clin. Med. 2019, 8, 1967
Figure 6. Implication of lung microbiome in asthma. TNF: Tumor necrosis factor; IL: Interleukin;




Lung microbiota diversity and composition have been investigated in patients with both severe
and non-severe eosinophilic asthma and compared with the corresponding features in non-eosinophilic
asthma. In a cohort of mild corticosteroid (CS)-naïve asthma, Sverrild et al. reported increased
α-diversity (a measure of bacterial taxa richness and evenness) and decreased β-diversity (an index of
heterogeneity between bacterial communities) in the BAL microbiome of eosinophil-high asthmatic
patients compared with eosinophil-low ones [107]. At the same time, various genera were significantly
enriched (e.g., Aeribacillus, Halomonas, and Sphingomonas) or depleted (e.g., Neisseria, Bacteroides,
and Actinomyces) in eosinophil-high as opposed to eosinophil-low asthma. On the contrary, in another
cohort encompassing patients with both severe and non-severe asthma, the Actinomycataceae family
members were significantly more abundant in eosinophilic compared with non-eosinophilic, asthma
and their relative abundance was positively associated with the eosinophil count in sputa [108].
Tropheryma whipplei has also been identified as a prevalent member of the lung bacterial community in
severe asthmatic patients of the eosinophilic inflammatory phenotype [105].
Instead of directly comparing lung microbiome composition in patients with eosinophilic and
non-eosinophilic asthma, other groups have focused on the investigation of potential associations
between features of microbiome and markers of eosinophilic airway inflammation. Eosinophil
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infiltration of bronchial tissue and eosinophil count in BAL fluid have been associated with lower
total bacterial loads and diversity in EB samples from patients with mostly severe asthma [48,104].
Particularly, Rickettsia and certain Actinobacteria have been positively correlated with lung eosinophilia,
whereas taxa negatively correlated mostly belong to Proteobacteria (including Moraxellaceae) and
Firmicutes [48,104]. The bronchial epithelial cell expression of specific genes known to be involved
in the Th2-mediated immune response (CLCA1, SERPINB2 and POSTN) has also been examined in
relation to lung microbiome composition [62,104]. These three gene expressions correlated negatively
with total bacterial burden and relative abundance of certain taxa, including the previously mentioned
Moraxellaceae [62,104].
Despite significant variability and, to some extent, rather contradictory results between studies,
these data strongly support the existence of distinct features of lung microbiota burden, diversity,
and composition in patients with the eosinophilic asthma subtype. Overall, it appears that both
the eosinophilic inflammatory phenotype and the underlying Th2-high endotype correspond to
lung microbial communities with comparatively low bacterial load, substantial diversity but limited
heterogeneity, and possibly increased representation of Actinobacteria (perhaps most notably of the
Actinomyces genus) and decreased representation of certain Proteobacteria (potentially including
Moraxella sp) [110].
Neutrophilic Inflammation
Neutrophilic asthma, along with the paucigranulocytic inflammatory phenotype, belongs to the
non-Th2 (or Th2-low) asthma endotype and Th1 and/or Th17 immune processes have been implicated
in its pathogenesis [109,111], although therapeutic targeting of neither Th1- nor Th17-related cytokines,
namely anti-TNFa [112] and anti-IL17A receptor agents [113], have proved effective. On the other
hand, certain bacterial pathogens are established triggers of Th17-driven immune responses [114],
and there are some data showing reduction of neutrophilic inflammatory markers (primarily IL-8)
and quality-of-life improvement following treatment with clarithromycin in patients with severe
refractory non-eosinophilic asthma [115]. These observations have drawn attention to the investigation
of potential associations between lung microbiome and neutrophilic asthma in particular. In the
most recent and largest to-date study of lung microbiome in asthma, Taylor et al. classified 167
patients with moderate-to-severe asthma in eosinophilic, neutrophilic, paucigranulocytic, and mixed
granulocytic inflammatory phenotypes based on induced sputum differential cell count percentages
and searched for interphenotype dissimilarities in sputum bacterial diversity and composition [110].
Although limited by the uneven distribution of participants across the different phenotypes (only 14
had neutrophilic asthma), the study provided evidence for a significantly decreased bacterial diversity,
along with increased heterogeneity in patients with neutrophilic compared with both eosinophilic
and paucigranulocytic asthma. This was accompanied by a strong inverse correlation between
phylogenetic diversity and neutrophil percentage in sputum. Haemophilus and Moraxella genera were
found enriched in neutrophilic asthma samples and significantly correlated with asthma inflammatory
profile, with the opposite being the case for Streptococcus. In line with these results, Simpson et al. also
demonstrated a decreased bacterial diversity in induced sputa collected from patients with severe
neutrophilic compared with non-neutrophilic asthma in an earlier study [105]. Again, Proteobacteria,
particularly Haemophilus influenzae, was the phylum dominating in the neutrophilic airway microbiota,
with a relative depletion of Actinobacteria and Firmicutes. Similarly, others have shown positive
correlations between Moraxella catarrhalis, Haemophilus sp, and Streptococcus sp total abundance and
sputum neutrophils percentage and IL-8 concentration in severe asthma [103].
Although observational, and thus not establishing causality, these studies may support a case
for lung microbiota dysbiosis in the pathogenesis of neutrophilic asthma. It appears that the LRT of
asthmatic patients with predominantly neutrophilic airway inflammation harbors a relatively uniform
microbiome, in which Proteobacteria, most prominently the potentially pathogenic Haemophilus and
Moraxella genera, have outgrown the taxa normally over-distributed in the lung microbiota (e.g.,
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Firmicutes). These gradually expanding new colonizers of the asthmatic airways may, in fact, constitute
the triggering factor for the aberrant Th17 immune response, along with other inflammatory pathways
activation, observed in neutrophilic asthma. Indeed, non-typeable Haemophilus influenzae intranasally
administered at a sublethal dose has been shown to produce a robust Th17 response in the lungs of
experimental mice [116] and, even more relevantly, infection with non-typeable Haemophilus influenzae
may lead to reduced eosinophilic inflammation and increased neutrophilic infiltration of the airways
in an IL-17-dependent manner in a murine model of allergic asthma [117]. Although the cause of
Proteobacteria overgrowth in the LRT of certain asthmatics remains elusive and may be multifactorial
(e.g., selective bacterial growth favored by structural changes and/or inflammatory mediators in the
airways as a result of the underlying disease process), it must be noted that, as previously discussed,
inhaled corticosteroid (ICS) treatment itself may promote Proteobacteria enrichment in the lung
microbiota and, thus, contribute to the development of neutrophilic asthma [2]. Apparently, if this
hypothetical association between respiratory dysbiosis and neutrophilic asthma pathogenesis stands
true, strategies aiming at the manipulation of lung microbiome, possibly through Proteobacteria
suppression and normal diversity restoration, may open up new avenues for the treatment of this,
until now, untargeted asthma phenotype. Macrolides may be part of such strategies.
2.7.2. Corticosteroid Responsiveness
Several data support the correlation between lung microbiota burden and diversity and
corticosteroid responsiveness. Goleva et al, in a study on CS sensitive and CS resistant asthmatics,
demonstrated that, although bacterial composition both at the phylum and at the genus level was quite
similar between the two groups overall, unique patterns of bacterial expansions were observed in the
majority of patients with both CS-resistant and CS-sensitive asthma [50]. In CS-resistant asthmatics,
the genera Neisseria, Haemophilus, and Tropheryma were abundant, while the genera Pasteurella and
Fusobacterium were predominant in CS-sensitive asthma. Of note, CS-resistant patients had significantly
higher levels of interleukin (IL)-8 mRNA in their BAL cells, implying that distinct lung microbiota
profiles may be responsible for CS resistance in the neutrophilic asthma phenotype. To further
validate their findings, the authors subsequently incubated alveolar macrophages isolated from BAL
samples of asthmatic patients, with either Haemophilus parainfluenzae (a genus solely expanded in CS
resistant patients) or Prevotella melaninogenica, and found a significantly reduced CS responsiveness
in vitro following treatment with dexamethasone in cells cultured with H. parainfluenzae, but not P.
melaninogenica. Durack et al. assessed bacterial composition in ten ICS responders and an equal
number of ICS non-responders, both with mild ICS-naive asthma [62]. They reported significantly
different microbiota profiles in the two groups, with responder’s lung microbiome synthesis sharing
more resemblance with that of healthy controls. In particular, the Microbacteriaceae and Pasteurellaceae
(including Haemophilus) families were found enriched in ICS non-responders and expansions of
the Streptococcaceae, Fusobacteriaceae, and Sphingomonodaceae families were shown in responders.
Interestingly, in the same study, lack of CS responsiveness was associated functionally with increased
expression of bacterial genes involved in biodegradation pathways, which may explain resistance to
CS treatment.
Finally, Huang et al. demonstrated a significant positive correlation between lung microbiota
diversity and FKBP5 gene expression, a marker of steroid response [104]. In terms of bacterial
composition, increased FKBP5 gene expression was associated mainly with Actinobacteria and
Proteobacteria phyla enrichment. These results suggesting an association between lung-microbial
community diversity and CS responsiveness in severe asthma are further supported by more recent
data showing a significant inverse correlation linking phylogenetic diversity in induced sputum
specimens collected from patients with moderate-to-severe asthma and ICS dose with the use of both
univariate and multivariate regression analyses [110].
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2.7.3. Effect of Treatment
Data regarding the effect of asthma treatment on lung microbiome are scarce in literature. In their
study, after initial bronchoscopic sampling (EBs) for lung microbiome assessment at enrollment, Durack
et al. randomized (2:1 ratio) 42 patients with mild well-controlled asthma, who had not received ICS
previously, to receive a six-week course of a medium dose of ICS (250mcg fluticasone propionate
twice daily) or placebo and repeated EBs post-treatment [62]. Despite limitations related to sample
quantity insufficiency, the authors did not discern changes in bacterial burden and diversity after ICS
treatment. However, they did find fluticasone-induced alterations in the relative abundance of certain
taxa, namely an expansion of the Microbacteriaceae family and the Moraxella and Neisseria genera and
a depletion of Fusobacterium, in those who responded to ICS treatment.
In another study, patients with both mild and more severe asthma were stratified according to the
use of corticosteroids (inhaled and oral) [48]. Both those on ICS only and those on combined ICS and OCS
treatment regimens exhibited significant alterations in EBs bacterial composition at the phylum, as well
as the genus, level compared with corticosteroid-naïve asthma patients. These alterations comprised
Proteobacteria enrichment and Bacteroidetes (specifically Prevotella) and Fusobacteria depletion in
all corticosteroid groups, with decreased Veillonella and increased Pseudomonas abundance in those
on ICS only and OCS, respectively. Although limited and centered exclusively on corticosteroids,
these data clearly imply that asthma treatment may modify important compositional characteristics
of the lung microbiome, including selection of potentially pathogenic species, with as yet unknown
potential consequences.
Interestingly, most recent studies have attempted to provide insights into the possible functional
properties of lung microbiome in asthma. Durack et al. employed an algorithmic prediction model
(PICRUSt) to infer lung bacterial metagenomic characteristics based on 16S-rRNA sequencing in patients
with mild asthma and showed potentially increased expression of genes involved in pathways mediating
the metabolism of amino acids and carbohydrates, particularly SCFAs, in these patients compared
with healthy controls [62]. On the contrary, a relative reduction was predicted in the activation of LPS
synthesis-specific processes. Using the same analytical method in severe asthmatic patients, Huang et
al. managed to associate distinct metabolic (e.g., carbohydrate digestion, indole alkaloid biosynthesis)
and immune (e.g., NOD-like and RIG-I-like receptor signaling) pathways with taxa (positively or
negatively) correlated with specific phenotypical features of asthma, including body-mass index (BMI),
asthma control assessed by Asthma Control Questionnaire (ACQ), corticosteroid responsiveness,
and Th17-driven inflammation [104]. The authors concluded that concrete members of the asthmatic
lung microbiota may be actively engaged in the pathogenetic mechanisms leading to the acquisition
of different disease characteristics between asthmatics (i.e., phenotypes). Furthermore, Sverrild et
al., again with the use of PICRUSt, showed different predicted functional profiles of lung microbiota
associated with mild eosinophilic compared with non-eosinophilic asthma [107]. Clearly, further
research taking advantage of the novel technologies in metagenomic analysis of lung microbiota is
urgently needed to better describe the potential mechanistic role of lung microbiome alterations in
asthma pathogenesis and disease phenotype/endotype determination.
2.7.4. Bronchial Hyperresponsiveness (BHR)
BHR to direct or indirect stimuli, in addition to airway inflammation, has long been considered
inherent to asthma. However, neither its presence nor its severity is uniform or stable in all asthmatic
individuals, and, thus, BHR may potentially constitute a contributing factor in asthma phenotyping [118].
BHR (indicated by metacholine PC20 concentrations) has been shown to correlate significantly with
lung microbiota diversity in asthma, with greater bacterial diversity associated with lower metacholine
PC20 concentrations [101]. In the same study, Proteobacteria comprised the majority of resident taxa
correlated with greater BHR. Likewise, lung microbiota diversity was greater in those patients with
asthma that exhibited the larger reductions in BHR following a course with clarithromycin [101].
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2.7.5. Lung Function
The potential impact of lung microbiome composition on lung function in patients with asthma has
mainly been addressed by the study of Denner et al. [48]. The authors stratified their cohort of asthmatic
patients (from across the range of disease severity) according to FEV1 and noticed a significantly
decreased relative abundance of various bacterial phyla (Firmicutes, Bacteroidetes, and Actinobacteria)
and genera (Prevotella, Veillonella, and Gemella) in the BAL fluid of those with the lowest FEV1 values
(FEV1 < 60%). In contrast, Lactobacillus was found to be enriched in patients with the most severely
impaired lung function. Similar positive correlations between the abundance of the Bacteroidaceae
family or lung microbiota phylogenetic diversity and FEV1 have also been reported elsewhere [108,110].
Others have reached different conclusions with respect to taxa-specific associations with lung function
in severe asthma, showing significantly reduced FEV1 levels in those patients with M. catarrhalis,
Haemophilus sp, or Streptococcus sp predominance in induced sputa microbiota compared with others
who had different taxa dominating the bacterial communities of their sputa [103].
2.7.6. Obesity
Obesity has repeatedly been identified in cluster analyses of asthmatic populations as a key
clinical feature discriminating a distinct subset of patients (mostly female) with adult onset, non-Th2
mediated, highly symptomatic and difficult-to-treat asthma from other asthma phenotypes [119–121].
Although the exact pathogenetic mechanisms linking obesity with asthma remain unknown, studies in
obese asthmatics have shown improvements in BHR, asthma control, lung function, and inflammatory
indices following bariatric surgery [122,123] or diet-induced [124,125] weight loss.
In a cohort of patients with severe asthma, high BMI was significantly associated with a distinctive
lung microbiota composition, mainly consisting of Bacteroidetes (including Prevotella species) and
Firmicutes (e.g., Clostridium species) [104]. As expected, these obese asthmatic individuals presented
less bronchial eosinophilic infiltration in EB specimens (non-eosinophilic asthma). It is noteworthy
that bacterial taxa associated with obesity in this study exhibited distinct predicted functions,
including activation of pathways involved in host immune response, such as NOD-like receptor
signaling. These data suggest a potential role for lung microbiome in shaping the obesity-related
asthma phenotype.
2.7.7. Smoking Asthma
Although no significant difference has been reported in BAL bacterial communities composition
between healthy smokers and non-smokers [42], an analysis of induced sputum microbiota profiles in
patients with severe asthma demonstrated increased total bacterial diversity and relative abundance
of Fusobacteria in ex-smokers compared with never smokers, while smoking intensity (assessed
by pack–years of smoking) was directly associated with the prevalence of Actinobacteria [105].
These findings raise the possibility that smoking may be involved in shaping lung microbiome
alterations observed in asthma.
2.8. Lung Microbiome and Asthma Exacerbations
The most common precipitating factor triggering asthma exacerbations is viral respiratory tract
infections, particularly from rhinoviruses [126]. On the contrary, bacterial lung infections have
not been shown to trigger asthma exacerbations but for in a minority of cases, with the possible
exception of the self-limiting atypical bacterial infections caused by Mycoplasma pneumoniae and
Chlamydophila pneumoniae for both of which a relative prevalence of 18% has been serologically detected
during asthma attacks in adults and children, respectively [127]. On the other hand, considerably
high rates of the potentially pathogenic Proteobacteria Haemophilus influenzae (the most prevalent),
Streptococcus pneumoniae, and Moraxella catarrhalis have been detected by both culture-based and
molecular techniques from upper- and lower-respiratory-tract samples of asthmatic children during
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exacerbation periods [128,129]. Moreover, a cluster analysis based on sputum cellular and mediator
profiles in adult asthmatic patients during exacerbations has linked the predominance of different
bacterial phyla in lung microbiota with specific clinical features and inflammatory markers [130] (see
Figure 7).
 
Figure 7. Exacerbation biologic clusters in asthmatic and COPD patients using the subjects’ discriminant
scores. Adapted from ref. [130], Creative Commons Attribution License (CC BY).
In order to provide an explanation for the above observations, a model of respiratory
dysbiosis involving an altered lung microbiome and a dysregulated host immune response has
been proposed to delineate the occurrence of asthma (and other chronic respiratory diseases)
exacerbations [131]. According to this model, an acute stimulus, most commonly a viral infection,
induces an immune-mediated inflammatory response, leading to a modification of local conditions
in the airways, which may promote alteration of lung microbiota composition by favoring the
predominance of specific previously underrepresented species and/or by predisposing to invasion by
new potentially pathogenic strains. In turn, this deranged microbial growth may result in a further
amplification of local airway inflammation, presumably via bacterial metabolite production and
activation of signaling pathways mediated by the interaction between PAMPs and PRRs. Ultimately,
a self-perpetuating vicious cycle arises, leading to the overwhelming inflammatory response that
underlies asthma exacerbations.
Indeed, there is considerable evidence suggesting that viral infections can increase susceptibility
to bacterial growth and invasion. Viral infections may impair mucociliary clearance through diverse
mechanisms, including increased mucous production, ciliary dyskinesia, and cilia depletion [132,133].
Moreover, rhinoviral and possibly other viral infections have been reported to facilitate bacterial
transmigration by increasing airway epithelial barrier permeability in vitro, and this effect has been
attributed to the loss of occludins, a major component of tight junctions connecting adjacent epithelial
cells [134,135]. Respiratory viruses alter the nasopharyngeal microbiome and may be associated with
a distinct microbial signature. In the study by Rosas-Salazar et al. [136], which mostly included children
<6 months of age, nasopharyngeal microbiome of infants during HRV and RSV acute respiratory tract
infections (ARIs) was largely dominated by Moraxella, Streptococcus, Corynebacterium, Haemophilus,
and Dolosigranulum. In addition, there was a higher abundance of Staphylococcus and a trend toward
a higher abundance of Haemophilus in RSV-positive infants, and in the overall bacterial composition
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between infants with HRV and RSV ARIs. Furthermore, Santee et al. [137] showed that previous
history of acute sinusitis influences the composition of the nasopharyngeal microbiota, characterized
by a depletion in relative abundance of specific taxa. Diminished diversity was associated with
more frequent upper-respiratory infections. These, among many other published data, highlight the
possibility that virus-specific compositional shifts in the nasopharyngeal microbiome contribute to
worse outcomes after early-life ARIs.
Various viruses, including human rhinovirus (HRV), respiratory syncytial virus (RSV),
and influenza virus, can augment the expression of adhesion molecules, such as ICAM-1, CEACAM-1,
CEACAM-6, and PAFR, on the surface of epithelial cells, thus promoting invasion by certain
bacterial species, including H influenza, S pneumoniae, and M catarrhalis [138–140]. Apart from
the upregulation of host receptors, some viral structures appear to directly promote bacterial binding
to host tissues [141,142].
Furthermore, viral infections may interfere with host immune system integrity and function and,
consequently, increase susceptibility to bacterial colonization and infection. For instance, HRV infection
has been shown to attenuate the inflammatory response to H. influenzae and delay bacterial elimination
by decreasing TLR2 responsiveness to bacterial insult [143]. An almost complete disappearance of
alveolar macrophages has been observed after influenza infection in a murine model [144] and HRV and
RSV have been found to compromise phagocytosis and diminish pro-inflammatory cytokine release
from alveolar macrophages in response to bacterial products [145,146]. Dendritic cell (DC) as well as CD4
and CD8 T-cell numbers and/or function may also be impaired after influenza or other viral infections
with detrimental effects on host defense against bacteria [147]. Finally, viral respiratory infections
induce changes in the lung microenvironment, such as increased temperature, nutrient availability,
and cytokine and catecholamine levels, all of which are potential enhancers of bacterial virulence
and immunogenicity [78,79,148]. The above mechanisms may act synergistically to elicit potentially
significant alterations in the composition and diversity of lung microbiota, thus resulting through the
dynamic microbiome–host immune system interplay, in the amplified and deregulated inflammatory
response characterizing asthma exacerbations and even predispose to recurrent exacerbations.
Conversely, there are data, albeit rather limited, suggesting that bacteria can influence susceptibility
to viral infections. In this context, several experimental studies have provided evidence for a protective
role of a healthy intact microbiome against influenza. Ichinohe et al. showed that mice with impaired
microbiome as a result of pretreatment with antibiotics presented attenuated CD4 and CD8 T-cell
responses and reduced antibody production following respiratory influenza virus infection [149].
Likewise, increased mortality has been reported in SPF mice intranasally infected with a lethal dose of
influenza virus compared with non-SPF mice, and this finding could be replicated by priming mice
with Staphylococcus aureus, used as a surrogate of upper-respiratory-tract commensal flora, before
influenza virus inoculation [150]. TLR2 signaling and an M2 alveolar macrophage phenotype were
essential for the relative insensitivity against influenza-induced lethal lung injury observed in this S
aureus-primed murine model. Other studies focusing on the nasopharyngeal microbiota in children
with RSV bronchiolitis have highlighted the potentially deleterious effects of a deranged Proteobacteria
(H influenzae, M catarrhalis)-dominated microbiome on the risk of viral infection [151,152]. RSV infection
occurrence and severity and pro-inflammatory cytokine concentrations were all found to be positively
correlated with nasopharyngeal colonization with the potentially pathogenic H. influenzae, M. catarrhalis,
and Streptococcus species. Similarly, S. pneumoniae colonization was associated with increased rates of
seroconversion to human metapneumovirus in infants in an older study [153]. This viral infection
predisposition conferred by the coexistence of potentially pathogenic bacteria could be the result of
upregulation of viral entry receptors and/or impaired antiviral immune response induced by these
bacteria. Such examples are the upregulation of the major HRV entry receptor ICAM-1 by H. influenza
in airway epithelial cells [154] or the reduction of TLR3 expression and IFN secretion in bronchial
epithelial cells infected with M catarrhalis [155].
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Collectively, these data strengthen the hypothesis that lung microbiome alterations observed in
asthma patients are actively involved in the pathogenesis of disease exacerbations and may represent
a potential therapeutic target in asthma exacerbations management.
2.9. Therapeutic Implications of Microbiome Manipulation
Based on the above, the proposed role of human microbiome in shaping both asthma susceptibility
and phenotypes renders exogenous manipulation of microbiome a potentially attractive therapeutic
strategy for both asthma prevention and treatment. Interventions in microbiome composition have
previously been recommended as putatively effective approaches in three areas of asthma management:
(1) prevention of asthma development during early life by favoring factors that promote immune
tolerance to allergens and minimizing those that predispose to the emergence of atopy; (2) management
of Th2-low asthma phenotypes/endotype, particularly neutrophilic asthma with frequent exacerbations;
and (3) reverse of CS resistance or prevention of its emergence [156]. As yet, potential interventions
applied for these purposes comprise lifestyle measures, vaccinations, and pharmacological treatment,
including (1) probiotics, (2) prebiotics, and (3) antibiotics. It must be emphasized that, until now,
only scarce data are available for the exact impact of these interventions on human microbiome
composition and function, and even less is known about their presumed ability to ameliorate clinically
meaningful outcomes in asthmatic patients. Furthermore, the effects of medications currently used in
asthma treatment, including CS and bronchodilators, on microbiome remain mostly undetermined,
and microbiome manipulations could ideally enhance beneficial actions and/or minimize side effects
possibly induced by these agents.
Theoretically, any environmental exposure capable of modifying the composition of human
microbiome during the dynamic period of its acquisition and maturation starting in utero and
extending to the first few years of life may influence the likelihood of subsequently developing allergic
asthma. This means that there is a so-called ‘window of opportunity’ estimated to operate within
the first 100 days of life, during which lifestyle interventions, as well as exogenously administered
microbial agents, could promote the formation of a tolerogenic microbiome, thus limiting the risk
of allergic asthma [157]. For instance, raw cow milk consumption and vitamin D and omega-3 fatty
acids supplementation during pregnancy have all been shown to diminish the risk of asthma in
the offspring, presumably by affecting the microbiome synthesis of the child [158]. Avoidance of
unnecessary maternal antibiotic exposure is another potentially beneficial pre-birth measure linked
with microbiome [89]. As previously mentioned, vaginal delivery, breastfeeding, reasonable antibiotic
use, pet ownership, exposure to ‘unhygienic’ traditional farming environments, and high-fiber dietary
content in infancy have, more or less consistently, been associated with favorable effects on human
body microbiota composition and function (especially in the gut) and a reduced risk of allergic asthma
development later in life. However, it must be stressed that available evidence is generally inconclusive
and probably only a few of these associations can be considered definite. Moreover, implementation of
some or even all of these measures may be practically unattainable for various reasons.
To overcome these limitations, more “interventional” approaches have been proposed. Probiotics
are live microorganisms (bacteria or fungi) that may favorably affect the host health, whereas prebiotics
are defined as non-digestible compounds that, after processing by intestinal microbiota, promote the
expansion and/or activation of beneficial commensals. Symbiotics refer to preparations containing
both probiotics and prebiotics [159]. A multitude of orally administered probiotics have been shown to
attenuate allergic airway inflammation in mice [160–163]. As described above, high-fiber diets and
SCFAs administration (which are essentially prebiotics) have also been found to mitigate inflammatory
changes in experimental models of allergic airway disease [99,100]. The potential effect of these biologic
agents with microbiome-modifying capacity on allergic asthma has further been studied in several
randomized placebo-controlled trials (RCTs). Daily supplementation of asthmatic school children
with the probiotic Lactobacillus gasseri A5 or a mixture of Lactobacillus acidophilus, Bifidobacterium
bifidum, and Lactobacillus delbrueckii for two to three months have both been shown to improve
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asthma symptoms and lung function [164–168]. Similarly, a symbiotic preparation consisting of
short-chain galacto-oligosaccharides, long-chain fructo-oligosaccharides, and the Bifidobacterium breve
M-16V increased PEF and reduced serum IL-5 in an adult cohort of allergic asthma [168]. However,
most [167–169], albeit not all [170], meta-analyses performed to date have failed to demonstrate
a beneficial effect of preventive probiotic supplementation to mothers during pregnancy and/or infants
during the first year of life on asthma risk. Further adequately powered and well-designed RCTs are
warranted to clarify the role of probiotics/prebiotics on asthma prevention and treatment.
While the possible propitious effects of orally administered probiotics/prebiotics on asthma are
thought to be derived by favorable alterations in the gut microbiota and the gut–lung axis, a more
targeted approach involving direct interventions to lung microbiome via inhalational delivery of
such agents remains relatively unexplored. In mice, intranasal administration of Acinetobacter Iwoffii,
Lactococcus lactis, or Staphylococcus sciuri, all of which had previously been isolated from cowsheds in
the context of farming asthma studies, have been shown to hinder eosinophilic airway inflammation
induced by ovalbumin sensitization and challenge [2,171]. Similar findings have also been reported
by another group for Escherichia coli administered via inhalation in the same murine model of
allergic airway inflammation [172]. In all cases, allergy protection conferred by inhaled bacteria was
associated with modifications in DC activation, leading to altered T-cell responses [172–174], in line
with the previously presented observations on SCFAs administration. However, the effects of inhaled
probiotic treatments on lung microbiota structure and function have not been addressed. In another
experimental study assessing the potential influence of the administration route on the protective
role of probiotics, Lactobacillus paracasei more efficiently suppressed eosinophilic inflammation when
administered intranasally rather than via a feeding tube [175]. These results might suggest superior
efficacy of microbiome-modifying therapeutic interventions, probiotics, and probably others (e.g.,
antibiotics) [176], when applied locally to the respiratory tract as compared to oral administration,
which additionally may affect other organs. As yet, no human data are available for inhaled probiotic
treatment in asthma.
The proposed role of human microbiome on shaping asthma phenotypes and exacerbation
susceptibility, as analyzed above, may form the conceptual basis for the use of antibiotics as a means
for therapeutic manipulation of the microbiome, aiming at the restoration of a symbiotic state between
the host and the resident microbiota through the suppression of overgrown detrimental taxa and
the foster of beneficial ones. This holds especially true for the Th2-low, CS-insensitive, exacerbation
prone, severe neutrophilic asthma phenotype, the treatment options for which are particularly limited.
As Proteobacteria-dominated changes in lung microbiome have quite consistently been identified
in relation with this phenotype, with Haemophilus influenzae and Moraxella catarrhalis being the
most prominent species involved, these taxa could probably be considered the primary targets of
microbiome-modifying antibiotic treatment in neutrophilic asthma. The anticipated gradual advent
of non-culture-based methods for lung microbiota identification in clinical practice may allow more
personalized approaches in antibiotic targeting of dysbiotic lung bacteria in the future.
Both in asthma and in a growing list of other respiratory diseases, macrolides have become
the subject of much attention due to the fact that they combine well-known antimicrobial activity
along with multiform immunomodulatory properties, including attenuation of neutrophil chemotaxis,
inhibition of biofilm formation, reduction of mucus hypersecretion, and even downregulation of
viral entry receptors with amplification of viral infection-induced IFN production [177–179]. Overall,
clinical trials of macrolides in asthma, most of which in patients with severe uncontrolled asthma,
have yielded conflicting results. However, in a pre-specified subgroup analysis of the AZISAST
multicenter randomized placebo-controlled trial, it was shown that a six-month course of azithromycin,
given at a dose of 250 mg, three times a week, in patients with severe asthma and frequent exacerbation,
significantly reduced a composite primary outcome comprising the rates of severe exacerbations
and lower respiratory-tract infections requiring antibiotics in the non-eosinophilic asthma subgroup
of patients [180]. More recently, the larger AMAZES randomized controlled trial (RCT) reported
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significantly decreased rates of exacerbations, along with improved asthma-related quality of life in
patients with uncontrolled asthma despite therapy with medium-to-high doses of ICS plus LABA who
received a higher dose of azithromycin (500 mg three times per week) for 12 months [181]. Interestingly,
in this trial, azithromycin appeared equally effective in all studied subgroups, including both those
of eosinophilic and non-eosinophilic asthma. Although these beneficial effects of azithromycin
(and perhaps other macrolides) on asthma exacerbations could be attributed to the aforementioned
immunomodulatory anti-inflammatory properties of macrolides, there are data showing alterations of
microbiota composition following treatment with azithromycin. In a research letter published in 2014,
Slater et al. described the longitudinal effects of six weeks of daily therapy with 250 mg azithromycin on
lung microbiota characteristics, using bronchoscopic washings for sampling and DNA pyrosequencing
analysis in five patients with moderate-to-severe asthma [182]. The study reported a reduction of lung
microbiota diversity post-treatment, accompanied by an increased relative abundance of Anaerococcus
and a decreased recognition of the potentially pathogenic genera of Pseudomonas, Staphylococcus,
and Haemophilus. Furthermore, in a bacteriological sub-study of the AZISAST trial, azithromycin
administration was associated with post-treatment changes in the microbiota composition of the
oropharynx compared with both pretreatment status and control patients receiving placebo [183].
At the phylum level, Firmicutes increased and Fusobacteria decreased in oropharyngeal swabs derived
from eight severe asthma patients after a six-month course of azithromycin. This finding corresponded
to an increased abundance of Streptococcus salivarius, with a parallel reduction of Leptotrichia wadei at
the species level. Of notice, in half of the washout samples collected one month following completion
of azithromycin treatment, the microbiota composition was almost identical to the pretreatment
oropharyngeal flora of the same patient, indicating a possibility for original microbiome recovery after
cessation of antibiotics administration and a consequent requirement for long-term treatment.
Admittedly, there are considerable limitations in the long-term use of antibiotics as a therapeutic
tool for favorable manipulations of the host microbiome. Apart from well-founded concerns with respect
to potential adverse effects (sometimes irreversible or life threatening) and emergence of antimicrobial
resistance arising from long-term antibiotic regimens, the lack of specificity in the elimination of resident
bacteria does not allow currently available antimicrobial agents to eradicate exclusively dysbiotic
members of the lung bacterial community while sparing beneficial commensals, and may, in fact,
produce the opposite results. As previously noted, maternal and early life antibiotic usage has been
associated with an increased risk of asthma development during childhood. The detrimental effects of
antibiotic use (and not necessarily long-term) on gut microbiome are firmly established and involve the
depletion of normal biodiversity and the overgrowth of potentially harmful bacterial strains, leading
to dysbiosis. Occasionally, this can be expressed clinically in the form of antibiotic-associated diarrhea
and pseudomembranous colitis. Such antibiotics-associated hazards (i.e., selection of potentially
pathogenic microbiota) are also pertinent to the lung microbiome, and broad-spectrum antibiotic use
may lead from a state of respiratory dysbiosis to another, each time dominated by different and probably
more-resistant strains. Despite potentially abolishing systemic adverse effects, inhaled antibiotics
are probably subject to these same limitations and cannot be considered as an ideal alternative to
systemically administered agents.
Novel approaches to microbiome-modifying therapies have focused on the manipulation of
metabolites known to be produced or processed by the (gut) microbiota and to act on the host [184,185].
Metabolite-targeting molecules are under development. Fecal transplantation has successfully been
used as a means of gut microbiota manipulation in several intestinal disorders [186]. Its potential role
in allergic and respiratory diseases remains unexplored.
The endeavor to therapeutically manipulate human microbiome is clearly still in its infancy,
and, by all means, intensive innovative research applying to all stages of the treatment discovery
and development pipeline is mandatory before any of these interventions could be incorporated into
clinical practice guideline recommendations.
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3. Conclusions
Studies conducted over the last two decades have dramatically changed our perspective on
LRT microbiology, with the use of culture-independent molecular techniques. It is now universally
accepted that the lung is far from a sterile organ. It has convincingly been shown that, in asthma,
lung microbiome undergoes significant alterations in terms of diversity and composition, with certain
species outgrowing others, functionally leading to a presumable state of respiratory dysbiosis. Many of
these alterations have been associated with specific phenotypic features of asthma, including disease
exacerbations, and aspects of this dysbiosis may represent the missing link in the pathogenesis of some
expressions of the asthmatic disease, perhaps, in particular, the neutrophilic inflammatory phenotype.
A considerably large body of evidence arising from both experimental and epidemiological studies
is now available, suggesting that early life environmental exposures affecting the gut microbiome
structure may be involved in shaping susceptibility for asthma development later in life by modifying
microbiota-derived factors thought to be actively involved in the configuration of the gut–lung axis,
such as the SCFAs. Given its proposed roles in influencing the risk for asthma development, as well as
the phenotypic expression of an established disease, microbiome has emerged as a potential therapeutic
target in asthma. As yet, interventions potentially modifying the microbiome have not clearly been
shown to be efficacious in preventing and/or treating asthma, with few exceptions.
More accurate delineation of lung microbiota structural and functional characteristics, both in
health and in asthma, remains an unmet need in the microbiome research. Larger longitudinal studies
applying standardized sampling methods in well-characterized asthmatic cohorts are indispensable in
this regard. Unquestionably, the impending widespread application of the novel “-omics” technologies
can be expected to provide invaluable insights into the functional effects of lung microbiome and their
presumable role in shaping asthma predisposition and phenotypes. Advancing our understanding
on the mechanistic links between human microbiome and asthma will hopefully culminate in the
discovery of novel therapeutic interventions targeting specific aspects of respiratory dysbiosis.
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Abstract: Severe asthma (SA) is a chronic lung disease characterized by recurring symptoms of
reversible airflow obstruction, airway hyper-responsiveness (AHR), and inflammation that is resistant
to currently employed treatments. The nucleotide-binding oligomerization domain-like Receptor
Family Pyrin Domain Containing 3 (NLRP3) inflammasome is an intracellular sensor that detects
microbial motifs and endogenous danger signals and represents a key component of innate immune
responses in the airways. Assembly of the NLRP3 inflammasome leads to caspase 1-dependent release
of the pro-inflammatory cytokines IL-1β and IL-18 as well as pyroptosis. Accumulating evidence
proposes that NLRP3 activation is critically involved in asthma pathogenesis. In fact, although
NLRP3 facilitates the clearance of pathogens in the airways, persistent NLRP3 activation by inhaled
irritants and/or innocuous environmental allergens can lead to overt pulmonary inflammation and
exacerbation of asthma manifestations. Notably, administration of NLRP3 inhibitors in asthma models
restrains AHR and pulmonary inflammation. Here, we provide an overview of the pathophysiology
of SA, present molecular mechanisms underlying aberrant inflammatory responses in the airways,
summarize recent studies pertinent to the biology and functions of NLRP3, and discuss the role of
NLRP3 in the pathogenesis of asthma. Finally, we contemplate the potential of targeting NLRP3 as a
novel therapeutic approach for the management of SA.
Keywords: severe asthma; innate immunity; immune regulation; NLRP3; IL-1β; allergic airway
inflammation
1. Introduction
Asthma represents a serious global health problem that affects 1%–18% of the population of
all age groups. Its prevalence has increased in the last decades, especially among children [1].
Asthma is characterized by variable symptoms of wheezing, dyspnea, chest tightness, coughing, and
reversible airflow obstruction, and is usually associated with airway hyperresponsiveness (AHR)
to innocuous environmental allergens and chronic airway inflammation. Factors, such as allergen
or irritant exposure, respiratory infections, exercise, climate changes, and stress, are responsible
for the disparities and severity of asthma symptoms [1]. Asthma has been long considered as a
heterogeneous chronic lung disease that encompasses multiple groups of patients characterized
by varying features or phenotypes [2,3]. A small percentage of asthmatics exhibit severe disease
exacerbations despite the fact that they are already under treatment with high doses of inhaled and/or
systemic corticosteroids [2,3]. These patients suffer from severe asthma (SA) that is poorly controlled
and, in some cases, life-threatening [4,5]. Although patients with SA comprise a small percentage
of the total asthma population (5%–10%), they denote 50% of total healthcare costs, rendering SA a
substantial health and socioeconomic burden [6,7]. SA is characterized by marked thickening and
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structural changes of the airway wall, excessive airway narrowing, and fixed airflow obstruction [6,7].
An in-depth understanding of the heterogeneity of SA and the immunological mechanisms underlying
its pathophysiology is critical for the identification of novel biomarkers and molecular pathways that
can be targeted in novel treatment modalities.
In the lung, innate immune responses provide the first line of defense against environmental
signals, including pathogens, allergens, and other irritants, and act through downstream signaling by
numerous extracellular and intracellular receptors, termed pattern recognition receptors (PRRs) [8–10].
NOD-like Receptor Family Pyrin Domain Containing 3 (NLRP3) is an intracellular PRR that detects
microbial motifs, endogenous danger signals, and environmental irritants, and induces the formation
and activation of the NLRP3 inflammasome. Although the NLRP3 inflammasome is essential for
providing protective immunity, overactivation of inflammasome-mediated responses can cause
excessive inflammation, tissue damage, and lead to chronic inflammatory diseases, including
asthma [10,11]. In this review, we describe the immunological mechanisms underlying aberrant
inflammatory responses in the airways and their link to SA pathogenesis. We also present the biology
and functions of NLRP3 and discuss its role in the initiation and propagation of SA features. Finally,
we present recent findings pertinent to targeting NLRP3 functions as a novel therapeutic approach for
the control of inflammatory responses in the airways.
2. Severe Asthma Pathogenesis
2.1. Type 2 Asthma
To address SA complexity, the concept of asthma endotyping has emerged [12–14]. Depending
on the type of immune cell responses implicated in disease pathogenesis, asthma endotypes are
categorized as (a) type 2 asthma, characterized predominantly by T helper type 2 (Th2) cell-mediated
inflammation and (b) nontype 2 asthma, associated with Th1 and/or Th17 cell inflammation [15–17].
Upon allergen exposure, dendritic cells (DCs) in the lung mucosa take up allergens, reach the
mediastinal lymph nodes, and present allergen components to naive T cells in the context of major
histocompatibility complex class II [18]. Allergens with proteolytic activity, such as those derived
from house dust mites (HDM), pollen grains, fungi, and occupational sensitizers activate protease
activated receptors expressed on DCs, disrupt epithelial tight junctions, and initiate inflammatory
responses [18]. Moreover, certain allergens and airborne particulates contain microbial components
which interact with PRRs, including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), on
DCs and airway epithelial cells, and serve as “danger signals” for the host immune response [18].
Upon interaction with allergen-loaded DCs, naive Th cells differentiate into Th1, Th2, Th9, or Th17
cells, depending on the type and dose of allergen and the local cytokine milieu [18]. Allergen-specific
Th2 cells, generated in the presence of type 2 cytokines, migrate into the airways wherein upon
allergen re-exposure, secrete cytokines and promote mucus secretion, subepithelial fibrosis, bronchial
remodeling, and AHR [19]. The production of Th2 cytokines also leads to the recruitment of innate
effector cells, including mast cells, basophils, and eosinophils, as well as to isotype switching of B
cell-secreted IgG to allergen-specific IgE [19]. Additionally, Th9 cells, a recently identified Th cell subset
characterized by high levels of IL-9, exacerbate allergic airway inflammation (AAI), predominantly
through activation of mast cell functions [20,21]. More specifically, experimental studies have shown
that IL-9 production by Th9 cells and by type 2 innate lymphoid cells (ILC2s) enhances the production of
IL-2 by mast cells, leading to further expansion of ILC2s, which activate Th9 cells, in a positive feedback
loop [22]. Of clinical relevance, increased numbers of Th9 cells were demonstrated in peripheral blood
mononuclear cells (PBMCs) isolated from HDM or pollen allergic subjects and correlated with IgE
levels [23]. Moreover, elevated IL-9-secreting T lymphocytes were observed in the bronchoalveolar
lavage (BAL) of asthmatics [24].
Apart from DCs, the asthmatic airway epithelium represents a major source of cytokines termed
“alarmins”, such as, IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), and chemokines, including
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RANTES (Regulated on Activation, Normal T cell Expressed and Secrete or CCL5), TARC (Thymus-
and Activation-Regulated Chemokine or CCL17), eotaxins (CCL11, CCL24 and CCL26), and MCP-3
(Monocyte Chemotactic Protein-3 or CCL7) that trigger Th2 cell polarization upon exposure to allergens,
pollutants, viral, fungal, and bacterial components [18]. As mentioned above, recent studies have
highlighted a key role for ILC2s in asthma immunopathogenesis [25]. ILC2s are activated in response
to TSLP, IL-25, and IL-33 signaling [25], and produce IL-5, IL-13, and prostaglandin [26], further
propagating Th2-cell mediated responses in the airways.
Type 2 asthma is characterized by any combination of the following processes: eosinophilia in
the sputum or blood, atopy and a high level of fractional exhaled nitric oxide (FeNO) [16]. Several
biomarkers of type 2 inflammation, such as FeNO, serum IgE, blood or sputum eosinophils, and serum
periostin distinguish type 2-high and type 2-low asthma phenotypes and also predict the responsiveness
to type 2 cytokine-targeted therapy [27]. Eosinophils play a crucial role in the initiation and propagation
of inflammatory responses in asthma [16]. Asthmatic patients with increased numbers of eosinophils
in the periphery suffer from more severe disease exacerbations and poorer disease control [16]. FeNO
represents an indicator of IL-13-mediated and corticosteroid-responsive airway inflammation, as
the presence of IL-13 activates inducible nitric oxide synthase (iNOS), leading to increased FeNO
production in the airways [16]. Approximately 70% of patients with asthma have an allergic phenotype,
characterized by allergen-specific IgE and elevated total IgE levels [16]. Periostin, an extracellular
matrix protein, induced by IL-4 and IL-13 signaling, is secreted by bronchial epithelial cells and
represents another important biomarker for severe eosinophilic type 2 asthma [28]. Periostin is
involved in airway remodeling, sub-epithelial fibrosis, eosinophil recruitment, and mucus production.
Notably, a high serum concentration of periostin denotes one of the most significant indicators of
eosinophilic inflammation in asthma [29].
Clustering studies revealed that one of the major reasons SA patients remain unresponsive to
corticosteroid treatment is that apart from Th2 inflammation, other mediators are also implicated in
disease pathogenesis [12,30]. Indeed, enhanced Interferon gamma IFNG expression was detected in
BAL cells, accompanied by increased secretion in SA patients compared to mild-to-moderate asthmatics
(MMA) [31]. The same study also showed elevated percentages of CD4+IFN-γ+ T cells in the BAL [31].
In line with above, increased IFN-γ mRNA levels were observed in lung tissue and sputum of SA
patients [32,33]. It must be asked what triggers these IFN-γ-mediated responses in the airways of SA
patients? It is known that persistent viral (especially rhinoviruses) and bacterial (Chlamydia pneumoniae,
Streptococcus pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and
Staphylococcus aureus) infections augment IFN-γ secretion in SA patients, highlighting a key role for
respiratory tract infections in disease severity and asthma exacerbations [34].
2.2. Nontype 2 Asthma
The pathophysiology of nontype 2 asthma remains less well characterized. Nontype 2 asthma is
denoted by the absence of type 2 biomarkers, such as eosinophils and IgE, and the predominance of
Th17 cells and neutrophils in the airways [35]. In fact, growing evidence has highlighted a key role
for IL-17 in the pathogenesis of nontype 2 asthma [35]. Tissue-infiltrating CD4+ T cells isolated from
bronchial biopsies of SA patients produce copious amounts of IL-17 and IL-22 upon ex vivo polyclonal
stimulation [36,37]. Another study revealed that in vitro administration of recombinant human IL-17
enhanced the secretion of IL-8 by human bronchial epithelial cells (HBECs) and venous endothelial
cells [38]. Moreover, conditioned medium from IL-17-treated HBECs increased neutrophil migration
in vitro [38]. Increased IL-17 mRNA levels are also observed in the sputum of SA patients [39].
In addition, IL-17 levels in the peripheral blood (PB) of SA patients positively correlate with disease
severity [40]. A very interesting recent study revealed that an IL-4Rα polymorphism associated
with SA leads to the conversion of regulatory T cells (Tregs) to Th17 cells in vitro [41]. In brief,
the authors isolated from the PB of asthmatics and healthy controls that were either wild type (WT)
(IL4RQ576/Q576), heterozygous (IL4RQ576/R576), or homozygous (IL4RR576/R576) for the mutated
allele, naive T cells, and differentiated them into Treg cells. Interestingly, naive CD4+ T cells from
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asthmatics bearing the IL4RR576 mutation exhibited defective induction of Treg cells and were skewed
towards a Th17-like phenotype, exemplified by increased secretion of IL-17 [41]. Still, targeting IL-17
has failed to improve disease symptoms in SA patients as opposed to anti-type 2 cytokine therapy,
suggesting that other mechanisms compensate for its pathogenic effects or that targeting pathogenic
Th17 cells specifically would be more appropriate [42,43].
To date, biomarkers of type 2-low or neutrophilic asthma have not been identified. Several studies
have shown that there is no inverse correlation between sputum eosinophil and neutrophil numbers
in SA patients and that eosinophils are present in excess, additionally to neutrophilic accumulation,
in the airways [44]. Moreover, although measuring eosinophil numbers in the periphery correlates
with the percentages of eosinophils in induced sputum, blood neutrophil parameters represent poor
surrogates for the proportion of neutrophils in the sputum [45,46]. Recent studies showed that the
levels of the chitinase-like protein YKL-40 in the blood of SA patients could potentially be used as a
marker for nontype 2 neutrophilic asthma [47]. In fact, combining the measurement of YKL-40 with
other clinical parameters of the disease may provide a more reliable strategy for defining nontype 2
asthma. Tumor necrosis factor (TNF)-α has been also shown to have a critical role in nontype 2 asthma
through acting on smooth muscle cells or by modifying the release of the cysteinyl leukotrienes, LTC4
and LTD4 [48]. TNF-α is increased in the BAL and bronchial biopsies in SA patients compared to
MMAs [49]. Importantly, the administration of inhaled recombinant TNF-α to normal subjects led to the
development of AHR and airway neutrophilia [50,51]. Subsequent clinical trials utilizing antiTNF-α
therapeutic administration contributed to the elucidation of the role of this cytokine in vivo [52].
Indeed, improvement in patient quality of life, lung function, and a reduction in AHR and exacerbation
frequency was observed in patients treated with antiTNF-α [52]. Still, considering the significant
heterogeneity observed in SA patients, benefit from antiTNF-α therapy is likely to occur only in a small
group of patients.
Apart from type 2 and nontype 2, asthma can be categorized into four endotypes (eosinophilic,
neutrophilic, mixed granulocytic, and paucigranulocytic) based on the type of airway infiltrating
immune cells [53]. Among these endotypes, paucigranulocytic asthma (PGA) presents no evidence of
increased eosinophils or neutrophils in induced sputum, and instead is characterized by low-grade
airway inflammation associated with airway smooth muscle (ASM) dysfunction, persistent airflow
limitation, and AHR [54,55]. Molecules involved in oxidative stress, matrix metalloproteinases,
neutrophil elastase, and galectin-3, commonly used for the discrimination between eosinophilic and
neutrophlic asthma, also remain unaltered in patients with PGA [56–59]. Moreover, patients with
PGA display lower FeNO levels compared to those with eosinophilic asthma [60]. Notably, Wang
and colleagues documented that PGA was the most common endotype observed in children with
stable asthma [61]. Corticosteroids do not seem to exert beneficial effects in this cohort of asthmatics,
irrespective of the dose used [62]. Considering that symptoms dominating in this cohort are mostly due
to ASM phenotypic changes and/or neuronal dysfunction, therapies directed toward ASM responses,
including mast cell-targeted therapies and/or bronchial thermoplasty, might benefit PGA patients [63].
Although the precise mechanisms of action remain incompletely understood, bronchial thermoplasty
is considered to diminish ASM mass through the delivery of localized thermal energy [63]. In addition,
factors associated with dysregulated ASM functions, as well as mediators involved in the thickening of
the subepithelial basement membrane, could be used as disease biomarkers and guide the design of
effective therapeutic approaches for PGA [56].
In sharp contrast to adult asthma, wherein the type of airway inflammation has been extensively
investigated due to the use of invasive and semi-invasive techniques, such as bronchial biopsies,
BAL, and induced sputum, the majority of analyses in childhood asthma have been performed
only in severe forms of disease [64–67]. The most common endotype of childhood asthma is the
eosinophilic, characterized by unrestrained symptoms, atopy, impaired lung function, enhanced AHR,
increased numbers of exacerbations, and steroid responsiveness [68]. The percentages of eosinophils
in induced sputum significantly vary over time in children with SA, and these variations are not
associated with asthma therapy [69]. Importantly, persistent airway eosinophilia has been detected in
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a small cohort of children with SA, even after a high dose of systemic corticosteroids [70]. Regarding
neutrophilic pediatric asthma, the functional role of airway neutrophils in asthma pathophysiology
remains elusive. Infiltration of neutrophils in the airways in pediatric SA represents a feature of airway
inflammation at all ages and is triggered by viral and/or bacterial infections, exacerbating asthma
symptoms [71]. Increased numbers of intraepithelial neutrophils, along with enhanced epithelial and
submucosal expression of IL-17R, have been observed in lung biopsies of a subgroup of children with
therapy-resistant SA. These findings correlate with improved lung function suggesting a potential
beneficial rather than adverse role for neutrophils in pediatric SA pathophysiology [72]. Other
studies show that neutrophils coexist with eosinophils in the airways of a group of children with SA,
highlighting the complexity of defining the distinct endotypes in children [73]. Overall, it becomes
evident that a more detailed and careful assessment of all the inflammatory endotypes is essential for
the characterization and management of severe pediatric asthma.
3. Targeted Therapies For Severe Asthma
In-depth investigation of the molecular and cellular mechanisms underlying SA pathophysiology
has significantly contributed to the development of novel therapeutic strategies for disease management.
Indeed, antibodies targeting factors involved in SA pathology are already being used as a first line
medication. An excellent example is omalizumab, a monoclonal antibody directed against IgE that has
become an established add-on therapy for patients with uncontrolled allergic asthma [74]. In addition,
monoclonal antibodies against IL-5 (reslizumab, mepolizumab), IL-5R (benralizumab), and IL-4R
(dupilumab) have been approved as add-on treatments for uncontrolled type 2 eosinophilic asthma [74].
Although these therapies have proven effective in certain asthma cohorts, some patients that suffer
from severe allergic and/or eosinophilic asthma, as well as most patients with severe non type 2 asthma,
experience weakly-regulated disease manifestations [74]. Notably, the reported adverse effects of these
monoclonal antibody therapies should be also considered. For example, administration of omalizumab
has been associated with an anaphylaxis rate of 0.09% that most frequently occurs within 2 hours after
the first dose and 30 min after subsequent doses, necessitating the close monitoring of patients [75,76].
Moreover, a higher incidence of cardiovascular and cerebrovascular adverse effects (AEs) has been
observed upon omalizumab administration [77]. Mepolizumab, the first anti-IL-5 monoclonal antibody
approved for eosinophilc asthma, has been associated with headaches, injection site reactions, back
pain, and fatigue [78]. The most common AEs of reslizumab, another FDA-approved anti-IL-5 antibody,
are a 0.3% anaphylaxis rate, elevated serum creatinine kinase, and musculoskeletal and oropharyngeal
pain [79]. Regarding benralizumab, an anti-IL-5R antibody that is currently undergoing phase 3 trials,
there have been no documented AEs apart from nasopharyngitis and injection site reactions [80].
AEs in patients receiving dupilumab, a monoclonal antibody that targets the common receptor for
IL-4 and IL-13, include nasopharyngitis, injection site reactions, and headaches [81]. Monoclonal
antibodies targeting TSLP, IL-33 and its receptor ST2, the receptor for stem cell factors on mast cells,
and a DNA enzyme directed at GATA3 are currently being evaluated for their efficacy in SA. It is worth
mentioning that a number of antagonists directed against other potential targets, such as, IL-25, IL-6,
TNF-like ligand 1A, CD6, and activated cell adhesion molecules are under consideration for future
clinical trials [74]. Results from these clinical trials will be of great importance as they may introduce
novel treatment modalities that will successfully replace the existing ones and lead to the efficient
management of SA.
Taken together, it becomes evident that as the airway lumen is continually exposed to external
and endogenous stimuli, its ability to distinguish between innocuous environmental allergens and
pathogenic agents is crucial for the maintenance of immune tolerance and lung homeostasis. In fact,
the complex interactions between innate and adaptive immune responses in the lung micromilieu
represent a major determinant of the development of tolerance or allergic inflammation. Innate immune
responses have considerable bearing on ensuing adaptive responses, and if left uncontrolled, can lead
to detrimental pathological consequences. Hence, delineation of the precise mechanisms involved in
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the regulation of innate immune reponses in the airways is essential for the design of more efficient
treatment modalities for SA patients.
4. Inflammasomes: A Key Component of Innate Immunity
The innate immune system acts as the first line of defense during exposure to environmental
pathogens. In the lung, innate immune responses act through downstream signaling by numerous
extracellular and intracellular receptors termed pattern recognition receptors (PRRs). PRRs recognize
pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS), bacterial and
viral RNA, danger-associated molecular patterns (DAMPs) in damaged and/or dying cells, including
reactive oxygen species (ROS), ATP and mitochondrial DNA, and homeostasis-altering molecular
processes (HAMPs) that detect alterations in cell homeostasis and elicit inflammatory responses in the
host [8,9]. PRRs are expressed on macrophages, monocytes, DCs, and on tissue-resident cells, including
airway epithelial cells, and upon ligand binding, induce the secretion of inflammatory cytokines and
chemokines [82,83]. PRRs consist of the Toll-like receptors (TLRs), the RIG-I-like receptors (RLRs), the
nucleotide-binding oligomerization domain-like receptors (NLRs), the Scavenger receptors, the C-type
lectin receptors (CLRs), and the absent-in-melanoma (AIM)-like receptors (ALRs). Among PPRs, TLRs
and NLRs represent the most well-known and studied receptors [83,84]. TLRs are located at the
cell membrane and the intracellular compartment, while NLRs are located solely in the cytosol [84].
Signaling through these receptors enables the innate immune system to monitor and respond to
infectious agents and other damage-inducing stimuli, eliciting protective immunity.
NLRs consist of a conserved nucleotide binding and oligomerization domain (NACHT),
a carboxy-terminal ligand-binding region, composed of leucine-rich repeats (LRRs), involved in ligand
binding or activator sensing, and an amino-terminal effector domain required for protein–protein
interactions [85–87]. The human NLR gene family consists of 22 members, classified into four
subfamilies depending on their N-terminal regions: NLRA, NLRB, NLRC, and NLRP. The NLRA
region contains an acidic transactivation domain, the NLRB a baculoviral inhibitory repeat-like domain,
NLRC contains a caspase activation and recruitment domain (CARD), and NLRP contains a pyrin
domain (PYD) [85–87]. The detection of PAMPs, DAMPs, and HAMPs by NLRs leads to the formation
of a large multimolecular signaling platform called the inflammasome. Inflammasomes respond to a
constellation of endogenous and pathogenic signals and are critical inducers of host defense. Five
major inflammasomes have been identified so far: NLRP1, NLRC4, RIG-I, AIM2, and NLRP3. These
consist of an active NLRP receptor, the inflammasome adaptor protein, Apoptosis-associated Speck-like
protein Containing CARD (ASC), and caspase-1 [88]. NLRP6, NLRP7, NLRP12, and IFI16, can also
form inflammasomes, but their composition remains unclear. Apart from the physiological role of
inflammasomes in providing protective immunity, inflammasomes also regulate cell proliferation
and tissue repair processes [11]. Still, overactivation of inflammasome-mediated responses can
cause excessive inflammation, tissue damage, and lead to chronic inflammatory diseases and
metabolic disorders.
5. Nlrp3 Biology and Functions
NLRP3 is expressed in granulocytes, monocytes, DCs, T cells, and epithelial cells [89]. The NLPR3
inflammasome consists of the NLRP3 receptor, the adaptor protein ASC, also known as Pycard, and
caspase-1 that acts as an effector protein [89]. The NLRP3 receptor is a tripartite protein that contains
an amino-terminal PYD, a nucleotide-binding NACHT, and a carboxy-terminal LRR domain. ASC has
two domains, an amino-terminal PYD and a carboxy-terminal CARD domain. NLRP3 activation leads
to protein–protein interactions between the NLRP3 and ASC via PYD domains. This facilitates ASC
polymerization to form long helical filaments that are condensed into an intracellular macromolecular
aggregate, known as ASC speck [90]. Subsequently, the ASC CARD domain associates with the CARD
domain of caspase-1, inducing caspase-1 self-cleavage and activation [91]. A serine–threonine kinase
known as NIMA-related kinase 7 (NEK 7) binds to NLRP3 directly and oligomerizes with NLRP3 into
a complex that is essential for ASC speck formation and caspase-1 activation [92]. Activated caspase-1
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cleaves the inactive pro-IL-1β and pro-IL-18 forms into bioactive cytokines that activate downstream
inflammatory pathways [93] (Figure 1). Recent studies have shown that ASC specks can be exocytosed
and accumulated in the extracellular space, retaining their ability to produce IL-1β. Extracellular ASC
specks can also be internalized by macrophages, further activating IL-1β production [94,95]. Moreover,
ASC specks isolated from cells can induce the aggregation of other ASC specks located intracellularly,
a feature shared with prionoid proteins. These findings suggest that extracellular ASC can propagate
inflammatory responses even at distinct sites, promoting systemic inflammation. Of note, increased
extracellular ASC specks were documented in bone marrow from patients with myelodysplastic
syndrome [96]. Pertinent to lung diseases, increased extracellularly-assembled ASC specks were
observed in the BAL of patients with chronic obstructive pulmonary disease and pneumonia compared
to patients with pulmonary hypertension and healthy controls [94]. Considering the documented
effects of extracellular ASC specks on the activation of distant cell populations, their presence in SA
patients may have important implications, and warrants further investigation.
Figure 1. Mechanisms involved in activation and regulation of NLRP3 canonical pathway. NLRP3
inflammasome activation requires two signals. The “priming” signal is triggered by PAMP/DAMP
recognition by PPRs (e.g. TLRs) and certain cytokines (e.g. TNF-α, IL-1β) and activates NF-κB in the cell
nucleus. This leads to NLRP3, pro-IL1-β and pro-IL-18 gene transcription. The second signal induces
the assembly of NLRP3, ASC, and caspase-1 to form an active NLRP3 inflammasome and ultimately
leads to the release of mature IL-1β and IL-18. Gasdermin D is cleaved and becomes inserted into the cell
membrane, forming pores and inducing pyroptosis. The mechanisms proposed for the second NLRP3
activating signals are shown and include: a) changes in cytosolic levels of ions, such as K+, Cl- and
Ca+2, b) lysosomal destabilization and the release of cathepsins, c) mitochondrial dysfunction-derived
signals such as mtROS, mtDNA and d) metabolic changes. PtdIns4P on dTGN drive NLRP3 activation.
Aerobic glycolysis pathways and the TCA cycle also activate NLRP3. Autophagy and mitophagy
inhibit NLRP3 inflammasome activation. IFNs also inhibit NLRP3 activation through NO production.
IL-1R, IL-1β receptor; TLR, Toll-like receptor; TNFR, tumor necrosis factor receptor; IFNAR, IFNα/β
receptor; NEK7, NIMA- related kinase 7; NF- κB, nuclear factor- κB; P2X7, P2X purinoceptor 7; PtdIns4P,
phosphatidylinositol-4-phosphate; PYD, pyrin domain; ROS, reactive oxygen species; HK1, hexokinase;
mTORC1, rapamycin complex 1; SDH, succinate dehydrogenase; EIF2AK2, eukaryotic translation
initiation factor 2-alpha kinase 2.
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IL-1β secretion upon NLRP3 inflammasome activation initiates acute phase reactions, including
the recruitment of inflammatory cells at the site of infection and expression of proinflammatory
cytokines, such as, IL-6, TNF-α, and chemokines [97]. Briefly, active IL-1β binds to the extracellular
domain of the IL-1 type 1 receptor (IL-1R) that recruits the second receptor chain, termed IL-1R accessory
protein (IL-1RAcP) [98]. This leads to the activation of intracellular signaling molecules, such as the
myeloid differentiation primary response 88 (MYD88), TNF receptor-associated factor 6 (TRAF6) and
IL-1R-associated kinases (IRAK), which, in turn, activate the nuclear factor-κB (NF-κB) transcription
factor, eliciting cytokine gene expression [99]. Active IL-1β exerts its functions through both autocrine
and paracrine mechanisms, and therefore its regulation is under tight control to circumvent pathologic
implications. IL-1β signaling is also involved in Th2 and Th17 cell differentiation and is implicated in
the pathogenicity of allergic airway inflammation [100]. The biological role of IL-18 is different from
that of IL-1β. IL-18 induces Th1 cell responses and the production of IFN-γ by CD4+ and CD8+ T cells,
natural killer cells, and macrophages, and is essential for antiviral immunity. IL-18 also plays a role
in Th2 cell differentiation and is involved in AHR in experimental models, as well as in asthmatic
patients [101,102].
Apart from proinflammatory cytokine release, a key outcome of NLRP3 inflammasome activation
is pyroptosis, a form of lytic cell death characterized by cell swelling, membrane rupture, and
release of proinflammatory cellular contents [103,104]. The formation of plasma membrane pores
during pyroptosis drives ion changes, inducing increased osmotic pressure, water influx, and cell
swelling. Pyroptosis is triggered by caspase-1-driven cleavage of the pore-forming protein gasdermin
D (GSDMD) that leads to the formation of the GSDM N-terminal fragment, that, in turn, introduces
pore formation upon insertion into the plasma membrane, thus killing cells from within [103,104].
Pyroptosis is a highly inflammatory process that is accompanied by the release of IL-1β, IL-18, IL-1α,
high mobility group box 1 protein, and lactate dehydrogenase to the extracellular milieu [103,105]
(Figure 1). NLRP3 inflammasome activation occurs through three distinct molecular pathways: the
canonical, the noncanonical, and the alternative pathways [11,86,89,92,105,106] (Table 1).
Table 1. Key characteristics of canonical, noncanonical and alternative NLRP3 activation.
Pathways of NLRP3 Inflammasome Activation Canonical Noncanonical Alternative
NLRP3-ASC-Casp1 signaling Yes Yes Yes
Caspase-1 cleavage, IL-1β maturation Yes Yes Yes
Caspase-11, 4, 5 cleavage No Yes No
Caspase-8 cleavage No No Yes
Signal 2 requirement Yes No No
Pyroptosome formation Yes Yes No
Cell Death Yes Yes No
6. Activation of the Canonical Nlrp3 Pathway
Activation of the NLRP3 inflammasome through the canonical pathway requires 2 steps: a priming
signal and a second activating signal (Figure 1). The priming signal is crucial for the transcription
of the inflammasome components, NLRP3, CASP1, and the IL1B and IL18 genes. The priming
signal is usually a PAMP, such as, LPS, lipoproteins, carbohydrates, and flagellin [107]. IL-1β and
TNF-α signaling can also induce NLRP3 priming, known as sterile priming. Gene transcription upon
priming is mediated predominantly through NF-κB activation and nuclear translocation [108,109].
Interestingly, recent studies have discovered a nontranscriptional priming process that relies on
post-translational modifications (PTMs), such as ubiquitylation, phosphorylation, and sumoylation of
NLRP3 components [110].
A wide variety of secondary stimuli activate the NLRP3 inflammasome, including bacteria,
viruses, environmental nanoparticles such as alum and silica, and endogenous molecules, including
ATP, monosodium urate (MSU), and cholesterol crystals. The main mechanisms through which these
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PAMPs and DAMPs trigger NLRP3 inflammasome activation are associated with: a) changes in
cytosolic levels of ions, such as, K+, Ca+2, and Cl-, b) lysosomal destabilization, c) ROS production,
and d) mitochondrial dysfunction [92,111]. The second activation signal leads to the assembly of the
NLRP3 complex, the activation of caspase-1, and the release of the mature forms of IL-1β and IL-18
(Figure 1).
Decreased extracellular K+ levels trigger NLRP3 activation, while high extracellular K+
concentrations block NLRP3 signaling [112]. For example, extracellular ATP, upon binding to
its receptor, the purine-dependent phenoxin-1 channel P2X7, induces K+ efflux and initiates NLRP3
assembly and downstream signaling [113,114]. The bacterial toxin nigericin also promotes activation
of NLRP3 by inducing K+ efflux in a pannexin-1-dependent manner [115]. In addition to ATP and
pore-forming toxins, alum, silica, and calcium pyrophosphate crystals also induce K+ efflux. Moreover,
the complement cascade component membrane attack complex (MAC) activates NLRP3 [116]. Apart
from K+ efflux, mobilization of Ca+2 in the cytosol through the opening of plasma membrane channels
or the release of endoplasmic reticulum (ER)-linked Ca+2 stores represents another upstream event in
NLRP3 activation [117]. It should be emphasized that K+ efflux regulates Ca+2 flux and these two
channels act cooperatively to activate NLRP3. In fact, NLRP3 activation induced by nigericin, alum,
MSU crystals, and the MAC depends on Ca+2 flux along with K+ efflux [118]. Cl- efflux through
chloride intracellular channel proteins (CLICs) enhances NLRP3 activation via the polymerization
of ASC [119]. Translocation of CLIC1, CLIC4, and CLIC5 to the plasma membrane depends on the
release of mitochondrial ROS (mtROS), whereas Cl- efflux occurs downstream of K+ efflux [119].
Lysosomal swelling and damage by phagocytosed but resistant to degradation crystals, such as silica,
β-amyloid, liposomes, and asbestos, represents another mechanism of NLRP3 activation [120,121].
Briefly, the accumulation of crystals intracellulary destabilizes the lysophagosome and leads to the
release of its components, including proteases, lipases, cathepsins, and Ca+2 in the cytosol, which, in
turn, drive NLRP3 assembly and activation in a K+ efflux-dependent manner [120,121] (Figure 1).
Numerous sources of ROS, such as, NADPH-oxidases, xanthine oxidase, cytochrome P450,
cyclooxygenases, and lipoxygenases, induce NLRP3 activation [122] (Figure 1). The production of
mtROS and mitochondrial DNA (mtDNA) also activate NLRP3. In fact, chemical inhibitors preventing
ROS production inhibit NLRP3 inflammasome activation in response to several activators. Furthermore,
factors that cause mitochondrial dysfunction increase the oxidation of mtDNA, which activates NLRP3
inflammasome. Increased mtROS production oxidizes thioredoxin (TRX), leading to its dissociation
from the thioredoxin (TRX)-interacting protein (TXNIP). The dissociated TXNIP directly binds to
NLRP3, leading to its activation [123]. Mitochondria also act as docking sites for NLRP3 inflammasome
assembly. For example, the mitochondrial antiviral signalling protein (MAVS), an adaptor protein
in RNA sensing, is critical for NLRP3 inflammasome activation during infections with RNA viruses
and stimulation with the synthetic RNA polyinosinic-polycytidylic acid. MAVS recruits NLRP3,
directing its localization to the mitochondria [124]. Still, MAVS is not essential for NLRP3 inflammation
induced by other NLRP3 stimuli. Recently, it was shown that trans-Golgi network disassembly into
vesicles, known as dispersed trans-Golgi network (dTGN), is another process that leads to NLRP3
inflammasome activation. More specifically, the phospholipid phosphatidylinositol-4-phosphate on
dTGN drives NLRP3 aggregation, ASC oligomerization and caspase-1 activation, and downstream
signaling [125].
Interestingly, recent studies have implicated cellular metabolic events in the activation of the
NLRP3 inflammasome. Indeed, aerobic glycolysis and the mitochondrial electron transport chain (ETC)
enhance NLRP3-driven responses [126–129] (Figure 1). In LPS-stimulated macrophages, activation
of mammalian target of rapamycin complex 1 (mTORC1) promotes hexokinase (HK1)-dependent
glycolysis which, in turn, induces NLRP3 activation [126–129]. Consequently, inhibition of mTORC1
or deficiency of Raptor, an mTORC1-binding partner, decreases HK1-dependent glycolysis and
suppresses NLRP3 signaling [126–129]. Moreover, glucose deprivation, 2-deoxyglucose (2-DG)
treatment, or HK-1 knockdown suppresses ATP-driven NLRP3 activation and inhibits IL-1β secretion
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by macrophages [126–129]. Additionally, saturated fatty acids, such as palmitate, suppress the
activation of the anti-inflammatory AMP-activated kinase, leading to increased ROS production and
NLRP3 activation [130].
Altogether, these secondary activating signals lead to IL-1β and IL-18 secretion downstream of
NLRP3 activation and also to pyroptosis (Figure 1). Still, despite extensive research in understanding
the upstream events during NLRP3 activation, there is still no single unifying model, and further
studies using genetic approaches, rather than pharmacological inhibition that could lead to indirect
and off-target effects, need to be performed.
7. Role of the Noncanonical and Alternative Nlrp3 Activation Pathways
The noncanonical pathway of NLRP3 activation is associated with the detection of intracellular
LPS generated following infection by Gram-negative bacteria, such as Escherichia coli, Salmonella
typhimurium, Shigella flexneri, and Burkholderia thailandensis [131–133]. As such, the noncanonical
NLRP3 pathway induces pyroptotic cell death and restricts the growth of intracellular bacteria
in myeloid and nonmyeloid cells. The noncanonical NLRP3 pathway requires signaling through
caspase-11 in mice and caspases 4 and 5 in humans. The binding of LPS to caspases 11, 4, and 5 results
in their autoactivation and cleavage of GSDMD, triggering pyroptosis and the secretion of IL-1α [134].
Pyroptosis enhances K+ efflux which activates the canonical NLRP3 pathway and the release of IL-1β
and IL-18. Hence, caspases 4, 5, and 11 do not cleave IL-1β and IL-18, but only lead to pyroptosis,
and the subsequent canonical NLRP3 inflammasome activation pathway is responsible for caspase-1
activation and cytokine secretion. Activated caspase-11 also cleaves pannexin-1, a membrane ATP
channel, which induces K+ efflux and activates the canonical NLRP3 pathway [131–133].
The cytosolic accessibility of LPS is driven by Guanylate-Binding Proteins (GBPs) and the Immunity
Related GTPase family member 10 (IRGB10) which lyse the Gram-negative bacterium-containing
vacuoles, releasing bacterial LPS into the cytoplasm [134,135]. Bacterial outer membrane vesicles
(OMVs) also deliver LPS into the cytoplasm through endocytosis. Another process through which
extracellular LPS activates the noncononical NLRP3 pathway is the binding and activating of its
receptor, TLR4. TLR4 induces TRIF and MyD88 signaling, and drives the production of type I IFNs
which, in turn, enhance the expression of the noncanonical inflammasome components, caspase-11,
GBPs and IRGB10 [135,136]. In fact, type I IFNs, along with the complement C3-C3aR axis, upregulate
caspase-11 expression. In neutrophils, the activation of the noncanonical NLRP3 pathway through
detection of cytosolic LPS induces the release of neutrophil extracellular traps (NETs) that, in turn,
activate the canonical NLRP3 pathway [137]. Reciprocally, IL-18 released upon NLRP3 inflammasome
assembly induces NETosis [137].
An alternative NLRP3 inflammasome pathway was recently discovered in human and porcine
monocytes and does not require a secondary signal [106]. LPS recognition by TLR4 induces the
intracellular activation of the TIR-domain-containing adapter-inducing interferon-β - Receptor-
interacting serine/threonine-protein kinase 1 - Fas-associated protein with death domain - Caspase-8
(TRIF-RIPK1-FADD-CASP8) cascade. Cleavage of caspase-8 induces NLRP3 activation and the
maturation of IL-1β and IL-18, through an as yet unknown mechanism. This alternative pathway of
NLRP3 activation occurs independently of K+ efflux and ASC speck formation. An additional unique
feature is that it does not trigger pyroptosis, and the secretion of IL-1β is independent of GSDM [106].
Notably, in mouse bone marrow-derived macrophages (BMDM), simultaneous TLR and NLRP3
stimulation leads to rapid inflammasome activation independent of de novo gene transcription [138].
This type of NLRP3 activation does not promote IL-1β secretion and pyroptosis, but enhances IL-18
production and provides a fast protective response against intracellular pathogen burden.
8. Regulation of Nlrp3 Functions
The activation of the NLRP3 inflammasome is associated with a diverse range of human diseases.
Mutations in the NLRP3 gene are associated with the dominantly inherited autoinflammatory diseases
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known as cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory
syndrome, Muckle–Wells syndrome, and chronic infantile neurological cutaneous and articular
syndrome [139–141]. Single nucleotide polymorphisms in the genes encoding NLRP3 inflammasome
components have been also associated with the pathophysiology of Crohn’s disease and rheumatoid
arthritis. Other studies have revealed that excessive NLRP3 activation is implicated in diseases driven
by metabolic dysfunction such as type 2 diabetes and nonalcoholic steatohepatitis, in neurodegenerative
diseases including Alzheimer’s disease and Parkinson’s disease, and in cancer [142–145]. Notably,
NLRP3 activation through exposure to crystals and protein aggregates is associated with silicosis
and fibrosis in the lung, atherosclerosis, gout flares, and kidney dysfunction [142]. Hence, stringent
regulation of NLRP3 responses is essential for the control of overactive inflammatory processes and
the prevention of tissue damage.
NLRP3 regulation takes place both at the transcriptional and the post-transcriptional levels. Type
I-IFNs repress the expression of pro-IL-1β through the secretion of IL-10 [146] (Figure 1). Type-I
IFNs also induce the expression of iNOS, which inhibits NLRP3 activation through the production
of Nitric oxide (NO ) and TRIM that reduces ROS release [147]. Post-transcriptional regulation of
NLRP3 involves signaling through the microRNA, mir-223, which binds to the 3’ untranslated region
UTR of NLRP3 and inhibits its expression [148] (Figure 1). PTMs can also negatively regulate NLRP3
responses. Indeed, the ubiquitylation of the LLR domain of NLRP3 by the membrane-associated
Ring finger protein 7 (MARCH-7), and the phosphorylation of its Ser291 residue, negatively regulates
NLRP3 activation [149,150].
One of the most important mechanisms that restrain NLRP3 functions is autophagy (Figure 1).
Autophagy is an endogenous recycling process utilized by the host to maintain cell homeostasis in
response to stress [151]. In autophagy, dysfunctional or unnecessary cellular components become
degraded. In addition, mitophagy promotes the clearance of damaged mitochondria from the cytoplasm
and reduces mtROS [151]. Recent studies have shown that activation of NLRP3 in macrophages deficient
in autophagy components, such as Beclin or Lc3b, leads to increased secretion of mtDNA and ROS,
and increased activation of caspase-1 and release of IL-1β and IL-18 [152,153]. Furthermore, in vitro
treatment of monocytes with rapamycin, an autophagy inducer, reduces IL-1β secretion in response
to LPS [154]. In addition, induction of mitophagy through activation of the receptor-interacting
serine/threonine-protein kinase 2 (RIP2) limits virus-induced NLRP3 activation [155]. Moreover,
infection with influenza A virus in mice deficient in Nod2 and Ripk2 results in defective mitophagy,
leading to excessive activation of NLRP3 and increased IL-18 production [155].
Signaling through metabolic regulators can also inhibit NLRP3 activation. Dimethyl fumarate
(DMF) activates the transcription factor NF-E2-related factor 2 (NRF2) that represses IL-1β and
NLRP3 gene expression in LPS-treated microglia and in the human acute monocytic leukemia
cell line (THP-1) [156]. NRF2 also regulates levels of antioxidant genes to support cell survival
during oxidative stress, and through limiting ROS levels, it inhibits NLRP3 activation [157]. DMF
also decreases mtROS release and suppresses NLRP3 assembly [156]. In addition, nicotinamide
adenine dinucleotide (NAD+) activates sirtuins (Sirt2) which inhibit NLRP3 inflammasome activation
and decrease pro-IL-1β production [158] (Figure 1). Some metabolites of fatty acids, including
β-hydroxybutyrate and α-linolenic acid, suppress NLRP3 activation via inhibiting K+ efflux and the
oligomerization of ASC, and by reducing ROS levels [159,160]. Interestingly, cholesterol metabolism
is also associated with the regulation of NLRP3 responses. Of note, a recent report documented
that bile acids through the TGR5-cAMP-protein kinase A axis inhibit NLRP3 activation and prevent
LPS-induced systemic inflammation, alum-mediated peritoneal inflammation, and type 2 diabetes in
mouse models [161]. Other studies in human primary monocyte-derived macrophages showed that
PGE2 treatment following LPS stimulation inhibits NLRP3 activation through increasing intracellular
cAMP levels [162]. In support, inhibition of cyclooxygenase 2, resulting in PGE2 blockade, enhances
NLRP3 activation in human macrophages. In response to PGE2, protein kinase A is also upregulated,
phosphorylates Ser295 of NLRP3, and attenuates its ATPase function [150]. Conversely, treatment of
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BMDM with PGE2 prior stimulation with LPS and ATP increased IL-1β and active caspase-1 release in
culture supernatants, highligting species-specific differences as well as differences dependent on the
timing of PGE2 administration [163].
Several small-molecule compounds have been described as potent inhibitors of NLRP3 activation,
including MCC950 [164], β-hydroxybutyrate (BHB) [159], Bay 11-7082 [165], dimethyl sulfoxide
(DMSO) [166], and type I IFN [167]. Seminal studies by Coll et al. have documented that MCC950
inhibits both the canonical and the noncanonical pathways of NLRP3 activation, while it does not
affect other inflammasomes. MCC950 prevents NLRP3-induced ASC oligomerization without affecting
NLRP3 priming, and inhibits IL-1β secretion by human and mouse macrophages [164]. Subsequent
studies demonstrated that MCC950 blocks nigericin-induced NLRP3 activation via inhibition of Cl-
efflux in LPS-primed BMDMs [168]. Moreover, MCC950 inhibits NLRP3 inflammasome formation
through blocking ATP hydrolysis [169]. Of relevance, preclinical studies have shown that MCC950
alleviates the severity of experimental autoimmune encephalomyelitis and prevents neonatal lethality
in a model of CAPS [164]. Pharmacological inhibition of NLRP3 with MCC950 also protected against
dopaminergic degeneration in a mouse model of Parkinson’s disease (PD), and reduced total leukocytes
and inflammatory macrophages in the BAL of mice infected with influenza A virus [170,171].
The aforementioned paragraphs highlight crucial functions for NLRP3 inflammasome activation in
the eradication of pathogens, the protection against damaged and/or dying cells, and the maintenance
of tissue homeostasis. However, several gaps in our understanding of the precise molecular pathways
involved in the initiation and regulation of NLRP3-driven inflammatory responses remain, and
represent promising avenues for future research. In the next section, we describe current knowledge
on the role of NLRP3 activation in the initiation and propagation of allergic airway inflammation and
human asthma, and discuss the implications of excessive NLRP3 responses in the pathogenesis of
allergic diseases.
9. Role of Nlrp3 Signaling in Allergic Airway Inflammation
NLRP3 inflammasome activation is involved in the initiation and the propagation of allergen-
driven inflammatory responses in the airways. Studies using mouse models of allergic asthma induced
by adjuvant-free ovalbumin (OVA) and adjuvant (aluminum hydroxide)-coupled OVA, demonstrate
enhanced protein levels of NLRP3 and caspase-1, along with elevated IL-1β and TNF-α release by
epithelial cells and macrophages in the airways, compared to Phosphate-buffered saline (PBS)-treated
mice [172]. Moreover, in mice sensitized with OVA and LPS and challenged with OVA (OVALPS-OVA),
as well as in HDM-instilled mice, increased ROS and mtROS production in BAL cells and in primary
tracheal epithelial cells was detected, inducing augmented NLRP3, caspase-1, and IL-1β protein
expression in the airways [173]. Interestingly, recent studies using three distinct HDM-induced mouse
models of allergic airway inflammation (AAI), corresponding to eosiniphilic, mixed granulocytic, and
neutrophilic asthma subtypes, documented increased expression of Nlrp3, Nlrc4, Nlrc5, Pycard, Casp-1
genes, and pro-IL-1β protein levels in the lungs, especially in the neutrophilic asthma model, while
mature IL-1β was not shown, suggesting that although inflammasome molecules are upregulated,
they do not form functional complexes without an additional trigger [174]. Moreover, increasing
inflammasome sensor, caspase-1, and pro-IL-1β expression was documented from eosinophilic to
neutrophilic asthma, illuminating an association of inflammasome signaling pathways with the type of
airway inflammation [174]. Notably, induction of neutrophilic airway inflammation in mice challenged
with HDM and polyinosinic-polycytidylic acid increased the concentration of Apolipoprotein E (APOE)
in the epithelial lining fluid and enhanced IL-1β levels in the BAL, pointing to a potential role of APOE
in IL-1β production [175].
Pertinent to the role of NLRP3 activation in allergic responses, studies using mice deficient in
NLRP3 and ASC in a model of OVA-induced AAI demonstrated decreased eosinophil influx, dampened
AHR and reduced airway inflammation, and goblet cell accumulation, accompanied by decreased IL-1β
expression in the airway, compared to wild type (WT) littermates [176]. Other studies also in a model
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of OVA-AAI, revealed that NLRP3-/- mice exhibit decreased pulmonary inflammation with suppressed
mucus secretion, Th2 cytokine and chemokine production, and IgE levels [177]. Interestingly, in a
model of OVA-AAI, production of IL-1α and IL-1β in the airways propagated Th2 cell-driven allergic
responses and exacerbated pulmonary eosinophilia in a process mediated by caspase-8 activation [178].
These studies highlighted a novel role for caspase-8 in NLRP3 activation in the allergic airway, which
was independent of caspase-1 and 11 signaling [178]. Other reports using a model of serum amyloid
A (SAA)-induced AAI documented that the secretion of IL-1β in response to SAA is dependent on
NLRP3 activation [179]. In fact, using mice deficient in NLRP3 and caspase-1, the authors demonstrated
a reduction in infiltrating neutrophils in the lung and decreased inflammatory cytokine/chemokine
release (IL-1β, IL-6, and MCP-1 or CCL2) in the BAL compared to WT controls [179]. Another
study using a complete Freund’s adjuvant (CFA)/HDM-induced mouse model of AAI showed that
administration of CRID3, an NLRP3 inhibitor, reduced IL1-β and Th2 cytokine production in the BAL
and inhibited AHR [180]. Interestingly, a recent report demonstrated that NLRP3, along with IRF4,
transactivates the Il4 promoter, enhances Th2 cell differentiation, and exacerbates asthma symptoms
in a mouse model [181]. Moreover, studies by Kim et al., in an experimental model of high fat
diet-induced obesity, demonstrated that obese mice had increased AHR driven by aberrant NLRP3
inflammasome-dependent responses in the adipose tissue, which contributed to the activation of
ILCs and increased IL-17 responses in the lung, in the absence of allergic sensitisation [182]. These
studies highlighted a novel NLRP3-IL-1β-Th17 link in AHR development in obesity-associated allergic
airway disease.
Notably, sensitization with OVA-alum or Aspergillus fumigates followed by challenge with OVA or
A. fumigates, respectively, increased ROS production in lung homogenates mediated by mitochondrial
Ca2+/calmodium-dependent protein kinase II (CaMK II), which induced NLRP3, active caspase-1 and
mature IL-18 at the mRNA, and protein levels in allergic lungs, as well as exacerbated OVA-AAI [183].
In contrast, inhibition of mitochondrial CaMK II reduced AHR, Th2 cytokine production and NLRP3
activation in the lungs [183]. Further studies in a mouse model of OVA-AAI, accompanied by infection
with Chlamydia muridarum or Haemofilus influenza, demonstrated an increased expression of NLRP3
in airway epithelial and infiltrating immune cells, as well as enhanced IL-1β and caspase-1 mRNA
levels in the lungs of infected mice [184]. Notably, in vivo administration of MCC950 decreased AHR
and neutrophil accumulation in the airways of infected mice [184]. Furthermore, using mice deficient
in NLRP3 and IL-1β, another study documented reduced airway inflammation and cytokine release
following rhinovirus (RV) infection in HDM-challenged mice, highlighting the implication of NLRP3
activation in RV-induced disease exacerbations [185]. Notably, subepithelial macrophages were the
major source of IL-1β in response to RV, with low IL-1β expression by the airway epithelium, suggesting
that NLRP3 activation mainly occurred in macrophages. Moreover, no induction of IL-18, either at the
mRNA or the protein levels, was observed in airway epithelial cells upon RV infection. It should be
emhpasized that, in contrast to the airway epithelium, the gut epithelium is characterized by increased
IL-18 and low IL-1β production in response to NLRP3 signaling. Indeed, IL-1β levels remained
unaltered in colonic intestinal epithelial cells from mice treated with a high-fibre diet, while active
caspase-1 and IL-18 were increased [186]. Notably, using NLRP3-/- mice, the authors showed that the
protective effects of a high-fibre diet against colitis were mediated through NLRP3 activation in colonic
epithelial cells. Altogether, these studies suggest that epithelial cells at distinct sites respond differently
to inflammasome activation, not only in terms of cytokine secretion but also in the inflammasome
sensor utilized, and propose a key role of the tissue micromilieu in governing epithelial cell-induced
inflammatory responses.
Contradictory data have been generated by studies showing that NLRP3 activation is not essential
for allergic disease development in OVA and HDM induced AAI. Allen et al. showed that the
adjuvant effects of aluminum hydroxide in the OVA-AAI model were not affected in NLRP3-/-, Casp-/-,
or PYCARD-/- mice [187]. In another study, NLRP3-/- mice did not exhibit significant differences in
airway eosinophilia, mucus production, AHR, and Th2 cell responses upon exposure to uric acid
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crystals compared to their WT counterparts [188]. Similar findings were observed in a combined
particular matter (PM)/Ova-induced mouse model of experimental asthma [189]. Finally, Madouri
et al. demonstrated that mice deficient in NLRP3-/-, Casp-/-, or PYCARD-/- exhibited enhanced lung
inflammation and pathology, including eosinophilic inflitration and Th2 cytokine release, upon
exposure to HDM, supporting the notion that NLRP3 activation exerts protective functions against
HDM-induced allergic lung inflammation [190].
10. Nlrp3 Signaling in Human Asthma
A series of recent studies suggest that NLRP3 activation is involved in human asthma pathogenesis.
Hirota et al. was among the first to describe NLRP3 and caspase-1 protein expression in human
lung sections and in primary airway epithelial cells from healthy volunteers following exposure to
PM10. In fact, they demonstrated that NLRP3 silencing using short hairpin (sh) NLRP3 attenuated
PM10-induced release of IL-1β by human airway epithelial cells [191]. In other studies, in vitro RV
infection of HBECs upregulated NLRP3, NLRC5, and caspase-1 protein levels that triggered IL-1β
secretion [192]. Knock down of NLRP3 or NLRC5, using shRNA, decreased IL-1β secretion by HBECs,
while simultaneous knock down of NLRP3 and NLRC5 abrogated IL-1β secretion. Moreover, HBEC
from asthmatics exhibited enhanced co-localization of caspase-1 and ASC and increased mRNA
expression of caspase-4 after IAV infection compared to healthy controls [193] (Figure 2). Still, it should
be emphasized that the previous studies were using human bronchial epithelial cells cultured in a
monolayer, and NLRP3 activation in airway epithelial cells cultured in an air–liquid interface (ALI),
which is a more physiologically relevant model, remains incompletely defined. Increased NLRP3 and
IL-18 protein levels were observed in airway epithelial cells in lung biopsies from asthmatics compared
to healthy individuals [183]. Notably, individuals with neutrophilic asthma had elevated mRNA
levels of NLRP3, caspase-1, and IL-1β, as well as NLRP3 and caspase-1 protein expression in sputum
macrophages and neutrophils, compared to eosinophilic and paucigranulocytic asthmatics [180,194]
(Figure 2). Increased expression of NLRP3 and IL-1β was also detected in the sputum of patients
with SA compared to MMA, and correlated with clinical parameters of disease, such as neutrophilic
airway inflammation, Asthma Control Questionnaire (ACQ) score, and Forced Expiratory Volume in 1
second (FEV1)% [184]. In another study, increased extracellular DNA (eDNA) sputum levels in SA
correlated with sputum neutrophilic inflammation, increased NETs formation, caspase-1 activity, and
IL-1β levels [195]. NLRP3 gene expression and IL-1β protein levels were also increased in sputum
inflammatory cells from obese asthmatics compared to non-obese asthmatics, and correlated with body
mass index [196] (Figure 2). Kim et al. showed higher expression of NLRP3 and caspase-1 in the BAL
of asthmatics compared to healthy subjects [173] (Figure 2). BAL macrophages from asthmatics treated
ex vivo with HDM also upregulated NLRP3 and pro-IL-1β expression, resulting in increased IL-1β
secretion in an APOE-dependent manner [174]. Lui et al. also showed that macrophages isolated from
the PB of patients with Th2/Th17-predominant asthma had higher mRNA and protein levels of NLRP3
components and IL-1β compared to healthy controls [197].
Pertinent to inflammasome related-cytokines, most studies have shown that IL-1β is increased in
the sputum and BAL of patients with neutrophilic asthma [198], and in the serum of asthmatic patients
with or without steroid treatment, compared to controls [199] (Figure 2). Contradictory findings were
observed regarding IL-18 release, with some studies showing increased IL-18 in the serum [200,201]
and sputum from SA patients [202,203], and others reporting decreased levels in induced sputum [204].
Considering the increased activation of the NLRP3 pathways, along with excessive IL-1β release,
in asthmatic patients, the concept of IL-1β blocking as a therapeutic approach in SA appears promising.
Therapeutic administration of canakinumab, a fully human anti-IL-1β monocloncal antibody, has
been widely used in conditions ranging from CAPS to rheumatoid arthritis, atherosclerosis, and lung
cancer [205–208]. Pertinent to asthma, there was only one randomized double-blind placebo-controlled
study that evaluated the safety and tolerability of canakinumab in mild asthmatic patients, as well as
its effects on the attenuation of the late asthmatic response (LAR) following allergen challenge [209].
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Canakinumab appeared to be safe and attenuated LAR compared to pretreatment values. Despite
these positive results, no further studies have been conducted since [209], and canakinumab is no
longer under investigation as a treatment for asthma (searched on clinicaltrials.org on 11/09/2019).
Figure 2. The role of NLRP3 inflammasome in the development of severe asthma. Exposure to
pathogens, allergens, cigarette smoke, and other noxious stimuli in the asthmatic airway triggers the
production of ROS, cytokines, and NETs which, in turn, can activate the NLRP3 inflammasome in
infiltrating eosinophils, neutrophils, and macrophages, as well as in airway epithelial cells. This results
in the enhanced release of IL-1β and IL-18, which leads to increased Th1 Th2 and/or Th17 cell infiltration
and associated pathological consequences, such as mucus hypersecretion, AHR, and airway remodelin.
eDNA, extracellular DNA; NETs, neutrophil extracellular traps; AHR, airway hyperresponsiveness.
In summary, a growing body of evidence suggests that NLRP3-induced inflammasome responses
are implicated in AAI both in experimental models and human asthma (Figure 2). Still, certain
controversial results obtained in animal studies are mainly associated with variations in the experimental
models utilized, including type and concentration of allergen, route and time of administration, as
well as mouse strain differences. The observed differences could be also associated with the distinct
housing conditions affecting the microbiota composition. Hence, further mechanistic studies are
warranted to resolve these disparities. More importantly, the precise role of NLRP3 activation in
experimental models of SA remains elusive and deserves investigation. Of note, certain findings
observed in animal studies were not observed in human asthmatics. For example, in human airway
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epithelial cells, it seems that other than NLRP3 inflammasome sensors become activated and trigger
IL-1β release. Moreover, the precise factors that initate inflammasome assembly and activation in
asthmatics remain incompletely defined. Mechanistic studies using animal models that more closely
resemble SA need to be performed to clarify the type of cells in which NLRP3 signaling is activated, as
well as its upstream regulators. In addition, functional studies using human primary airway epithelial
cells in ALI cultures are essential for the elucidation of the differences in NLRP3-induced signaling
in humans and mice. Finally, elucidation of the role of NLRP3 activation in the functional crosstalk
between airway epithelial cells and other lung structural cells, such as ASMs, may shed new light on
the mechanisms underlying tissue remodelling in SA.
11. Concluding Remarks
The past decade has witnessed a burgeoning appreciation of the existence of a wide range of
SA endotypes. Still, and particularly in the type 2 low asthma endotypes, there is a considerable
gap in our understanding of the cellular and molecular mechanisms involved and a remarkable
scarcity of relevant biomarkers. More importantly, no effective treatments targeted at these endotypes
have emerged. Growing evidence has illuminated a key role for NLRP3 inflammasome activation
in the development and exacerbation of allergic responses. Hence, targeting NLRP3 inflammasome
pathways in the airways of allergen-challenged mice, particularly in the context of SA, will improve our
understanding of how NLRP3 signaling contributes to the development of specific aspects of disease
severity. In fact, the direct comparison of the expression and activation of NLRP3 in mouse models and
patients with distinct asthma severities is essential for the identification of novel biomarkers pertinent
to the diverse asthma endotypes.
Current treatment modalities of NLRP3-related inflammatory human diseases target IL-1β
with IL-1β antibodies or recombinant IL-1βR antagonists, such as canakinumab and anakinra,
respectively. Nevertheless, most of these inhibitors are relatively nonspecific and have low efficacy.
Thus, the development of targeted NLRP3 inflammasome site-specific therapeutics may be more
beneficial in suppressing inflammasome-associated disease whilst not predisposing to infection.
However, a deeper understanding of the NLRP3 inflammasome assembly and activation is needed
before translation of these findings into therapies in clinical practice, especially in the context of
SA. To achieve this, we need the development and use of better in vivo models of SA, along with
complementary human studies using physiologically relevant in vitro models. Ultimately, this will
facilitate the development of personalized medicine for the growing numbers of patients with SA.
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Abstract: Before eosinophils migrate into the bronchial lumen, they promote airway structural
changes after contact with pulmonary cells and extracellular matrix components. We aimed to
investigate the impact of eosinophil adhesion to their viability and pro-proliferative effect on airway
smooth muscle (ASM) cells and pulmonary fibroblasts during different asthma phenotypes. A total
of 39 individuals were included: 14 steroid-free non-severe allergic asthma (AA) patients, 10 severe
non-allergic eosinophilic asthma (SNEA) patients, and 15 healthy control subjects (HS). For AA
patients and HS groups, a bronchial allergen challenge with Dermatophagoides pteronysinnus was
performed. Individual combined cells cultures were prepared between isolated peripheral blood
eosinophils and ASM cells or pulmonary fibroblasts. Eosinophil adhesion was measured by evaluating
their peroxidase activity, cell viability was performed by annexin V and propidium iodide staining,
and proliferation by Alamar blue assay. We found that increased adhesion of eosinophils was
associated with prolonged viability (p < 0.05) and an enhanced pro-proliferative effect on ASM
cells and pulmonary fibroblasts in asthma (p < 0.05). However, eosinophils from SNEA patients
demonstrated higher viability and inhibition of pulmonary structural cell apoptosis, compared to
the AA group (p < 0.05), while their adhesive and pro-proliferative properties were similar. Finally,
in the AA group, in vivo allergen-activated eosinophils demonstrated a higher adhesion, viability,
and pro-proliferative effect on pulmonary structural cells compared to non-activated eosinophils
(p < 0.05).
Keywords: eosinophil; adhesion; viability; proliferation; airway smooth muscle cell; pulmonary
fibroblast; phenotype; asthma
1. Introduction
Chronic eosinophilic inflammation is a major factor in the development of airway remodeling
in asthma [1]. The contribution of various cytokine networks makes asthma pathophysiology
very complex, and these mechanisms vary between patients with different asthma phenotypes.
Eosinophils are a significant source of cytokines, chemokines, growth factors, and enzymes [2],
therefore, their increased infiltration into asthmatic lungs leads to the disturbance of normal lung
homeostasis [3].
Eosinophils develop from bone marrow progenitors under the control of a dedicated set
of transcription factors and the cytokines interleukin (IL)-3, IL-5, and granulocyte-macrophage
colony-stimulating factor (GM-CSF) [4]. Eosinophils’ half-life is between 3 to 24 h in peripheral
J. Clin. Med. 2019, 8, 1274; doi:10.3390/jcm8091274 www.mdpi.com/journal/jcm113
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blood [5], while being in the lungs prolongs their half-life up to 36 h [6]. Survivability-promoting
signals can be different. IL-5 is the most important and specific survival factor for eosinophils [7],
but important mediators also include GM-CSF and IL-3 [8], tumor necrosis factor-α [9], leptin [10],
and cluster of differentiation 40 engagement [11]. It is known that combined culturing with pulmonary
structural cells promotes eosinophils survival [12–15], however, the precise mechanisms remain
unknown. Integrins as transmembrane molecular mechanosensors may change their activation
states under asthmatic conditions and transduce the signal through the cytoskeleton, thus regulating
eosinophil activity and viability [16,17].
In addition to chronic inflammation, both allergic and non-allergic phenotypes of asthma
are characterized by structural changes in the lungs, which is called airway remodeling [18].
Airway remodeling in asthma includes epithelial changes, subepithelial and airway smooth muscle
(ASM) thickening, as well as bronchial neoangiogenesis that develops after repetitive cycles of tissue
injury and abnormal repair processes because of chronic inflammation [19]. Airway remodeling
develops mainly because of disturbed ASM cells and pulmonary fibroblast proliferation that determine
the increase in tissue mass due to enhanced cell numbers and the release of the extracellular matrix
(ECM) [20]. Studies demonstrate that direct interaction with eosinophils promotes pulmonary
fibroblasts and ASM cell proliferation [21–24]. Eosinophil-released mediators, such as transforming
growth factor β-1 and cysteinyl leukotrienes, are the main ASM cells, as well as being pulmonary
fibroblast proliferation- and differentiation-promoting factors [25,26]; however, more research is
needed to understand increased eosinophil activity or prolonged viability dominates in their
pro-proliferative effect.
Asthma severity correlates with peripheral blood and sputum eosinophils count [27]. However,
as major symptoms and airway structural changes between allergic and non-allergic asthma phenotypes
overlap, the pathways through which the disease develops and how eosinophils are involved in the
disease pathogenesis are different [28]. This highlights the hypothesis that further course of the disease
during different asthma phenotypes or during disease exacerbation can be predicted not only by
increased eosinophil count but also by their different biological properties.
We hypothesized that adhesion of eosinophils may determine their survivability properties and
further effect on pulmonary structural changes in asthma. Isolated blood eosinophils demonstrate the
biological role closely related to lung eosinophil functions because they are mainly activated in the bone
marrow under the maturation and in peripheral blood by inflammatory mediators [29,30]. Therefore,
our use of a combined cell culture model between blood eosinophils and pulmonary structural cells
allows for imitation of in vivo processes. We evaluated the effect of adhesion to pulmonary structural
cells on eosinophil viability and pro-proliferative effects for different asthma phenotypes. Moreover,
we investigated, in vivo, how a provoked acute allergic asthma episode after a bronchial allergen
challenge affects eosinophil activity.
2. Experimental Section
2.1. Ethics Statement
The study protocol was approved by the Regional Biomedical Research Ethics Committee
of the Lithuanian University of Health Sciences (BE-2-13). Each participant was informed about
the ongoing investigation and gave his/her written consent. Trial registration: ClinicalTrials.gov
Identifier NCT03388359.
2.2. Study Population
The study population consists of only newly recruited, not studied individuals.
The study included steroid-free allergic asthma (AA) patients, severe non-allergic eosinophilic
asthma (SNEA) patients with high doses of inhaled steroids, and healthy non-smoking subjects
(HS) who comprised the control group. The participants were men and women between the ages of
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18–50 years old who signed written informed consent. The patients were recruited from the Department
of Pulmonology at the Hospital of the Lithuanian University of Health Sciences Kaunas Clinics.
The AA group were newly-established and untreated non-severe patients, approved with
symptoms and medical history for at least a 12 month period, having a positive skin prick test to
Dermatophagoides pteronyssinus allergen and positive bronchial challenge with methacholine.
The SNEA group was a non-allergic phenotype, approved by negative skin prick tests, and with
asthma diagnosis for at least 1 year. Peripheral eosinophil counts were≥0.3× 109/L during the screening
visit or ≥0.15 × 109/L if there was a documented eosinophil count ≥0.3 × 109/L in the 12 month period
before the screening. A severe course of the disease was approved with at least 12 month treatment of
high doses of inhaled steroids combined with long-acting beta-agonist ± long-acting antimuscarinic
agent ± episodic use of oral corticosteroids.
The HS group was without allergic and other chronic respiratory diseases.
Exclusion criteria for all groups were clinically significant permanent allergy symptoms,
active airway infection 1 month prior the study, exacerbation ≤ 1 month prior to study, use of
oral steroids ≤ 1 month prior to study, and smoking.
2.3. Study Design
Initially, all study subjects underwent physical examination, spirometry, a methacholine challenge
test, and a skin prick test to verify the inclusion and exclusion criteria. If individuals matched the
criteria, they were informed about the requirements for participation and informed written consent
was obtained.
At the first visit of the study, peripheral blood was collected and measured for exhaled fractional
exhaled nitric oxide (FeNO). Isolated peripheral blood eosinophils were counted, assessed in their
viability, and immediately prepared in combined cell cultures with ASM cells and pulmonary fibroblasts.
Additionally, AA patients and HS after primary collection of peripheral blood underwent a bronchial
allergen challenge with D. pteronyssinus allergen.
The second visit was 24 h after a bronchial allergen challenge for subjects whom this test was
performed, and all procedures were repeated according to the first visit. The experimental study
design is represented in Figure 1.
Eosinophil count (<1.5 × 106/20 mL blood), viability (<98%), and purity (<96%) after their isolation
processes, as well as eosinophil adhesion intensity (equal to control value) was used as experimental
exclusion criteria for all investigated subjects. All data provided in the manuscript were from subjects
who passed these criteria.
We performed the unblinded type of experiments, as well-planned preparation before the
recruitment of each study subjects was required, and the whole experimental plan was performed in
the same week.
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Figure 1. Experimental study design. CBC—Complete blood count; SNEA—Severe non-allergic
eosinophilic asthma; AA—Allergic asthma; HS—Healthy subjects; FeNO—Fractional exhaled nitric
oxide; ASM—Airway smooth muscle.
2.4. Lung Function Testing
Pulmonary function was tested by using an ultrasonic spirometer (Ganshorn Medizin Electronic,
Niederlauer, Germany). Baseline forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC),
and FEV1/FVC ratio were recorded as the highest of three reproducible measurements. The results
were compared with the predicted values matched for age, body height, and sex according to the
standard methodology.
Airway responsiveness was assessed using inhaled methacholine via pressure dosimeter (ProvoX,
Ganshorn Medizin Electronic, Niederlauer, Germany). Aerosolized methacholine was inhaled at 2 min
intervals, starting with a 0.0101 mg methacholine dose, and increasing it by steps up to 0.121, 0.511,
and 1.31 mg of the total cumulative dose was achieved, or until a 20% decrease in FEV1 from the
baseline. The bronchoconstriction effect of each dose of methacholine was expressed as a percentage of
decrease in FEV1 from the baseline value. The provocative dose of methacholine causing a ≥20% fall in
FEV1 (PD20M) was calculated from the log dose-response curve by linear interpolation of two adjacent
data points.
2.5. Skin Prick Testing
All patients were screened for allergy by the skin prick test using standardized allergen extracts
(Stallergenes, S.A., France) for the following allergens: D. pteronyssinus, Dermatophagoides farinae, cat and
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dog dandruff, five mixed grass pollens, birch pollen, mugwort, Alternaria, Aspergillus, and Cladosporium.
Diluent (saline) was used for the negative control, and histamine hydrochloride (10 mg/mL) was used
for the positive control. Skin testing was read 15 min after application. The results of the skin prick test
were considered positive if the mean wheal diameter was higher than 3 mm.
2.6. FeNO Measurement
All study subjects underwent fractional exhaled nitric oxide (FeNO) analysis with an on-line
method using a single breath exhalation and an electrochemical assay (NIOX VERO, Circassia, UK),
according to European Respiratory Society—American Thoracic Society guidelines. Patients made an
inspiration of FeNO-free air via a mouthpiece, immediately followed by full exhalation at a constant
rate (50 mL/s) for at least 10 s. The mean of three readings at the end of the expiration (plateau phase)
was taken as the representative value for each measurement. Values that were 12 ppb or more were
considered elevated values, according to ATS-ERS criteria.
2.7. Bronchial Allergen Challenge Test
Inhaled D. Pteronyssinus allergen (DIATER, Spain) was delivered via pressure dosimeter (ProvoX,
Ganshorn Medizin Electronic, Niederlauer, Germany). The starting point for the assessment of
bronchoconstriction effect was 2 min after nebulized saline inhalation. The aerosolized allergen
was inhaled at 10 min intervals, starting with 0.1 histamine equivalent prick (HEP)/mL allergen
concentration, increasing it by steps up to 1.0, 10.0, 20.0, 40.0, 60.0 HEP/mL, or if a 20% decrease in FEV1
from the baseline was achieved. The provocative dose of allergen causing a ≥20% fall in FEV1 (PD20A)
was calculated from the log dose-response curve by linear interpolation of two adjacent data points.
2.8. Analysis of Peripheral Blood Cells
The peripheral blood analysis for the complete blood count test was performed on an automated
hematology analyzer XE-5000™ (Sysmex, Kobe, Japan).
2.9. Granulocyte Isolation from Human Peripheral Blood and Eosinophil Enrichment
Approximately 24 mL of peripheral blood was collected into sterile Ethylenediaminetetraacetic
acid-containing vacutainers (BD Bioscience, San Jose, CA, USA). The whole blood was then diluted
with 1x phosphate-buffered saline (PBS) (GIBCO, Paisley, UK) up to 50 mL and mixed thoroughly.
The whole blood was layered on Ficoll-Paque PLUS (GE Healthcare, Helsinki, Finland) and centrifuged
at 400× g force for 30 min at room temperature. The supernatant was removed and the bottom-most
layer comprising the granulocyte fraction of cells and erythrocytes was collected. Then, hypotonic lysis
of erythrocytes was performed. Into the tubes with cells, half volume of sterile water was added and
gently mixed for no longer than 10 s, immediately supplementing the mixture with an equal volume of
2x concentrated PBS and centrifuged at 300× g force for 10 min. The procedure was repeated until no
red blood cells were left. Then, cells were counted and viability evaluated using an ADAM automatic
cell counter (Witec AG, Switzerland). Eosinophil enrichment was performed by negative selection from
the granulocyte fraction using Magnetic-activated cell sorting (MACS)magnetically-labeled MicroBeads
(Miltenyi Biotec, Somerville, MA, USA). The manufacturer confirms that eosinophil separation kits
do not influence eosinophil viability, and that separation efficiency is more than 96%. MACS buffer
(containing 0.5% bovine serum albumin (BSA) and 2 mM EDTA in PBS, with a pH of 7.2) was prepared
by diluting MACS BSA stock solution 1:20 in autoMACS rinsing solution. The granulocyte pellet
was resuspended in cold MACS buffer (40 μL per 1 × 107 cells) and incubated with biotin antibody
cocktail (biotin-conjugated monoclonal antibodies against CD2, CD14, CD16, CD19, CD56, CD123,
and CD235a (glycophorin A)) (10 μL per 1 × 107 cells) for 10 min. After incubation, 20 μL of anti-biotin
microbeads (microbeads conjugated to monoclonal mouse anti-biotin immunoglobulin(Ig)-G1 per
1 × 107 cells were added, mixed, and incubated for an additional 15 min at 4 ◦C. An large separation
column (Miltenyi Biotec, USA) was prepared during this time by placing the column in the magnetic
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field of a MACS separator and washing it with 2 mL of MACS buffer. A pre-separation filter (30 μm;
Miltenyi Biotec) was rinsed with MACS buffer and placed on top of the column. The cells were then
applied to the pre-separation filter/LS column, and the magnetically labeled non-eosinophils were
retained on the column in the magnetic field of the separator while the unlabeled eosinophils passed
through the column. Cells were eluted with 5 mL of MACS buffer and centrifuged (300× g, 10 min,
4 ◦C), and the pellet was resuspended in 5 mL of PBS. Eosinophils were counted using an ADAM
automatic cell counter. To check eosinophil purity after magnetic separation, a diluted eosinophil
suspension was analyzed by flow cytometer FacsCalibur (BD, USA) according to forward and side
light scattering to determine whether there were any other cells in the suspension (Figure 2). As an
internal control, after usage of the new isolation kit, eosinophil purity was tested with alternative
May-Grunwald Giemsa staining and inspected by light microscopy.
Figure 2. Eosinophil enrichment. (A) peripheral blood granulocytes after high-density centrifugation
and erythrocyte lysis. (B) peripheral blood eosinophils after negative magnetic labeling and separation.
Collected cell number—1 × 105. Eosinophil quantity expressed from total collected cells counts
rejecting debris.
2.10. Combined Cell Cultures between Isolated Eosinophils and ASM Cells or Pulmonary Fibroblasts
Individual combined cell cultures (co-cultures) of eosinophils and pulmonary structural cells
were prepared for all experiments. We used healthy human ASM cells, immortalized by stable
expression of human telomerase reverse transcriptase as described in [31] and a commercial MRC-5
(Sigma, Ronkonkoma, NY, USA) lung fibroblast line. The main cell line was cultivated under standard
culture conditions of 5% CO2 in air at 37 ◦C with medium renewal every 3 days. For all experiments,
passaged ASM cells were grown on plastic dishes in Dulbecco’s modified Eagle’s medium (DMEM)
(GIBCO by Life Technologies, UK) and MRC-5 pulmonary fibroblasts in minimum essential Eagle’s
medium (EMEM) (GIBCO, Paisley, UK), supplemented with streptomycin/penicillin (2% v/v; Pen-Strep,
GIBCO by Life Technologies, Paisley, UK), amphotericin B (1% v/v; GIBCO, Paisley, UK), and fetal
bovine serum (10% v/v; GIBCO by Life Technologies). After reaching sufficient confluence, cells were
passaged by trypsinization. Cells were serum-deprived in respective medium, supplemented with
antibiotics and insulin, transferrin, and selenium reagent (GIBCO by Life Technologies) before each
experiment to stop cell proliferation and avoid possible errors due to the effect of mediators in serum.
The same lines of ASM and MRC-5 cells were used for whole investigating subjects. Avoiding a
decrease in cell activity and viability after repeated times of passage, the new cells of the mainline
were unfrozen every time after six passages.
ASM and MRC-5 cells were grown in six-well (confluency approximately 16 × 104 cells) or
24-well (confluency approximately 4 × 104 cells) culture plates (CytoOne, StarLab, Brussels, Belgium.).
Co-cultures with isolated eosinophils were prepared by adding 5 × 104 or 1.25 × 104 of eosinophils,
respectively. For observing and visualization of cell growth and co-cultures, we used an inverted
microscope (CETI Inverso TC100, Medline Scientific, Chalgrove, UK) with a 10×/22 mm wide-field
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eyepiece and phase contrast 10×/0.25 objective and an installed XM10-IR-2 camera (Olympus, Tokyo,
Japan) (Figure 3).
At the study day, experiments were divided into different groups, according to the growth
medium supplements. Investigated individual blood serum—2% of v/v—was used to maintain further
eosinophil activation after isolation processes and to verify if the eosinophils were isolated in their
most activated form, whilst 25 nm of vitamin C (ascorbic acid) was used as the most accessible
natural antioxidant to eliminate eosinophil-released reactive oxygen species and verify its effect on the
proliferation of pulmonary structural cells.
 
Figure 3. Combined cell cultures between eosinophils and ASM cells. (A) the picture at 10× objective.
(B) the picture at 40× objective. (C) remaining eosinophil number after combined cell culture separation.
Collected cell number—1 × 105. Eosinophil number is expressed from total collected cell count,
rejecting cell debris.
2.11. Eosinophils Adhesion Assay
ASM or MRC-5 cells were seeded in 24-well plates and grown for 3 days in 5% CO2 at 37 ◦C until
a confluency of approximately 4 × 104 cells. Then, the medium was removed, and wells were washed
twice with warm PBS. The medium was changed 24 h before the experiments by adding serum-free
medium, supplemented with 1% insulin-transferrin-selenium reagent. Eosinophil adhesion was
measured after 1 h of incubation, which is a sufficient period for eosinophils to adhere in co-culture [22].
After incubation, non-adhered eosinophils were removed, and the remaining cells were washed twice
with warm PBS. Eosinophil adhesion was determined by measuring residual eosinophil peroxidase
(EPO) activity as described [32]. Because intercellular EPO levels were identified as being decreased in
eosinophils from asthmatic individuals owing to degranulation [33], we normalized it by preparing a
calibration curve of fixed eosinophil count EPO activity for each experiment. To assay EPO activity,
116 μL of DMEM medium without phenol red and 116 μL of EPO substrate (1 mM H2O2, 1 mM
o-phenylenediamine, and 0.1% Triton X-100 in Tris buffer, pH 8.0) were added to each well. After 30 min
at 37 ◦C, 68 μL of 4 M H2SO4 was added to each well to stop the reaction and the absorbance was
measured at 490 nm by a microplate reader. Results were expressed as % of adhered eosinophil
number from max added, calculated from a calibration curve. Added eosinophil number—1.25 × 104
(double amount—2.5 × 104).
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2.12. Cell Viability Assay
Viability of ASM cells, pulmonary fibroblasts, and eosinophils were performed by fluorescent
staining with annexin V for apoptotic cells and propidium iodide (PI) for necrotic cells.
ASM cells and pulmonary fibroblasts were grown in six-well plates until confluency of
approximately 16 × 104 cells. On the day of experiments, a co-culture with 5 × 104 of isolated
eosinophils was prepared in the serum-free growth medium, or medium supplemented with 2% (v/v)
of investigated subjects’ blood serum. After 24 h of co-culturing, used eosinophils were collected into
15mL centrifuge tubes (Corning Inc., New York, NY, USA), together with eosinophils incubated alone
at the same conditions. Then, ASM cells and pulmonary fibroblasts were trypsinized, collected and,
together with eosinophils, centrifuged at 400× g for 10 min.
For the cell viability assay, we used an fluorescein isothiocyanate (FITC) Annexin V Apoptosis
Detection Kit II (BD Bioscience, San Jose, CA, USA) and adapted the method according to the
manufacturer’s recommendation. Before every experiment, we used additional controls of unstained
cells, cells stained with FITC annexin V (no PI), and cells stained with PI (no FITC annexin V).
For the viability assay of structural cells as a control, we used ASM cells or pulmonary fibroblasts
without co-culturing with eosinophils. Eosinophil’s effect was compared with normal ASM and
pulmonary fibroblast apoptosis in the serum-free growth medium, but was supplemented with an
insulin-transferrin-selenium compound to maintain normal conditions.
For the viability assay of eosinophils, we normalized the data according to the results received
from the centrifuged growth medium, which was used in the control structural cell cultures without
co-culturing with eosinophils and excluding possible errors from cellular debris. Eosinophils and
structural cells significantly differ in size and granularity, therefore, appropriate gating on forward and
side scattering excludes any remaining culture heterogeneity.
2.13. Alamar Blue Proliferation Assay
Cells for proliferation measurements were grown in 24-well plates in conditions described
previously in fetal bovine serum-supplemented growth medium until confluency of approximately
4 × 104 cells/well. Growth medium was changed into the serum-free medium 24 h before the
experiments. ASM cells or pulmonary fibroblasts were co-cultured with a respective group of
eosinophils isolated from AA patients, SNEA patients, or the HS for 72 h. Thereafter, all cells were
washed twice with warm PBS, plates were gently smashed in the middle of the plate to detach residual
eosinophils who were significantly more weakly adhered compared with structural cells, and again
were washed twice with warm PBS. Proliferation was evaluated by incubating wells with Hank’s
balanced salt solution containing Alamar blue solution (10% v/v; Invitrogen by Life Technologies,
Paisley, UK). Conversion of Alamar blue to the reduced form was dependent on the metabolic
activity of structural cells and was assayed by dual-wavelength spectrophotometry at wavelengths
of 570 nm and 600 nm. As indicated by the manufacturer, the degree of Alamar blue conversion
is proportional to the number of viable cells. The data are expressed as the percent increase or
decrease in Alamar blue conversion by ASM cells or pulmonary fibroblasts compared with control cells
(without co-culturing with eosinophils), which did not proliferate during the culturing period because
serum-free growth medium were used. Added eosinophils number—1.25 × 104; 2x amount—2.5 × 104;
1/2x amount—0.6 × 104. Used investigated subjects blood serum volume—2% v/v; ascorbic acid
concentration—25 nM.
2.14. Statistical Analysis
Statistical analysis was performed with GraphPad Prism 6 for Windows (ver. 6.05, 2014;
GraphPad Software Inc., San Diego, CA, USA). Significant differences between two independent
groups were determined using the Mann–Whitney two-sided U-test. The Wilcoxon matched-pairs
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signed-rank two-sided test was used for dependent groups. Minimum limit for statistically significant
values—p < 0.05.
3. Results
3.1. Characteristics of the Studied Participants
We investigated 39 nonsmoking adults (14 men and 25 women): 14 steroid-free non-severe allergic
asthma (AA) patients, 10 severe non-allergic eosinophilic asthma (SNEA) patients, and 15 healthy
non-smoking control subjects (HS). The main characteristics of the study participants are shown in
Table 1. The highest eosinophils count was observed in the SNEA group, however, in AA patients,
it was also increased compared with HS. The IgE levels were significantly increased in AA and SNEA
patients, compared with HS, but the highest level was in the AA group. FeNO was equally increased in
both the AA and SNEA groups, compared with HS. Moreover, at the baseline, significant deterioration
of lung function was observed only in SNEA patients.
Table 1. Demographic and clinical characteristics of the study population.
Healthy Subjects SNEA Patients AA Patients
Number, n 15 10 14
Sex, M/F 3/12 4/6 7/7
Age, years 28.4 ± 1.8 46.5 ± 3.0 #,* 28.0 ± 2.3
BMI, kg/m2 23.2 ± 1.2 26.9 ± 2.2 24.7 ± 1.6
PD20M, geometric mean (range), mg NR ND 0.08 (0.02–0.26)
PD20A, geometric mean (range), HEP/mL NR ND 0.84 (0.15–3.04)
IgE, IU/mL 29.5 ± 6.0 147.2 ± 30.7 * 202.8 ± 41.9 *
FEV1, L 3.9 ± 0.18 2.0 ± 0.4 #,* 3.9 ± 0.2
FEV1, % of predicted 106.6 ± 3.7 57.6 ± 8.6 #,* 95.9 ± 3.3
Blood eosinophil count, ×109/L 0.18 ± 0.02 0.52 ± 0.11 #,* 0.36 ± 0.07 *
FeNO, ppb 12.9 ± 1.5 44.9 ± 10.7 * 59.5 ± 11.5 *
AA—Allergic asthma; SNEA—Severe non-allergic eosinophilic asthma; F—Female; M—Male;
FEV1—Forced expiratory volume in 1s; PD20M—The provocation dose of methacholine causing a 20%
decrease in FEV1; PD20A—the provocation dose of allergen D. pteronyssinus causing a 20% decrease in FEV1;
BMI—Body mass index; FeNO—Fractional exhaled nitric oxide; IgE—Immunoglobulin E; NR—Not responded;
ND—Not done. Data presented as the mean ± standard error of the mean, except PD20M and PD20A which are
provided as geometric mean (range). * p < 0.05 compared with HS group; # p < 0.05 compared with AA group.
Statistical analysis—Mann–Whitney two-sided U-test.
3.2. Eosinophil Adhesion and Survivability
We observed that 71.7% ± 3.5% of AA patients’ and 66.6% ± 5.8% of SNEA patients’ eosinophils
adhere onto the surface of ASM cells after 1 h of incubation, and this count was significantly increased
compared to healthy eosinophils (47.2% ± 3.7%, p < 0.05) (Figure 4A). Supplementing growth
medium with investigated individuals’ blood serum had a significant negative effect only in the
SNEA group—the adhered eosinophils ratio decreased to 46.7% ± 7.9% of the added eosinophils
count, p < 0.05. Moreover, by using double the amount of added eosinophils in the culture well,
we received a significant (p < 0.05) decrease in the adhered eosinophils ratio in the AA and SNEA
groups to 53.8% ± 5.0% and 50.5% ± 6.4% of the total added eosinophil count, respectively, with no
differences in the HS group (Figure 4A). Similar results were obtained by measuring AA and HS
eosinophil adhesion to pulmonary fibroblasts—adhered eosinophils’ number in the AA group was
61.2% ± 4.6%, and 37.3% ± 3.7% in the HS group, p < 0.05. Significant differences after supplementing
the medium with blood serum were not observed in both groups. Moreover, in the AA group,
the adhered eosinophil ratio decreased to 43.8% ± 7.4% after using double the amount of added
eosinophils (p < 0.05) (Figure 4B).
Moreover, we observed that AA and HS eosinophils’ peroxidase activity, evaluated as the
ability to oxidize o-phenylenediamine in the presence of their peroxidases, are similar—The average
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absolute value values of oxidized o-PD was 0.21 ± 0.04 optical density (O.D) and 0.2 ± 0.3 O.D,
respectively. The average SNEA eosinophil peroxidase activity was only 0.12 ± 0.02 O.D; however,
there was no statistical significance upon comparison with AA and HS groups, p = 0.069 and 0.073,
respectively (Figure 4C).
Figure 4. The efficiency of eosinophil adhesion. (A) Eosinophil adhesion in co-culture with airway
smooth muscle (ASM) cells; (B) eosinophil adhesion in co-culture with pulmonary fibroblasts.
(C) Eosinophil peroxidase (EPO) substrate activity of 12,500 eosinophils. EOS—eosinophils,
AA—Allergic asthma, SNEA—Severe non-allergic eosinophilic asthma, HS—Healthy subjects.
Results from independent experiments of AA—n = 14; HS—n = 15; SNEA—n = 10. * p < 0.05
compared with adhesion of the healthy eosinophil group. Added blood serum: 2% of V/V.
Statistical analysis: between investigated groups—Mann–Whitney two-sided U-test; within one
study group—Wilcoxon matched-pairs signed-rank two-sided test.
Furthermore, we investigated the eosinophil adhesion effect on their survivability. We observed
that 71.5% ± 1.1% of HS eosinophils are still viable after 24 h of incubation in serum-free growth
medium, and that this amount is significantly lower when compared with the viability of AA and
SNEA patients’ eosinophils at 74.6% ± 0.5% and 77.1 ± 0.5%, respectively. The number of viable
eosinophils increased significantly to 82.3% ± 0.4% in the AA group and to 74.2% ± 0.5% in the
HS group when the medium was supplemented with 2% of v/v of the investigated subjects‘ blood
serum (p < 0.01), but it had no effect on the SNEA patient group. Making co-cultures with ASM
cells in serum-free medium had the same effect as blood serum—In the AA group, the number of
viable eosinophils increased to 83.6% ± 0.4%; in the SNEA group, to 84.2% ± 0.4%; in the HS group,
to 75.1% ± 0.8% (p < 0.05), and this effect in AA and SNEA groups was significantly greater compared
with HS (p < 0.05). A similar effect was obtained when co-cultures of eosinophils were taken from
AA and HS groups with pulmonary fibroblasts–viability increased to 82.3% ± 0.4% and 73.0% ± 1.2%,
respectively, (p < 0.05). Supplementing co-culture growth medium with investigated subjects’ blood
serum did not have any additional effect on the viability of eosinophils (Figure 5).
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Figure 5. Eosinophil viability. Changes in the number of viable eosinophils during different incubation
conditions. Results from independent experiments of AA—n = 14, HS—n = 15, SNEA—n = 10;
AA—Allergic asthma, SNEA—Severe non-allergic eosinophilic asthma, HS—Healthy subjects. * p < 0.05
compared with the viability of the healthy eosinophil group; # p < 0.05 compared with the viability of
the SNEA eosinophil group; Added blood serum—2% of v/v. Statistical analysis: between investigated
groups—Mann–Whitney two-sided U-test; within one study group—Wilcoxon matched-pairs
signed-rank two-sided test.
3.3. Eosinophil Effect on Pulmonary Structural Cell Proliferation and Apoptosis
After 72 h of co-culturing, eosinophils promoted ASM cell proliferation by 13.0% ± 2.4%
in AA and 9.3% ± 3.2% in SNEA, and the effect was significantly higher compared to the HS
group—proliferation increased by 4.0% ± 1.6% (p < 0.05). Supplementing growth medium with 2% of
investigated subjects’ blood serum had a positive effect on ASM cell proliferation. In the AA group,
proliferation increased by 23.8% ± 7.0% if ASM cells were cultured alone in serum-supplemented
medium and did not significantly different if they were cultured in serum-supplemented medium
with eosinophils—proliferation increased by 27.2% ± 8.7%. The same results were received in the
SNEA group (proliferation increased by 34.3% ± 10.8% and 28.1% ± 10.4%, p < 0.05) and the HS group
(increased by 25.4% ± 5.7% and 30.8% ± 4.6%, p < 0.05). Moreover, supplementing serum-free growth
medium with 25 nM of ascorbic acid significantly decreased ASM proliferation by 36.3% ± 11.6% in
AA, 27.4% ± 17.6% in SNEA, and 22.3% ± 12.5% in the HS group. The combined cell culture with
eosinophils did not change the ascorbic acid effect on ASM cell proliferation in the AA and SNEA
groups (decreased by 33.9% ± 10.7% and 33.6% ± 14.8%, respectively) but removed its negative effect
in the HS group (Figure 6A).
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Figure 6. Eosinophils’ effect on pulmonary structural cell proliferation. (A) Eosinophils’ effect on
ASM cell proliferation; (B) eosinophils’ effect on pulmonary fibroblast proliferation; (C) the effect of
adding a different eosinophil count on ASM cell proliferation; (D) the effect of adding a different
eosinophil count on pulmonary fibroblast proliferation. Results from independent experiments of
AA—n = 14, HS—n = 15, SNEA—n = 10. * p < 0.05 compared with control ASM cells or pulmonary
fibroblasts without co-culturing with eosinophils, # p < 0.05 compared with the healthy subject group.
Added eosinophils count—1/2x = 6,250, 1x = 12,500, 2x = 25,000. Added blood serum—2% of v/v.
Ascorbic acid concentration—25 nM. Statistical analysis: between investigated groups—Mann–Whitney
two-sided U-test; within one study group—Wilcoxon matched-pairs signed-rank two-sided test.
We measured the AA and HS eosinophil effect on the proliferation of another structural cell
type—Pulmonary fibroblasts. We received similar results—Proliferation significantly increased
by 11.4% ± 2.3% in AA and 4.6% ± 1.6% in HS groups after co-culturing with eosinophils.
Supplementing growth medium with blood serum also had a positive effect—The pulmonary fibroblast
cell number increased by 18.4%± 5.3% and 10.8%± 4% in the AA and HS groups, respectively. However,
co-culturing with eosinophils in serum-supplemented growth medium increased proliferation by
19.2% ± 4.1% in the AA group, but in the HS group, the effect of eosinophils was the same as in
serum-free medium. Different results, compared with co-cultures with ASM cells, were seen by
evaluating the effect of ascorbic acid on the proliferation of pulmonary fibroblasts. In the AA group,
fibroblasts did not lose their proliferative activity after supplementing growth medium with 25 nM of
ascorbic acid; however, a significant decrease (6.5% ± 2.6%) was observed when measuring the effect of
HS eosinophils on fibroblast proliferation in ascorbic acid-supplemented growth medium (Figure 6B).
Finally, we investigated how adding different quantities of eosinophils correlate with their effect
on structural cell proliferation. We determined that in the AA group, half (1/2x) the number of
eosinophils had a similar effect as a typically-used eosinophil number on ASM cell proliferation and
increased it by 13.02% ± 4.2%; however, after using twice (2x) the number of eosinophils, the significant
pro-proliferative effect was lost. By using pulmonary fibroblasts, the results were different—1/2x
and 2x quantity of eosinophils had no positive effect on cell proliferation. In the SNEA group,
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we used only co-cultures with ASM cells and observed that a 1/2x quantity of eosinophils had no
significant proliferative effect, but a 2x quantity increased ASM proliferation by 12.4% ± 5.2% (p < 0.05),
without significant differences to the effect of a typically-used eosinophil number. In the HS group,
we determined that a 1/2x quantity of eosinophils had no effect on ASM cells or pulmonary fibroblast
proliferation; however, for a 2x eosinophil quantity, both cases significantly decreased the eosinophil
proliferation by 8.5% ± 3.4% and 12.0% ± 5.5%, respectively (p < 0.05) (Figure 6C,D).
We investigated the mechanisms through which eosinophils affect pulmonary structural cell
proliferation. We measured the eosinophil effect on pulmonary structural cell apoptosis after 24 h of
co-culturing. Approximately 9.2% ± 0.6% of ASM cells and 7.5% ± 0.4% of pulmonary fibroblasts in
culture are apoptotic after culturing and detachment procedures. After co-culturing with eosinophils,
the apoptotic ASM cell number significantly (p < 0.05) decreased to 5.3% ± 0.5% in the AA patients
group, to 4.0 ± 0.3 in the SNEA patients group (p < 0.05 compared with AA), but had no significant
effect (p = 0.14) in the HS group. Co-culturing with eosinophils reduced the number of apoptotic
pulmonary fibroblasts in the AA patient group by 5.5% ± 0.4% (p < 0.05) but had no effect in the HS
group. Supplementing growth medium with blood serum (2% of v/v) of the investigated individuals
enhanced the effect of eosinophils, and the apoptotic ASM cell number decreased from 7.9% ± 0.9% in
serum-free medium to 4.9% ± 0.7% in serum-supplemented medium (p < 0.05). Unlike in the ASM
cells group, supplementing growth medium with blood serum enhanced the effect of eosinophils on
pulmonary fibroblasts only in the AA patients group—the apoptotic number reduced from 5.5% ± 0.4%
to 3.7%± 0.5% of the total cell count in culture. Moreover, considering that ascorbic acid is a well-known
antioxidant and can eliminate the effect of the released reactive oxygen species of eosinophils on ASM
cells or pulmonary fibroblast apoptosis, we supplemented the growth medium with a minimum of
25 nM of final concentration of ascorbic acid and obtained the result that the apoptotic ASM cell
number increased to 11.1% ± 0.9% in the AA group, to 12.3% ± 1.1% in the SNEA patient group, and
11.2% ± 1.1% in the HS group (p < 0.05), as well as the pulmonary fibroblast number to 13.0% ± 2.4%
in the AA patient group and 11.5% ± 1.0% in the HS group (p < 0.05) (Figure 7).
Figure 7. Eosinophils’ effect on pulmonary structural cell apoptosis. (A) Apoptosis of ASM cells;
(B) apoptosis of pulmonary fibroblasts. AA—Allergic asthma, SNEA—Severe non-allergic eosinophilic
asthma, HS—Healthy subjects. Results from independent experiments of AA—n = 14, HS—n = 15,
SNEA—n = 10. * p < 0.05 compared with the healthy eosinophils group; # p < 0.05 compared with
the SNEA eosinophils group. Added blood serum—2% of v/v; ascorbic acid concentration—25 nM.
Statistical analysis: between investigated groups—Mann–Whitney two-sided U-test; within one study
group—Wilcoxon matched-pairs signed-rank two-sided test.
3.4. The Effect of Bronchial Allergen Challenge to Eosinophil Activity
The bronchial challenge with D. pteronysinnus allergen was performed for 11 individuals from
the AA patient group and 11 individuals from the HS group. The effect of in vivo allergen provoked
125
J. Clin. Med. 2019, 8, 1274
disease exacerbation to eosinophil activity and was evaluated by comparing the results before and
24 h after a bronchial allergen challenge of the same study subject. A significant increase was
observed in the peripheral blood eosinophil count in the AA group following allergen exposure from
0.38 ± 0.08 × 109/L to 0.45 ± 0.06 × 109/L of cells, without significant changes in the HS group.
Eosinophil adhesion 24 h after a bronchial allergen challenge increased only in the AA group
with no effect on HS eosinophils. The number of adhered eosinophils in co-cultures with ASM cells
increased from 69.5% ± 5.4% to 87.06% ± 3.1% and in co-cultures with pulmonary fibroblasts from
59.4% ± 4.3% to 76.2% ± 4.2% of the total added eosinophil count (p < 0.05) (Figure 8).
Figure 8. Bronchial allergen challenge effect on the efficiency of eosinophil adhesion. (A) Eosinophils
adhesion in co-culture with ASM cells; (B) eosinophils adhesion in co-culture with pulmonary
fibroblasts. Results from independent experiments of AA—n = 11, HS—n = 11; EOS—Eosinophils,
AA—Allergic asthma, HS—Healthy subjects. * p < 0.05 compared with the adhesion of the healthy
eosinophil group. V1—Visit 1 (before bronchial allergen challenge); V2—Visit 2 (24 h after bronchial
allergen challenge). Statistical analysis: between investigated groups—Mann–Whitney two-sided
U-test; within one study group—Wilcoxon matched-pairs signed-rank two-sided test.
A bronchial allergen challenge activated eosinophils in vivo and had a positive effect on AA patients
eosinophils viability—The number of non-viable eosinophils decreased by 7.6% ± 1.8% if eosinophils
were incubated alone or in serum-free growth medium (p < 0.005), but had no effect on healthy
eosinophils. However, by using in vivo allergen-activated eosinophils and serum-supplemented
growth medium, a positive effect was only obtained in the HS group (non-viable eosinophils number
decreased by 6.3% ± 1.8%, p < 0.01), but had no effect on the AA patient group compared with
non-activated eosinophils. Moreover, AA patients’ allergen-activated eosinophil viability was increased
if they were co-cultured with pulmonary structural cells in serum-free medium (non-viable eosinophils’
number decreased by 7.6% ± 2.7% in co-culture with ASM cells, and by 8.3% ± 2.1% in co-culture with
pulmonary fibroblasts, p < 0.01). Co-culturing in investigated subjects’ blood serum-supplemented
growth medium did not have any further effect on eosinophil viability (Figure 9).
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Figure 9. The bronchial allergen challenge effect on the number of non-viable eosinophils. Results from
independent experiments of AA—n = 11, HS—n = 11; AA—Allergic asthma, HS—Healthy subjects.
* p < 0.05 compared with the viability of the healthy eosinophil group; & p < 0.05 compared
with the viability of eosinophils before the bronchial challenge. Added blood serum—2% of v/v.
Statistical analysis: between investigated groups—Mann–Whitney two-sided U-test; within one study
group—Wilcoxon matched-pairs signed-rank two-sided test.
Moreover, we evaluated in vivo the effect of activated AA and HS eosinophils on structural cell
proliferation. We observed that eosinophils’ pro-proliferative effect on ASM cells after a bronchial
allergen challenge was enhanced by 11.6% ± 8.7% in the AA group and by 9.8% ± 4.1% in the HS
group, compared with the effect of non-activated eosinophils. An enhanced pro-proliferative effect on
pulmonary fibroblasts was only observed in the AA group (enhanced by 7.2% ± 2.5%), compared with
the effect of non-activated eosinophils (Figure 10).
Figure 10. Bronchial allergen challenge effect on pulmonary structural cell proliferation.
(A) The effect of a bronchial allergen challenge on eosinophil-promoted ASM cell proliferation;
(B) the effect of a bronchial allergen challenge on eosinophil-promoted pulmonary fibroblast
proliferation. Results from independent experiments of AA—n = 11, HS—n = 11; V1—Visit 1
(before the bronchial allergen challenge); V2—Visit 2 (24 h after the bronchial allergen challenge).
Statistical analysis: between investigated groups—Mann–Whitney two-sided U-test; within one study
group—Wilcoxon matched-pairs signed-rank two-sided test.
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Finally, a bronchial allergen challenge enhanced the effect of eosinophils on the reduction of ASM
cells and pulmonary fibroblast apoptosis. The apoptotic ASM cell number reduced from 5.5% ± 0.5%
of the total cell count in culture, to 4.2% ± 0.4% in the AA patient group, and from 7.7% ± 0.7% to
5.8% ± 0.3% in the HS group. Meanwhile, the number of apoptotic pulmonary fibroblasts reduced
from 5.3% ± 0.4% to 3.9% ± 0.4% in the AA patient group, and from 7.2% ± 1.3% to 4.7% ± 0.5%
in the HS group. After supplementing growth medium with the blood serum of the investigated
individuals—collected after the bronchial allergen challenge—the effect of eosinophils on the reduction
of apoptosis in pulmonary fibroblasts was only enhanced in the AA patients group—the apoptotic cell
number decreased from 3.7% ± 0.5% in serum-free medium to 1.8% ± 0.6% in serum-supplemented
medium (p < 0.05) (Figure 11).
Figure 11. The effect of a bronchial allergen challenge on pulmonary structural cell apoptosis. (A) The
effect of a bronchial allergen challenge on eosinophil-induced ASM cell apoptosis. (B) The effect of
a bronchial allergen challenge on eosinophil-induced pulmonary fibroblast apoptosis. Results from
independent experiments of AA—n = 11, HS—n = 11; V1—Visit 1 (before the bronchial allergen
challenge); V2—Visit 2 (24 h after the bronchial allergen challenge). Added blood serum—2% of v/v;
ascorbic acid concentration—25 nM. Statistical analysis: between investigated groups—Mann–Whitney
two-sided U-test; within one study group—Wilcoxon matched-pairs signed-rank two-sided test.
4. Discussion
Increased eosinophil adhesion and prolonged viability in asthma could be the reason for the
increased eosinophil number in asthmatic lungs because of their delayed migration to the bronchial
lumen, which contributes to more intense development of airway remodeling. In this study, we found
that adhesion of eosinophils of AA and SNEA patients to ASM cells or pulmonary fibroblasts was
increased when compared to the HS group. Adhesion to pulmonary structural cells had a significant
effect on prolonging the viability of eosinophils in all the investigated groups; however, the highest
effect was observed in SNEA patients. Moreover, serum-activated eosinophils from AA and SNEA
patients demonstrated an enhanced pro-proliferative effect on pulmonary structural cells. Furthermore,
eosinophils from SNEA patients had a more pronounced effect on reducing apoptosis of ASM
cells and pulmonary fibroblasts, however, with a similar pro-proliferative effect when compared
with eosinophils from patients with AA. In the AA group, in vivo allergen-activated eosinophils
demonstrated higher adhesion, viability, and pro-proliferative effects on pulmonary structural cells
compared to non-activated eosinophils.
Airway eosinophilia is associated with more frequent exacerbations of asthma, which contributes
to the development of airway remodeling [34–36]. Eosinophil infiltration from the circulation into the
asthmatic airway depends on the activation sites of eosinophils, which leads to their arrest on activated
endothelium, extravasation into the airway wall, and migration through airway tissues into the airway
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lumen. Airway eosinophils demonstrate increased activity of two main eosinophils integrins—α4β1
and αMβ2 [37]; moreover, blood eosinophil integrins are found to be in a more-activated state
during asthma [38]. Previously, we demonstrated that increased expression of eosinophil integrins
in asthma leads to increased eosinophil adhesion and is associated with eosinophil-induced airway
remodeling [22,23]. In the current study, we showed that in the bloodstream of the HS, between 40%
and 50% of eosinophils exist, which could rapidly (within the hour) adhere onto other cell or ECM
proteins, while during asthmatic conditions, this number increases to 60–70%, with no significant
difference between AA and SNEA phenotypes (Figure 4A,B). Moreover, pre-activation of isolated
eosinophils with mediators found in blood serum does not affect their adhesion properties; on the
contrary, blood serum from SNEA patients reduced the maximum number of adhered eosinophils,
probably because of the use of inhaled steroids. It demonstrates that eosinophils do not lose their
activity during the isolation processes. Furthermore, eosinophil degranulation, assessed by EPO
activity, did not statistically differ between the investigated groups; however, the EPO activity of
eosinophils of SNEA patients is prone to decrease (Figure 4C).
Eosinophils adhere when their integrins recognize and connect to counter-receptors on other cells
or ligands in the ECM proteins. However, there is a limited number of these counter-receptors that
could restrict eosinophil adhesion. We showed that after increasing the number of more-adhesive
eosinophils from AA and SNEA patients in the co-cultures, the ratio of adhered eosinophils to total
added eosinophils significantly decreased and became the same as in the HS group (Figure 4A,B).
We assumed that the management of pulmonary structural cell adhesion molecules and ECM component
expression could play an important role by regulating eosinophil-induced airway structural changes.
Increased eosinophil adhesion intensity could be explained by increased expression of outer membrane
integrins [22] or by their different activation states [37,39]. Integrins exist in an inactive bent,
an intermediate-activity extended closed, and a high-activity extended open conformation, and in
that way modulate eosinophil adhesion and migration [40,41]. The severity of the disease or disease
exacerbation could affect eosinophil’s integrin expression and its activation states, contributing to
eosinophil’s further pro-inflammatory effect. However, it requires expanded investigation in a
background of different asthma phenotypes and allergen-induced eosinophil activation.
Eosinophil’s contribution to airway remodeling in asthma depends not only on its increased
infiltration, but on its survivability in airways as well, which prolongs the effect of eosinophils on
pulmonary structural cells. It was primarily described from several scientist teams, who revealed
the importance of direct contact with pulmonary structural cells to their survivability, probably via
signaling through GM-CSF and IL-1β [12–15]. Circulating eosinophils are contained in the mixture of
various mediators found in peripheral blood, which regulates eosinophils’ activation and survival.
We found that AA and SNEA patients‘ eosinophils are characterized by greater survival compared with
those of HS; moreover, the highest eosinophil viability was observed in the SNEA group (Figure 5).
As eosinophils were incubated in serum-free growth medium, this demonstrated that SNEA patients‘
eosinophils had the strongest cytokine-induced survivability signals in peripheral blood. If eosinophils
were incubated in investigated individual serum-supplemented medium, AA eosinophils’ survival
significantly increased and remained higher when compared with HS eosinophils. Blood serum
enhanced eosinophils viability, thus demonstrating the healing process of isolated eosinophils if they
are not pre-activated by mediators found in asthmatic blood serum. However, SNEA patients‘ blood
serum had no effect on eosinophils’ survival, probably due to fully-occupied survivability regulating
receptors after eosinophil activation in vivo, or medications present in the blood serum (Figure 5).
Activation of eosinophilopoietin receptors [42] may not be the only factors regulating eosinophil
viability. Adhesion through integrins can also be understood as a survival signal [43]. Incubation for
24 h with ASM cells or pulmonary fibroblasts significantly increased AA and SNEA patients’ eosinophil
viability, compared with eosinophils cultured alone, and the highest effect was observed in the SNEA
patient group. This highlights the importance of contact with the opposite cell or their released
extracellular matrix proteins on eosinophils’ viability. Moreover, eosinophils equally adhere to ASM
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cells and pulmonary fibroblasts without preference for one cell type (Figure 4). However, more detailed
research is needed to understand whether eosinophils adhere more to adhesion molecules on the
surface of structural cells, or to specific sites on ECM proteins, and how this determines eosinophils’
viability. Furthermore, a longer incubation period between eosinophils and structural cells should
be used to find out how long eosinophils can stay viable for with or without an external stimulus in
different asthma phenotypes.
Asthma-related airway remodeling mostly involves the airway epithelium, ASM, and extracellular
matrix components [44]. As the number of eosinophils in asthmatic airways is enhanced, their role
in disturbing local homeostasis is indisputable. It is known that ASM cells proliferate more during
asthma; however, there is only minimal research showing that eosinophils influence this process [21–23].
Likewise, there is lack of information regarding the effect of eosinophils on pulmonary fibroblast
proliferation [24], which could significantly contribute to ECM remodeling in asthma, as well as
how eosinophils of SNEA patients affect pulmonary structural cell proliferation. When eosinophils
migrate to the airways, the surrounding mediators might change, and further activation of eosinophils
mostly depends on their activation in peripheral blood or pre-activation by released mediators of
pulmonary structural cells. In the current study, we investigated the effect of eosinophils on ASM cells
or pulmonary fibroblast proliferation in the context of individuals’ blood serum that might maintain
the initial activation of eosinophils. Our results demonstrated that eosinophils, isolated from SNEA
patients, have the same effect on ASM cell proliferation as eosinophils isolated from AA patients.
Moreover, both ASM cells and pulmonary fibroblasts respond similarly to the pro-proliferative effect
of eosinophils (Figure 6A,B).
There are many mechanisms through which cell proliferation can be promoted [45]. One of the
mechanisms revealed in this study demonstrated that eosinophils significantly inhibit pulmonary
structural cell apoptosis in AA and SNEA groups, but not in HS (Figure 7A,B); however, the precise
mechanism is unknown. Blood serum is important for structural cell proliferation and had a higher
pro-proliferative effect compared with eosinophils in all the investigated groups. However, there is no
exact information regarding the concentrations of mediators in the surrounding ASM cells and the
pulmonary fibroblast environment in vivo, which could be different from those used in vitro. Apoptosis
measurements also demonstrated that blood serum does not enhance the effect of eosinophils on
reducing ASM cell apoptosis in the AA and SNEA groups, as these eosinophils did not lose their
primary activity in peripheral blood after 24 h of incubation. However, less-activated eosinophils in the
HS group were pre-activated by blood serum and demonstrated a more pronounced effect in reducing
structural cell apoptosis (Figure 7A).
Eosinophils release not only remodeling-related mediators [1] but could also be toxic to many
tissues because of released cytotoxic cationic proteins [46]. The best known and most accessible
antioxidant is ascorbic acid, in which the blood levels are linked to asthma pathogenesis and its
prevention [47,48]. A concentration of more than 100 nM ascorbic acid could be toxic to many cells
while demonstrating a lower proliferative effect [49]. We used a concentration of only 25 nM ascorbic
acid, avoiding possible changes in growth-medium pH levels. However, our data showed that
ascorbic acid alone significantly reduced ASM cells, but not pulmonary fibroblast proliferation, which
could be partially explained by the close interface between ascorbic acid and collagen synthesis [50].
In combination with eosinophils, a negative ascorbic acid effect on ASM cells was eliminated only
in the HS group, but was evidenced for pulmonary fibroblasts. Moreover, eosinophils in ascorbic
acid-supplemented medium significantly increased ASM cells and pulmonary fibroblast apoptosis
in all the investigated groups (Figure 6A,B). However, there is no clear explanation of these results
according to the literature data, and therefore more research should be done with different ascorbic
acid concentrations and cell densities in co-cultures.
Eosinophils have two sides to their biological role that could be partly explained by existing
distinct eosinophil phenotypes in peripheral blood and lung tissues [51] with different biological roles.
One phenotype is inflammation-related, another one has a greater effect on the remodeling processes.
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It shows that in the AA, SNEA, and HS groups there can exist different proportions of eosinophil
phenotypes; therefore, an increased or decreased number of eosinophils in co-cultures disbalance the
effect of the predominant phenotype effect (Figure 5C,D). In the AA group, a twofold reduced number
of eosinophils had the same proliferative effect on ASM cells, but the effect was lost to pulmonary
fibroblasts; however, a twofold increased number of eliminated eosinophils induced ASM cells and
pulmonary fibroblast proliferation, probably due to an increased effect of the inflammation-related
eosinophil phenotype. In the SNEA group, a reduced number of eosinophils had no effect on ASM
proliferation, while normal and increased numbers of eosinophils had a similar positive effect. In the
HS group, the reduced eosinophil number eliminated their effect on ASM cells and pulmonary
fibroblast proliferation; however, a twofold increase in the number of eosinophils significantly reduced
structural cell proliferation. Different ratios of eosinophil phenotypes in peripheral blood during
AA, SNEA, and HS could explain these findings. In the HS group, as there should be less of specific
disease-related signals for the attraction of homeostatic eosinophils, the predominant phenotype might
be more inflammation-related eosinophils, which started to dominate after an increase in their count.
With the SNEA group, the predominant phenotype was remodeling-related homeostatic eosinophils,
and their proliferative effect correlated with their count, whereas in AA, the ratio should have been
intermediate and increased the number of added eosinophils, eliminating the proliferation-promoting
effect. However, the number of inflammatory eosinophils was not enough to reduce this effect
(Figure 5C,D). Moreover, there is a lack of studies about different eosinophil phenotypes; therefore,
more data is needed to confirm these results.
Asthma is a heterogeneous disease with multiple possible targets in its pathogenesis. AA severity
is associated with the frequency of exacerbations after exposure to allergens that may contribute to the
development of airway remodeling [52]. We sought to find out the role of eosinophils during an acute
asthma episode, which is determined only by their quantitative differences or can be characterized
by significant changes in their activity. During an allergen attack, released alarmins promote Th2
cells to produce eosinophilopoetins that may affect the number and functions of eosinophils [53].
Allergen-induced late asthmatic responses are mainly described by an increased number of airway
inflammatory cells; however, the exact changes in eosinophil activity under allergen-induced disease
exacerbation are mostly unknown. Our team previously demonstrated that during allergen-induced
late-phase airway inflammation, peripheral blood eosinophils demonstrated further alterations of
their functional activity, manifested by enhanced spontaneous reactive oxygen species production,
increased chemotaxis, and diminished apoptosis in patients with AA [54]. Our findings show
that the exposure of allergens activates AA patients’ eosinophils in vivo, or they are released from
bone marrow in a more activated state. They demonstrated increased adhesion and survivability
properties and confirmed that after an acute episode, released eosinophils can survive in an asthmatic
airway for a longer period (Figures 7 and 8). Moreover, allergen exposure had an effect on HS
eosinophils, also promoting their viability, although subjects from the HS group were not sensitized
to D. pteronyssinus. We used one of the most common home dust mite allergens with which the
whole human population frequently comes into contact. It allowed us to assume that after a constant
natural exposure of D. pteronyssinus, a memory of this allergen develops. The reaction of organisms to
the high doses of inhaled concentrated allergen is too weak for bronchoconstriction; however, it is
enough to slightly stimulate type-2 inflammation and activate eosinophils. This is important for future
investigations, which should aim to understand possible AA development later in life.
More-enhanced eosinophil activity during allergen-induced asthma exacerbation required more
intense disease treatment. Allergen-activated eosinophils demonstrated a twofold increased effect
to ASM cells and pulmonary fibroblast proliferation via reduced apoptosis (Figures 9 and 10).
It demonstrates that asthma exacerbation is associated with more intense development of airway
remodeling via eosinophils’ pro-proliferative effect. Tang and colleagues discovered that recruitment
of eosinophils into asthmatic lungs during allergen-induced airway responses proceed via the
IL-25/IL-25R axis and IL-25 neutralization and may be a potential therapeutic target for the attenuation
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of allergen-induced asthmatic responses mediated by airway eosinophilia [55]. However, there exists
other well-known alarmins, such as IL-33 or thymic stromal lymphopoietin, that could also contribute
to the recruitment of eosinophils into asthmatic lungs. Our findings suggest that eosinophil adhesion is
important for their activity and effect on pulmonary structural cells; therefore, inhibiting their adhesion
properties, together with chemotaxis, could be an effective way of attenuating their negative role
during different asthma phenotypes and disease exacerbations.
5. Conclusions
Increased adhesion of eosinophils prolonged their viability, and might be related to enhancing their
pro-proliferative effect on ASM cells and pulmonary fibroblasts in asthma. Moreover, eosinophils from
SNEA patients demonstrated higher viability and inhibition of pulmonary structural cell apoptosis
compared to the AA group, while the adhesive properties and pro-proliferative effects were similar for
both. In the AA group, in vivo allergen-activated eosinophils presented enhanced adhesive properties,
viability, and a pro-proliferative effect on pulmonary structural cells compared to non-activated
eosinophils. These results could be important in the development of new therapeutic tools for the
suppression of eosinophil functions in asthma, focusing not only on eosinophils’ depletion but also on
their survivability.
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Abstract: Asthma is a heterogeneous disease with varying severity. Severe asthma is a subject of
constant research because it greatly affects patients’ quality of life, and patients with severe asthma
experience symptoms, exacerbations, and medication side effects. Eosinophils, although at first
considered insignificant, were later specifically associated with features of the ongoing inflammatory
process in asthma, particularly in the severe case. In this review, we discuss new insights into the
pathogenesis of severe asthma related to eosinophilic inflammation and the pivotal role of cytokines
in a spectrum that is usually referred to as “T2-high inflammation” that accounts for almost half of
patients with severe asthma. Recent literature is summarized as to the role of eosinophils in asthmatic
inflammation, airway remodeling, and airway hypersensitivity. Major advances in the management
of severe asthma occurred the past few years due to the new targeted biological therapies. Novel
biologics that are already widely used in severe eosinophilic asthma are discussed, focusing on the
choice of the right treatment for the right patient. These monoclonal antibodies primarily led to a
significant reduction of asthma exacerbations, as well as improvement of lung function and patient
quality of life.
Keywords: severe asthma; eosinophil; inflammation; interleukin-5 (IL-5); anti-IL-5; interleukin-4
1. Severe Asthma and Eosinophils
It is well established that asthma is a disease with a great spectrum of symptoms among patients
and wide differences in treatment efficacy. In particular, severe asthma is noted to include various
specific phenotypes and endotypes, which differ in their clinical presentation, their unique pathogenetic
mechanisms, and their responsiveness to treatment [1]. In order to determine the severity of asthma, it
is crucial to evaluate patients’ responsiveness to the controller therapy, such as inhaled corticosteroids
(ICS) and long-acting β2 agonists (LABA). In other words, clinicians need to evaluate how difficult it is
to control asthma symptoms and exacerbations [2]. Therefore, severe asthma presents a challenge as it
is defined as a disease which cannot be handled by conventional means of treatment—a medium–high
dose of ICS combined with LABA or even oral corticosteroids [3]. A different approach has to be
taken to improve asthma outcomes in these patients, and researchers began analyzing the cellular
mechanisms that characterize severe asthma. The results were quite intriguing, as they yielded a
number of different “types” of severe asthma which have to be recognized and treated accordingly.
Eosinophils emerged as the hallmark of a prevalent type of severe asthma, which also involves T
cells (T helper 2 (Th2) mainly, but also type 2 innate lymphoid cells) and was labeled the T2-high
endotype [4].
Eosinophils were described almost 150 years ago by Paul Ehrlich as granulocytic leucocytes with
a bilobed nucleus. Their primary location is within tissue and not in the bone marrow, residing mostly
in the gastrointestinal tract in normal conditions [5]. They contain numerous cationic proteins, with
four being the most notable: major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil
peroxidase (EPO), and eosinophil-derived neurotoxin (EDN); they are mostly associated with parasitic
infections, since they have the ability to orchestrate the immune response against helminths in a Th2
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cytokine cascade, very similar to that in asthmatic patients with the Th2 endotype [6]. This cascade
commences when immunoglobulin E (IgE) reacts with an antigen; although, in helminthic infections,
the antigen is indeed threatening for the host, in asthmatic patients, IgE targets are rather innocuous
agents such as tree pollen or animal fur. Nevertheless, IgE activates mast cells, macrophages, and
basophils, which in turn lead to the production of histamine and other inflammatory cytokines. The
ongoing inflammatory process attracts cluster of differentiation 4 (CD4)+ T cells and more eosinophils
to the site of damage in this aberrant reaction, leading to the Th2-high endotype of severe asthma with
high blood and sputum eosinophils [7].
2. Eosinophil Production and Development in the Bone Marrow
First of all, it is important to distinguish the two major types of eosinophils in the lungs. Even
though the simplistic view we had in the past about eosinophils is still viable, recent studies showed
that, except for eosinophils that emerge from the bone marrow and are directly recruited to sites of
inflammation, a distinct type of eosinophil with different characteristics resides in tissues in homeostatic
conditions. This eosinophil population is called “homeostatic eosinophils” (hEos) [8]. These hEos were
mostly examined in mice, and they differ from the regular inflammatory eosinophils (iEos). Both of these
populations are produced in the bone marrow from the CD34+ progenitor stem cells and specialized
CD34+ interleukin-5 receptor (IL-5R)+ hematopoietic progenitor cells via a complex activation of
transcription factors, the most important being GATA-1, PU.1, and CAAT enhancer-binding proteins
α and ε [9]. Notably, the actions of GATA-1 and PU.1 are antagonistic regarding the differentiation
of other hematopoietic cells; nevertheless, they synergize when it comes to eosinophil production,
as it was shown in studies where in vitro enhancement of PU.1 resulted in an amplified GATA-1
transcriptomic effect [10].
Several cytokines also take part in the development of eosinophils apart from the transcription
factors previously mentioned, IL-5, IL-3, and GM-CSF(Granulocyte-macrophage colony-stimulating
factor). IL-3 and GM-CSF are not selective, and they stimulate the development of other leucocytes
such as neutrophils and macrophages more efficiently; however, IL-5 solely affects eosinophils and
basophils [11]. The major difference in the production and recruitment of the two eosinophil populations
is that hEos are differentiated in the bone marrow semi-independently from IL-5, while iEos need IL-5
in order to be produced from their precursor cells and trafficked to the lungs [12]. This was proven
in IL-5 knock-out (KO) mice which could not produce a Th2-high response due to the lack of IL-5,
but the number of hEos in the lung was only reduced by half, meaning that they could be recruited
via different pathways. It also explains why, in patients treated with an anti-IL-5 agent, eosinophils
can still be found in both their blood and lungs [13]. Moreover, stimulation of CD34+ progenitor
cells with IL-3, IL-5, and GM-CSF resulted in an upregulation of the IL-5R in these stem cells, thus
prolonging eosinophil differentiation as long as they were stimulated by IL-5 [14]. However, mice that
were lacking GM-CSF/IL-3/IL-5 functions were not observed to have a complete halt of eosinophil
production. Instead, these mice had the ability to produce low numbers of eosinophils, indicating that
there are more unidentified factors taking part in their development [15].
Even more interesting is the observation that hEos do not take active part in the allergic
inflammation, as well as halting this aberrant response. They express several genes that cannot be
found in the normal iEos that take part in the immunoregulation of lung and reduce the Th2 response
after contact with allergens. Mice who were stripped of the prevalent eosinophil production gene
(ΔdblGATA) showed a more severe allergic reaction after contact with dust mites, proving that hEos
do not participate in the inflammatory process and they also downregulate the Th2 response, most
probably by inhibiting the functionality of dendritic cells [12].
3. Eosinophil Migration to the Lung
Eosinophil trafficking from the bone marrow to the lungs is the first major step of the blooming
inflammatory process. Even though various chemoattractants were discovered, most of them are
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not selective and can also draw other leucocytes. Activated Th2 cells and type 2 innate lymphoid
cells (ILC2) synthesize IL-4, IL-5, and IL-13, while eotaxin-1 (CCL11) is produced by epithelial and
endothelial cells after an allergen challenge. Specifically, IL-5 and eotaxin-1 play a pivotal role in
eosinophil trafficking and synergize in promoting lung eosinophilia [16]. Although IL-4 is not a
direct eosinophil mediator, it is crucial in the activation of the IgE cascade while also promoting the
development of more Th2 lymphocytes, thus sustaining the migratory process [17]. The same applies
to IL-13 as it induces eotaxin production [18].
IL-5 is the most crucial cytokine not only in recruiting eosinophils but also in prolonging their
survival in tissues. This was observed in IL-5 KO mice which showed a greatly reduced number of
eosinophils in the lungs when compared to IL-5 transgenic mice [19,20]. This is largely attributed to
the IL-5 receptor that is also expressed in mature eosinophils apart from their progenitors, thus being
able to respond to the stimulus of the cytokine via a Janus kinase signal transducer and prolong their
half-life (T1/2) by almost 50% [21]. IL-5 was also administered routinely to guinea pigs over a period of
time, resulting in a reduction of eosinophils in the bone marrow and a concomitant increase of their
number in circulation, indicating that it clearly mobilizes them and aids their trafficking into tissues [22].
It is synthesized mostly by activated Th2 lymphocytes and in smaller proportions by eosinophils
and mast cells. IL-5 is already the primary target of monoclonal antibody treatment in asthmatic
patients, highlighting even more its central role in the pathogenesis of the T2-high inflammatory
response. Another source of IL-5 is innate lymphocytes termed ILC-2 cells that may initiate or amplify
eosinophilic inflammation. These cells may also produce other Th2-related cytokines such as IL-4, IL-9,
and IL-13. That is why the cytokine pattern above is usually termed as T2 instead of Th2 [23].
Eotaxin-1 was first described as a novel component in the bronchoalveolar lavage (BAL) of guinea
pigs sensitized and challenged by ovalbumin and was later isolated from human tissue as well. It
was the first eosinophil-specific chemoattractant discovered until two more CC chemokines named
eotaxin-2 and eotaxin-3 were isolated later on [24]. Eotaxins are produced by epithelial cells of the lung
but also in lower numbers by eosinophils, mast cells, macrophages of the alveoli, vascular endothelial
cells, and smooth muscle cells of the airways after stimulation by IL-4 and IL-13 [25]. Eosinophils
express receptors for the CC groups of chemokines, a classic G-protein transmembrane receptor, while
eotaxins interact specifically with the CCR3 receptor and synergize with IL-5 and between themselves,
in order to recruit eosinophils to the lungs [26]. It should be noted that the CCR3 receptor is constantly
expressed on the eosinophil membrane, but its expression is further increased after an inflammatory
stimulus [27]. Characteristically, it was demonstrated that the airways of asthmatic patients have a
higher number of cells producing messenger RNA (mRNA) for CCR3 and its ligands, compared to
healthy individuals [28]. Other cells expressing CCR3 receptors are basophils, mast cells, Th2 cells, and
eosinophil progenitor cells. Activation of the CCR3 receptor by eotaxin results in the internalization of
the ligand and induces chemotaxis via calcium mobilization and actin polymerization [29]. Studies
showed that all three eotaxins are upregulated after an allergen challenge and have a pivotal role in
different phases of the immune response.
Eotaxin-1 is needed in the first steps of the inflammatory response, whereas eotaxins 2 and 3 are
needed to prolong eosinophil survival later on [30]. Their synergistic role is clearly demonstrated in
studies between single eotaxin-1 or eotaxin-2 KO mice and both eotaxin 1 and 2 KO mice. The latter
group had far fewer eosinophils in their lungs after an allergen challenge when compared to the single
KO group [31]. Eotaxin-1 is also crucial in mobilizing eosinophils from the bone marrow, with its
levels being correlated with the eosinophil number in blood and lungs in pig specimens. However,
inhibition of IL-5 in those pigs showed that eotaxin-1 alone cannot mobilize eosinophils from the bone
marrow, thus highlighting the importance of the cooperation between those two chemokines [32].
The same applies to their mobilization from circulation to tissues, since administration of eotaxin-1
without abolishing IL-5 effects increases blood eosinophilia but fails to increase their number in tissue.
On the contrary, administration of IL-5 without abolishing eotaxin-1 demonstrated a notably higher
number of tissue eosinophils, further underlining the important role of IL-5 in the tissue infiltration
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process [33]. Eotaxin-2 synergizes with IL-5 and drives the production of IL-13, with which it later
synergizes to promote lung eosinophilia [34]. Eotaxin-3 levels start to rise at a later time, and it is
thought to prolong the eosinophil recruitment in lungs [35]. The CCR3 receptor was targeted for the
development of new targeted treatment of asthma, since it is expressed in all the cells taking part in
the inflammatory process, making it evident that blocking the eotaxin/CCR3 axis might prove greatly
important in future trials.
Eosinophils, which are found in circulation after being mobilized mostly by IL-5 and eotaxin-1
as previously mentioned, still need to migrate from the vasculature to the lung tissue. In this phase,
several eosinophil-specific adhesion molecules with the most important being the β1 integrin very
late antigen (VLA-4), the vascular cell adhesion molecule (VCAM-1), and the P-selectin glycoprotein
ligand (PSGL-1) play an important role [36]. VLA-4 is an integrin which is expressed on the membrane
of eosinophils after a stimulus from eotaxin-1. It ligands with the VCAM-1 integrin expressed at the
vasculature membrane, resulting in the activation and firm adhesion of eosinophils to it, aiding their
transit from the endothelium to tissues [36]. Usage of inhibitors of the VLA-4 and VCAM-1 interaction
in mice studies showed a greatly reduced inflammatory response and eosinophil number in lungs,
compared to normal mice [37]. Apparently, this ligand is a selective eosinophil adhesion chemokine,
since it does not cause the adhesion of other leucocytes to the endothelium; therefore, more research is
needed as to whether a VLA-4/VCAM-1 inhibitor could be used in the treatment of severe eosinophilic
asthma. PSGL-1 on the other hand binds to P-selectin and modulates the first steps of the interaction
between eosinophils and the endothelium, more specifically the rolling and adhesion stages. It is
also solely expressed by eosinophils, which means that tampering with the PSGL-1/P-selectin ligand
can reduce the transit of eosinophils to tissue. Trials were conducted in mice with ablation of the
P-selectin gene and, indeed, those mice had fewer eosinophils in their lungs [38]. Inhibitors targeting
this selectin ligand are currently being investigated in clinical trials; however, they are yet to yield
promising results.
Recent studies highlighted the fact that eosinophilopoiesis can also occur in situ in the airways of
severe asthmatics, since the number of CD34+ and CD34+ IL-5Rα+ hematopoietic progenitor cells was
much higher in this population’s sputum when compared to mild asthmatics. Even more interesting
was the fact that eosinophil progenitor cells did not vanish after anti-IL-5 treatment in these patients,
which means that in situ eosinophilopoiesis is an important mechanism of persistent eosinophilia in
the airways [39]. This could be attributed to the action of bronchial epithelial cells which, after being
triggered by an extraneous stimulus, produce several cytokines, such as IL-25 and IL-33, along with
thymic stromal lymphoid proteins (TSLPs) known as alarmins. Their expression was found to be
higher in the airways of asthmatic patients, while they also correlate with disease severity [40]. The T2
cascade is sustained by the production of these alarmins, since they can promote eosinophil progenitor
cell recruitment and trigger T2 cells, especially ILC2 cells, in producing IL-4, IL-5, and IL-13 [41]. This
persistent production of cytokines by ILC2 cells facilitates the eosinophil progenitor cell homing to
the lungs and provides fertile soil for their in situ maturation, causing persistent eosinophilia in these
patients [42].
4. Eosinophilic Inflammation in the Lung
Eosinophils are the predominant cells of the inflammatory response in the lungs, contributing
greatly to two major events: the remodeling and the hyperresponsiveness of the airways (AHR).
Persistent inflammation caused by eosinophils leads to constant damage of the airways. The
regeneration process is not flawless and results in hypertrophy of the smooth muscles, hyperplasia
of goblet cells, and deposition of extracellular matrix proteins, causing membrane thickening and
fibrosis [43].
The damage caused at the bronchial level is attributed to the degranulation of eosinophils and
the release of their toxic proteins. Degranulation can occur in three different ways: (i) exocytosis,
(ii) piecemeal degranulation, and (iii) cytolysis. In exocytosis, most specifically the subtype compound
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exocytosis, multiple granules inside the cell fuse and are then secreted to the extracellular space. This is
the classic way that eosinophils act against helminths [44]. Piecemeal degranulation was demonstrated
to be the most prevalent mechanism of eosinophil degranulation in asthmatic patients. In this highly
regulated mechanism, the cytoplasmic proteins are “packaged” selectively in small vesicles, and then
transported to the membrane through a tubulovesicular system until they are finally released by
exocytosis. Various chemokines carefully regulate this process, such as Interferon-gamma (IFN-γ)
and eotaxin-1, with studies showing that stimulating human eosinophils with a cytokine leads to
the selective release of an eosinophilic protein [45,46]. In cytolysis, the cell dies; however, unlike
apoptosis, its granules are released in the microenvironment, fully potent and active. Eosinophils
which do not undergo piecemeal degranulation release their content through cytolysis [47]. Even if
these mechanisms normally exist to protect tissues from damage, in this inflammatory process, the
released proteins damage the epithelium, increase vascular permeability, and activate mast cells [48].
The release of eosinophilic granules and other mediators was proven to damage the airways in
multiple ways. The smooth muscles of the airways contract via the M3 receptor after being triggered by
acetylcholine. The M2 receptor limits its release and acts as a regulatory mechanism [49]. Eosinophils
release MBP which is an allosteric antagonist of the M2 receptor, leading to an uncontrollable stimulation
of the M3 receptor by acetylcholine and, thus, to bronchoconstriction [50]. MBP and other eosinophilic
proteins were also shown to damage epithelial cells in vitro in similar concentrations to those found
in the lungs of asthmatic patients, further proving their toxic effects [51]. However, MBP-abolished
mice were not protected from AHR, meaning that other factors also contribute to this process [52].
Leukotrienes are abundant inside eosinophils, and their release causes bronchoconstriction and
activates mast cells and basophils, which also excrete prostaglandins, histamine, and more leukotrienes
to support the ongoing inflammation [53]. Eosinophils may induce AHR in a more indirect way, since
eosinophil-ablated mice could still develop AHR when injected with T cells producing IL-13, which
was demonstrated to cause AHR despite the absence of eosinophils [54]. More studies highlighted
this indirect effect on AHR, since mast cells were proven to be more important in developing AHR
in patients with eosinophilic asthma [55]. Blocking both CCR3 and IL-5 experimentally could not
distinguish the effects of eosinophils and mast cells in AHR, since CCR3 is expressed in both types of
cells. Nevertheless, use of CCR3 antagonists showed a significant reduction of both AHR and airway
remodeling in animal studies, demonstrating the importance of the CCR3/eotaxin-1 axis [56]. Genetic
ablation of eosinophils in mice via the GATA-1 gene showed no protection from AHR when compared
to normal mice in asthmatic models [57]. Therefore, while AHR is definitely one of the hallmarks of
asthma, its correlation with eosinophils is debatable and seems to be more of a secondary effect of the
generalized inflammatory process.
Nevertheless, eosinophils were proven to be one of the main factors behind airway remodeling.
In a study designed with the same concept as the previous one mentioned, Δdbl-GATA mice were
challenged by allergens and compared with wild-type mice. The latter group was found to exhibit
all the features of airway remodeling, whereas the eosinophil-naïve mice were protected from it [58].
Similar results were demonstrated in both IL-5 KO mice and patients treated with anti-IL-5 agents,
proving that reducing the number of eosinophils indeed reduces the deposition of extracellular matrix
proteins (ECMs) such as collagen I in the airway lumen [59–61]. Eosinophils are activated by the effect
of tumor necrosis factor-alpha (TNF-α) and, as recent studies showed, by IL-1beta; they secrete matrix
metalloproteinase-9 which is one of the main enzymes found in asthmatic patients, highly correlated
with the remodeling process and the persistent recruitment of eosinophils [62,63]. They also are a
potent resource of transforming growth factor-β (TGF-β) which acts as a chemoattractant for fibroblasts
and activates local fibroblasts to differentiate into myofibroblasts and even into smooth muscle cells,
inducing ECM production in the meantime [64]. Mice treated with an anti TGF-β agent did not show
evidence of airway remodeling, even if the inflammatory process was not altered, highlighting the
pivotal role of TGF-β—mostly its correlation with the thickening of the basement membranes [65].
TGF-β is not only an eosinophil product; its mRNA was found increased in all the inflammation stages,
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with reports suggesting that eosinophils are its primary source in the first stages of the disease [61].
Nitric oxide (NO) is another toxic molecule secreted from eosinophils, and its levels correlate with
the biomarker FeNO which is discussed later on [66]. Reactive oxygen species (ROS) are yet another
product of eosinophils with clear potential to damage the airway and induce a fibrotic process [67].
Summarizing, eosinophils clearly contribute to airway remodeling, and the inhibition of eosinophil
adhesion and activation may also reduce the inflammatory process and airway remodeling.
5. Biomarkers in Severe Eosinophilic Asthma and Endotyping
There was always a notion that the heterogeneity of asthma is due to the different phenotypes
and endotypes of the disease. Nevertheless, endotyping became a necessity throughout the years;
therefore, the need for specific biomarkers of every distinct type increased. These biomarkers include
serum IgE, blood eosinophil levels, sputum eosinophils, and levels of exhaled nitric oxide in breath
(widely known as FeNO) [68].
Sputum eosinophils are the most interesting biomarker in severe eosinophilic asthma due to the
insight they provide into airway eosinophilia, despite the difficulty of collecting and analyzing them
in every patient routinely. Treatment of patients based on sputum eosinophils showed a reduction
of the rate of exacerbations, especially in those with severe asthma. [69] Both European Respiratory
Society/American Thoracic Society (ERS/ATS) and Global Initiative for Asthma (GINA) guidelines
support the use of sputum eosinophils for severe asthma management [1]. Sputum eosinophils ≥ 3%
are correlated with airway eosinophilia [70]. Sputum mRNA can also be used in order to determine
whether patients belong in the T2-high or the T2-low group, according to the expression of cytokines
found in their sputum. Although this is a more costly method, it can “mark” candidates for biological
treatments [71].
Blood eosinophils were used in the past few years as a marker for severe eosinophilic asthma
requiring biological treatment with an anti-IL-5 agent, since they are correlated with sputum eosinophils.
The threshold was put in several counts during trials, with the most often picked numbers being
150 cells/μL or 300 cells/μL; however, the most important from a clinical point of view is that blood
eosinophil count—an easy and inexpensive biomarker—was chosen over sputum eosinophil number
for eligibility for anti-IL-5 therapy [72]. During the anti-IL-5 trials, many biomarkers were evaluated, but
none were deemed superior to blood eosinophils. The use of blood eosinophil counts as a biomarker for
airway eosinophilia is based upon the relationship between blood and sputum eosinophil counts [73].
However, it should be noted that, although airway eosinophils are considered to better reflect eosinophil
involvement in airway inflammation, peripheral blood eosinophils do not necessarily parallel airway
eosinophils. High blood eosinophil numbers present good specificity for airway eosinophilia [74,75].
On the other hand, low blood eosinophil numbers might not accurately reflect the absence of airway
eosinophilia [76,77]. This was demonstrated in a study including children with severe asthma, in
which, despite 86% of them having blood eosinophil counts within normal levels, 84% still presented
airway eosinophilia [78]. It should also be taken under consideration that blood eosinophil counts
are influenced by high-dose ICS and mainly oral corticosteroids (OCS) [79]. A single measurement of
blood eosinophil count of at least 150 cells/μL was shown to predict subsequent measurements on
average of at least 150 cells/μL in 85% of patients [80].
FeNO is another marker that is used commonly and can inform us about the ICS response we
should expect from a patient [81]. Nevertheless, there are several protruding factors that can confuse
the results, the most important being smoking, allergic rhinitis, and female gender [82,83]. FeNO
>50 ppb in adults suggests the presence of Th2-high inflammation, whereas FeNO < 25ppb suggests
a Th2-low process. In another study, it was shown that, in patients with severe asthma refractory
to treatment, an FeNO level >19ppb was indicative of sputum eosinophilia [84]. However, current
guidelines from ATS/ERS do not recommend FeNO-guided management for patients with severe
asthma [1]. This could be attributed to the fact that FeNO is correlated with the NO produced in
asthmatic airways by other cells apart from eosinophils, such as epithelial cells and macrophages.
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Thus, NO cannot be solely linked to eosinophils and the need for biological treatment, and it is more
likely correlated with other aspects of the Th2 inflammation [85].
Volatile organic compounds (known as VOCs) are a modern biomarker also found in exhaled
breath, like FeNO, and they are bound to predict with great accuracy both eosinophil and neutrophil
counts in blood, while they are also correlated with eosinophil number in BAL [86]. They are processed
by a meticulous algorithm called eNOSE (electronic nose), and early research suggested that they
could be superior in estimating the risk of exacerbations and insensitivity to corticosteroids [87]. A
recent study demonstrated that particular VOCs (hexane and 2-hexanone) had a high classification
performance for eosinophilic asthma in a large asthmatic population classified according to their
sputum cell count. Moreover, the combination of FeNO, blood eosinophils, and VOCs gave a very
satisfactory prediction of eosinophilic asthma with an area under the curve (AUC) of 0.9 [88]. However,
more data are needed if this method is to be applied on a daily basis. Last but not least, serum periostin,
which derives from epithelial cells of the lung after stimulation by IL-13, was used as a biomarker of
the T2-high endotype [89]. It was used in various studies as a predictor of Th2 inflammation and, even
though the BOBCAT study showed that it was superior to regular biomarkers, the follow-up studies
could not support these findings [75].
A combination of biomarkers may be better than using one alone, and this trend was followed
in many studies. In the U-BIOPRED cohort study, a specific endotype of severe asthma involving
eosinophils was described as “late-onset asthma with past or current smoking and chronic airflow
obstruction with a high blood eosinophil count” [90]. A similar endotype was discovered by both the
SARP and the Leicester cohorts using blood eosinophilia as an inflammatory marker, describing “late
onset asthma associated with nasal polyps and resistance to corticosteroid therapy” and “a late-onset
disease along with rhinosinusitis and numerous exacerbations”, respectively [91]. The majority of these
patients needed oral corticosteroids to achieve control of the disease and minimize exacerbations [92].
Although endotyping may not seem simple, it reveals individual therapeutic targets by means of
specific treatable traits and mechanisms, leading to precision medicine, with the aid of biomarkers. For
instance, Th2-high patients with severe asthma under ICS and LABA had higher FeNO, as well as
blood and sputum eosinophil counts, compared to those with Th2-low inflammation in research using
the IL-13 genes in epithelial cells of the bronchial tree.
Concluding, it is clear that biomarkers have a role to play in guiding therapy of severe asthma.
However, a combination of biomarkers may be used in order to achieve a greater predictive value.
Also, new biomarkers with better correlation to specific endotypes and their respective molecular
pathways need to be discovered in order to achieve optimal therapy.
6. Anti-IL-5 Therapy in Severe Eosinophilic Asthma
6.1. Mepolizumab
The story of anti-IL-5 treatment in asthma is definitely a fascinating one. Given the central
role of eosinophils both in the allergic and non-allergic cascade of asthmatic inflammation, along
with the fact that IL-5 is the cytokine mainly responsible for the differentiation, maturation, airway
trafficking, and survival of eosinophils, the development of monoclonal antibodies against IL-5 raised
high expectations for new treatment approaches, primarily in severe asthma.
However, the first studies were somewhat disappointing. In one study, mepolizumab prevented
the rise in eosinophil numbers both in blood and sputum after inhaled allergen challenge, but it did
not ameliorate allergen-induced asthmatic responses [93]. In another study including a small number
of patients with difficult-to-treat asthma who were receiving high-dose ICS and/or oral CS, anti-IL-5
was able to reduce blood eosinophils but did not have an effect on other clinical outcomes apart from a
small improvement in lung function— forced expiratory volume in the 1st second (FEV1) [94]. A few
years later, in another study, mepolizumab was administered in a large group of not well-controlled
patients with moderate to severe asthma, despite being treated with ICS and receiving four puffs of
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beta2-agonist daily as recue medication. Again, anti-IL-5 diminished blood eosinophils but did not
manage to improve any clinically important outcome [70]. In the high-dose group, there was a trend
toward reducing severe exacerbations, but the study was not powered to show such an effect. In spite
of the consistent effect of anti-IL-5 in the reduction of blood eosinophils, the lack of a favorable effect in
clinical asthma outcomes was obvious. These findings supported the dismal statement of the “final
nail in the coffin for anti-IL-5 treatment in asthma”.
However, in 2009, two small but well-designed randomized controlled trials were contracted
that meant to change the road of anti-IL-5 treatment in asthma. In the first study, 20 asthmatics
received either mepolizumab or placebo at five monthly intravenous infusions. These patients had
corticosteroid-resistant eosinophilic asthma, and it is important to note that, although they were
receiving a median dose of 10 mg of prednisone for a mean time of nine years and a high ICS dose,
they still had >10% sputum eosinophils [95]. In the second study, 61 asthmatics received 12 infusions
of either mepolizumab or placebo monthly [85]. Both studies revealed a significant reduction of
exacerbations, accompanying a significant reduction in blood and sputum eosinophils. In the first
study, the reduction of exacerbations occurred along with a reduction in prednisone dose. Still, there
was no other clinically meaningful improvement in symptoms or lung function (FEV1) in both studies.
These studies highlighted the importance of eosinophils in the pathogenesis of asthma exacerbations,
but more clearly paved the way for the future of anti-IL-5 treatment by focusing—in contrast to
previous studies—on two main determinants. Firstly, the primary outcome benefit from anti-IL-5
treatment relies mainly on the reduction of exacerbations; secondly, this benefit is obvious when
selecting asthmatics with persistent eosinophilic inflammation despite regular corticosteroid (inhaled
and/or oral) treatment.
Apart from a clear link with exacerbations, eosinophils are also important in airway remodeling
in asthma. TGF-beta derived from eosinophils is involved in this process. In a study including
24 atopic asthmatics, anti-IL-5 treatment with mepolizumab reduced airway eosinophil numbers
and significantly decreased the expression of three extracellular matrix proteins (tenascin, lumican,
procollagen III) in the reticular basement membrane. It also reduced the percentage and the number
of eosinophils expressing TGF-beta 1. These findings are extremely important, especially taking into
consideration that the asthmatics included in this study were mild and received only short acting beta
agonists (SABA) and not ICS. Firstly, these findings indicate that remodeling is present even in mild
asthma, and it is driven to some degree by eosinophil-derived TGF-beta 1; secondly, anti-IL-5 can
prevent this process by regulating the TGF-beta-enhanced deposition of matrix proteins through the
reduction of eosinophils [60].
One of the largest studies in severe asthma, the DREAM study, including 621 patients was
undertaken in order to examine the effect of mepolizumab in reducing the rate of clinically significant
exacerbations. As such were defined the exacerbations that required oral corticosteroids or visit to an
emergency department or hospitalization. All asthmatics had a history of at least two exacerbations
requiring systemic corticosteroids in the previous year and signs of eosinophilic inflammation despite
treatment. These signs were either sputum eosinophils>3%, peripheral blood eosinophils> 300 × 106/L,
FeNO > 50 ppb, or loss of asthma control after a ≤ 25% reduction in regular corticosteroid dose (inhaled
or oral). The study had a duration of 52 weeks, and patients received 13 infusions of one of three doses
of IV mepolizumab (75, 250, and 750 mg). All three doses equally and significantly reduced the rate
of asthma exacerbations. Moreover, they reduced the number of blood and sputum eosinophils and
they were well tolerated. No improvements in FEV1 and AQLQ (asthma quality of life questionnaire)
were observed, and this, in accordance with previous studies, indicated the dissociation of measures
of control and exacerbations. This study also provided clinically valuable information regarding
predictors of efficacy of mepolizumab treatment. The two main determinants were the baseline
peripheral blood eosinophil number and the number of exacerbations in the previous year. Higher
numbers indicated a more likely response to treatment. Other factors such as baseline FEV1, acute
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response to bronchodilators, IgE level, and atopic status were not associated with probability of
response to mepolizumab [73].
In a following study (MENSA), 576 asthmatics treated with high-dose ICS with or without oral
corticosteroids were randomized to receive either 75 mg of mepolizumab IV, 100 mg of mepolizumab
subcutaneously (SC), or placebo every four weeks for 52 weeks. These asthmatics had at least
two exacerbations requiring systemic corticosteroids the previous year and evidence of eosinophilic
inflammation reflected by an eosinophil count of 150 cells/μL at screening or above 300 cells/μL at
some time point in the previous year. The primary outcome was the annualized rate of exacerbations,
and they were significantly reduced by both IV and SC mepolizumab by 47% and 53%, respectively.
This was the first study to show that mepolizumab was associated with a significant improvement in
lung function (FEV1), quality of life (AQLQ), and asthma control (ACQ-5) [96].
Another study (SIRIUS) explored the systemic corticosteroid-sparing effect of mepolizumab. In
total, 135 asthmatics with severe eosinophilic asthma were randomized to receive either mepolizumab
(100 mg SC) or placebo every four weeks for 20 weeks, and the primary outcome was the percentage
reduction of the oral corticosteroid dose. The evidence of eosinophilic asthma was determined—similar
to MENSA—by an eosinophil count of 150 cells/μL at screening or above 300 cells/μL at some time
point in the previous year. In contrast to the MENSA study where 25% of asthmatics received oral
steroids, in SIRIUS, all of the included patients received a mean dose of 10 mg of prednisone. This
study involved a so-called optimization phase, in which a reduction of the dose of oral steroids was
attempted before the start of mepolizumab, so as to establish that the patients genuinely needed
this dose for their asthma control. The study showed that mepolizumab permitted the reduction
of oral corticosteroid dose; moreover, despite this reduction, it also significantly reduced the rate of
exacerbations and improved asthma control and quality of life (secondary outcomes in this study) [97].
In a 12-month open-label extension study of MENSA after the cessation of mepolizumab treatment,
it was found that eosinophils increased both in blood and sputum, returning to pre-treatment levels
within three months of cessation. As for asthma control, 12 months after the stop of medication, the
exacerbation rates were similar to the pretreatment levels [98]. This study showed deterioration in
exacerbation frequency after the cessation of mepolizumab that was preceded by a rebound worsening
of eosinophilic inflammation.
In a post hoc analysis of the DREAM and MENSA studies, patients were stratified according to
baseline blood eosinophil count in order to evaluate whether this biomarker could be used to predict
response to mepolizumab. It was shown that using a threshold of 150 cells/μL could predict a favorable
outcome in reducing exacerbations. Most importantly, this reduction was higher with increasing
baseline blood eosinophil count (52% versus placebo for those with baseline blood eosinophils >150
and 70% for those with baseline blood eosinophils >500 cells/μL) [99]. In a subgroup analysis of the
studies DREAM, MENSA, SIRIUS, and MUSCA, it was demonstrated that asthmatics with baseline
eosinophils 150–300 cells/μL showed benefits in terms of reducing exacerbations and reducing the
need for systemic corticosteroids that were clinically meaningful and comparable to patients with
baseline >300 eosinophils/μL [100].
In patients with severe eosinophilic asthma previously treated with omalizumab, a post hoc
analysis from MENSA and SIRIUS demonstrated that the response to mepolizumab was the same
regardless of previous use of omalizumab [101]. This is clinically important because a subgroup of
patients eligible for mepolizumab is also eligible for omalizumab treatment. Accordingly, a lack of
response to omalizumab does not preclude a favorable response to mepolizumab in such asthmatics.
Another 32-week study (OSMO) included 145 patients who were eligible for both omalizumab
and mepolizumab and were not controlled with omalizumab (median time of omalizumab treatment
was 29.6 months). These asthmatics were switched immediately after the last dose of omalizumab to
mepolizumab and achieved significant improvement, reflected by a 64% reduction in exacerbations
compared to the previous year, better asthma control (measured by ACQ-5), and better quality of
life (measured by Saint George’s respiratory questionnaire—SGRQ). These outcomes were achieved
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early within 8–12 weeks and were kept or even improved during the study, indicating no evidence
of possible additional action of the two antibodies until the wash-out of omalizumab. This study
provided support to clinical practice in terms of switching from one biologic agent to another [102].
A study (MUSCA) assessed the effect of mepolizumab in the quality of life of patients with severe
eosinophilic asthma and found a significant improvement in SGRQ of 7.7 (surpassing the minimal
clinically important difference of four units), with a safety profile comparable to placebo [103].
Regarding safety, in a 52-week, open-label extension study of MENSA and SIRIUS (COSMOS
study), mepolizumab had a favorable long-term safety profile, without any increase in the rate of
adverse events [104]. Similarly, in the COLOMBUS study, an extension of the DREAM study lasting
3.5 years with a maximum exposure of 4.5 years, mepolizumab was safe and maintained its efficacy in
the reduction of exacerbations [105].
Using data from five phase III studies with mepolizumab, it was shown that few patients developed
anti-drug antibodies that had no impact on safety or efficacy of mepolizumab. Only one patient (from
the SIRIUS study) was positive for neutralizing antibodies, but pharmacokinetic samples were not
quantifiable during follow-up. These data show the low immunogenic response of mepolizumab [106].
6.2. Reslizumab
Reslizumab is a humanized anti-IL-5 IgG4 monoclonal antibody that binds with high affinity to
the alpha subunit of the cytokine IL-5, thus preventing the interaction with its receptor [107].
Initially, a pilot safety study including 32 asthmatics showed that reslizumab at a dose of 1 mg/kg
given intravenously reduced blood and sputum eosinophils but had no effect in lung function and airway
hyperresponsiveness [94]. In the following phase IIb randomized, double-blind, placebo-controlled
study, 106 patients with asthma and sputum eosinophils ≥3% were administered reslizumab at a dose
3 mg/kg IV every four weeks. Reslizumab managed to decrease sputum eosinophils significantly and
improve FEV1, as well as improve asthma control (ACQ) in those patients with nasal polyps [108].
The two main phase III studies included 953 asthmatics that were randomized to receive either
reslizumab (3 mg/kg IV) or placebo. All included patients had a baseline peripheral blood eosinophil
count of > 400 cells/μL, ACQ-7 >1.5, at least 12% FEV1 reversibility, and at least one exacerbation
requiring OCS in the last year; they were also on regular treatment with high-dose ICS plus additional
controller with or without OCS (up to 10 mg of prednisone). The duration of the studies was 52 weeks,
and the primary outcome was the rate of exacerbations defined either as need for OCS or doubling the
ICS dose. Reslizumab was effective in reducing exacerbations significantly, improving FEV1, ACQ-7,
and AQLQ, as well as reducing rescue medication and blood eosinophils [109]. In a post hoc analysis
of these two studies, it was demonstrated that late-onset asthma (defined as onset after the age of 40)
showed a better response to reslizumab compared to early-onset asthma [110].
In conclusion, these studies showed that reslizumab at a dose of 3 mg/kg IV is safe and more effective
in patients with severe eosinophilic asthma and a peripheral blood eosinophil count > 400 cells/μL.
In another study including 10 patients with oral corticosteroid-dependent asthma, weight-adjusted
intravenous reslizumab was more effective in reducing sputum eosinophilia compared to fixed-dose
SC mepolizumab that was administered for at least one year with inadequate response. This was
associated with a greater improvement in asthma control measured by ACQ-5 [111].
6.3. Benralizumab
Benralizumab is a humanized, afucosylated, monoclonal antibody targeting the IL-5α receptor. In
comparison to anti-IL-5 monoclonal antibodies, benralizumab induces a direct, fast, and nearly complete
depletion of blood eosinophils through enhanced antibody-dependent cell-mediated cytotoxicity, via
natural killer cells [112]. As IL-5 receptors are expressed not only on eosinophils, but also on eosinophil
progenitors and basophils, it is expected to affect all these populations. A study evaluating the effect
of benralizumab on eosinophils in different compartments such as bone marrow, peripheral blood,
sputum, and airways showed that bone marrow and peripheral blood eosinophils were completely
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suppressed while airway eosinophils (tissue and sputum) were also extensively depleted [113]. Two
phase III trials, SIROCCO and CALIMA demonstrated that benralizumab significantly reduced the
rate of asthma exacerbations in patients with severe, uncontrolled asthma and blood eosinophil counts
≥300 cells/μL [114,115]. In the SIROCCO study, benralizumab administered either every four weeks or
every eight weeks (after the first three doses given every four weeks) reduced the rate of exacerbations
by up to 51% after 48 weeks of treatment. It also improved lung function (expressed as an increase
in pre-bronchodilator FEV1) and asthma control [114]. The effect compared to placebo was greater
for the eight-weekly dosage, with the potential to lower the burden of asthma and reduce costs in
comparison to other biologics that need to be given on a monthly basis. In CALIMA, a study of similar
design to SIROCCO with a duration of 56 weeks, it was confirmed that benralizumab reduced asthma
exacerbations up to 36% in patients with severe eosinophilic asthma and blood eosinophil counts ≥
300 cells/μL. Again, as found in SIROCCO, a substantial improvement in lung function and asthma
symptoms was observed [115]. Although there were no direct comparisons between biologics, it seems
that the increases in lung function were greater with benralizumab than with other biologics.
In both studies, benralizumab produced a direct, rapid, and nearly complete depletion of
eosinophils as early as four weeks, providing support for its mechanism of action directly on the
IL-5α receptor, causing eosinophil apoptosis. Benralizumab depletes eosinophils directly, whereas
mepolizumab and reslizumab reduce eosinophil number rather than deplete them entirely. This
way, benralizumab is likely to overtake potential issues such as the induction of increased cytokine
production due to cytokine-directed antibodies. A pooled analysis from the SIROCCO and CALIMA
studies demonstrated that benralizumab was safe and effective in patients with severe eosinophilic
asthma and blood eosinophils > 150 cells/μL [116].
A subsequent pooled analysis of the SIROCCO and CALIMA studies stratified patients according
to baseline blood eosinophil count and by number of exacerbations (two and three or more). In
this analysis, the rates of asthma exacerbations were increasingly reduced with increasing blood
eosinophil thresholds and with greater exacerbation history. These reductions were even greater with
a combination of high blood eosinophils and a history of more frequent exacerbations [117].
Another phase III study, ZONDA, showed that benralizumab significantly reduced the dose of
oral prednisone in OCS-dependent patients, while also reducing the rate of exacerbations. All patients
received oral corticosteroids for at least six months prior entering the study. The study included a
run-in phase where the dose of prednisone was reduced to the minimum while maintaining asthma
control, and this preceded the first administration of benralizumab. After 28 weeks, 50% of the patients
managed to stop oral corticosteroids, while the likelihood of reducing the dose was four times higher
in benralizumab-treated than in placebo-treated asthmatics [118].
A phase III extension study, BORA, included patients who completed the SIROCCO and CALIMA
studies and evaluated the safety and tolerability of benralizumab. Interestingly, patients that received
placebo in SIROCCO and CALIMA were randomized to receive benralizumab either every four weeks
or every eight weeks (after administration of the first three doses every four weeks). The study
confirmed the two-year safety of benralizumab as the percentage of patients experiencing adverse
events was not different between BORA and the SIROCCO and CALIMA studies. No increased risk
of infection was observed in patients receiving benralizumab for two years despite the long-term
depletion of eosinophils. Moreover, asthmatics who were treated with benralizumab in BORA but
received placebo in SIROCCO and CALIMA showed a comparable reduction in exacerbation rate with
those receiving the active drug from the first year [119].
It is of high clinical importance to assess baseline characteristics in patients with severe eosinophilic
asthma that may predict the response to treatment with benralizumab. In a study including patients
from the SIROCCO and CALIMA phase III studies, it was shown that OCS use, nasal polyps, forced
vital capacity (FVC) < 65% pred adult onset of asthma (>18 years), and three or more exacerbations
in the previous year were associated with a greater response to benrlizumab, measured either as
annual exacerbation rate or change in pre-bronchodilator FEV1 for those with > 300 eosinophils/μL.
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Interestingly, OCS use, nasal polyps, and FVC < 65% pred could predict a better response to
benralizumab in decreasing the rate of exacerbations, even in patients with < 300 eosinophils/μL [120].
This study highlights the importance of assessing these clinical features when evaluating an asthmatic
patient eligible for benralizumab, and adds to the already known baseline blood eosinophil count
predictive information for responsiveness to treatment.
Another study assessed the effect of benralizumab treatment by stratifying patients according
to atopic status (atopic or non-atopic) and IgE level (high > 150 kU/L or low < 150 kU/L). The study
again included patients from the phase III SIROCCO and CALIMA studies and demonstrated that
the efficacy of benralizumab in reducing the exacerbation rate and improving lung function was not
affected by atopic status and serum IgE level [121]. This is clinically important because it indicates
that benralizumab is effective in patients with severe eosinophilic asthma that might be eligible for
omalizumab treatment as well.
There are no head-to-head trials for direct comparison between the different anti-IL-5 biologics.
In a matching-adjusted indirect comparison, benralizumab and mepolizumab similarly reduced
exacerbation rate and improved lung function. No comparison could be made between benralizumab
and reslizumab due to differences in study populations [122]. Another indirect comparison
demonstrated that, in patients with similar blood eosinophil counts, mepolizumab was more effective
in reducing exacerbations than benralizumab and reslizumab. As for lung function, benralizumab
was associated with a greater improvement in FEV1 compared to reslizumab for patients with a blood
eosinophil count > 400 cells/μL [123]. However, all these findings of the indirect comparison trials
should be viewed with caution because of the differences in study populations and in the number of
exacerbations in the previous year of the included patients. Moreover, there were differences in the
treatment the patients received before starting the biologic (either the ICS dose and/or OCS dose). The
studies for reslizumab enrolled asthmatics with baseline blood eosinophils > 400 cells/μL, a higher
number compared to those enrolled in studies for mepolizumab and benralizumab. Accordingly, a
greater effect might have been expected.
There are no studies evaluating possible co-administration of biologics with different mechanisms
such as anti-IgE and anti-IL-5 for those who present a mixed phenotype (severe allergic and eosinophilic
asthma). In these patients, it is logical to assess the predominant characteristics and decide which
biologic to start [124].
It is suggested that anti-IL-5 antibodies be administered for at least 16 weeks in order to assess
efficacy. However, this time may be extended up to 12 months as there are some late-responders, and
16 weeks is possibly too short a length of time to evaluate reduction in exacerbations [125].
There are still some unanswered questions with major clinical importance. How long should an
anti-IL-5 be prescribed in a patient with severe eosinophilic asthma? It seems that, after stopping it,
there is a relapse of exacerbations following an increase in blood and sputum eosinophils, and this was
shown with mepolizumab and benralizumab. This relapse of eosinophilic inflammation is compatible
with a lack of long-term bone marrow suppression after discontinuation of medication [98,119]. Is
there a rationale for moving from an anti-IL-5 antibody to an anti-IL-5 receptor antibody or vice versa?
The mechanism of action is different, and benralizumab is associated with almost a depletion of blood
eosinophils while mepolizumab reduces them significantly but does not deplete them. However, no
difference in efficacy in any outcome (exacerbation rate, lung function) was observed. One possible
explanation is that these antibodies exert their effect by reducing the eosinophil pool in the bone marrow,
thus reducing exacerbations through the reduction of eosinophils that are available for mobilization
and trafficking in the airways.
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7. Anti-IL-4 therapy in Severe Asthma
Dupilumab
Dupilumab is a fully human anti-interleukin-4α receptor monoclonal antibody, recently approved
for moderate-to-severe eosinophilic asthma or oral steroid-dependent asthma. It blocks interleukin-4
and interleukin-13, which are key mediators in type-2-mediated inflammation.
The first study on dupilumab included 52 asthmatics with severe eosinophilic asthma and a
baseline blood eosinophil count of > 300 cells/μL or sputum eosinophils > 3% who were treated
with medium-to-high-dose ICS plus LABA. The patients received dupilumab (300 mg SC) or placebo
weekly for 12 weeks or until an exacerbation occurred. The design of the study was provocative since
asthmatics discontinued LABA by week four and gradually tapered and discontinued ICS at weeks
6–9. Dupilumab was associated with an 87% reduction in exacerbations compared to placebo and also
improved lung function and reduced markers of Th2 inflammation [126].
The following phase IIb study included 769 patients with severe asthma on medium-to-high
ICS plus LABA, irrespective of baseline blood eosinophil count. They received 200 mg or 300 mg of
dupilumab or placebo every two or every four weeks for a total duration of 24 weeks. Dupilumab
improved FEV1 and reduced the exacerbation rate significantly in the total population and also in
the subgroups of patients with less than or more than 300 eosinophils/μL [127]. In a post hoc analysis
of this study, the favorable effects of dupilumab were demonstrated regardless of the exacerbation
frequency in the previous year, although treatment effects tended to be greater with higher number
of exacerbations in the year prior to study entry. In another post hoc analysis of the above study,
dupilumab (200 mg SC) every two or every four weeks was associated with clinically meaningful
improvements in asthma control (as assessed by ACQ-5) and quality of life (assessed by AQLQ),
while it also improved asthma symptoms and reduced productivity loss [128]. In another study of
similar design, 1902 patients with severe uncontrolled asthma were assigned to receive dupilumab
(200 or 300 mg SC) or matched placebo every two weeks for 52 weeks. The study again confirmed
the favorable effect of both doses in reducing annual exacerbation rate and improving lung function.
These effects, although observed irrespective of baseline blood eosinophils, were greater in those with
> 300 cells/μL [129].
As with anti-IL-5 antibodies, dupilumab was assessed regarding its efficacy in reducing OCS
in asthmatics with oral steroid-dependent asthma. Accordingly, 210 patients received dupilumab
(300 mg) or placebo every two weeks for 24 weeks. Oral steroid doses were reduced from week four
to week 20 and then remained at a stable dose for another four weeks. Dupilumab reduced oral
corticosteroid dose by 70% compared to 42% reduction of placebo, and simultaneously decreased the
rate of exacerbation by 59% compared to placebo; this effect was observed despite the reduction in the
OCS dose. It also significantly improved lung function [130]. In the studies by Castro et al. and Rabe
et al., transient eosinophilia was observed in few patients who received dupilumab.
A meta-analysis involving 3369 asthmatics from five studies concluded that treatment with
dupilumab was effective in reducing exacerbations and improving lung function, asthma symptoms,
asthma control and quality of life. Dupilumab was safe and well tolerated, and the most frequent
adverse event was injection-site reaction [131].
Chronic rhinosinusitis with nasal polyps (CRSwNP) is often a comorbidity of severe eosinophilic
asthma. In a subgroup analysis of a study involving patients with CRSwNP who received dupilumab
as add-on therapy to mometasone fuorate nasal spray, those patients with comorbid asthma showed
improvements not only in nasal polyp burden but also in asthma control, quality of life, and lung
function [132].
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8. Anti-IgE Therapy in Severe Asthma
Omalizumab
Omalizumab is a humanized monoclonal antibody that binds free IgE and prevents it from binding
to the high-affinity IgE receptor on basophils and mast cells [133]. Omalizumab is now approved for the
treatment of moderate-to-severe allergic asthma in patients > 6 years of age. Omalizumab was the first
biologic approved for use in asthma 15 years ago. To be eligible for omalizumab, the asthmatic should
demonstrate sensitization to one of the perennial allergens on skin prick testing. Levels of total IgE
combined with body weight are used to calculate the dose and the frequency of dosing. Omalizumab
is administered subcutaneously either once a month or every two weeks. It was extensively studied in
both clinical trials and real-world observational studies and was found to reduce the annual relative
risk of asthma exacerbation by 38% and the risk of emergency visits by 47% compared with controls,
according to pooled data from seven randomized studies [134]. The benefit of omalizumab in reducing
exacerbations in relation to the presence of biomarkers reflective of T2 inflammation was evaluated in a
study, showing that asthmatics with peripheral blood eosinophils ≥ 260 cells/μL and FeNO ≥19.5 ppb
had a greater reduction of exacerbations compared to those with biomarker values below the above
cut-off levels [135]. Accordingly, these biomarkers could be beneficial in selecting patients who are
more likely to respond to omalizumab treatment. However, more recent data from real-world studies
suggest that blood eosinophil levels are not predictors of reduction in exacerbations [136,137].
9. Other Therapies
Thymic stromal lymphopoietin (TSLP) is produced by airway epithelial cells in response to
inhaled allergens and proinflammatory stressors [138,139].
Tezepelumab is a human monoclonal antibody that binds to TSLP, inhibiting its stimulatory action
on dendritic cells and innate lymphoid cells, thus preventing the induction of type 2 cytokines (e.g.,
IL-5, IL-4, and IL-13). One phase II, randomized, double-blind, placebo-controlled trial evaluated
the efficacy and safety of tezepelumab in patients with uncontrolled asthma, despite treatment with
long-acting beta-agonists and medium-to-high doses of inhaled corticosteroids. Three dose levels
of subcutaneous tezepelumab were compared to placebo over 52 weeks. The primary end point
was the annualized rate of asthma exacerbations. Exacerbation rates were significantly reduced in
tezepelumab groups—regardless of the baseline blood eosinophil count—compared to placebo by
61% in the low-dose group, 71% in the medium-dose group, and 66% in the high-dose group. Lung
function was improved irrespective of the dose, while health-related quality of life improved only in
the high-dose group [140].
Prostaglandin D2 (PGD2) is mainly released from mast cells, but platelets, alveolar macrophages,
Th2 cells, and dendritic cells can also produce smaller amounts of PGD2. Prostaglandin D2
contributes to T2 inflammation through binding of the G-protein-coupled receptor chemoattractant
receptor-homologous molecule expressed on Th2 cells (CRTH2) [141]. Fevipiprant is an oral competitive
antagonist of CRTH2.
In a phase II study, including 170 patients with mild-to-moderate persistent, allergic asthma,
fevipiprant produced a significant improvement in FEV1 AUC0–24 only in patients with high serum
IgE and blood eosinophils > 300/μL [142].
In another phase II study, including 61 patients with moderate-to-severe, persistent asthma and
sputum eosinophilia (≥ 2%), fevipiprant produced a significant, 3.5-fold greater decrease in sputum
eosinophilia than placebo during the 12-week treatment period. In addition, fevipiprant reduced
bronchial submucosal eosinophil numbers in bronchial biopsies compared to placebo. However, no
change in blood eosinophil count was observed [143].
Finally, in another phase IIb study, including 1058 patients with allergic asthma uncontrolled with
inhaled corticosteroids, fevipiprant—as well as montelukast—improved pre-dose FEV1 compared
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to placebo. However, no evidence of a higher efficacy in any predefined subgroup, including blood
eosinophil count was observed [144].
10. Summary
In order to consider a biologic therapy for severe asthma, it is fundamental to firstly confirm
asthma diagnosis and then solve possible problems related to non-adherence to medication, improper
inhaler technique, and treatment of comorbid conditions.
For severe eosinophilic asthma, targeted therapies directed against IL-5 and IL-4 are available up
to date (Table 1). These agents proved effective mainly in reducing asthma exacerbations but also in
improving lung function and asthma control. It is clinically desirable that these antibodies seem to
work specifically for uncontrolled asthma despite the use of daily oral corticosteroids. This led to the
option of systemic steroids as the last alternative for GINA step 5, which will likely be entirely erased
as a treatment option in the years to come.
Another major benefit from the use of biologics in severe asthma is the opportunity for a better
insight into asthma pathophysiology mechanisms. An important but still unanswered question is
whether biologics have an effect on moderate asthma or produce a disease-modifying effect. Until
then, and while expecting more biologics to come (e.g., tezepelumab), we hope to gain experience and
understand more from the longer use of the current anti-T2 biologics.
Table 1. Studies on biologic therapies for severe eosinophilic asthma.
Study Medication Patients Duration Outcome
Pavord et al. [73]
(DREAM study)
Phase III
Mepolizumab 621 52 weeks Reduced number of exacerbations
Ortega et al. [96]
(MENSA study)
Phase III
Mepolizumab 576 52 weeks
Reduced number of exacerbations and improved
lung function (FEV1), asthma control (ACQ-5), and
quality of life (AQLQ)
Bel et al. [97]
(SIRIUS study)
Phase III
Mepolizumab 135 20 weeks Reduced oral corticosteroid dose and number ofexacerbations
Chapman et al. [102]
(OSMO study)
Phase III
Mepolizumab 145 32 weeks
Reduced number of exacerbations and
improvement in asthma control (ACQ-5) and
quality of life (SGRQ)
Chupp et al. [103]
(MUSCA study)
Phase III
Mepolizumab 551 24 weeks Improvement in the SGRQ total score
Castro et al. [109]
Phase III Reslizumab 953 52 weeks
Reduced number of exacerbations and
improvement in lung function (FEV1), asthma
control (ACQ-7), and quality of life (AQLQ)
Bleecker et al. [114]
(SIROCCO study)
Phase III
Benralizumab 1205 48 weeks Reduced number of exacerbations, improved lungfunction (FEV1), and asthma control
FitzGerald et al. [115]
(CALIMA study)
Phase III
Benralizumab 1306 56 weeks Reduced number of exacerbations and improvedlung function (FEV1)
Nair et al. [118]
(ZONDA study)
Phase III
Benralizumab 220 28 weeks Reduced oral corticosteroid dose and number ofexacerbations
Busse et al. [119]
(BORA study)
Phase III
Benralizumab 1576 56 weeks Validated 2-year safety of benralizumab use
Wenzel et al. [127]
Phase IIb Dupilumab 769 24 weeks
Reduced number of exacerbations and improved
lung function (FEV1)
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Table 1. Cont.
Study Medication Patients Duration Outcome
Castro et al. [129]
Phase IIb Dupilumab 1902 52 weeks
Reduced number of exacerbations and improved
lung function (FEV1)
Rabe et al. [130]
Phase III Dupilumab 210 24 weeks
Reduced oral corticosteroid dose, number of
exacerbations, and improved lung function (FEV1)
Corren et al. [140]
Phase II Tezepelumab 550 52 weeks
Improved lung function (FEV1) and reduced
number of exacerbations
Erpenbeck et al. [142]
Phase II Fevipiprant 170 28 days
Improved lung function (FEV1) in patients with
high blood eosinophil number or high serum
immunoglobulin E (IgE)
Gonem et al. [143]
Phase II Fevipiprant 61 12 weeks Reduced sputum eosinophilia
Bateman et al. [144]
Phase IIb Fevipiprant 1058 12 weeks Improved lung function (FEV1)
Abbreviations: FEV1—forced expiratory volume in the first second; ACQ—asthma control questionnaire;
AQLQ—asthma quality of life questionnaire; SGRQ—Saint George’s respiratory questionnaire.
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and revised the manuscript and made the final approval of the version to be published.
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Abstract: Bronchial asthma (BA) and obstructive sleep apnea (OSA) are common respiratory
obstructive diseases that may coexist. It would be interesting to study the possible influence of
that coexistence on both diseases. Until now, reviews focused mainly on epidemiology. The aim of
this study was to review the literature in relation to epidemiology, pathophysiology, consequences,
screening of patients, and treatment of the coexistence of OSA and BA. We pooled studies from
the PubMed database from 1986 to 2019. OSA prevalence in asthmatics was found to be high,
ranging from19% to 60% in non-severe BA, reaching up to 95% in severe asthma. Prevalence was
correlated with the duration and severity of BA, and increased dosage of steroids taken orally or by
inhalation. This high prevalence of the coexistence of OSA and BA diseases could not be a result of
just chance. It seems that this coexistence is based on the pathophysiology of the diseases. In most
studies, OSA seems to deteriorate asthma outcomes, and mainly exacerbates them. CPAP (continuous
positive airway pressure) treatment is likely to improve symptoms, the control of the disease, and the
quality of life in asthmatics with OSA. However, almost all studies are observational, involving a
small number of patients with a short period of follow up. Although treatment guidelines cannot be
released, we could recommend periodic screening of asthmatics for OSA for the optimal treatment of
both the diseases.
Keywords: obstructive sleep apnea; bronchial asthma; alternative overlap syndrome
1. Introduction
Bronchial asthma is a common inflammatory respiratory disease affecting up to 1–18% of the
population in different countries. It is characterized by bronchial hyper-responsiveness (BHR) and
presents with variable symptoms including wheezing, shortness of breath, chest tightness, and cough
that vary according to disease severity [1]. The gold standard for the diagnosis is the improvement of
forced expiratory volume in the first second (FEV1) >12% and 200 mL, 10–20 min after the inhalation
of 100–200 mg of salbutamol [1].Almost 5–10% of asthmatics have severe, refractory asthma despite
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optimal therapy, and experience frequent exacerbations, hospital admissions, and healthcare utilization.
They often use high doses of inhaled or oral steroids. A significant percentage of asthmatic patients, up
to 70%, experience symptoms during sleep, and therefore have nocturnal asthma [2]. Both nocturnal
symptoms in asthma and uncontrolled asthma have a profound effect on sleep quality [3]. The aim
of asthma treatment is to achieve asthma control, which means having very few symptoms. Asthma
control is assessed using validated questionnaires such as the asthma control questionnaire (ACQ) and
the asthma control test (ACT) [1].
Obstructive sleep apnea (OSA) is the most frequent sleep-related breathing disorder. OSA with
excessive daytime sleepiness ranged in frequency between 3% and 18% in men and 1–17% in women [4].
OSA is an under-diagnosed disorder [5] that is characterized by recurrent collapses of the upper airway
during sleep, leading to a remarkable reduction or complete cessation of airflow despite ongoing
breathing efforts. That airflow obstruction leads to repetitive hypoxia and fragmented sleep, and is
therefore associated with hypertension, cardiovascular disease, diabetes, and stroke [6–8]. The gold
standard diagnostic test is the overnight attended polysomnography (PSG), which is rather expensive
and time-consuming. As a result, researchers often use validated questionnaires, such as the Berlin
questionnaire (BQ), stop bang questionnaire (SBQ), and the sleep apnea scale of the sleep disorders
questionnaire (SA–SDQ), to estimate the risk of having OSA [9–11]. The severity of OSA is determined
using the apnea hypopnea index (AHI), which is defined as the number of apneas and hypopneas per
hour of total sleep time (TST). Continuous positive airway pressure (CPAP) is the treatment of choice
as it decreases long-term mortality [12].
OSA and BA share some common characteristics. First, they are both obstructive respiratory
diseases, but with different mechanisms and anatomy of obstruction. A patient with BA and OSA
has both upper and lower airway obstruction during sleep. Second, both diseases share common
co–morbidities like obesity, allergic rhinitis, and gastro-esophageal reflux (GER). Patients with OSA
and BA also have poor quality of sleep and may have increased morbidity and mortality. When they
coexist, a bidirectional relationship may additionally affect each other. Since 2013, the coexistence of
OSA and BA was defined as alternative overlap syndrome (AOS) to distinguish it from the overlap
syndrome that is referred to as chronic obstructive pulmonary disease (COPD) and OSA [13]. While
there are reviews in the literature, they mainly focused on the epidemiology. In order to determine
the current state-of-the-art knowledge, we conducted a literature review, targeting epidemiology,
pathophysiology, clinical consequences, screening, and treatment of AOS. We additionally aim to point
out possible gaps for future research.
2. Methods
A review of the literature was performed pooling studies in English from the PUBMED database
from 1986 to 2019. The following search terms were used: obstructive sleep apnea, bronchial asthma,
and alternative overlap syndrome. We decided to focus on studies addressing the prevalence, diagnosis,
pathophysiology, clinical outcomes, treatment, and screening of patients with obstructive sleep apnea
and bronchial asthma (alternative overlap syndrome). During the search process, 673 articles emerged.
Studies were excluded if not written in the English language or were carried out on a pediatric
population (<18 years of age). Additionally, studies that were not relevant to our review were excluded.
Finally, 92 articles were selected for this review.
3. Epidemiology
The vast majority of studies mainly referred to the prevalence of OSA in asthmatic populations.
The prevalence was increased, ranging from 19% to 60% [14–16], and reaches up to 95% in severe BA
in two studies [17,18], which suggests that the two diseases did not accidentally coexist. The great
variability of this prevalence was the result of:
1. The diagnostic method used for OSA diagnosis. Early studies used questionnaires regarding
OSA symptoms like habitual snoring, witnessed apneas, and daytime sleepiness [19–22]. Later, studies
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used validated questionnaires estimating the risk of having OSA [23–25]. Some used cardio-respiratory
polygraphy [18,26], while a few used attended overnight polysomnography [14,27–29]. Other studies
used a combination of the above-referred sleep studies [30–32].
2. The cut-offs used for the determination of OSA diagnosis. Some studies used AHI ≥5 [14,33],
others AHI ≥15 [18,34], while others used the RDI (respiratory disturbances index includes apneas,
hypopneas, and respiratory effort related arousals) [17].
3. The diagnostic method used for BA diagnosis. Few studies used spirometry or provocation
tests [28,33,35]. The majority used questionnaires, where patients were asked to answer if they had
asthma symptoms, receive asthma medications, or they have been informed about having asthma by
their physicians [14,27,29,31].
4. The heterogeneity of the populations in relation to age, smoking status, and weight.
Early questionnaire-based, cross-sectional studies depicted a statistically significant higher
prevalence of OSA symptoms, such as habitual snoring and witnessed apneas, in patients with BA
as compared to the general population, independently of the body mass index (BMI), gender, age,
or smoking status [19–22]. BA has been confirmed as an independent risk factor for habitual snoring,
which is the mild end of the spectrum of sleep disordered breathing (SDB) [36].
In 2015, a large retrospective cohort study using data from the National Health Insurance of
Taiwan, collected 38.840 newly diagnosed asthmatics between 2000 and 2010. Each patient matched to
four people without asthma according to gender, age, and the date of the diagnosis. The occurrence
of OSA was followed until the end of 2011. The overall incidence of OSA was 2.51-fold greater in
the asthma cohort than in the comparison group (12.1 vs. 4.84 per person-years). Among asthmatics,
the adjusted hazard ratio (HR) for OSA increased to 1.78 for asthma patients with one or less annual
emergency room (ER) visits, and 23.8 for those who visited the ER more than once per year. Additionally,
the adjusted HR in patients with inhaled steroids compared to those without receiving steroids was
1.33. The authors concluded that asthmatics had a greater risk for OSA, which was much greater when
the asthma was more severe [33].
The same year, in another large study, this time a prospective population-based study, 547 selected
subjects free of OSA at baseline (AHI < 5) on two consecutive overnight-attended PSG studies were
followed every four years for OSA incidence. The BA diagnosis was based on questionnaires. Patients
with asthma had a 39% increase in the risk of developing incident OSA as compared with controls,
independently of the baseline covariates such as BMI, AHI, and BMI change over time. The risk was
duration-dependent: for each 5-year increment in asthma duration, the risk for incident OSA increased
by 7%. An asthma duration >10 years increased the risk by 65% [14].
In a recent meta–analysis of 26 studies (7675 patients), the prevalence/relative risk of OSA and
the OSA risk (OSA diagnosis based on questionnaires) was 49.5%/2.64 and 27.5%/3.73, respectively,
in asthmatics. Patients with BA and OSA had significantly greater BMI (average difference 2.15 kg/m2
p < 0.004), and sleepiness (average difference on the Epworth sleepiness scale, ESS = 3.98, p = 0.004)
compared to asthmatics without OSA, while no difference was observed in FEV1 [16].
There is evidence in the literature that the prevalence of OSA in asthmatics is positively correlated
with the severity of BA, ranging from 50 to 95% in severe asthma [17,18], and with the dosage of the
received oral or inhalational steroids in a dose-dependent manner [17,37]. The possible association
between the severity of BA and the severity of OSA remain controversial [18,28].
While the vast majority of studies address asthmatic populations, Alhabri et al. studied the
relation between OSA and BA in the opposite direction. They found that patients with OSA diagnosed
with PSG had a 35% increased prevalence of BA and these patients had a greater BMI, AHI, and the
lowest oxygen saturation during sleep compared with OSA patients without BA. It seems like BA
deteriorated OSA. Obesity (BMI > 35 kg/m2) was the only independent factor that could predict BA
in OSA patients [27]. Increased prevalence of BA was also reported in OSA patients in some studies
where the prevalence was not the primary endpoint. Kauppi et al., in a sample of 1586 patients with
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OSA, reported 13% having BA based on a questionnaire [31], while Wang et al. studying a sample of
466 patients in a sleep laboratory found that 16.5% had BA [35].
4. Pathophysiology
The exact mechanisms through which these diseases interact with each other are unknown,
although much work has been done regarding this issue. The role of inflammation is a key contributor.
Common co–morbidities like allergic rhinitis, obesity and GER also play an important role. Some of
the proposed mechanisms are discussed below.
5. How BA Could Affect or Lead to OSA?
5.1. Mechanical Effects
Asthmatics with nocturnal asthma symptoms demonstrate hyperinflation during the day, meaning
their functional residual capacity (FRC) is increased compared to healthy controls. However, the normal
drop in FRC during sleep is exaggerated in asthmatics and specifically during Rapid Eye Movement
(REM) sleep. This results in an increased airway resistance as an inverse relationship between lung
volume and airway resistance is known to exist [38]. Moreover, Irvin et al. demonstrated that in
asthmatics with nocturnal symptoms, there is an airway–parenchyma uncoupling, probably due to
neural mechanisms, meaning that during the night, airway resistance is increased independently of
lung volume [39]. Airway resistance could attenuate the normal tracheal tug inducing upper airway
collapse [40].
5.2. Alterations in the Upper Airway Anatomy
The inflammatory infiltration of the upper airway in asthma [41], the increased fat deposition in the
pharyngeal walls due to steroids use [17], or the presence of comorbidities such as obesity [42], lead to
a diminished cross-sectional diameter of the upper airway. Moreover, allergic rhinitis, nasal polyps,
and adenoids hypertrophy, which frequently accompany asthma, increase airflow resistance and create
high negative pressure during inspiration that increase the risk of upper airway collapse [43,44].
Additionally, bronchial asthma possibly influences pharyngeal muscle function, either directly
affecting neural sensor pathways because of inflammation or indirectly due to muscle weakness caused
from the steroids that is the cornerstone of BA treatment [1]. Pharyngeal muscle myopathy increases
collapsibility of the upper airway, increasing the risk of OSA. Yigla et al. reported a high prevalence of
OSA (95%) among asthmatics receiving long-term chronic or frequent bursts of oral steroid therapy
and indentified a positive dose–response relationship between steroids and OSA [17]. Other studies
reported similar results [33,37]. The possible mechanisms through which asthma affects OSA are
summarized from the authors in the figure below, although the impact of steroidsuse still remains
controversial (Table 1).
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Table 1. The effect of asthma on Obstructive Sleep Apnea.
Attenuation of the Normal Tracheal Tug/Alteration in the Upper Airway Anatomy
Diminished cross-sectional diameter of the upper airway due to
Asthma inflammation Nasal obstruction due to Nasal polyps







Upper airway muscle dysfunction
• Steroid use
• Disruption of sensory neural pathways due to inflammation Allergic rhinitis
6. How Could OSA Affect or Lead to BA?
The key factor seems to be the inflammation induced by OSA, both through the airway and
systemic. The repeated episodes of a collapsed upper airway lead to hypoxia and eventually oxidative
stress, which then cascades to systemic inflammation with increased serum levels of cytokines such
as C-reactive protein, interleukin-6 (IL-6), and tumor necrosis factor (TNF-α). The distal airway
inflammation seen in BA increases the probability of asthma attacks [45,46].
Additionally, in OSA, a neutrophil-predominant inflammation seems to begin from the nose,
expands to the distal airways infiltrating the airway walls [47,48], and is related to the disease severity.
Studies in experimental animal models have showed that the increased inspiration effort against
the closed upper airway combined with intermittent hypoxia is associated with inflammation of the
lungs [49,50].
Teodorescu et al. studied a large and objectively diagnosed sample of 255 asthmatic patients
and estimated the risk of having OSA using the SA-SDQ questionnaire. A higher SA-SDQ score was
associated with increased asthma symptoms, β2-agonist use, healthcare utilization, and worse asthma
quality of life. They also conducted sputum induction and found higher percentages of neutrophils
in asthmatics’ sputum with a high OSA risk compared to those without a high OSA risk (p = 0.001),
whereas sputum eosinophil percentages were similar (p = 0.66). There was a significant association
of SA-SDQ with sputum neutrophils. Namely, each increase in SA-SDQ by its standard deviation
(6.85 units) was associated with a rise in sputum neutrophils of 7.78% (95% CI 2.33–13.22, p = 0.0006),
independently of obesity and other confounding factors [24]. Authors concluded that OSA may be an
important contributor to neutrophilic asthma.
The same results were also confirmed in 55 patients with severe asthma and OSA diagnosed using
cardiorespiratory polygraphy [26]. Furthermore, by receiving bronchial biopsies with bronchoscopy,
researchers found that the thickness of the bronchial basement membrane was negatively associated
with the AHI [26]. Although more studies are needed, we may suggest that the coexistence of OSA
in asthma patients may divert asthma inflammation to being neutrophilic, may contribute to airway
remodeling, and eventually may result in a difficult-to-treat asthma.
Moreover, additional factors seen in OSA like GER, cardiac dysfunction, obesity, and increased
levels of vascular endothelial growth factor (VEGF) and leptin have been proposed to increase BHR
and deteriorate asthma outcomes [51–54].
The overall pathophysiologic mechanisms involved in the BA–OSA interaction are depicted in
Figure 1.
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Figure 1. Pathophysiological mechanisms between Obstructive Sleep Apnea and Asthma. Adapted
from Alkhalil et al. Sleep Medicine, 2009 [55].
7. Clinical Consequences of the Alternative Overlap Syndrome
There is strong clinical evidence to support the claim that OSA deteriorates BA outcomes.
Namely, the coexistence of OSA in asthmatics causes an increase in persistent nocturnal asthmatic
symptoms compared with those without OSA [56–58]. Later, Teodorescu et al. investigated whether
OSA was associated with daytime in addition to night-time asthma symptoms. Among 752 asthmatics,
high OSA risk (using the SA-SDQ questionnaire) was associated with persistent daytime and night-time
asthma symptoms (p < 0.0001 for each). A diagnosis of OSA was associated with both persistent
daytime (p < 0.0001), in addition to night-time (p = 0.0008), asthma symptoms. The associations were
retained in regression models where other known asthma aggravators, like obesity, were included.
They concluded that unrecognized OSA may be the cause of persistent BA symptoms, both daytime
and nocturnal [23].
OSA is the fifth independent risk factor (adjusted OR 3.4) among 13 clinical and environmental
factors studied for recurrent exacerbations in difficult to treat asthma. The first four are psychological
dysfunctioning, recurrent respiratory infections, GER, and severe chronic sinus disease [59]. Therefore,
according to Global Initiative for Asthma (GINA) recommendations, chest physicians should investigate
the possibility of underlying OSA in patients with difficult-to-treat asthma [1]. Moreover, in 2017,
Wang et al. reported that the severity of OSA was independently correlated with the number of severe
asthma exacerbations (OR = 1.32, p < 0.001) in a prospective cross–sectional cohort study [15].
Regarding asthma control, studies using ACT and ACQ questionnaires showed worse asthma
control in asthmatics with OSA, although this was not statistically significant in all studies [25,60,61].
There is not much evidence addressing pulmonary function in asthmatic patients with OSA.
The natural history of FEV1 decline in asthmatic patients has been reported to be 38–40.9 mL/year [62].
Known factors contributing to FEV1 decline in asthmatic patients are age, sex, smoking, acute
exacerbations, obesity, and hypoxia [63–65]. In a recent retrospective study, using a sleep laboratory
population with OSA patients, 77 asthmatic patients with OSA (diagnosed using PSG) were selected
and followed for more than 5 years with spirometry. Asthmatic patients with OSA had substantially
greater declines in FEV1per year compared to those without OSA in an AHI–dependent manner.
Asthma patients with severe OSA (AHI > 30) had a decline in FEV1of 72.4 ± 61.7mL/year as compared
to 41.9 ± 45.3 mL/year in those with mild to moderate OSA (5 < AHI ≤ 30) and 24.3 ± 27.5mL/year in
those without OSA (AHI ≤ 5).The severity of OSA was the only independent factor for this decline
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after adjusting for other confounding factors like BMI, age, current smoking status, and number of
emergency room visits/year. CPAP treatment significantly decreased the FEV1decline in the patients
with severe OSA [35]. However, in a meta-analysis, in asthmatic patients with and without OSA,
no significant difference was seen in FEV1 (mean difference = −2.28, p = 0.32) [16].
It is known that asthmatics have a low quality of sleep due to a variety of factors such as the
increased frequency of nocturnal asthma, co-morbidities, bronchodilators, and corticosteroids [20,66].
As a result, they present excessive daytime sleepiness more frequently compared to controls [20]. For the
first time in 2006 in a cross-sectional, clinic-based study investigating all these factors, Teodorescu et
al. reported that sleepiness is common in asthmatics and may reflect occult OSA more often than the
effects of asthma itself, other co-morbidities, or asthma medications [22]. Asthmatics with OSA have
greater sleepiness than OSA-free asthmatics, scoring higher on the ESS [15,16].
The European Sleep Apnea Database (ESADA) cohort addressed the differences between asthmatics
and non-asthmatics referred to sleep centers. An interesting finding was that asthmatic patients are
under-referred for sleep studies, meaning that physicians are not aware or underestimate the coexistence
of OSA and asthma in clinical practice. In that cohort, asthmatic women (with or without OSA)
were more obese and reported more daytime sleepiness (according to ESS) than the non-asthmatic
ones. This shows that obesity is the main factor for sleep referral in asthmatic women but may give
implications about the existence of a specific phenotype as well [67].
There are very few reports investigating the objective parameters of sleep in subjects with AOS.
In 2018, 384 adult women from the Sleep and Health Program in Sweden, an on-going community-based
study, underwent overnight polysomnography. Women with both asthma and OSA had a longer sleep
time in non-deep sleep stages N1and N2, and less time in the REM stage than the control group with no
asthma or OSA. The group with BA and OSA had a lower mean oxygen saturation (93.4% vs. 94.7%,
p = 0.004) than the group with OSA alone and spent more time with oxygen saturation below 90%
than the patients with OSA only. The results remained after adjusting for age, BMI, and smoking
status. BA was independently associated with lower oxygen saturation, while OSA was not. Authors
concluded that coexisting OSA and BA is associated with poorer sleep quality and more profound
nocturnal hypoxemia than either of the diseases alone [29]. Similar results concerning sleep architecture
had already been reported in other studies [28,68].
While studies have highlighted OSA among asthma patients in outpatient settings, such data in
the inpatient setting was sparse until 2015 when Becerra et al., using a 2009–2011 U.S. Nationwide
Inpatient Sample, studied the impact of two common asthma co-morbidities—OSA and obesity—on the
length and cost of hospitalization and on the need for invasive mechanical ventilation. They reported
that OSA and obesity significantly increased the length of stay (OR = 1.07 in males and 1.14 in females,
and 1.07 in males and 1.08 in females, respectively) and the total hospital charges in both genders
(15% in males and 19% in females, and 8.6% in males and 9.6% in females, respectively). Furthermore,
when they coexisted, this led to multiplied increases in the length of stay (OR = 1.19 in males and 1.24
in females) and hospital charges (24.9% in males and 28.5% in females).
OSA alone in asthmatics (OR = 2.56 in males and 3.22 in females) or in coexistence with obesity
(OR = 2.85 in males and 3.60 in females) significantly increased the use of mechanical ventilation while
obesity alone did not (OR = 0.97 in males and 1.01 in females) [69].
OSA and BA are associated with increased rates of systemic arterial hypertension [70,71],
with inflammation being proposed as the basic pathophysiologic cause [72,73]. OSA in asthmatics
lead to greater prevalence of arterial hypertension compared to asthmatics without OSA (adjusted
OR = 2.20), as Ferguson et al. reported in a cross-sectional, questionnaire-based study. The authors
concluded that the inflammation of the diseases act additionally [74].
The only study addressing the mortality in AOS is a retrospective study from South Korea. Kyu–Tae
Han et al. used data from the National Health Insurance Service (NHIS) National Sample Cohort
2004–2013 in order to investigate the association between sleep disorders (International Classification
of Diseases ICD–10: G.47) and mortality in patients with newly diagnosed BA (ICD–10: J.45) during
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outpatient care between 2004 and 2013. They excluded patients with sleep disorders diagnosed prior
to the BA diagnosis. They studied asthmatic patients that were difficult to be controlled, had increased
sleep disorders prevalence, and frequently used health services. The study sample consisted of 186.491
asthmatic patients newly diagnosed with asthma. A sleep disorders diagnosis that followed the asthma
diagnosis and mortality was studied in these patients. A total of 5179 patients died during the study
period (2.78%) because of lung cancer (10.5%), senility (6.1%), COPD (4.5%), myocardial infarction
(4.4%), and stomach cancer (3.7%). Asthmatic patients with coexisting sleep disorders had an increased
risk of death compared with asthmatics without sleep disorders after adjusting for confounding
variables like age, sex, gender, income, and co-morbidities (hazard ratio [HR]: 1.451 (95% confidence
interval [CI]: 1.253–1.681). The mean duration between the asthma diagnosis and death was shorter in
asthmatics with sleep disorders (mean duration: 103.85 months), compared with asthmatics without
sleep disorders (mean duration: 116.05 months, p < 0.0001). Authors concluded that the presence of
sleep disorders in patients with asthma was associated with a high risk of mortality, as shown using
Kaplan–Meier survival curves and a log rank test [75]. We summarize the findings concerning the
impact of OSA on asthma in Table 2.
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8. Treatment
Early CPAP application has shown a favorable effect on asthma parameters’ main symptoms.
Most of these studies were retrospective, included a small number of subjects (9to16), having a short
period of follow up (maximum 9 months), adherence to treatment was not based on objectives criteria,
and there was a broad heterogeneity regarding the assessment of the results [56–58].
The first study investigating the impact of the long-term use of CPAP on asthma symptoms and
on the control of the disease in a large number of patients was a questionnaire-based one. A survey
questionnaire was distributed to all OSA patients using CPAP therapy in 2013. They received 1586
answers and 13% of them had BA. The mean duration of CPAP-usage was 5.7 years and their CPAP
daily use was 6.3 h. Self-reported asthma severity (measured using a visual analogue scale) decreased
significantly and the ACT score increased significantly from 15.35 to 19.8 (p< 0.001) without a significant
change in the BMI [31].
The first prospective, multicenter study recently conducted in Spain examined asthma outcomes
6 months after CPAP use in 99 adult asthmatics with OSA. ACQ and the mini–asthma quality of life
questionnaire (mini–AQLQ) was used for asthma control and quality of life, respectively, and objective
measures of BA (spirometry) and OSA (PSG) as well. Both the control of the disease and the quality
of life were significantly improved in general, but when the diseases were categorized according to
their severity, only patients with moderate and severe BA and severe OSA, and patients who used
CPAP >4 h/day, were significantly improved. There was a significant decrease in the percentage of
asthma exacerbations seen in the six months after the use of CPAP (from 35.4% to7.2%, p = 0.015),
a significant improvement in bronchial reversibility, symptoms of GER, rhinitis, and exhaled nitric
oxide levels (eNO) (all p < 0.05). However, no significant changes were observed in the asthma
medication used, drugs, body weight, and other asthma co-morbidities [32].
The favorable impact of CPAP on AOS has been attributed to the decrease of the local and systemic
inflammation [76,77], and the improvement of both the heterogeneity of alveolar ventilation [78] and
GER [79].
There is one retrospective study that reported an improvement in FEV1 after CPAP treatment [35].
This finding was not confirmed in other studies [32,58,80], but the follow-up period was too short
(maximum 6 months).
The impact of CPAP on BHR in patients with AOS is still a matter of controversy. Although
most studies reported a decrease in BHR [81,82], this was not a constant finding [80]. However, more
research is needed using a longer follow-up period in order to draw conclusions regarding the effect of
CPAP treatment on pulmonary function.
According to current OSA guidelines, there is clear evidence in treating patients with moderate or
severe OSA, whereas treatment should be restricted in mild OSA patients that are symptomatic or
have serious co-morbidities, but still, asthma is not one of them. Considering asthmatic patients with
mild OSA, there is no clear evidence regarding the best practice for treating these patients.
We therefore conclude that the optimal treatment practice for AOS is the best treatment of each
disease separately and the recognition and treatment of the co-morbidities like obesity, GER. and more
importantly allergic rhinitis, which is probably the basic reason of the high prevalence of OSA among
the asthmatics. In a recent population-based study, a history of allergic rhinitis was associated with an
increased risk of sleep-disordered breathing in the elderly and it was an independent risk factor of OSA
in asthmatics (adjusted OR = 1.90, p = 0.046), while neck circumference was not (adjusted OR = 1.02,
p = 0.654), although this is traditionally the most significant factor that predicts OSA [34].Patients who
received intranasal corticosteroids had a significant improvement in OSA [83]. Another issue that
needs investigation is the heterogeneity of the severity of both diseases in the same patient. Perhaps all
the possible combinations may co-exist. Therefore, patients may have severe moderate or mild BA
with severe, moderate, or mild OSA in any combination, as it happens with chronic bronchitis and
emphysema in COPD. Consequently, treatment should be personalized.
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We summarize the main studies addressing the effects of CPAP treatment for OSA on asthma
outcomes in Table 3.
The role of alternative treatment in OSA like uvulopalatopharyngoplasty, oral appliances,
upper-airway stimulation, or surgical interventions on AOS has not been investigated yet. Bariatric
surgery is known to improve asthma control, pulmonary function, BHR, and quality of life. Bariatric
surgery also improves OSA parameters [84,85]. The effect of bariatric surgery on AOS has not been
studied yet.
The effect of biological asthma treatments and leukotriene inhibitors have not been studied
regarding AOS.
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9. Screening
From the above-mentioned data it is obvious that BA is a risk factor for OSA occurrence and
development, and OSA might aggravate BA reciprocally. OSA worsens asthma outcomes [25,59,69].
On the other hand, there is strong evidence that long-term use of CPAP in patients with BA and OSA
improves symptoms, asthma control, and quality of life [31,32]. That is why the need for screening
asthmatics for OSA is imperative. Apart from the overnight-attended PSG, which is an expensive and
time-consuming method, and therefore, it is inconvenient for screening a large number of subjects,
there is a gap in the literature regarding the use of OSA questionnaires in asthmatic populations.
For the first time, Huan et al. compared the SBQ with BQ in 123 objectively diagnosed asthmatics
undergoing overnight-attended PSG. Compared with BQ, SBQ had a higher diagnostic sensitivity
(84.4% vs. 60%), lower specificity (79.5% vs. 91%), lower positive predictive value (70.4% vs. 79.4%),
and higher negative predictive value (90% vs. 80%) to detect moderate-to-severe OSA at an AHI cut-off
of 15/h. They concluded that SBQ is the preferable sleep questionnaire over BQ for detecting the risk of
having moderate-to-severe OSA in asthmatics [86].
10. Summary
OSA has been found to have increased prevalence, ranging from 19 to 60%, in asthmatic patients,
and even reaching 95% in severe asthma cases. The diagnosis of OSA has been made either using
a questionnaire or an overnight-attended PSG. Home sleep apnea testing (HSAT) is likely to be
much more accurate than questionnaires and better for identifying moderate to severe OSA, but it
is not recommended in patients with severe cardiorespiratory disease and there are no special
recommendations for asthmatic patients [87,88].Given that patients with AOS usually suffer from
severe asthma, and therefore studies using HSAT would not have included them, we did not focus on
HSAT in the current review. However, we included studies that have evaluated asthmatic patients using
HSAT and PSG, as seen in Table 1 (Sundbom et al.) and Table 2 (Kauppi et al., Serrano Pariente et al.).
It is difficult to accurately estimate the prevalence of AOS based on the fact that the prevalence of
OSA depends on the definition used and the population studied, and ranges between 2% and 10% in
women and between 4% and 31% in men [89–91]. More specifically, while the Wisconsin study found
a prevalence of sleep-disordered breathing (SDB) defined as an AHI ≥5/hr to be 9% in women and
24% in men [89], in a more recent systematic review, the overall prevalence for AHI ≥5 events/h was
found to range from 9% to 38% and was higher in males and in some elderly groups, and it increased
reaching 90% in men and 78% in women. For AHI ≥15 events/h, the prevalence ranged from 6% to
17% in the general population, reaching 49% in the advanced ages. OSA prevalence increases with
obesity and age [92].
The prevalence of OSA in asthmatics is positively correlated with the severity and duration of
asthma and the dosage of oral or inhaled steroids. It seems that asthma is a risk factor for the OSA
occurrence, but in order for a causal relationship to confirmed, large prospective studies are needed
with objective pulmonary function and sleep measurements.
As the impact of OSA on asthma causes a neutrophilic inflammation, contributes to airway
remodeling, increases nocturnal and diurnal persistent symptoms, worsens sleep quality and nocturnal
hypoxemia increasing sleepiness the next day, deteriorates asthma outcomes, is an independent
risk factor for asthma exacerbations, and increases the days of hospitalization and health resource
utilization, OSA should not be seen as a simple co-morbidity. AOS is a new asthma phenotype that
should be uncovered. Additionally, although it is clear that the co-existence of asthma and OSA
increases asthma exacerbations, the association of the number of exacerbations with sleep parameters
like AHI, ODI (oxygen desaturation index), and AI (arousal index) has not yet been defined.
Finally, since we lack data from double-blind studies, there are currently no available treatment
guidelines for the combination of OSA and asthma, and the treatment of asthma and OSA is limited to
each specific disease’s guidelines. In Table 4, we outline the major take away points, as well as areas
where further research is needed.
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GINA guidelines urge physicians to look for OSA in asthmatics [1]. However, there are limitations
in diagnosing OSA in a primary care setting, which may lead to the under-diagnosis of OSA.
This problem is worse when asthma coexists because of overlapping nocturnal symptoms. Although
SBQ has not been validated in large asthmatic populations, there is an urgent need to use it periodically
forasthmatics, especially in those with refractory asthma, obesity, allergic rhinitis, and GER. These
patients will need to be tested for OSA at the sleep lab. Early diagnosis of OSA in asthmatic patients
will lead to the appropriate treatment with CPAP and will stop the vicious circle of OSA worsening
asthma control and escalating asthma pharmaceutical treatment.
We conclude that there is an urgent need for the early diagnosis of OSA in asthmatic patients in
order to effectively treat both diseases and lessen the economic burden.
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Abbreviations
AHI Apnea Hypopnea Index
ACQ Asthma Control Questionnaire
ACT Asthma Control Test
AI Arousal Index
AM Morning
AOS Alternative Overlap Syndrome
AQLQ Asthma Quality of Life Questionnaire





COPD Chronic Obstructive Pulmonary Disease
CPAP Continuous Positive Airway Pressure
CRP C-Reactive Protein
e-NO exhaled- Nitric Oxide
ER Emergency Room
ESS Epworth Sleepiness Scale
FEV1 Forced Expiratory Volume in One Second
FRC Functional Residual Capacity
GER Gastro-Esophageal Reflux
GINA Global Initiative for Asthma
HSAT Home Sleep Apnea Testing
HR Hazard Ratio
ICD–10 International Classification of Diseases
IL–6 Interleukin–6
Mini–AQLQ Mini Asthma Quality of Life Questionnaire
OSA Obstructive Sleep Apnea
ODI Oxygen Desaturation Index
OR Odds Ratio
PEFR Peak Expiratory Flow Rate
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PM Afternoon
PSG Polysomnography
REI Respiratory Events Index
REM Rapid Eye Movement
RDI Respiratory Disturbances Index
SABA Short Acting B Agonist
SBQ Stop Bang Questionnaire
SA-SDQ Sleep Apnea of Sleep Disorders Questionnaire
SDB Sleep Disordered Breathing
TNF Tumor Necrosis Factor
TST Total Sleep Time
VEGF Vascular Endothelial Growth Factor
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Abstract: Managing pediatric asthma includes optimizing both asthma control and asthma-specific
quality of life (QoL). However, it is unclear to what extent asthma-specific QoL is related to asthma
control or other clinical characteristics over time. The aims of this study were to assess in children
longitudinally: (1) the association between asthma control and asthma-specific QoL and (2) the
relationship between clinical characteristics and asthma-specific QoL. In a 12-month prospective
study, asthma-specific QoL, asthma control, dynamic lung function indices, fractional exhaled
nitric oxide, the occurrence of exacerbations, and the use of rescue medication were assessed every
2 months. Associations between the clinical characteristics and asthma-specific QoL were analyzed
using linear mixed models. At baseline, the QoL symptom score was worse in children with
asthma and concomitant chronic rhinitis compared to asthmatic children without chronic rhinitis.
An improvement of asthma control was longitudinally associated with an increase in asthma-specific
QoL (p-value < 0.01). An increased use of β2-agonists, the occurrence of wheezing episodes in the
year before the study, the occurrence of an asthma exacerbation in the 2 months prior to a clinical
visit, and a deterioration of lung function correlated significantly with a decrease in the Pediatric
Asthma Quality of Life Questionnaire (PAQLQ) total score (p-values ≤ 0.01). Chronic rhinitis did
not correlate with changes in the PAQLQ score over 1 year. The conclusion was that asthma control
and asthma-specific QoL were longitudinally associated, but were not mutually interchangeable.
The presence of chronic rhinitis at baseline did influence QoL symptom scores. β2-agonist use
and exacerbations before and during the study were inversely related to the asthma-specific QoL
over time.
Keywords: asthma; asthma-specific quality of life; chronic rhinitis; disease-specific quality of life;
health-related quality of Life (HRQLQ); children; longitudinal study
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1. Introduction
Respiratory symptoms have a significant influence on the daily life of children with asthma [1,2].
In the management of asthma, monitoring of both the asthma control and the quality of life (QoL)
is important. International guidelines mention optimal QoL as an important objective in asthma
management, but offer no guidance on how or when to base clinical decisions on asthma-specific
QoL [3–5].
As guidelines recommend medication titration predominantly based on asthma control,
additional knowledge about the longitudinal relationship between pediatric asthma control and
asthma-specific QoL is important [3–5]. Studies focusing on asthma-specific QoL found a fair to good
cross-sectional association between the QoL and the asthma level of disease control in children [1,6–12].
However, several important questions remain. First, as asthma is a chronic disease, it is relevant to
know whether changes in the quality of life over the course of time are correlated with changes in the
asthma control. To date, longitudinal data on this topic are lacking [1,6–13].
Second, there is no information available about the course and variation of asthma-specific QoL in
children. This information may give insight into the frequency with which asthma-specific QoL should
be monitored in clinical care. Third, as similar questions were used to assess the asthma control and
the QoL in some studies, it is unclear to what extent this may have over-exaggerated the correlation
between the asthma control and the QoL [9,12]. Fourth, very little is known about the longitudinal
relationship between asthma-specific QoL and clinical characteristics, such as the presence of chronic
rhinitis, the use of rescue medication, the daily dosage of inhaled corticosteroids, the exacerbation
rate, lung function, atopy, airway inflammation (e.g., fractional exhaled nitric oxide (FeNO) levels),
and bronchial hyperresponsiveness.
Although it is generally assumed that these clinical characteristics affect the QoL, there are little
longitudinal data in children to confirm this.
Therefore, the objectives of this study are to determine the association over time:
1) between asthma control and asthma-specific QoL;
2) between clinical characteristics (e.g., the presence of chronic rhinitis, daily dosage of inhaled
corticosteroids, lung function impairment, use of rescue medication, FeNO, and the occurrence of
asthma exacerbations) and asthma-specific QoL.
2. Methods
2.1. Study Design and Patients
Children with persistent asthma aged 6–17 years were included in this one-year longitudinal
cohort study (clinicaltrial.gov NCT 01239238) as described previously [14]. Patients were recruited at
the outpatient clinics of 2 clinical centers (Sittard and Maastricht) in the Netherlands. All asthmatic
children were treated at the outpatient clinic of these 2 specialized pediatric pulmonology centers
for at least 6 months and had received inhaled corticosteroids (ICS) in the year preceding the study.
All children met the Global Initiative for Asthma (GINA) criteria and the following criteria of the
Dutch Society of Pediatrics for an asthma diagnosis: (1) recurrent episodes of wheezing, coughing,
breathlessness, or chest tightness [3,5]; (2) reversibility to a bronchodilator defined as an increase in
the forced expiratory volume in 1 s (FEV1) of ≥ 9% of the predicted value [5,15]; and/or (3) bronchial
hyperresponsiveness to histamine defined as a 20% drop in the FEV1 after inhalation of histamine
≤ 8 mg/mL [5]. Patients were excluded in the case of cardiac abnormalities, mental retardation,
congenital abnormalities or existence of a syndrome, active smoking, immunotherapy, or no technical
satisfactory performance of lung function measurements.
For this study, ethical approval was obtained by the Medical Ethical Committee of the Maastricht
University Medical Centre (NL33101.068.10/METC 10-2-064). All parents and children aged twelve
years and older signed an informed consent form before the start of the study. All methods and
measurement were performed in accordance with the relevant guidelines and regulations.
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2.2. Study Parameters
Every 2 months, regular outpatient visits at the hospital took place. During these clinical visits,
measurements of asthma control, lung function, FeNO and asthma-specific QoL were taken by a
trained research nurse or a medical doctor.
2.3. Questionnaires on Asthma Control, Asthma-Specific QoL, and the International Study of Asthma and
Allergies in Childhood (ISAAC)
Asthma control was assessed using 2 methods: (1) an Asthma Control Questionnaire (ACQ)
and (2) the GINA criteria [16,17]. The following cut-off points for the level of control were used:
ACQ≤0.75 controlled asthma, 0.75< ACQ ≤1.5 partly controlled, and ACQ >1.5 uncontrolled asthma.
In addition, the asthma control level during the previous 2 weeks was assessed by scoring symptoms
in combination with a FEV1 assessment, as recommended in the GINA—Asthma Management and
Prevention-guidelines [3].
To assess the asthma-specific QoL, children completed the Pediatric Asthma Quality of Life
Questionnaire (PAQLQ) [8,11,18]. The standardized version of the PAQLQ contains 23 questions in
3 domains, i.e., activity limitations, symptoms, and emotional function. The range in scores is from 1–7,
which represents poor to good asthma-specific QoL [8]. All children completed the ACQ and PAQLQ
by themselves, so interference of parents was avoided as much as possible.
2.4. FeNO
Children performed a FeNO online measurement using a NIOX analyzer (NIOX MINO®,
Aerocrine, Solna, Sweden) according to American Thoracic Society (ATS) and European Respiratory
Society (ERS) standards [19].
2.5. Dynamic Spirometry and Reversibility
Patients were instructed to stop short-acting bronchodilators at least 8 h, and long-acting
bronchodilators at least 48 h, before measurement. First, dynamic spirometry was performed by means
of the ZAN 100® spirometer, according to ATS/ERS standards (nSpire Health GmbH, Oberthulba,
Germany) [20]. The highest value of 3 correctly performed maximal expiratory flow-volume (MEFV)
curves was used for analysis. The recorded parameters included the FEV1, forced vital capacity (FVC),
and maximum expiratory flow at 50% of FVC (MEF50), all expressed as a percentage of the predicted
value. Second, the patient inhaled 400 μg of salbutamol, and after 15 m lung function measurements
were repeated in order to test for reversibility to a bronchodilator.
2.6. Bronchial Hyperresponsiveness
Bronchial hyperresponsiveness at baseline was evaluated by the histamine challenge test [21].
At first, an aerosol of buffered saline was inhaled, followed by aerosols of histamine solutions with a
doubling of the concentration from 0.03 to 16 mg/mL at intervals of 5 m. The FEV1 was measured at
30, 90, and 120 s after completed inhalation. The percentage decline in the FEV1 was calculated and
the test was stopped when a drop of 20% in the FEV1 occurred (PC20), or the highest concentration of
16 mg/mL was administered. The PC20 threshold was calculated from a log concentration versus dose
response curve. After reaching the threshold, children inhaled 800 μg of salbutamol, and then 3 MEFV
curves were performed.
2.7. Atopy
Sensitization to allergens was objectified by the Phadiatop® (Phadia, Uppsala, Sweden), RAST®
(Pharmacia, Uppsala, Sweden) or allergen skin test. These tests were performed preceding the study
or at baseline.
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2.8. Medication Titration
Patients were treated according to the GINA guidelines [3]. Medication titration was performed
on the basis of asthma control levels based on the GINA criteria (Table 1).
Table 1. Criteria for medication titration (step up, no change, or step down).
Step up
Uncontrolled asthma in 1 visit, or
partly controlled asthma during 2 consecutive visits.
No change in treatment
One visit with controlled asthma, or
one visit with partly controlled asthma.
Step down
Two consecutive visits with controlled asthma.
2.9. Definition of Exacerbation
The definition of an asthma exacerbation was based on the latest ATS/ERS guidelines [22].
2.10. ISAAC Questionnaire and Chronic Rhinitis
At baseline, parents completed electronically the ISAAC (International Study of Asthma and
Allergies in Childhood) questionnaire [23]. The items focusing on asthma symptoms were used for
statistical analysis. The ISAAC questionnaire was completed by 94% of all parents. A child was
considered to have chronic rhinitis in the case of a positive response to 2 ISAAC questions (‘chronic
rhinitis without a cold’ and ‘chronic rhinitis in the past 12 months’).
2.11. Exposure to Second-Hand Smoke
Parental smoking was assessed using an electronic questionnaire, which was completed by 94%
of all parents. Passive smoking or exposure to second-hand smoke was defined as smoking of one or
both parents in the presence of the child.
2.12. Data Collection
The collected data were checked and cleaned by an independent monitoring board (Clinical Trial
Centre Maastricht). All recorded data during visits were stored in a secured database. In addition,
all electronic questionnaires were completed at home.
2.13. Data Analysis
The description of baseline characteristics occurred as follows: numerical variables were
expressed as the mean and standard deviation (SD) or as the median and interquartile ranges
(IQR, i.e., 25th–75th percentile) and categorical variables were expressed as numbers and percentages.
The variation of baseline PAQLQ scores for different asthma control levels was described as the mean
and standard deviation. In addition, at baseline the coefficient of variation was calculated for each
asthma control level (CV =mean/standard deviation).
To control for interdependency between repeated measurements in the same participant,
linear mixed models were used [24]. All participants were included in the analysis, including
children who dropped out during the study. In the mixed models, the PAQLQ total scores and,
thereafter, the domains were included as the dependent variable. First, the course of the PAQLQ
scores during the study was tested for significance in a simple model without the correction of any
clinical variable. Second, in order to analyze the association between asthma control and the PAQLQ
scores, the ACQ and GINA asthma control levels were included as an independent variable separately.
Third, the clinical characteristics, FEV1 percentage of the predicted value, and β2-agonist use were
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included in a new model, while asthma control was excluded. Asthma symptoms represent 1 domain
of the PAQLQ; therefore, symptoms were not included as a separate independent variable in any
model. Besides, in all models the age, sex, trial site, season, bronchial hyperresponsiveness, atopy,
exposure to second-hand smoke, FeNO, and the inhaled daily dose of corticosteroids were included as
independent variables. The p-values < 0.05 were considered significant. Data were analyzed using
SPSS 20 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Patient Characteristics
A total number of 331 children with doctor-diagnosed asthma were asked to participate in the study,
of which 96 children actually participated [14]. The majority of subjects were atopic and had severe
bronchial hyperresponsiveness despite the use of a moderate daily dose of inhaled corticosteroids.
Active parental smoking was reported in the cases of 26% of the children, whereas exposure to
second-hand smoke was reported in the cases of 8% of the children (Table 2). There were no clinical
important differences in the baseline characteristics between the two centers.
Table 2. Characteristics of the total population at baseline (n = 96).
Parameter Value
Mean age [range], in years 10 [6–17]
Sex male/female, n 50/46
ACQ score, median [IQR] 0.6 [0.3–1]
PAQLQ total score, median [IQR] 6.4 [5.9–6.7]
Symptoms domain, median [IQR] 6.4 [5.5–6.7]
Activity limitations domain, median [IQR] 6.2 [5.3–6.6]
Emotional functioning domain, median [IQR] 6.9 [6.5–7.0]
FeNO, ppb: median [IQR] 12.5 [8.0–31.0]
FEV1 % predicted, mean ± SD 96.8 ± 14.2
Reversibility, increase in FEV1 % predicted: mean ± SD 6.6 ± 8.5
ICS dose of inhaled fluticasone or equivalent, mean ± SD * 269 ± 175
PC20, mg/mL: median [IQR] † 1.2 [0.3–2.9]
Atopic, n % ‡ 76
Chronic rhinitis, % 70
Wheezing episodes past year, % 58
Parental smoking, % 26
Exposure to second-hand smoke, % 8
ACQ = Asthma Control Questionnaire, IQR = interquartile range, PAQLQ = Pediatric Asthma Control Quality
of Life Questionnaire, FeNO = fractional exhaled nitric oxide, FEV1: forced expiratory volume in 1 second, SD =
standard deviation, ICS = inhaled corticosteroids. * At baseline 94% of the children used ICS. † PC20: concentration
of histamine inducing a 20% drop in FEV1. ‡ Atopy is defined as a positive Phadiatop (Phadia, Uppsala, Sweden),
or a positive allergen skin test.
3.2. Influence of Chronic Rhinitis on QoL at Baseline
In comparison with children without chronic rhinitis (n = 27), children with rhinitis (n = 62)
had a lower PAQLQ symptoms domain score (mean score (SD) of 5.8 (1.1) versus a score of 6.3 (0.6),
p = 0.016), a comparable PAQLQ activity limitation score (mean (SD) of 5.9 (1.0) versus 6.1 (0.7), p =
0.352) or a PAQLQ emotional domain (mean (SD) of 6.5 (1.0) versus 6.6 (0.6), p = 0.516), and a tendency
towards a lower PAQLQ total score (mean (SD) of 6.1 (1.0) versus 6.4 (0.5), p = 0.076). A lower PAQLQ
score indicates a worse quality of life.
3.3. Course and Variability of Asthma-Specific QoL during the Study
Overall asthma-specific QoL and asthma control improved during the year (p-value < 0.01)
(Figure 1). The mean level of the symptoms and activity limitations domain was lower than the level
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of the emotional functioning domain (Figure 1). In 46% of the children, this emotional functioning
domain at baseline showed a maximum score of seven. The variability of the PAQLQ total scores at
baseline was larger in the partly or uncontrolled children (coefficient of variation, CV = 19%), than in
the controlled children (CV = 6%). This variability is shown in Figure 2, where all the measurements of
all the children are included.
Figure 1. Overview of the course of the PAQLQ and ACQ scores during 12 months. On the right-hand
side, the scale and numbers of the ACQ score are given, on the left-hand side, the scale and numbers of
the PAQLQ score.
Figure 2. Associations between ACQ asthma control and PAQLQ total scores in a linear mixed
model—all measurements taken during one year were included. The regression line is based on a model
in which the ACQ level of asthma control is included; the estimates of this model are given in Table 3.
For factors in the equation other than ACQ asthma control, mean values were used. ACQ asthma
control: 0 = uncontrolled, 1 = partly controlled, and 2 = controlled.
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Table 3. Results of the multivariate models with the PAQLQ score as the dependent variable and
independent predictors of asthma control (assessed by the ACQ) and other (clinical) parameters (dose
of fluticasone or equivalent, age, sex, trial site, season, chronic rhinitis, wheezing episodes in the
preceding year, PC20 histamine test, atopy, FeNO, exacerbations in the previous 2 months, and exposure
to second-hand smoke). Only significant results are shown.
PAQLQ total score PAQLQ symptoms domain PAQLQ activity limitations domain
β CI Pvalue β CI Pvalue β CI Pvalue
ACQ asthma level of control* 0.43 0.37, 0.50 <0.01 0.63 0.54, 0.71 <0.01 0.60 0.50, 0.69 <0.01
Fluticasone daily dosage or equivalent per
100 μg † −0.04 −0.07, −0.008 0.01 −0.06 −0.10, −0.02 <0.01 −0.04 −0.08, −0.0004 0.05
Season‡ ‡ ‡ 0.01 0.01 - - -
Sex§ - - - - - - −0.19 −0.36, −0.02 0.03
ACQ =Asthma Control Questionnaire, ICS = inhaled corticosteroids, PAQLQ = Pediatric Asthma Control Quality of
Life Questionnaire, β = estimate of corresponding factor in the model, CI = 95% confidence interval of the estimate.
The presented data are adjusted for trial site, age, chronic rhinitis, occurrence of wheezing episodes in the preceding
year, PC20 histamine test, atopy, FeNO, exacerbation in the previous 2 months, and exposure to second-hand smoke.
* Increase in the PAQLQ score for an improvement of ACQ asthma control from uncontrolled to partly controlled
and partly controlled to controlled. † Decrease in the PAQLQ score per increase of 100 μg fluticasone daily dosage or
equivalent. ‡ Decrease in the PAQLQ score for summer versus winter ((estimate) (95% CI) (−0.16) (−0.28, −0.04)) or
summer versus spring ((estimate) (95% CI) (−0.17) (−0.28, −0.07)). § Decrease in the PAQLQ score for female versus
male. Model with the PAQLQ emotional functioning domain as the dependent variable: of all factors, only the ACQ
asthma level of control had a significant association (see text).
3.4. Association between Asthma Control and PAQLQ Scores during a One Year Follow-up
Asthma control based on the ACQ had the strongest longitudinal association with the PAQLQ total
scores compared to the occurrence of wheezing episodes in the preceding year and the occurrence of an
exacerbation in the previous 2 months (p-value (estimate); <0.01 (0.43)) (Table 3). The estimate of 0.43
means that an improvement of asthma control from uncontrolled to partly controlled, or from partly
controlled to controlled disease, resulted in an increase of the PAQLQ total score of 0.43. Therefore,
deterioration of asthma control from controlled to uncontrolled was associated with a clinically relevant
decrease in the PAQLQ total score of 0.86. Additionally, with the PAQLQ subdomains, asthma control
had the strongest association of all the clinical characteristics. The estimates for the subdomains were
highest for the symptoms and activity limitation and small but significant for the emotional functioning
domain (p-value (estimate) (95% CI); <0.01 (0.05) (0.03, 0.08)).
We also performed an analysis with asthma control according to the GINA criteria. Similarly to
asthma control based on the ACQ, a strong longitudinal association with the PAQLQ total score and
a comparable pattern for the PAQLQ domains was found (Table 4). Additionally, the occurrence of
wheezing episodes in the preceding year was associated with the PAQLQ total score. Of all the PAQLQ
domains, the emotional functioning domain had the smallest association with asthma control based on
the GINA criteria (p-value (estimate) (95% CI); <0.01 (0.09) (0.05, 0.13). All models were adjusted for
clinical characteristics, as described in the method section.
3.5. Factors Independently Related to PAQLQ Scores during One Year Follow-up
Finally, a model consisting of all predefined clinical characteristics (except the ACQ or GINA
asthma control) showed that three factors were independently associated with a decrease in the PAQLQ
total scores: (1) an increased use of β2-agonists (Table 5 and Figure 3), (2) the occurrence of wheezing
episodes in the year preceding the study, and (3) the occurrence of an asthma exacerbation in the
2 months preceding the PAQLQ assessments (Table 5). Although the FEV1 percentage of the predicted
value was also significantly associated with the PAQLQ total score, the estimates were small (p-value
(estimate); <0.01 (0.05)) (Table 5, Figure 4). The daily dose of inhaled corticosteroids and FeNO levels
showed no longitudinal association with the PAQLQ scores (Table 5). In contrast to the model in which
the asthma control was included, no factor in this model was associated with the PAQLQ emotional
functioning domain. The presence of chronic rhinitis was not associated with changes in the PAQLQ
total score or subdomain scores.
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Table 4. Results of the multivariate models with the PAQLQ score as the dependent variable and
independent predictors (asthma control according to GINA, dose of fluticasone or equivalent, age,
sex, trial site, season, wheezing episodes in the preceding year, PC20 histamine test, atopy, FeNO,
exacerbations in the previous 2 months, and exposure to second-hand smoke). Only significant results
are shown.
PAQLQ total score PAQLQ symptoms domain PAQLQ activity limitations domain
β CI Pvalue β CI Pvalue β CI Pvalue
GINA asthma level of control* 0.38 0.30, 0.46 <0.01 0.57 0.47, 0.66 <0.01 0.56 0.44, 0.67 <0.01
Wheezing episodes preceding year no/yes† −0.29 −0.10, −0.49 <0.01 −0.42 −0.16, −0.69 <0.01 −0.36 −0.05, −0.66 0.02
Age in years‡ - - - −0.04 −0.08, <0.01 0.03 −0.05 −0.1, −0.01 0.02
Exacerbation in previous 2 months no/yes§ - - - −0.19 −0.35, −0.02 0.03 - - -
GINA = Global Initiative for Asthma, PAQLQ = Pediatric Asthma Control Quality of Life Questionnaire, β =
estimate of corresponding factor in the model, CI = 95% confidence interval of the estimate. Adjusted for trial
site, sex, season, PC20 histamine test, atopy, FeNO, use of fluticasone or equivalent, and exposure to second-hand
smoke. * Increase in the PAQLQ score for an increase of the level of control from uncontrolled to partly controlled to
controlled based on the GINA criteria. † Decrease in the PAQLQ score in the case of wheezing episodes having
occurred in the preceding year. ‡ Decrease in the PAQLQ score when age increase. § Decrease in the PAQLQ score in
the case of the occurrence of exacerbations in the preceding 2 months. Model with the PAQLQ emotional functioning
domain as the dependent variable: of all factors, only the GINA asthma level of control had a significant association
(see text).
Figure 3. Associations between β2-agonist use and the PAQLQ total score in a linear mixed model—all
measurements taken during one year are included†. * Use of rescue medication during the week
preceding the clinical visit: 0 = 0 puffs most days, 1 = 1–2 puffs most days, 2 = 3–4 puffs most days, 3 =
5–8 puffs most days, 4 = 9–12 puffs most days, 5 = 13–16 puffs most days, and 6=more than 16 puffs
most days. The regression line is based on the model in which the asthma control levels were excluded,
the estimates of this model are given in Table 4. For factors in the equation other than the use of rescue
medication, mean values were used.
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Table 5. Results of longitudinal associations between the PAQLQ scores and FEV1 percentage of the
predicted value, β2-agonist use, dose of fluticasone or equivalent, age, sex, trial site, season, wheezing
episodes in the preceding year, PC20 histamine test, atopy, FeNO, exacerbations in the previous 2
months, and exposure to second-hand smoke. Only data of significant predictors are shown and asthma
control was excluded from the analysis.
PAQLQ total score PAQLQ symptoms domain PAQLQ activity limitations domain
β CI Pvalue β CI Pvalue β CI Pvalue
FEV1 per 10% predicted value * 0.05 0.01, 0.08 <0.01 0.08 0.03, 0.12 <0.01 0.06 0.00, 0.11 0.04
β2-agonist use
† −0.25 −0.32, −0.18 <0.01 −0.40 −0.49, −0.31 <0.01 −0.39 −0.49, 0.28 <0.01
Exacerbation previous 2 months no/yes ‡ −0.18 −0.30, −0.07 <0.01 −0.36 −0.51, −0.20 <0.01 - - -
Wheezing episodes preceding year no/yes § −0.23 −0.06, −0.41 0.01 −0.30 −0.06, −0.54 0.02 −0.27 −0.01, −0.53 0.04
FEV1: forced expiratory volume in 1 second, β2-agonist = use of rescue medication, PAQLQ = Pediatric Asthma
Control Quality of Life Questionnaire, β = estimate of corresponding factor in the model, CI = 95% confidence
interval of the estimate. Adjusted for: seasons, trial site (Maastricht or Sittard), sex, age, PC20 histamine test, atopy,
exposure to second-hand smoke, FeNO, and daily dose of fluticasone or equivalent. * Increase in the PAQLQ
score/10% increase of the FEV1 percentage of the predicted value. † Decrease in the PAQLQ score/increase in the
ACQ score concerning a β2-agonist use. ‡ Decrease in the PAQLQ score in the case of the occurrence of exacerbations
in the preceding 2 months. § Increase in the PAQLQ score in the case of increasing wheezing episodes during the
year preceding the study. Model with the PAQLQ emotional functioning domain as the dependent variable: no
factor was associated with the PAQLQ emotion functioning domain (see text).
Figure 4. Associations between lung function and the PAQLQ total score in a linear mixed model—all
measurements taken during one year were included. The regression line is based on the model in which
the asthma control levels were excluded, the estimates of this model are given in Table 5. For factors in
the equation other than the FEV1 percentage of the predicted value, mean values were used.
4. Discussion
This study showed that, at baseline, the presence of chronic rhinitis in the children with asthma
was significantly related to a lower QoL symptom score and a tendency towards a lower QoL total
score. Deterioration of asthma control was associated with a clinically relevant decrease in the pediatric
asthma-specific QoL (PAQLQ) score during 12 months. In addition, the level of asthma control,
as assessed by the ACQ and according to the GINA criteria, were to the same extent independently
related to asthma-specific QoL. Moreover, we found that an increase in β2-agonist use, the occurrence
of an exacerbation in the previous 2 months, and the occurrence of wheezing episodes in the year
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preceding the study were associated with a decrease in pediatric asthma-specific QoL. Of all domains,
asthma control was most strongly associated with the symptoms and activity limitations domain and
weakly with the emotional functioning domain of the PAQLQ. The presence of chronic rhinitis was not
related to changes in PAQLQ scores during one year.
This prospective study showed that β2-agonist use, the occurrence of an exacerbation in the
previous 2 months and the occurrence of wheezing episodes in the preceding year were related to
pediatric asthma-specific QoL. Lung function impairment as assessed by the FEV1 percentage of
the predicted value had a weak association with asthma-specific QoL. This finding is in line with a
meta-analysis which determined the degree of association between the lung function and subjective
measures in 8994 children and adults from 27 randomized controlled trials [25]. In this meta-analysis,
a moderate correlation between the lung function and asthma-specific QoL at time points 0 and 12
weeks was found [25]. Moreover, we found no association between a measure of airway inflammation
(FeNO) and asthma-specific QoL. This finding is consistent with the data of De Jongste et al. in a study
of 151 children with atopic asthma, in which medication was titrated based on FeNO plus symptom
telemonitoring or symptom monitoring only [26]. Daily FeNO monitoring did not improve asthma
control or asthma-specific QoL completed by caregivers [26].
In our cohort, asthma exacerbations were associated with a decrease in asthma-specific QoL.
This is supported by Luskin et al., who showed that a greater severity and number of exacerbations
were associated with a decrease in asthma-specific QoL [27]. Furthermore, the association between the
asthma level of control and asthma-specific QoL we found is consistent with other studies focusing
on asthma-specific QoL in children [1,6–12,27–32]. It is known that chronic rhinitis in children with
asthma is not only frequently occurring but also an underestimated problem by both patients, parents,
and doctors [3]. Indeed, at baseline, we found a negative influence of chronic rhinitis on the QoL
symptom scores although no clear effect of chronic rhinitis in the longitudinal analysis was found.
This stresses the importance of the proper treatment of chronic rhinitis as this probably will affect
asthma control and QoL in a positive way [3].
A strength of our prospective one-year study is that it provides insight into the longitudinal
associations between clinical characteristics and asthma-specific QoL. This is valuable information
because asthma is a chronic disease [28]. Furthermore, the PAQLQ questionnaire in this study was
completed by children and not by their parents. This is preferable because previous studies have shown
that parents are not able to indicate the quality of life of their child [30,31]. A limitation of our study
may have been the absence of additional demographic parameters. However, we predefined a factor
with a negative influence on asthma that is associated with social economic status, namely exposure
to second-hand smoke. Another limitation may have been the relatively high emotional functioning
domain scores at baseline. This may limit the possibility of finding associations with other variables
over time. However, in this study, a significant increase in the PAQLQ total scores was demonstrated
and significant associations with asthma control were found for this total score and the other domains.
Moreover, although there was no power or sample size calculation performed for this explorative
study, there was a significant result for the primary research question (a significant association between
ACQ and PAQLQ over time) This indicates that the study was not underpowered for detecting a
significant effect for the primary endpoints.
How can the findings of our study be explained? First, there was a close association between
asthma control and asthma-specific QoL, suggesting that the actual level of disease control determined,
to a large extent, the perceived disease-specific QoL. However, we also found that asthma control and
asthma-specific QoL were not mutually interchangeable. These variables reflect two different aspects
of asthma as shown in Figure 2; at a certain level of asthma control, there was still a considerable
variation in levels of asthma-specific QoL, even in children with controlled asthma. From our
study it was unclear what caused this variation and discrepancy. Other researchers found evidence
that emotional/psychological factors influence the asthma-specific QoL [13,26]. In a longitudinal
observational study in patients of 13 years and over, the association between asthma triggers and
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asthma-specific QoL was investigated [27]. Of all triggers, emotional stress was most strongly
associated with asthma-specific QoL, which may explain part of the variation in QoL at a certain
asthma control level. Second, the increase in the PAQLQ total scores in this study could be a study
effect, which may be explained by the strict titration of asthma medication based on the GINA criteria
every 2 months. This explanation was supported by our finding that asthma control levels also
improved during the 12-month study period and these were independently related to the PAQLQ total
scores. Third, we found that wheezing episodes in the year preceding the study, the occurrence of
exacerbations in the 2 months prior to the clinical visit, and the use of a β2-agonist were related to a
lower asthma-specific QoL. These findings confirm that exacerbations have significant impact on the
experienced well-being of children with asthma. It is known that exacerbations often require urgent
care or even emergency care visits and are a source of anxiety and uncertainty in both children and
parents [3]. More use of β2-agonists are linked to an increase in asthma symptoms, to limitations in
physical activity, and possibly to extra clinical visits [3]. This appeared to have a negative influence on
asthma-specific QoL in this longitudinal study. Fourth, in contrast to the use of β2-agonists, we found
no substantial influence of the daily dose of inhaled corticosteroids on asthma-specific QoL. This is
probably because the ICS dose was more closely correlated to the chronic course of the disease and has
no direct symptom-relieving effect, whereas β2-agonists are more closely related to acute increases in
disease activity and have a direct effect on symptoms. Moreover, the side effects of ICS are often mild.
The findings of our study imply that, in pediatric asthma, the level of asthma control or the
presence of other clinical characteristics cannot be used as a substitute for asthma-specific QoL.
We found an association between asthma control based on the ACQ and all PAQLQ domains. However,
some children with controlled asthma had a relatively low asthma-specific QoL (Figure 2). This suggests
that the measurement of asthma-specific QoL in children during clinical contact in addition to asthma
control may be valuable, because it may reveal, in some cases, a relatively low QoL while a child has
controlled asthma.
In conclusion, a strong longitudinal relationship between pediatric asthma-specific QoL and
asthma control during a 12 month follow-up study was found. The presence of chronic rhinitis at
baseline was associated with a worse QoL. Moreover, an increase of β2-agonist use, the occurrence
of wheezing episodes in the year preceding the study, and the occurrence of an asthma exacerbation
during the study were negatively related to asthma-specific QoL in children.
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Abstract: Asthma is a chronic inflammatory lung syndrome with an increasing prevalence and a rare
but significant risk of death. Its pathophysiology is complex, and therefore we investigated at the
systemic level a potential implication of oxidative stress and of peripheral blood mononuclear cells’
(PBMC) mitochondrial function. Twenty severe asthmatic patients with severe exacerbation (GINA
4–5) and 20 healthy volunteers participated at the study. Mitochondrial respiratory chain complexes
activities using different substrates and reactive oxygen species (ROS) production were determined
in both groups by high-resolution respirometry and electronic paramagnetic resonance, respectively.
Healthy PBMC were also incubated with a pool of plasma of severe asthmatics or healthy controls.
Mitochondrial respiratory chain complexes activity (+52.45%, p = 0.015 for VADP) and ROS production
(+34.3%, p = 0.02) were increased in asthmatic patients. Increased ROS did not originate mainly
from mitochondria. Plasma of severe asthmatics significantly increased healthy PBMC mitochondrial
dioxygen consumption (+56.8%, p = 0.031). In conclusion, such asthma endotype, characterized by
increased PMBCs mitochondrial oxidative capacity and ROS production likely related to a plasma
constituent, may reflect activation of the immune system. Further studies are needed to determine
whether increased PBMC mitochondrial respiration might have protective effects, opening thus new
therapeutic approaches.
Keywords: asthma; exacerbation; reactive oxygen species; PBMC; mitochondrial function
1. Introduction
Asthma is a common disease that affects 300 million people worldwide (1 in 10 children and
1 in 12 adults) resulting in a substantial morbidity and an important annual healthcare expenditure.
The disease is characterized by chronic inflammation of the conducting airway resulting in bronchial
obstruction, mucus overproduction, airway remodeling and bronchial hyper-responsiveness [1,2].
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Different mechanistic pathways are involved in such complex pathology. Locally, generation of
oxidative stress with increased reactive oxygen species (ROS) production and mitochondrial dysfunction
have been observed (bronchus, airway epithelium) in murine models of ovalbumin-induced asthma
and in bronchial epithelial cell cultures [3–8]. Increased ROS production results in oxidative lipid
peroxidation, protein and DNA damages (single-stranded and double-stranded breaks) [9], thought to
aggravate the airway inflammation and to play a role in bronchial smooth muscle impairment and mucus
secretion. Damaged antioxidant defense mechanisms, altered homeostasis of the airway surface liquid
and acute or chronic bacterial airway infections also seem to aggravate oxidative stress in asthma [10].
Several studies highlighted an imbalance between oxidative species and antioxidant mechanisms
in asthma. A decrease of superoxide dismutase, gluthation peroxidase or catalase activity was
correlated with an aggravation of bronchial obstruction and asthma severity [11–15]. A self-entertaining
phenomenon of inflammation and oxidative stress production occurs and damage-associated molecular
patterns (so called alarmins), activate immune cells and their specific tissue [16].
In turn, immune cells of asthmatic patients exposed to an allergen, generate ROS, such as hydroxyl
radicals, superoxide, peroxydes, peroxynitrite and nitric oxide [9]. This ROS generation was observed
in sputum, exhaled breath condensates and bronchoalveolar lavages (BAL) of asthmatic patients,
especially in severe asthma [11–14].
Besides this local characterization of the asthma mechanism, there are relatively few data focused
on a potential involvement of mitochondrial function of inflammatory circulatory cells. However,
dysfunction of the mitochondrial respiratory chain is likely to play a role in the initiation and progression
of other inflammatory pathology such as cardiovascular diseases and anaphylactic choc [17–20].
Furthermore, impairments in mitochondrial function and/or elevation of ROS production have been
found in allergic diseases such as atopy, atopic dermatitis and allergic rhinitis [3,4,21,22]. Recently,
studying systemic involvement in local allergic rhinitis, we observed an impaired mitochondrial
function in peripheral blood mononuclear cells (PBMC) 6 hours after an allergen challenge in patients
with allergic rhinitis [23].
In the present study, therefore, we tested the hypothesis that peripheral blood mononuclear cell
might demonstrate impaired mitochondrial function together with increased ROS production in severe
asthmatic patients with severe exacerbation, as compared to healthy subjects.
2. Population and Methods
2.1. Patients and Study Design
Twenty healthy volunteers and 20 severe asthmatic patients experiencing severe exacerbation
were enrolled in a prospective and controlled study. Severe asthma was defined as a stage 4 or 5 of
GINA classification and severe exacerbation as a need for hospitalization or for systemic steroids (or its
increase) for more than 3 days [2]. Exclusion criteria were active smoking, smoking cessation <1 year;
ancient smoking >10 packs a year, current depression, cardiovascular insufficiency or severe sepsis.
The study design included the clinical characterization of patients and, peripheral blood
mononuclear cells mitochondrial respiratory chain complexes’ activities and ROS production in
both control subjects and asthmatic patients. Further, after determining an eventual contribution of
mitochondria to ROS production, we analyzed the effects of plasma on healthy PBMC. Thus, PBMC
from healthy volunteers were placed in contact with heterologous platelet poor plasma of healthy
volunteers or severe asthmatics experiencing severe exacerbation.
The study was approved by the ethics committee of the Strasbourg University Hospital (number
2016-69) and informed consent was obtained from each patient.
2.2. Peripheral Blood Mononuclear Cells (PBMC) Isolation
Thirty mL of venous blood was sampled in Sodium Heparinate tubes for each patient. 1mL was
kept (on ice) for the study of ROS production. The remaining part of the sample was used to separate
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peripheral blood mononuclear cells (PBMC) and plasma. Briefly, blood was placed on a ficoll density
gradient (Eurobio, Lymphocytes separation medium, Courtabeauf France, France) and centrifuged
(2100 rpm, 25 min, 18 ◦C, without brakes). PBMC (lymphocytes and monocytes) were sampled, washed
in a DPBS solution (Dulbecco’s Phosphate Buffer Saline 0067M, Hyclone, South Logan, UT, USA) and
centrifuged (1600 rpm, 10 min, 18 ◦C, without brakes). Finally, PBMC were counted by flow cytometry
(Muse Cell Analyser, Merck Millipore, Darmstadt, Germany).
2.3. Mitochondrial Respiration
The study of the mitochondrial respiratory chain was performed with a high resolution oxygraph
(Oxygraph-2k; Oroboros Instruments, Innsbruck, Austria) at 37 ◦C. 2.5 × 106 PBMC /mL were
introduced in the Oxygraph-2k’s chamber with continuous stirring. The dioxygen consumption was
analyzed using the DatLab software 4.3 (Oxygraph-2k; Oroboros Instruments, Innsbruck, Austria).
At the beginning, cell membranes were permeabilized with saponine (125 μg/mL), and complex I was
activated with glutamate (5 mM), and malate (2 mM), this step is the basal dioxygen consumption.
After reaching a steady state for V0, different substrates and inhibitors were introduced in the
oxygraph’s chamber. ADP (2 mM) induced the activation of ATP synthase (mitochondrial Complex V)
and allowed the study of mitochondrial complexes I, III, IV, V. Then, succinate (25 mM) was introduced,
an activator of the mitochondrial Complex II, for the study of mitochondrial Complexes I, II, III, IV,
V. The addition of rotenone (0.5 μM) allowed analysis of mitochondrial Complexes II, III, IV, V by
inhibiting the Complex I. TMPD/ascorbate (0.5 mM/0.5 mM) was then added to give electrons to the
Complex IV, so allowed preferentially the complex IV. The result was expressed in pmol/s/106cell.
2.4. Reactive Oxygen Species (ROS) Production
2.4.1. Measurement of Superoxide Anions in Blood
ROS production in venous blood was assessed by exploring the superoxide anions production,
using electron paramagnetic resonance (EPR), (E-scan, Bruker-Biospin, Rheinstetten, Germany)
at 37 ◦C, as previously described [24]. Briefly, 1 mL venous blood was kept on ice in order to
perform the analysis 1 hour after sampling; 25 μL of blood were mixed with spin probe CMH
(1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine HCl, 200 μM). Then, the mixture was
introduced in a glass EPR capillary tube (Noxygen Science Transfer & Diagnostics, Elzach, Germany),
and then placed inside the cavity of the e-scan spectrometer (Bruker, Rheinstetten, Germany) for data
acquisition. Detection of ROS production was conducted using BenchTop EPR spectrometer E-SCAN
under the following EPR settings: center field g = 3477,452; sweep width 60 G; microwave power
21.85 mW; modulation amplitude 2.4 G; time constant 40.96 ms; conversion time 10.24 ms; number of
lag curve points 6. The EPR signal is proportional to the unpaired electron numbers. The result was
expressed in μmol/min.
2.4.2. Mitochondrial ROS Measurement
We determined mitochondrial PBMC ROS production using a fluorescent probe MitoSOX, a red
mitochondrial superoxide indicator for live cell imaging (Molecular Probes; Life technologies) [25].
MitoSOX (Invitrogen, Eugene, Oregon, USA) (5 μM) was incubated with 2.5 × 106 PBMC diluted in
DPBS, for 10 min at 37 ◦C. Then, cells were washed and centrifuged (1600 rpm, 10 min). Excitation
was set at 510 nm and emission at 580 nm A positive control group of mitochondrial ROS production
was elaborated with Antimycin. All the experiments were achieved in a light-protected environment.
The result was expressed in AU of fluorescence.
2.5. Mitochondrial Dioxygen Consumption of Healthy PBMC in Contact with Heterologous Plasma
PBMC from 7 healthy volunteers were extracted following the same technique as presented above.
Then 2 × 106 cells/mL were placed into each oxygraph’s chamber with a pooled heterologous platelet
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poor plasma. In one chamber, plasma came from a pool of 6 healthy volunteers, and in the other one,
plasma came from a pool of 6 severe asthmatics experiencing severe exacerbation.
Before introducing the PBMC, the basal respiration of both pooled plasmas was recorded in the
oxygraph’s chambers (Oxygraph-2k; Oroboros Instruments, Innsbruck, Austria) at 37 ◦C.
After 6 h exposure to heterologous plasma, PBMC basal consumption of dioxygen (V0) was
measured and different substrates and inhibitors were added in order to study the mitochondrial
respiratory chain complexes’ activities. Using plasma as the respiratory solution, the uncoupling
protocol was more adapted than the classic one. Therefore, an ATP-synthase inhibitor (oligomycine
1.25 μmol/L) was added, to induce a dioxygen consumption mainly due to the leakage of
protons through the inner mitochondrial membrane [26]. Then, the uncoupler carbonyl cyanide
4-(trifluoro-methoxy)phenylhydrazone (FCCP 40 μM) was added in order to measure maximal oxygen
flux. Rotenone (2 μM) was added to inhibit the complex I. Finally, Complex III was inhibited
by antimycine (1.85 μM). Dioxygen consumption was calculated by subtracting the basal plasma
respiration as previously described [20,26,27]. The result was expressed in pmol/s/106cell.
Simultaneously, ROS production was measured by the evolution of using fluorescent probe
Amplex Red (20 μM) and Horseradish peroxidase (HRP, 1 U/mL). We also calculated the free radical
leak (FRL) corresponding to the fraction of electrons which reduces O2 to ROS in the mitochondrial
respiratory chain (percentage of free radical leak) instead of reaching cytochrome oxidase to reduce
O2 to water [28]. Because two electrons are needed to reduce one mole of O2 to H2O2, whereas four
electrons are transferred in the reduction of one mole of O2 to water, the FRL (percent) was calculated
as the rate of H2O2 production divided by twice the rate of O2 consumption, and the result was
multiplied by 100 [29].
2.6. Statistical Analysis
All values are presented as mean ± standard error of the mean (SEM). Qualitative variables were
described as numbers and percentages. When values followed the normality curve, Student’s test was
used. But, if values did not follow the normality curve, a non-parametric Mann–Whitney test was used
to compare the control and the asthmatics groups. Concerning data obtained with PBMC exposed
to pooled heterogenous control plasma or pooled heterogenous asthmatic plasma, a non-parametric
paired test was realized (Wilcoxon test). All analysis were performed with GraphPad Prism 5 (Graph
Pad Software, Inc., San Diego, CA, USA). Statistical significance was determined as p < 0.05.
3. Results
3.1. Clinical Characteristics of the Subjects
Twenty patients (mean age 50.95± 4.06 years, 5 men and 15 women) were admitted for exacerbation
of severe asthma at the Strasbourg University Hospital with a need for hospitalization or systemic
steroids for more than 3 days. The control group included 20 healthy volunteers (mean age 50.10 ±
3.77 years, 6 men and 14 women) with no medical history of pulmonary or atopic diseases.
Subjects’ characteristics are summarized in Table 1. There was no difference in age, sex and
smoking between severe asthmatic patients and the control group. Asthmatic patients had a body
mass index (BMI) of 28.01 ± 1.47 kg/m2 versus 23.0 ± 0.72 kg/m2 in the control group (p = 0.0040).
Severe asthmatic patients had mainly an uncontrolled allergic asthma. Fourteen patients presented
with atopic and eosinophilic asthma whereas 2 patients had a non-atopic and eosinophilic asthma
and 4 patients had non-Th2 mediated asthma. 14 patients had an associated allergic rhinitis, 8 had
a basal FEV1 < 80% of the maximal theoretical value. The main cause of exacerbation was bronchial
and pulmonary infection and 9 patients were treated by steroids for more than 24 h at the time of
inclusion and blood sampling.
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Table 1. Demographic, clinical, and biological characteristics of the patients.
Control Group (n = 20) Severe Asthmatic Patients (n = 20)
Mean age (years) 50.10 ± 3.77 50.95 ± 4.06
Women 14 15
Male 6 5
Mean body mass index (BMI) (kg/m2) 23.0 ± 0.72 28.01 ± 1.47




Arterial hypertension 3 8
Venous thrombosis/pulmonary
embolism 0 1
Other lung diseases 0 2
Neoplasia 0 1
Acute coronary syndrom with










BMI: Body mass index, PA: packs a year, LVEF: left ventricular ejection fraction.
3.2. Mitochondrial Respiratory Chain Complexes’ Activities Are Enhanced in Asthmatic Patients
The maximal mitochondrial respiratory chain activity was significantly increased in patients with
severe asthma experiencing severe exacerbation in comparison with the control group (Figure 1). Data
using specific substrates are presented below.
3.2.1. Basal Consumption of Dioxygen (V0)
V0 was increased in severe asthmatic patients in comparison with the control group (3.51 ± 0.43
and 2.10 ± 0.22 pmol/s/106cell respectively, +67.1%, p = 0.005).
3.2.2. Mitochondrial Complexes I + III + IV + Vactivities
VADP was significantly increased in the severe asthma group compared to the control group
(8.78 ± 1.11 vs. 5.76 ± 0.48 pmol/s/106cell respectively in asthmatic patients and in control subjects,
+52.4%, p = 0.015).
3.2.3. Mitochondrial Complexes I + II + III + IV + Vactivities
Vsucc was also significantly increased in the severe asthma group compared to the control group
(15.64 ± 2.06 and 9.48 ± 0.91 pmol/s/106cell, +64.97%, p = 0.007).
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3.2.4. Inhibition of the Mitochondrial Complex I by Rotenone
Rotenone injection showed no significant difference between both groups but the combined
activity of the Complexes II + III + IV + V tended to be increase in the severe asthmatic patients (10.89 ±
1.70 and 7.22 ± 0.67 pmol/s/106cell respectively in asthmatic patients and in control subjects, +50.83%).
Figure 1. Peripheral blood mononuclear cells (PBMC) mitochondrial respiration in control and severe
asthmatic patients. * p < 0.05, ** p > 0.01, *** p < 0.001. ns: non significant.
3.2.5. Complex IV Activity
VTMPD/ascorbate showed an increase of cytochrome C oxidase’s activity in asthmatic patients
(34.87 ± 2.99 and 20.03 ± 2.02 pmol/s/106cell, +74.09%, p = 0.0003).
V0 corresponds to the basal O2 consumption, with glutamate, and malate as substrates. VADP
corresponds to the ADP-stimulated respiration, with glutamate and malate as substrates. Vsucc
represents the activation of all complexes (I, II, III, IV, V). VROT represents the complexes II, III, IV, V
activities. VTMPD corresponds to the complex IV contribution. Results are expressed as means ± SEM.
n = 20 per group.
To further investigate a possible effect of corticosteroid or obesity, we analyzed PBMC
mitochondrial respiration in asthmatic patients with and without corticosteroid (Figure 2) and
with and without a BMI ≥ 30 kg/m2 (Figure 3).
Figure 2. PBMC mitochondrial respiration in severe asthmatic patients treated or not with corticoids.
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Figure 3. PBMC mitochondrial respiration in severe asthmatic patients, without or with a BMI ≥
30 kg/m2.
Concerning the corticosteroids, no significant difference was observed whatever the mitochondrial
respiratory chain complex studied between patients treated or not with systemic steroids for more
than 24 h.
V0 corresponds to the basal O2 consumption, with glutamate, and malate as substrates. VADP
corresponds to the ADP-stimulated respiration, with glutamate and malate as substrates. Vsucc
represents the activation of all complexes (I, II, III, IV, V). VROT represents the complexes II, III, IV, V
activities. VTMPD corresponds to the complex IV contribution. Results are expressed as means ± SEM.
n = 11 without and 9 with corticoid, respectively.
Moreover, although mitochondrial respiration tended to increase in severe asthmatics patients
with a BMI ≥ 30 kg/m2 as compared to patients with a BMI < 30 kg/m2, this increase failed to reach
statistical significance (23.01 ± 6.43 vs. 13.80 ± 1.88 pmol/s/106cell, p = 0.09 respectively for Vsucc, and
17.07 ± 5.43 vs. 9.35 ± 1.51 pmol/s/106cell, p = 0.08, for Vrot).
V0 corresponds to the basal O2 consumption, with glutamate, and malate as substrates. VADP
corresponds to the ADP-stimulated respiration, with glutamate and malate as substrates. Vsucc
represents the activation of all complexes (I, II, III, IV, V). VROT represents the complexes II, III, IV, V
activities. VTMPD corresponds to the complex IV contribution. Results are expressed as means ± SEM.
n = 16 without and 4 with obesity, respectively.
3.3. Reactive Oxygen Species Are Increased in the Blood of Asthmatic Patients
ROS were significantly increased in the venous blood of severe asthmatic patients in comparison
with the control group (0.94 ± 0.08 vs. 0.70 ± 0.07 μmol/min respectively +34.3%, p = 0.02, n = 16
per group, Figure 4A). To investigate the origin of such ROS, we determined the mitochondrial
ROS production.
Mitochondrial ROS production tended to be increased in severe asthmatic patients experiencing
severe exacerbation and the control group (2983.0 ± 135.8 and 2571.0 ± 252.2 UA respectively, p = 0.07,
n = 8 per group, Figure 4B).
Systemic steroid treatment > 24 h and obesity did not influence the ROS production.
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Figure 4. Reactive oxygen species (ROS) in control and severe asthmatic patients experiencing severe
exacerbation. (A): total ROS level on whole blood was obtained using electron paramagnetic resonance.
n= 16 per group. (B): ROS level on PBMC was detected by MitoSOX-based spectrofluorimetry detection.
Results are expressed as means ± standard error of the mean (SEM). n = 8 per group. * p < 0.05.
3.4. Effect of Heterologous Plasma of Healthy or Asthmatic Subjects on Mitochondrial Dioxygen Consumption
and of Healthy PBMC
Investigating whether plasma of asthmatic patients per se might modulate PBMC mitochondrial
function, we observed using different substrates, an enhanced mitochondrial respiration of PBMC in
presence of asthmatic plasma as compared to normal plasma (n = 7 per group, Figure 5A).
Thus, basal dioxygen consumption Vo was significantly increased in severe asthmatic plasma
(1.55 ± 0.29 and 0.64 ± 0.28 pmol/s/106 cell, +142.2%, p = 0.016).
After ATP synthase inhibition mitochondrial respiration was activated by an uncoupler (FCCP).
The Maximal mitochondrial respiratory chain activity was significantly increased in healthy PBMC
in contact with pooled plasma from severe asthmatic patients in comparison with healthy PBMC in
contact with pooled control plasma (2.87 ± 0.44 and 1.83 ± 0.28 pmol/s/106cell, +56.8%, p = 0.031).
Similarly, when the complex I was inhibited by rotenone injection mitochondrial activity was
significantly increased in healthy PBMC in contact with pooled plasma from severe asthmatic patients
in comparison with healthy PBMC (1.82 ± 0.45 and 0.84 ± 0.26 pmol/s/106cell, +116.7%, p = 0.016).
Finally, when the complex IV was inhibited by antimycin injection, mitochondrial activity tended
to increase in healthy PBMC in contact with pooled plasma from severe asthmatic patients as compared
to the control group (1.34 ± 0.45 and 0.80 ± 0.26 pmol/s/106cell, p = 0.297, +67.5%)
The free radical leak was not statistically increased in healthy PBMC in contact with pooled
plasma from severe asthmatic patients, in comparison with the control one. These results are presented
in Figure 5B.
Figure 5. Effect of healthy and asthmatic plasma on PBMC mitochondrial respiration and free radical
leak. (A) Mitochondrial respiration after different substrates injected. (B) Free radical leak. PBMC:
peripheral blood mononuclear cell. FCCP: carbonyl cyanide 4-(trifluoro-methoxy)phenylhydrazone,
ROT: rotenone, ANTIMY: antimycin. Results are expressed as means ± SEM. n = 7 per group. * p < 0.05.
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4. Discussion
The main result of this study is to demonstrate that mitochondrial respiratory chain complexes’
activities of PBMC are stimulated in severe asthmatic patients with severe exacerbation, and that
such enhancement is associated with increased reactive oxygen species. Furthermore, the plasma
of asthmatic patients—but not of healthy subjects—appears responsible for PBMC mitochondrial
oxidative capacity enhancement.
Asthma is a frequent and severe disease affecting a large proportion of the human
population, including children and young people and implying a tremendous socioeconomic burden.
The pathophysiology of asthma and the balance between oxidant/antioxidant is the subject of
intense ongoing research and some studies have explored the local role of mitochondria in atopic
diseases [1–9,16,29]. However, still little is known on the connection between mitochondria and the
immune response in asthma, especially in peripheral blood.
Interestingly, our study shows that severe asthmatic patients with severe exacerbation had
a significant increase in their PBMC mitochondrial respiratory chain activity, in comparison with the
control group. These data contrast with a previous report showing that acute nasal allergen challenge
induces mitochondrial dysfunction of peripheral blood mononuclear cells in allergic rhinitis [23]
and with the fact that PBMC mitochondrial respiration is generally impaired in cardiovascular
diseases [18,19]. Thus, the increase observed in asthmatic patients is particularly interesting. In fact,
peripheral blood immune cells like T and B lymphocytes or monocytes (PBMC) were activated in
severe asthmatic patients with severe exacerbation [1]. At the mitochondrial level, this activation was
expressed by an increased maximal function of the mitochondrial respiratory chain. Interestingly, this
is consistent with data obtained on PBMC mitochondrial function in septic shock, often showing an
increased mitochondrial respiration after an early impairment [20,30]. Such a response was thought to
compensate for the initial mitochondrial dysfunction [30].
The underlying mechanisms still deserve further study but oxidative stress might play a key role.
In our study, severe asthmatic patients with severe exacerbation had a significant elevation of ROS
in their blood. These ROS did not seem to be mainly produced by mitochondria since the Mitosox
analysis was similar in both groups and since the FRL showed no statistically significant difference
in the number of O2 molecules used for the production of ROS in the mitochondria between the two
groups. Thus, as previously reported in asthma, reactive oxygen species could have been produced by
NADPH-oxidase and/or by xanthine oxidase rather than by the mitochondrion [31,32].
Obesity might also have played a role since there is a link between mitochondrial dysfunction,
obesity and asthma or metabolic syndrome [33,34]. Accordingly, PBMC mitochondrial respiration
tended to be increased in asthmatic patients presenting with a BMI≥ 30kg/m2. Although not statistically
significant and focused only on several respiratory chain complexes, this result supports further studies
on a potential relationship between obesity per se and the mitochondrial respiration of circulating cells.
Similarly, corticosteroids might modulate PBMC mitochondrial respiration. Indeed, steroids
mediated apoptotic signals in human eosinophils through a mitochondrial pathway [35]. However,
in our study, no significant change was observed when comparing asthmatic patients with and without
the corticoid therapy.
Finally, we tested whether patients with eosinophilia and hyper-eosinophilia, defined by a blood
count of ≥300 and ≥500/mm3 respectively, presented with exacerbated PBMC mitochondrial respiration
as compared to asthmatic patients without eosinophilia. No difference was observed between both
groups, suggesting the eosinophilia might not be a key factor associated with an enhanced PBMC
mitochondrial respiration.
The clinical significance of such enhanced mitochondrial respiratory chain complexes’ activities
in severe asthmatic patients in exacerbation remains to be further investigated. However, recent
studies suggest that during the activation of the adaptive immune response, the shift of dendritic cell’s
mitochondrial respiration toward either a glycolytic or an oxidative metabolism might be related to
a pro-inflammatory or to an anti-inflammatory differentiation of T cells, respectively. Thus, a reduced
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mitochondrial respiration seemed to be associated with pro-inflammatory effects whereas an increased
dendritic cell’s mitochondrial respiration might antagonize TLR effects [36–38]. Therefore, one might
hypothesize that the enhanced mitochondrial respiration we observed could reflect a trend toward
a potentially beneficial anti-inflammatory effect.
Accordingly, besides their well-known deleterious effects corresponding to oxidative stress,
ROS signaling might also allow protective effects through mitochondrial biogenesis and anti-oxidant
system enhancements [39]. In asthma, ROS could have a different role depending on their producing
cells. In epithelial and in bronchial smooth muscle cells, ROS likely induce local tissue damages
and aggravate inflammation [9,10]. In peripheral blood, the increased ROS was observed without
concomitant mitochondrial dysfunction, and could participate in the activation of circulating T
lymphocytes, potentially playing a role in the “homing” of immune cells to the inflammatory upper
airways [16].
Interestingly, recent data support a link between antigen-specific IgE receptor expression on
PBMC and atopic asthma within school-aged children [40]. Furthermore, basophil counts in PBMC
populations during childhood acute wheeze/asthma were associated with future exacerbations [41].
Whether the mitochondrial function of PBMC could be used in the future as a biomarker in severe
asthma or for a targeted therapy cannot be inferred from our results. But, these data emphasize the
potential interest of analyzing PBMC metabolic characteristics, in conjunction with the search of other
potential biomarkers in severe asthma [42–44].
Limitations of the Study
Although 20 subjects in each group allowed us to discover interesting characteristics of asthmatic
patients, studies with a greater number of subjects will be useful to further investigate the underlying
mechanisms. In this context, a study specifically directed toward obese patients and a longer follow-up
in order to characterize the patients after the exacerbation will be very interesting for better defining
the clinical significance of these data.
5. Conclusions
This study further supports the concept of crosstalk between the mitochondrion and the immune
system in asthma. The enhanced mitochondrial respiration observed in the PBMC of patients with
severe asthma in exacerbation, likely related to a plasmatic factor potentially including ROS, might
participate in the patient’s defense mechanisms. However, this issue still has to be investigated and
further studies are needed to determine whether circulating cells’ mitochondrial function might be
used as a biomarker in asthma and whether maintaining healthy mitochondria in asthmatic patients’
PBMC might be an interesting therapeutic avenue, as proposed in lung injury [16,45]. Thus, further
longitudinal studies exploring the systemic aspects of mitochondrial function and the ROS production
in asthma appear warranted.
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Abstract: Asthma is a common illness throughout the world that affects the respiratory system
function, i.e., a system whose operational adequacy determines the respiratory gases exchange. It is
therefore expected that acute severe asthma will be associated with respiratory acid-base disorders.
In addition, the resulting hypoxemia along with the circulatory compromise due to heart–lung
interactions can reduce tissue oxygenation, with a particular impact on respiratory muscles that have
increased energy needs due to the increased workload. Thus, anaerobic metabolism may ensue,
leading to lactic acidosis. Additionally, chronic hypocapnia in asthma can cause a compensatory
drop in plasma bicarbonate concentration, resulting in non-anion gap acidosis. Indeed, studies have
shown that in acute severe asthma, metabolic acid-base disorders may occur, i.e., high anion gap
or non-anion gap metabolic acidosis. This review briefly presents studies that have investigated
acid-base disorders in asthma, with comments on their underlying pathophysiology.
Keywords: asthma; lactic acidosis; hyperchloremic acidosis; hypocapnia; hypercapnia
1. Introduction
Asthma is a common yet complex airway disease, characterized mainly by chronic airway
inflammation and temporal variability in symptoms and expiratory airflow limitation. A complete
analysis of the pathophysiology of the disease is beyond the scope of this paper, but a brief review
of the main mechanisms involved in disease exacerbations is necessary to better grasp the acid-base
derangements often encountered in these patients. Although asthma is increasingly being recognized as
a heterogeneous disease with many different phenotypes, the mechanics of disease exacerbation seem to
be common amongst patients. In acute asthma exacerbations, exposure to a precipitating factor leads to
an exaggerated inflammatory response in the airways owing to an innate airway hyperresponsiveness
in these patients. The immediate result of this inflammatory response is contraction of bronchial smooth
muscles, bronchial edema, and mucus hypersecretion leading to mucus plugging. The consequent
narrowing of airway diameter leads to increases in airway resistance and limitation of expiratory flow,
and hence to air trapping and dynamic hyperinflation. As tidal breathing then starts taking place
within the flat portion of the pressure-volume curve, the elastic work of breathing is dramatically
increased. Hyperinflation essentially leads to the generation of an inspiratory threshold, which is
reflected by the presence of positive end-expiratory pressure (auto-PEEP). This inspiratory threshold
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must be overcome by the inspiratory muscles during each breath in order for inspiratory flow to begin.
Another deleterious factor is the disadvantageous positioning of respiratory muscle length-tension
curves in these large lung volumes, necessitating the recruitment of accessory inspiratory and expiratory
muscles, further contributing to respiratory muscle fatigue [1].
The aforementioned pathophysiological mechanisms eventually lead the deteriorating patient
towards ventilatory failure. Nonetheless, acute respiratory failure is a far more common event in
acute asthma. Indeed, hypoxemia is widely prevalent, with PaO2 levels of less than 60 mmHg
even in non-severe asthma [2] having being reported in several studies [3]. Even though this effect
was attributed to ventilation/perfusion (VA/Q) inequalities owing to regional differences in airflow,
it was not until the advent of the multiple inert gas elimination technique that this phenomenon was
adequately demonstrated [4].
The pathophysiological disorders in asthma result in various acid-base disturbances; these are
summarized in Figure 1 and are briefly discussed below.
Figure 1. Acid-base disorders in asthma. FEV1 = forced expiratory volume in 1 s. AG = anion-gap.
2. Respiratory Alkalosis
Acute asthmatic crisis is usually accompanied by hyperventilation and hypocapnia with respiratory
alkalosis [3,5]. However, it seems that mild, asymptomatic asthma is also associated with hypocapnia.
Studies that have demonstrated hypocapnia in asymptomatic asthmatics, as well as during asthmatic
attacks, are presented in Table 1.
Table 1. Respiratory alkalosis.
Study Study Design Study Population Methods Significant Findings
Osborne C.A. et al.,





PaCO2 and PETCO2 lower in
asymptomatic asthmatics
Van den Elshout et al.,






increases in airway resistance
in asthmatic patients
Raimondi et al.,







in less severe asthma
exacerbations
Abbreviations used: ASA = acute severe asthma, ABGs = arterial blood gases, PETCO2 = end-tidal carbon dioxide.
In a study, asymptomatic patients with asthma had significantly lower partial pressure of carbon
dioxide (PCO2) in arterial blood and end-tidal PCO2 (PETCO2) values compared to normal subjects,
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with no difference in the ventilatory pattern [6]. To note, there was no statistically significant difference
in the other acid-base variables between asthma patients and healthy controls, i.e., the pH values were
similar in both groups. Hypocapnia was attributed to airway hyperresponsiveness. In another study,
similar results were found; normal subjects had higher PETCO2 at rest compared to asthmatic patients.
This study evaluated the effect of hypocapnia and hypercapnia in patients with asthma and in healthy
subjects. It was found that while the fall of PCO2 increased airway resistance in asthmatic patients,
it did not significantly change the respiratory resistance in normal individuals [7]. It was suggested that
hypocapnia is probably associated with the airway obstruction observed in asthmatics, thus having an
important role in the pathophysiology of asthma. Low PCO2 has been demonstrated to increase airway
smooth muscle tension in animal models, as well; the proposed mechanism by which hypocapnia
affects smooth muscle contraction is the alteration of calcium uptake due to an increase in intracellular
pH [9,10]. Corroborating the above findings, it has further been shown that high PCO2 values cause
bronchodilation and reduce airway resistance in both asthma patients and normal subjects [7,11].
As hypocapnia has been implicated in the pathophysiology of asthma, training techniques have been
proposed to improve patients’ respiratory pattern, reduce hyperventilation, and increase PCO2, in an
attempt to reverse the bronchoconstrictive effect of hypocapnia. Breathing retraining has been used in
the management of asthma. The Buteyko breathing technique, an innovative treatment approach for
asthma, named after Professor Konstantin Buteyko, has been widely applied [12]. In a recent trial,
breathing training programs improved disease-related quality of life in adult asthmatic patients [13].
3. Respiratory Acidosis
Respiratory acidosis is a very common acid base disturbance in acute severe asthma and is widely
considered to be an ominous finding. Its early recognition and treatment is important and decisive
for the final outcome, as it can lead to respiratory failure and arrest if prolonged. Studies relating
hypercapnia during asthmatic attacks are presented in Table 2.
Table 2. Respiratory acidosis.
Study Study Design Study Population Methods Significant Findings
Mountain et al.,
1988 [14] Retrospective




Hypercapnic patients had more
severe airway
obstruction, symptoms
Lee K.H. et al.,
1997 [15] Retrospective
48 patients with
49 admissions to the ICU
due to ASA
Various outcomes documented Respiratory acidosis linked tohigher mortality
Raimondi et al.,






FEV1 and respiratory acidosis.
Inability to perform spirometry





127 patients with severe
exacerbation of asthma and
COPD in the ED
Acute respiratory acidosis
documented and linked to
clinical presentation






Abbreviations used: ICU = intensive care unit, COPD = chronic obstructive pulmonary disease, pCO2 = partial
carbon dioxide pressure, ED = emergency department.
In asthmatic patients, hypercapnia and respiratory acidosis occur in clinical exacerbations
characterized by severe airway obstruction [14]. Simpson et al., in one of the earliest published
studies, noted that hypoxemia and respiratory acidosis are common in children with acute severe
asthma, as in 10 out of the 24 acute attacks that were studied CO2 retention was observed, while three
patients developed carbon dioxide narcosis [17]. On the other hand, Weng et al. found that the
degree of hypoxemia correlated with the degree of airway obstruction, but neither PaCO2 nor pH
did. This study reported 177 events in 139 asthmatic children, both symptomatic and asymptomatic.
Respiratory acidosis or mixed acidosis was present in severely dyspneic patients [18]. Lee et al. noted
that PaCO2 was significantly higher and the arterial blood pH lower in asthmatics who died, and delays
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in providing mechanical ventilation led to worse outcomes [15]. Several studies have attempted to
find clinical signs that could be correlated to the presence of respiratory acidosis. Cham et al. tried to
find clinical predictors for acute respiratory acidosis in 141 episodes in patients with either asthma
or chronic obstructive pulmonary disease (COPD). A total of 41 patients had hypercapnia (32.3%),
and acidosis was present in 27 (65.9%). The frequency of acute respiratory acidosis was 0.39 in COPD
and 0.10 in asthma. Drowsiness, flushing, and intercostal retractions were strong predictors for acute
respiratory acidosis [16]. It has also been reported that the absence of pulsus paradoxus makes the
presence of hypercapnia unlikely, although it is noted that clinical signs and symptoms during acute
severe asthma often are not correlated with the severity of the functional impairment [19]. Raimondi et
al. performed a case series study exploring acid-base patterns in patients admitted for acute severe
asthma, in correlation with forced expiratory volume in 1 s (FEV1) values [8]. Airway obstruction
severity did not seem to correlate significantly with PaO2 values, a finding also reported in several
other studies in the past [18,20,21] and thought to be due to VA/Q mismatch not being connected to
air flow rates; moreover, treatment with β-agonists may lead to further widening of VA/Q mismatch.
A statistically significant reverse correlation was demonstrated between FEV1 and PaCO2 levels.
Inability to complete spirometry was shown to be accompanied with a significantly higher frequency
of respiratory acidosis, with some patients being deemed unable to undergo a spirometry maneuver by
the attending physician. Less severe cases of acute asthma presented mostly with respiratory alkalosis.
Hypercapnia in asthma, in addition to the severity of the disease, is also associated with the
therapeutic administration of oxygen. Thus, in patients with severe asthma exacerbation, significant
increase (≥4 mmHg) in transcutaneous PCO2 (PtCO2) was observed in a higher proportion in those
receiving high oxygen mixtures (>8 L/min), compared to those who received titrated oxygen (to achieve
oxygen saturation of 93–95%) [22]. Hypercapnia induced by hyperoxia has been known for quite some
time, and has been mainly studied in patients with COPD. For the pathophysiological interpretation of
the mechanism involved, the simplistic view of Campbell (1960) had prevailed, who assumed that in
chronic COPD patients with hypercapnia, respiratory control is based only on hypoxic drive as their
hypercapnic respiratory drive is blunted [23]. Subsequent studies, mainly in patients with COPD,
did not confirm this hypothesis. It was found that oxygen-induced hypercapnia does not indicate a
deficiency/impairment of the respiratory control system for CO2 homeostasis and is not correlated with
changes in ventilation. Instead, the reduction of VA/Q matching was proposed as the cause, due to the
release of hypoxic pulmonary arterial vasoconstriction, with a consequent increase in functional dead
space ventilation [24–28]. However, in another study in COPD patients, oxygen-induced hypercapnia
was characterized by reduction in ventilation; the increased dead-space ventilation in the group of
patients where PCO2 increased more than 3 mmHg (retainers) was attributed to bronchodilation due
to the higher CO2 tension [29]. Another mechanism implicates the Haldane effect, in which oxygen
displaces the CO2 dissociation curve to the right, increasing PaCO2, which cannot be normalized as
patients with severe COPD are unable to increase ventilation [25,30].
4. Metabolic acidosis
Non-anion gap (non-AG) metabolic acidosis as well as increased AG acidosis may occur in asthma
(Table 3).
Table 3. Metabolic acidosis.
Study Study Design Study Population Methods Significant Findings
Mountain, R.D. et al.,
1990 [31] Retrospective
229 acute asthma
episodes in 170 patients
(Hospital Admissions)
Clinical features and arterial
blood gases examined
Simple or mixed metabolic
acidosis in 28% of the episodes.






10.1% AG acidosis, 29.4% NAG
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Table 3. Cont.
Study Study Design Study Population Methods Significant Findings
Rabbat, A. et al.,
1998 [33] Prospective
29 non-intubated






finding on admission (59%) or
during treatment (100%). No
prognostic value, no correlation
with PaCO2 or PEF




105 children with ASA




Primarily type B lactic acidosis
(associated with normal oxygen
delivery). Presumed to be due to
β-adrenergic stimulation
Raimondi et al.,





Most cases of metabolic acidosis
attributed to chronic hypocapnia.
Hyperlactatemia attributed
mostly to adrenergic stimulation
Abbreviations used: AG = anion-gap, NAG = non-anion gap, PEF = peak expiratory flow, PICU: pediatric intensive
care unit, PaCO2 = partial carbon dioxide tension.
4.1. Non-Anion Gap Metabolic Acidosis
Although metabolic acidosis in asthma is often considered to be secondary to hyperlactatemia,
non-anion gap (non-AG) metabolic acidosis has also been reported. The presence (and absence thereof)
of non-AG in patients with acute asthma has been a subject of debate in medical literature, with many
studies [3,4] reporting no such findings, and others [35,36] documenting simple or mixed metabolic
acidosis in as many as 38% of the study population. Mountain et al. noted that metabolic acidosis in
acute asthma was more likely to occur in male patients and in patients with greater airflow obstruction
and lower FEV1 [31]. Rashid et al. studied the clinical outcome in 109 adult patients hospitalized for
asthma exacerbations. These patients were divided in three groups: group I included those patients
who did not present with metabolic acidosis, group II those with AG metabolic acidosis, and group III
those with non-AG metabolic acidosis. Out of these, 32 (29.4%) developed non-AG metabolic acidosis,
while metabolic acidosis with elevated anion gap occurred in 11 patients (10.1%) [32]. The group of
patients with non-AG metabolic acidosis had significantly higher chloride anion (Cl−) concentrations,
with a tendency to hyperchloremia, while sodium (Na+) and potassium (K+) concentrations were
not different compared to patients without acidosis or with elevated AG acidosis. The patients with
non-AG acidosis were also at increased risk of respiratory failure and need for invasive, mechanical
ventilation. Another study evaluated the acid-base status in 22 patients with acute severe asthma [36].
Ten patients had metabolic acidosis, defined by a base deficit > 2 mEq/L. None of these patients had an
elevated AG. The most likely explanation for the observed metabolic acidosis in these patients, as in the
previous study, was the renal loss of bicarbonates (HCO3−) due to renal compensation for preexistent,
sustained hypocapnia. The HCO3− levels were low-normal or decreased in these patients, while the
pH values ranged from alkaline to moderately acidotic. It appears that non-AG acidosis is a frequent
acid-base disorder in asthmatic exacerbations, due to the excretion of HCO3−, in response to chronic,
sustained hypocapnia. Hypocapnia immediately shifts the dissociation reaction of H2CO3 to the left
CO2 + H2O↔ H2CO3 ↔ H+ + HCO3− (1)
reducing H+ and HCO3− concentrations and increasing pH. In the short term, the decrease in PaCO2
alkalinizes the extracellular fluid, to the extent predicted by the Henderson–Hasselbalch equation.
Persistent hypocapnia causes a further decrease in HCO3− concentration, due to suppression of renal
acid secretion/increase of HCO3− excretion [37,38]. By definition, the primary metabolic acidosis of
this type, i.e., with non-elevated AG, is accompanied by an increase in the concentration of Cl−, i.e.,
hyperchloremic acidosis [39]. Hyperchloremic, non-AG acidosis, secondary to chronic hypocapnia,
was also noted in the study of Rashid et al. [32], in asthmatic patients. However, in an earlier animal
study it was found that, during compensation for hypocapnia, the reduction in renal proton excretion
was associated with increased Na+ excretion and not with Cl− retention and hyperchloremia [40].
Furthermore, in another study, chronic hypocapnia was found to suppress renal acid secretion while
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inducing renal K+ wasting [41]. Interestingly, in a recent study [42], ascent to high altitude elicited a
hypoxic ventilatory response in normal adults, resulting in increased ventilation and decreased PaCO2;
hypocapnia was accompanied by strong ion difference (SID) reduction, signaling metabolic acidosis
according to Stewart’s view [43]. Concerning the non-AG metabolic acidosis in patients with asthma,
as a compensatory response to chronic hypocapnia, we should comment on the following issues:
1. Insofar as chronic hypocapnia in these patients is accompanied by hyperchloremia, the role of
Cl− channels in vascular and non-vascular smooth muscle contraction, as in the human airways,
must be stressed, e.g., an alteration of Cl− concentration changes the myogenic tone in the blood
vessels [44,45]. Additionally, Cl− channels in epithelial cells may affect mucus hydration on the
airway surfaces [46]. Overall, Cl− may have a critical role in asthma pathophysiology.
2. In conditions like asthma exacerbations, where an acute acid-base disorder complicates a chronic
respiratory disorder, such as chronic hypocapnia in asthmatics, the use of base excess (or base deficit)
method [47] to assess the severity of metabolic acidosis can lead to ‘erroneous assessment’ of the
patient’s acid-base status, lacking any clinical relevance. Thus, in the study of Okrent et al. [36],
in patients with acute severe asthma, metabolic acidosis was diagnosed by the increase of base deficit
> 2 mEq/L. In this study, authors supported that this indicated a true loss of the body’s alkaline
reserve. Nevertheless, one of the patients with the more severe metabolic acidosis, diagnosed with
the base excess criterion (−4.9 mEq/L), had hypocapnia (PCO2 = 27 mmHg), pH higher than the
mean physiological value (7.43), and HCO3− concentration lower than the normal value (19 mEq/L),
for which, however, no treatment is indicated, and which actually corresponds to the expected
metabolic compensation for a chronic respiratory alkalosis (the expected HCO3− concentration
reduction (Δ(HCO3−)) equals 0.4 × ΔPCO2, i.e., (HCO3−) = 18.8 mEq/L) [37]. Thus, the physiologic
compensation for an uncomplicated acid-base disturbance has been viewed as a serious metabolic
acidosis superimposed on the chronic respiratory disorder. Overall, caution is needed in assessing
the metabolic component of these acid-base disorders by utilizing the base excess values; diagnostic
errors and therapeutic ill-practices may occur when they are not considered alongside the required
clinical information. Criticism on the subject has long been made by Schwartz and Relman [48],
which even took the form of a ‘transatlantic debate’ with arguments from both sides [49].
3. Finally, regarding the increased clinical risk demonstrated in asthmatics with non-AG acidosis
(accompanied by hyperchloremia) [32], it should be noted that there are several studies suggesting
that hyperchloremia per se is associated with poor outcome in hospitalized and critically ill
patients [50–52]. Hyperchloremia induced by intravenous administration of crystalloid solutions
with high Cl− concentration is not to be overlooked [53,54], although there is no study investigating
this issue exclusively in patients with acute severe asthma. In addition, hypocapnia, besides
the acid-base balance, can have serious effects on the organs and systems in the body, and can
adversely affect outcome in the critically ill [55].
4.2. Lactic Acidosis
Hyperlactatemia is a very common finding in patients with acute severe asthma. Lactic acidosis
has two types: type A, which is associated with impaired oxygen delivery; and type B, where the
oxygen delivery is normal but cellular function is impaired. The exact cause of lactic acidosis in
these patients remains elusive, and several possible mechanisms have been proposed over the years.
Acute severe asthma is characterized by hypoxemia [3,56] and may be accompanied by functional
cardiac disorders (heart-lung interaction); increased right ventricular (RV) afterload during acute severe
asthma, with increased impedance to RV ejection, and reduction of left ventricular (LV) preload and LV
compliance due to leftward septal shift may reduce cardiac output [57,58]. Thus, lactate increase may
result from severe hypoperfusion and decrease in oxygen supply to the tissues. In addition, respiratory
muscle fatigue, due to increased respiratory muscle work load, can also increase lactate levels [59,60],
especially under hypoxic conditions along with compromised tissue perfusion. In patients with acute
severe asthma, a negative correlation between the peak lactate levels and the phosphate levels on
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admission was found [33]. In this study, hypophosphatemia preceded the increase in lactate levels in
most patients. Hypophosphatemia may complicate treatment with bronchodilators in acute severe
asthma patients [61]. Low phosphate levels in the blood may lead to reduced ATP synthesis in
the muscles, accounting for muscle weakness and respiratory and heart failure [62]. Additionally,
hypophosphatemia is known to impair the contractile properties of the diaphragm [63] and increase
the hemoglobin affinity for oxygen due to a decrease in 2,3-diphosphoglycerate (2,3-DPG) [64],
compromising tissue oxygenation. In a state of low cardiac output, hepatic perfusion decreases;
also, the RV function disorder can increase the right heart filling pressures and lead to hepatic
congestion [65–67]. Thus, hepatic dysfunction during acute severe asthma may result in impaired
lactate clearance and hyperlactatemia [68,69]. An increase in lactate levels can also be observed during
clinical improvement after bronchodilator treatment. It has been suggested that reperfusion of the
previously ischemic organs, e.g., respiratory muscles, can lead to lactate release [70,71]. That is, the
increase in lactate intracellular levels during the period of ischemia and anaerobic respiration may not be
reflected in the lactate circulating levels in the serum. Serum lactate concentration can be increased after
restoring tissue perfusion. Increased catecholamines in plasma may increase metabolic rate and lactate
production without coexisting cell hypoxia. Increased levels of catecholamines in the blood have been
found in patients with asthma, especially norepinephrine [72]. Additionally, catecholamines are used
therapeutically during acute severe asthma, to promote bronchodilatation [73] and/or hemodynamic
support. However, catecholamines have marked metabolic effects and may cause hyperlactatemia [74].
Treatment with bronchodilators has also been implicated in the lactate increase, i.e., the use of
β2-adrenergic agonists, such as salbutamol [75]. In animals, β2-adrenoreceptor stimulation after
salbutamol administration induced a significant increase in plasma lactate concentration; lactate
increase was inhibited by clonidine (α2-adrenoreceptor agonist), a drug with opposite effects on the
system of adenylate cyclase [76]. Stimulation of β2-adrenergic receptors increases glycogenolysis in
the liver and muscle as well as lipolysis, through the increase of intracellular cAMP [77]. Free fatty
acids liberated during lipolysis inhibit the oxidation of pyruvate by pyruvate dehydrogenase and
may further increase lactate production [78]. Finally, theophylline and glucocorticoids may have a
role in the increased lactate production during acute severe asthma. Theophylline is a non-selective
5’-phosphodiesterase inhibitor and potentiates the activity of β-adrenergic agents by increasing
the intracellular concentration of cAMP [79–81]. Glucocorticoids are also known to increase the
β-receptor’s sensitivity to β-adrenergic agonists [82]. Thus, when treating severe asthma attack, despite
improvement in bronchospasm, a patient may hyperventilate and look more dyspneic; this may be a
compensatory mechanism for lactic acidosis induced by therapy, to maintain pH within normal limits,
and should not be seen as a worsening of airway obstruction [83]. In order to distinguish the type of
lactic acidosis (A and B), the ratio of the concentration of lactate to the concentration of pyruvate in
the blood can be used. Under aerobic conditions, this ratio is normally low, whereas under anaerobic
conditions, due to the inability of cells to further metabolize pyruvate in mitochondria, this ratio
increases to levels > 25:1 [84,85]. Thus, in a study concerning children with asthma, lactic acidosis was
found to be predominantly of type B, with normal oxygen supply to the tissues, and was attributed to
β-adrenergic stimulation [34].
5. Conclusions
Various acid-base disorders, of complex etiology, have been observed in asthma. Airway
hyperresponsiveness leads to hyperventilation and chronic hypocapnia with a consequent increase
in renal bicarbonate loss. This results in hyperchloremic acidosis, which becomes more clinically
evident-with a clear effect on blood acidity-during severe asthma attacks, in case PCO2 normalizes or
increases. Hypocapnia, and possibly hyperchloremia, may be related to the pathogenicity of the disease.
Hypercapnia characterizes severe asthma attacks, with imminent risk for intubation and mechanical
ventilation. Hypercapnia has been attributed to both the severity of the functional respiratory disorder
and treatment with high oxygen mixtures (hyperoxia induced). Finally, increased AG metabolic
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acidosis has also been observed in asthma, i.e., lactic acidosis. Its etiology includes: a. disturbance of
tissue oxygenation, e.g., by cardiac output reduction and hypoxemia or increased oxygen demands of
respiratory muscles due to increased workload, b. reduced lactate clearance due to liver congestion
and dysfunction, and c. treatment effect, e.g., β-agonists, on cellular metabolism, resulting in increased
lactate production. The thorough and careful evaluation of acid-base disorders in asthma will serve the
differential diagnostic approach concerning the underlying pathogenetic disorder and its treatment.
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Abstract: Asthma is a chronic airway inflammatory disease that is associated with variable expiratory
flow, variable respiratory symptoms, and exacerbations which sometimes require hospitalization
or may be fatal. It is not only patients with severe and poorly controlled asthma that are at risk for
an acute severe exacerbation, but this has also been observed in patients with otherwise mild or
moderate asthma. This review discusses current aspects on the pathogenesis and pathophysiology of
acute severe asthma exacerbations and provides the current perspectives on the management of acute
severe asthma attacks in the emergency department and the intensive care unit.
Keywords: acute severe asthma exacerbation; near fatal asthma
1. Introduction
Asthma is a chronic inflammatory disorder of the airways, a common and potentially serious
chronic disease that is associated with variable expiratory flow, airway wall thickening, respiratory
symptoms, and exacerbations (flare-ups), which sometimes require hospitalization and may be fatal [1].
In reference to asthma, an exacerbation is defined as an event characterized by change from the
patient’s previous status, including a progressive increase in relevant symptoms and a decrease in
respiratory function. The latter can be quantified by respiratory function measurements such as peak
expiratory flow (PEF), and forced expiratory volume in 1 s (FEV1), which when compared with the
patient’s previous or predicted values, reflect the deterioration in expiratory airflow, the prominent
pathophysiological effect of an asthma attack.
The most common causes of these exacerbations are exposure to external agents, such as indoor
and outdoor allergens [2–4], air pollutants [5], and respiratory tract infections (primarily viral mainly
human rhinovirus (HRV) [6,7]. The mechanisms by which these environmental stimuli and viruses
initiate asthma or cause worsening of the disease are under research.
Asthma exacerbations may also be triggered by exercise [8], weather changes [9], foods [10,11],
additives, drugs [1–14], and extreme emotional expressions [15,16]. The physiological hallmarks of
asthma are airway inflammation, airway remodeling and bronchial hyperresponsiveness (BHR) [17].
Exposure to the above-mentioned external stimuli and specifically to inhaled allergens is capable
of inducing an inflammatory response in sensitized individuals and as a result to lead to
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exacerbations [18,19]. A hypothesis explaining this fact is that the inflammatory response resulting
from inhaled allergen may drive BHR directly, or induce structural changes in the airway leading to
persistent BHR [17,20]. Experimental mouse models of asthma have shown that allergen exposure
protocols induce immune-mediated airway inflammation defined by: elevated levels of asthma
biomarkers (IgE, the T-helper cell 2 (Th2) cytokines, interleukins (IL)-4, -5 and -13, and eosinophils),
induction of airway remodeling (increases in airway smooth muscle, collagen deposition and goblet
cell hyperplasia), and BHR that is sustained after the resolution of eosinophilic inflammation [21–23].
Other factors that may cause exacerbations are rhinitis [24] or sinusitis [25], polyposis [26],
gastroesophageal reflux [27], menstruation [28,29], or even pregnancy [30,31]. They can happen either
to patients with known asthma of any level of severity, or less frequently as a first presentation.
Exacerbations vary in severity, as well as in response to therapy. This has led to an effort of categorize
the severity of these exacerbations. The most frequently proposed categories include elements of the
clinical presentation of the asthma patient, as well as a measurement of their respiratory function at
the time of the exacerbation. It is of paramount importance for the clinician to distinguish the severe
exacerbations, because these are the ones that correlate with worse consequences.
2. Definition of Acute Severe Asthma
The Global Initiative for Asthma guidelines refers to a severe asthma exacerbation describing
a patient who talks in words, leans forward, is agitated, uses accessory respiratory muscles, has a
respiratory rate > 30/min, heart rate > 120/min, O2 saturation on air < 90% and PEF ≤ 50% of their
best or predicted value [1]. According to the 2014 British Guidelines for Asthma, acute severe asthma
is defined as the asthma exacerbation that presents with any of the following: PEF 33–50% best or
predicted, respiratory rate ≥ 25/min, heart rate ≥ 110/min and inability to complete sentences in one
breath [32]. The ATS/ERS task force defines a severe asthma exacerbation by the fact that they require
urgent action in order to prevent a serious outcome, such as hospitalization or death from asthma [33].
This task force recommends that the definition of a severe asthma exacerbation for clinical trials should
include at least one of the following: (a) use of systemic corticosteroids (tablets, suspension, or injection),
or an increase from a stable maintenance dose, for at least three days; and (b) a hospitalization or
emergency department visit because of asthma, requiring systemic corticosteroids. Although these
definitions are not identical, the point remains that identifying this condition is important as it is
correlated with worse outcomes and greater risk of needing mechanical ventilation.
There are other entities similar but not identical to that of acute severe asthma that also require
precise definitions. Kenyon et al. proposed the term Critical Asthma Syndromes (CAS) to identify any
child or adult who is at risk of fatal asthma [34]. This term includes acute severe asthma, refractory
asthma, status asthmaticus, and near fatal asthma, all of them conditions that can lead to respiratory
exhaustion and arrest. Refractory asthma is, according to a definition set by the Unbiased Biomarkers
for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) consortium in 2011, patients with
asthma in whom after excluding any alternative diagnoses, after treating comorbidities and removing
trigger factors cannot maintain good asthma control, despite high-intensity treatment and confirmed
compliance with treatment. These patients have frequent severe exacerbations (≥2 per year), or can only
be well when receiving systemic corticosteroids [35]. Near fatal asthma (NFA) is defined as an asthma
exacerbation resulting in respiratory arrest requiring mechanical ventilation or a pCO2 ≥ 45 mm Hg.
Some writers tend to recognize status asthmaticus and acute severe asthma as the same condition
and define it mainly by its response to treatment, thus referring to it as an exacerbation that does not
respond to repeated courses of β2-agonist therapy [36].
3. Epidemiology
According to the Global Asthma Report, approximately 334 million people in the world suffer
from asthma, thus being the most prevalent chronic respiratory disease, with chronic obstructive
pulmonary disease (COPD) affecting only half of the aforementioned number of people [37]. However,
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according to Eurostat [38], in most European countries age standardized asthma admission rates
declined from 2001–2005 to 2011–2015, with an over two-fold reduction in some countries. (Figure 1)
The latest World Health Organization (WHO) estimates, released in December 2016, present that there
were 383,000 deaths due to asthma in 2015. There has been a decrease of almost 26% in the asthma
deaths, when comparing 2015 to 1990 [37]. However, international mortality statistics for asthma are
limited to those countries reporting detailed causes of death. Figure 2 depicts the age-standardized
mortality rates for asthma among countries reporting asthma separately in two recent five-year periods
(2001–2005 and 2011–2015) [38].
 
Figure 1. Age-standardized admission rates for asthma (all ages) in 30 European countries in two time
periods: 2001–2005 and 2011–2015. Source: Eurostat updated from ec.europa.eu/Eurostat/web/health/
health-care/data/database (version dated November 2017).
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Figure 2. Age-standardized mortality rates for asthma (all ages) by country in two time periods:
2001–2005 and 2011–2015. Source: Eurostat updated from ec.europa.eu/Eurostat/web/health/health-
care/data/database (version dated November 2017).
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Although asthma is a disease not only of low- and lower-middle-income countries,
most asthma-related deaths occur in those areas [38]. There is an established connection between
asthma deaths and the Socio-Demographic Index (SDI), but interestingly not with SDI and asthma
prevalence. A recent study in Brazil demonstrated that urbanization has affected public health, resulting
in higher asthma related morbidity and mortality, despite the fact that the urbanized population now
has improved access to the health system [39]. There are no accurate figures describing the rate of acute
severe asthma, but there are sufficient data regarding the asthma related hospitalizations and asthma
related mortality. Recent studies estimate the risk of death of the patients who are hospitalized as a
result of asthma exacerbation as less than 0.5% [40,41]. That risk is greater when the patient requires
intubation and mechanical ventilation, which underlines the importance of identifying and promptly
treating acute severe asthma. Four percent of asthma related hospitalizations result in mechanical
ventilation. There is a substantial economic burden associated with asthma hospitalizations, and it has
been demonstrated that in the US in 2012 the overall cost was more than 2 billion dollars, which is a
significant percentage (more than 1/3) of the annual asthma related expenditure [41]. Middle aged
women are more likely to get hospitalized with asthma related morbidities [41].
With regards to the identified phenotypes of asthma, data from a recent cluster analysis from Japan
revealed a wide heterogeneity among asthma patients who presented and were admitted with severe
and life-threatening asthma in 17 institutions across the country [42]. Another recent group-based
trajectory analysis on patients with problematic and uncontrolled asthma, showed that near fatal events
were noted in all groups, but were more frequent in patients with persistent frequent exacerbations [43].
It is not only patients with severe and poorly controlled asthma who are at risk for having an acute
severe asthma exacerbation, but this has been observed as well in patients with otherwise mild or
moderate asthma. The current literature describes two distinct clinico-pathophysiological entities of
acute severe asthma attacks that present at the emergency department: the slow onset, late arrival
and the sudden onset fatal asthma. It has been estimated that the majority (80–85%) of asthma-related
fatalities belong to the slow onset group. These patients may have symptoms and uncontrolled disease
for several days prior to the presentation with acute severe asthma. Sudden onset has been defined
as severe airflow obstruction established after 1–3 h of symptom presentation. Barr et al. reported
that patients presenting with sudden onset asthma, were more likely to have been exposed to an
exacerbation trigger such as a respiratory allergen, exercise and psychosocial stress and less often
respiratory infection and had greater improvement when compared with the slow onset cohort [44].
A retrospective cohort study in the United States demonstrated evidence that the sudden-onset patients
were older, were more likely to present during the night and early morning hours at the emergency
department, more often required intubation and mechanical ventilation, and had higher rate of ICU
admission, but, on the other hand, had shorter hospital stay [45]. In this study the sudden onset cohort
was only 6% of 1260 patients in 30 hospitals.
4. Risk Factors for Asthma Exacerbations
Many factors have been studied regarding their correlation with acute severe asthma and asthma
related death (Table 1). In adults, asthma exacerbations are more often in females [46,47]. This is
difficult to be explained since female asthmatics have lower levels of total serum IgE [48] and the
incidence of atopy is actually lower in comparison to males [49]. A possible explanation could have to
do with the connection between asthma worsening and the menses, which is a recognized contributing
factor of asthma worsening [50]. Furthermore, pregnancy in asthmatic women is a condition that
requires special considerations, considering the effect of the disease, as well as the medication on
the mother and the fetus. Pregnancy is not always correlated with worse asthma control, although
there seems to be a correlation between asthma severity and morbidities and exacerbations during
pregnancy [51]. There has been reported a cluster of obese females with late-onset corticosteroid asthma
with frequent exacerbations although they preserve a relatively good baseline lung function [52].
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Table 1. Risk factors for fatal asthma exacerbations.
A History of Near Fatal Asthma Requiring Intubation and Mechanical Ventilation
Hospitalization or emergency care visits for asthma in the past year
Currently using or having recently stopped using oral steroids
Not currently using inhaled steroids
SABA over-use (more than one canister of salbutamol/month (or equivalent))
History of psychiatric disease or psychosocial problems
Female Sex
Age > 40 years
Smoking history
Poor perception of airflow limitation
Hyperinflation in chest radiograph
Poor adherence with asthma medications and/or poor adherence
(or lack of) with a written asthma action plan
Food allergy
SABA, short acting beta agonist. Adapted from Global Initiative for Asthma (GINA) guidelines 2018 [1].
Obesity per se has also been correlated with worse asthma control, as well as more frequent and
severe exacerbations. This correlation is strengthened by the apparent effect of weight loss and bariatric
surgery on better control and less exacerbations and hospitalizations [53].
Ethnicity and socioeconomic status [54,55] are robust determinants of asthma exacerbation rates.
African Americans have 4.2- and 2.8-fold higher rates of emergency room visits and hospitalizations
for asthma exacerbation, respectively, compared to Caucasians, followed by Hispanics [39]. A possible
explanation for these differences could be the poorer adherence to treatment [56] and the poorer quality
of healthcare in ethnic minorities [57]. A significant genetic component might also contribute, since an
increased risk of exacerbations has been documented in males with African ancestry [58].
Severe exacerbations may occur in patients with mild or well controlled asthma [59,60]. However,
poor asthma control is an independent risk factor for future acute exacerbations [61–65]. A history
of a recent exacerbation is the strongest predictor of future exacerbations in children and adults
with asthma [66–69]. A small percentage of asthmatics exhibit severe disease exacerbations,
despite the fact that they are already under treatment with high doses of inhaled and/or systemic
corticosteroids [70,71]. These patients suffering from severe asthma (SA) that is poorly controlled and
in some cases life-threatening [34,35], although comprising a small percentage of the total asthma
population (5–10%), they denote 50% of total healthcare costs, rendering SA a substantial health and
socio-economic burden [36,37].
Finally, poor perception of airflow limitation may affect patients with a history of near-fatal asthma
and appears to be more common in males [72,73]. On the other hand, regular or overuse of short
acting beta agonists (SABA) causes down regulation of beta receptors and leads to lack of response,
leading in turn to overuse [74]. Overuse may also be habitual. Dispensing ≥3 SABA canisters/year
(average 1.5 puffs/day or more) is associated with increased risk of emergency department visits or
hospitalizations no matter what the severity of asthma is [75], while dispensing ≥12 canisters/year
(1/month) increases the risk of death [76]. Incorrect inhaler technique (seen in up to 80% of asthma
patients) [77], as well as suboptimal adherence to treatment (seen in up to 75% of patients) are important
modifiable factors contributing to symptoms and exacerbations [77].
There has been a lot of interest regarding the effect of psychological factors on the risk for fatal or
near fatal asthma, this however has not been established, as shown in a 2007 systematic review by
Alvarez et al. [78]. Anxiety, depression and socio-economic problems are very common in patients
with difficult to treat asthma and contribute to poor symptom control, poor adherence to treatment
and impaired quality of life [79].
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Obesity and other comorbidities other than the psychiatric conditions already mentioned
that contribute to persistent symptoms, exacerbations and poor quality of life include chronic
rhinosinusistis [80], inducible laryngeal obstruction (often referred as vocal cord dysfunction, VCD),
gastroesophageal regurgitation disorder (GERD), chronic obstructive pulmonary disease (COPD),
obstructive sleep apnea, bronchiectasis, cardiac disease, and kyphosis due to osteoporosis (followed by
corticosteroid overuse) [80].
5. Factors that Trigger Asthma Exacerbations
Severe exacerbations usually occur in response to a variety of external agents (e.g., respiratory
pathogens, allergens, air pollutants, smoke, and cold or dry air).
5.1. Respiratory Pathogens
Viral respiratory infections are the most common triggers for a severe asthma exacerbation,
comprising up to 76–80% of the causes of an acute asthma exacerbation in adults [81]. Human rhinovirus
(RV) (types A and C), influenza virus (types A and B), para-influenza virus, and respiratory syncytial
virus (RSV) are frequent causes of an acute exacerbation and hospitalization [56,82]. Coronaviruses,
meta-pneumoviruses, bocaviruses, and adenoviruses may also trigger a severe acute exacerbation,
however to a lesser extent [57]. During the 2009 H1N1 influenza A pandemic, mortality and admissions
to the ICU with H1N1 infections were frequently associated with asthma [82,83]. In contrast to other
respiratory viruses (i.e., RSV and Influenza Virus), RV does not exert a definite cytopathic effect [84];
instead, it compromises the function of the epithelial barrier through the release of reactive oxygen
species during viral replication [85]. During this process, the induction of immune and adaptive
immune response activates the synthesis and early secretion of IFNs and other pro-inflammatory
cytokines (i.e., IL-10, IL-6, IL-8, RANTES, and ENA-78) [86], which play a significant role in the
protective mechanisms against viral infection [87,88]. There is evidence that in asthmatic patients there
is dysregulated immune response against RV [89]. Several studies have demonstrated the implication
of interferons in the susceptibility to asthma exacerbations in children and adults in the context of a
viral respiratory infection. Miller et al. [90] showed that RV was related to asthma exacerbation with
the implication of IFN III. Similarly, Jones et al. [91] documented an increased susceptibility to severe
respiratory viral infections during the first years of life through dysregulated type III IFN responses,
while recent studies [92,93] document a varying susceptibility to asthma exacerbations depending on
the type and level of expression of cytokines and IFNs upon viral infection. Finally, Fedele et al. [94]
documented that RV infection more frequently induces a Th2-mediated immune response than RSV
infection, justifying the higher incidence of asthma prevalence after RV infections.
Bacterial infections may also trigger acute exacerbations, usually on the basis of impaired
anti-bacterial defense after a viral respiratory infection [95]. There are bidirectional interactions
between viruses and bacteria that seem to have an impact on the severity of asthma as well as the
likelihood of an acute exacerbation. Viral infections facilitate the disruption of airway epithelial layers
and the expression of airway receptors that bacteria use in order to invade [96]. Furthermore, in the
presence of co-infection, an increased release of inflammatory cytokines and mediators is induced,
heightening the burden of inflammation and predisposing to a higher risk of exacerbations [97].
Specifically, co-infections of respiratory viruses and Moraxella catarrhalis, Hemophilus influenza, and/or
Streptococcus pneumonia have a greater impact on the risk for more severe acute asthma exacerbations [97].
The clarification of the mechanisms implicate the case of co-infections on inter-relationship for providing
evidence for potential novel therapeutic targets that may prevent acute asthma exacerbations.
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5.2. Allergen Sensitization and Viral Infections
Evidence support the theory that allergic sensitization increases the susceptibility for viral
infections and probably their ability to provoke further inflammation [98].
For example, it has been shown that the combination of RV infection and direct exposure to
allergens cause epithelial cell production of IL-25 and IL-33 in the airways, mediators involved in Th2
type inflammation and remodeling [99,100]. Moreover, in a murine model of asthma RV infection
acquired in early life stages in mice induced an IL-13- and IL-25-mediated Th2 immune response with
parallel suppression of IFN-γ, IL-12, and TNF-α [101], with detrimental changes in airway homeostasis,
consisting of innate lymphoid cell expansion, mucous hypersecretion, and airway responsiveness.
Furthermore, recurrent RV infections stimulate airway remodeling by upregulating molecules such
as VEGF and TGF-β, as well as chemoattractants for airway smooth muscles (i.e., CCL5, CXCL8,
and CXCL10) [102,103].
Other data show that the occupancy of the IgE membrane receptors inhibits antiviral induction of
interferon-a from plasmacytoid dendritic cells leading to subsequent increased susceptibility to viral
infections and asthma exacerbations. It is noteworthy that an inverse correlation between interferon
levels and airway eosinophilia, IL-4 levels, and total serum IgE was observed [104].
5.3. Allergen Exposure, Tobacco Smoke, and Environmental Pollutants
Indoor or outdoor exposure to allergens may lead to poor asthma control and severe asthma
exacerbations in sensitized patients [105–109]. Allergens activate mast cells to release histamine,
prostaglandin D2, and cysteinyl leukotrienes. These induce inflammatory responses, airway smooth
muscle constriction, increased microvascular permeability, and mucus secretion, diminishing at
the same time the innate immune responses and subsequently increasing the susceptibility to viral
infections [106,107]. Of great importance is the mold sensitization, which has been associated with the
phenotype of severe asthma and with severe asthma attacks. High airborne concentrations of mold
have been associated with increased emergency visits for asthma exacerbations [108]. Specifically,
Alternaria is associated with highly increased risk (almost 200-fold) of severe exacerbations and need
for ICU admittance in both children and adults [109]. Furthermore, cockroach and mouse antigens are
associated with early wheeze and atopy in an inner-city birth cohort [110].
Exposure to multiple allergens has been documented as being a common feature in several studies
of indoor exposure [111,112]. Salo et al. [112] showed that more than 50% of subjects were sensitized at
least to six detectable allergens, while 45% were sensitized at least to three allergens. In a study from
China, Kim et al. [111] showed sensitization to one or more allergens in almost 50% of the subjects
with most common sensitizers being shellfish, dust mites, and cockroaches. However, less than 1% of
these subjects had clinically important food allergy or asthma.
Indoor exposure to endotoxin and pollutants (such as particulate matter and nitrogen dioxide)
has also been found to increase the risk of severe exacerbations in children with asthma and the use of
particulate filters seem effective in reducing exposure levels and therefore, asthma control [113,114].
Differences in allergic sensitizations by race and genetic ancestry have also been documented [115],
and along with the location of residence seem to be more important predictors of allergic sensitization
than genetic ancestry. This fact points out the hypothesis that disparities in allergic sensitization by
race may be observed as an effect of environmental rather than genetic factors.
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Tobacco smoke remains one of the most significant triggers of disease, despite increased public
awareness of the detrimental effects of smoking. Asthma patients who smoke have more frequent
emergency department visits and hospitalizations for an exacerbation than asthma patients who do
not smoke [116]. Several studies of patients with allergic rhinitis have shown the significant effect of
smoking on the development of asthma. Polosa et al. [117] showed that in a 10-year period smoking
had a dose-related effect on the development of asthma in allergic rhinitic patients resulting in an
odds ratio of 2.05 for incident asthma for smoking 10 pack-years, and 3.7 and 5.05 for 11–20 and
>20 pack-years, respectively.
Second-hand smoke is also associated with deteriorated lung function, poor treatment response,
and frequent emergency department visits for asthma [118–120]. The measurement and monitoring of
cotinine levels in serum, urine, and saliva have become a useful tool in determining passive smoke
exposure as well as in evaluating uncontrolled asthma. Hassanzad et al. demonstrated that higher
cotinine levels were associated with a higher risk for severe asthma. [121]. Increasing interest has
also raised on the potential hazards of third-hand smoke (THS) in children. THS is residual nicotine
and other chemical pollutants remaining in the indoor environment and on household surfaces for
weeks to months after active tobacco smoking has stopped. It seems that young children may be more
susceptible to the adverse effects of THS exposure since they crawl and tend to ingest several items
from the surrounding [122]. However, more research is needed to assess the real extent of the hazards
arising from THS.
Environmental pollutants, such as particulate matter, ozone, sulfur dioxide, nitrogen dioxide,
and diesel exhaust, may act synergistically with viral infections to cause asthma exacerbations [123]
The effects of air pollution on severe asthma exacerbations may be affected by other exposures, such as
stress, vitamin D insufficiency, and seasonality [4,5]. This was demonstrated in a study of children
aged 0–18 years in California, where particulate matter (size, 2.5 mm; PM2.5) and ozone were associated
with severe asthma exacerbations in the warm season, while in the cool season exacerbations were
associated with articulate matter of PM2.5, carbon monoxide, and NOx (NO1NO2) [124,125].
6. Genetic Associations with Asthma Exacerbations
Genome-wide association studies of asthma in children and adults have identified polymorphisms
for IL33, IL1RL1/IL18R1, HLA-DQ, SMAD3, and IL2RB9 and the locus on chromosome 17q21 including
the genes ZPBP2, GSDMB, and ORMDL3 that are implicated in epithelial barrier function and innate and
adaptive immune responses in asthma [126,127]. Genetic variants in the class I major histocompatibility
complex-restricted T cell-associated molecule gene (CRTAM) was associated with an increased rate
of asthma exacerbations in children with low circulating vitamin D levels [128]. One of the most
well replicated genetic regions affecting asthma risk is the 17q12–21 locus, which includes ORMDL3
and GSDMB. The TT allele at rs7216389 is associated with an odds ratio of 1.6 of having an asthma
exacerbation when compared with the CC allele [129].
Furthermore, polymorphisms for FCER2 have been associated with decreased FCER2 gene
expression, increased serum IgE levels and risk of severe exacerbations [130]. Association was
also found between variants in chitinase 3-like 1 (CHI3L1; YKL-40) and asthma exacerbations and
hospitalizations [131,132]. Specifically, studies in murine models of asthma implicate YKL-40 in IgE
induction, antigen sensitization, dendritic cell accumulation and activation, and alternative macrophage
activation [133], while purified YKL-40 induces interleukin-8 secretion in bronchial epithelial cells [134].
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7. Pathogenesis-Immunobiology
Asthma is a heterogeneous condition with complex observable characteristics (phenotype) and
their underlying mechanisms (endotype), resulting from complex host–environment interactions
(Figure 3). Usually, inflammatory cells are present and activated in the airways of severe asthmatics
and persist despite treatment, but their relevance to lack of control and disease severity is largely
unknown. These cells include not only eosinophils and neutrophils, but also T-lymphocytes, mast cells,
macrophages and airway structural cells which are also crucially involved in the inflammatory
reaction and remodeling in asthma. Although it is well accepted that asthma is characterized
by eosinophilic infiltration, inflammatory phenotypes of severe asthma can be characterized by
persistence of eosinophilic or neutrophilic infiltration, as well as by absence of inflammatory infiltration
(paucigranulocytic) [135,136]. Depending on the type of immune cell responses implicated in disease
pathogenesis, asthma endotypes are categorized as type 2 asthma, characterized predominantly by T
helper type 2 (Th2) cell-mediated inflammation and non-type 2 asthma, associated with Th1 and/or
Th17 cell inflammation [137,138]. Eosinophilic, Th2 airway inflammation is present in around 50% of
adults with asthma, and is estimated to be higher in the absence of corticosteroids [139].
Figure 3. Pathogenesis of acute exacerbations in asthma.
Th2 mediated airway inflammation plays a central role in the pathophysiology of allergic
eosinophilic asthma. The allergic sensitization of dendritic cells (DCs) in the presence of thymic
stromal lymphopoietin (TSLP), induces Th2 lymphocytes to produce cytokines such as interleukins
IL-4, IL-5, and IL-13 [140]. Chemokines such as eotaxin 1, 2, 3 (CCL11, CCL24 and CCL26, respectively)
induce through their receptors (chemokine receptor 3, CCR3) [141] and other chemoattractant agents,
such as mast cell derived prostaglandin D2 (PGD2) eosinophil recruitment in the mucosa. Furthermore,
IL-4 and IL-13 activate B lymphocytes to produce allergen specific IgE, which binds to the high affinity
mast cell receptors, leading to their activation [140].
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In non-allergic eosinophilic asthma, airway epithelial damage caused by pollution and pathogens
leads to IL-5 and IL-13 production by innate lymphoid cells (ILC2s), in response to PGD2, TSLP, IL-25
and IL-33 [142]. ILC2s and Th2 cells are a significant source of type 2 cytokines and play a role in
eosinophilic inflammatory response, allergy and remodeling in asthma [143,144]. Increased circulating
and sputum IL-5 and IL-13-producing ILC2s were detected in severe asthma compared to mild asthma
patients [145]. Furthermore, increased numbers of IL-5+ and IL-13+ ILC2s were found in sputum after
allergen challenge in asthma patients [146]. IL-13-expressing ILC2 and Th2 cells are also responsible
for bronchial epithelial tight junction barrier leakiness in asthma patients [147,148].
Chronic inflammation that characterizes severe asthma leads to tissue remodeling, fixed airway
obstruction, and no response to bronchodilatory treatment [149]. It seems that chronic persistent
inflammation and the release of a plethora of cytokines (IL-5, IL-9, IL-13, osteopontin, and activin-A9),
chemokines (CCR3 dependent) and growth factors (TGF-β1 and VEGF) from inflammatory and
epithelial cells play a central role in the establishment of airway remodeling [150].
Physiologically, airway inflammation is counteracted by inhibitory molecules and suppressor
cells including CD4+ regulatory T cells (Tregs) [151,152] which becomes visible upon Treg depletion
which causes spontaneous asthma-like airway pathology [153]. Patients suffering from allergic asthma
have reduced numbers of Tregs that furthermore show impaired suppressive capacity [154–157].
Some currently applied therapies aim at enhancing Treg cell number and function [154,158], whereas
adoptive transfer of Tregs can suppress both the priming and the effector phase of allergic airway
inflammation in experimental models of murine asthma [159–161].
Mixed eosinophilic and neutrophilic inflammation of the airways are commonly found in severe
asthma [162] and this mixed inflammatory pattern can be a biomarker of the most severe types
of the disease [163]. Elevated sputum neutrophil counts were found to be associated with more
severe asthma phenotypes and with poor response to treatment with steroids in a cluster analysis
from the Severe Asthma Research Program (SARP) [164]. Airway neutrophilia has been associated
with persistent airflow obstruction in patients with refractory asthma and a progressive loss of lung
function [165] Furthermore, it is associated with higher bronchial hyperresponsiveness independent of
eosinophilia [166].
It is suggested that increased neutrophil counts in peripheral blood and sputum could be
secondary to the treatment with corticosteroids, since the anti-apoptotic effect of corticosteroids on
neutrophils is well established [167]. However, neutrophilic inflammation may be observed regardless
of corticosteroid treatment in patients with refractory asthma or in patients experiencing acute severe
exacerbations [168–170].
Neutrophil recruitment and activation into the airways have been associated with stimulation of
toll-like receptors (TLR) signaling and activation of innate immunity, causing a shift toward Th1 and
Th17 responses. This process leads to increased production of interleukin (IL)-8, IL-17A, neutrophil
elastase, and matrix metalloproteinase 9 [171]. Neutrophils are triggered by IL-8 to produce enzymes
and other factors that contribute to eosinophil activity [171]. Evidence suggests that neutrophil subsets
may mediate differential effects on immune surveillance and microbial killing. A variety of epithelial
insults (ozone, bacteria, and viruses) induce secretion of chemokines and cytokines that promote
neutrophil trafficking. Neutrophils primarily traffic to inflamed sites and then secrete granular enzymes,
reactive oxygen species, and proteins to eliminate invading bacteria, fungal elements, and viruses.
Undoubtedly, neutrophils play pivotal roles in innate immunity [172]. During asthma exacerbations,
the presence of chemokines and cytokines (IL-8 and IL-17A) prolongs neutrophils’ lifespan thus
enabling them to migrate from tissue to the systemic circulation or to lymph nodes to modulate
adaptive immune responses, Figure 4. The combined functions of these cytokines and activated
enzymes promote airway structures to contribute to the lower FEV1, remodeling and fixed airway
obstruction seen in adult patients with severe neutrophilic asthma [173].
235
J. Clin. Med. 2019, 8, 1283
Figure 4. The role of the neutrophil in modulating local inflammatory responses.
8. Biomarkers Correlating with Risk of Asthma Exacerbations
The better understanding of the pathophysiology of asthma has led to the recognition of biomarkers
with a potential to predict severe exacerbations. Among T2-high asthma biomarkers sputum and blood
eosinophil count, serum IgE, serum periostin levels, and levels of nitric oxide in exhaled breath (FeNO)
seem to associate with the severity of asthma and the rate and severity of exacerbations.
Sputum eosinophils have been correlated with increased asthma severity and airway
responsiveness. Increased sputum eosinophil counts have been used as a measure of better response
to corticosteroid treatment, in terms of reducing exacerbations. In the systematic review by Petsky
et al. [174] it was demonstrated that asthma treatment guided by sputum eosinophil counts led to a
significant reduction in the exacerbation rate. In children, elevated blood eosinophil count is associated
with persistent asthma symptoms, and responsiveness to treatment can be predicted by the number of
eosinophils without having set though a validated cut-off point [175]
Baseline blood eosinophil count is being used as a biomarker that predicts the clinical efficacy of
anti-IL5 therapy in patients with severe eosinophilic asthma with a history of exacerbations [176–178],
with eosinophil cut-offs set to ≥150 to ≥300 cells/μL [179] in mepolizumab trials. It has been
demonstrated, however, that higher eosinophil counts than these cut-offs are associated with poor
asthma control and more severe exacerbations [180]. In the study of Zieger et al. [181], a blood
eosinophil count > 400 cells/μL was found to be an independent risk factor for exacerbations,
emergency department visits or hospitalizations for asthma. Although blood eosinophil count levels
predict the rate of exacerbations, this is not the case with sputum eosinophil count [179,182].
Total serum IgE level is a biomarker used in severe allergic asthma for the treatment with anti-IgE
antibody (omalizumab). In association with elevated levels of fractional exhaled nitric oxide (FENO)
(>19.5 parts per billion) and blood eosinophil count (>260/μL), it significantly predicts which patients
with severe allergic asthma will respond to omalizumab, reducing the exacerbation rate [183].
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The production of nitric oxide in the airways indicates Th2 type inflammation [184,185] and
FeNO is a noninvasive biomarker of eosinophilic airway inflammation. There are contradictory
data on whether FeNO has the ability to classify asthma severity [186–188]. Studies have shown
that FeNO can predict accelerated decline of lung function [189], asthma relapse after corticosteroid
treatment discontinuation [184], and degree of airway inflammation [190]. However, its ability to be
used as a biomarker to predict exacerbations seems to be limited, even when combined with clinical
features [191]. In the study by van der Valk et al. [192], repeated measurements of FENO predicted
moderate asthma exacerbations (not requiring systemic corticosteroids or hospitalizations) but not
severe asthma exacerbations.
Exhaled breath condensate (EBC) has been used in assessing exacerbations. Low EBC pH,
various cytokines, chemokines, NO-related products, leukotrienes, and volatile organic compounds,
better in combination, have been used as biomarkers associated with clinical characteristics and
exacerbations [193].
Serum periostin is a biomarker of allergic eosinophilic asthma and has been used in the
identification of patients who will respond to Th2-directed therapies [194]. However, limited data
suggest that the serum periostin level predicts asthma exacerbations [195]. Sputum periostin, on the
other hand, is associated with persistent airflow limitation, eosinophilic asthma refractory to ICS [196],
while it is a potential marker for airway remodeling, as well [197,198].
There is an increasing need for developing biomarkers that will guide clinicians in the
management of asthma, in terms of better and easier phenotyping asthma, predicting exacerbations,
and treatment response.
9. Pathophysiology
Acute severe asthma commonly presents with abnormal arterial gas exchange. Arterial hypoxemia
is largely attributed to ventilation/perfusion mismatch (V/Q mismatch). Hypercapnia, on the other
hand, is not only present due to V/Q mismatch, but also due to respiratory muscle fatigue leading to
alveolar hypoventilation. Trying to assess the exact profile of the V/Q mismatch that characterizes acute
severe asthma, studies have demonstrated that although in asthma patients there is a wide spectrum
of V/Q abnormalities, the most common in acute severe asthma (ASA) patients is having increased
blood flow, in the context of high cardiac output, distributed in alveolar spaces with low ventilation
and remarkably low V/Q ratios [199]. The pattern of ventilation-perfusion is bimodal in acute severe
asthma, ranging from normally perfused areas to areas of hypoxic pulmonary vasoconstriction.
With regards to the mechanics of the respiratory system, acute asthma exacerbation is characterized
by reversible bronchoconstriction and increased airway resistance, followed by low flow rates,
premature small airway closure, decreased elastic recoil, pulmonary hyperinflation and increased
work of breathing. There is a substantial decrease in the FEV1 and the PEF of the patients, whereas the
residual volume may increase as much as 400% of the normal and the functional residual capacity
may even reach double the normal values [199]. In severe asthma exacerbations, total lung capacity
(TLC) is also increasing. These changes in lung volumes help constricted airways remain open.
During passive expiration of the lungs, the driving forces of the respiratory system are the elastic
forces. The lower the elastic forces are, or the higher the resistive forces, the longer will the time
needed to full expiration of the inspired tidal volume be, characteristic that may be quantified by a long
expiratory time constant of the respiratory system. Incomplete exhalation of delivered tidal volume
makes inspiration begin at a volume at which respiratory system exhibits a positive recoil pressure.
The presence of flow at the end of the expiration is due to the presence of positive alveolar pressure at
the end of expiration. This process is called dynamic hyperinflation and the positive end-expiratory
alveolus pressure associated with higher relaxation volume is called intrinsic (auto) Positive End
Expiratory Pressure (PEEP) [200] (Figure 5). Dynamic hyperinflation depends on the expiratory time
constant, expiratory flow limitation, expiratory time, inspiratory muscle activity during exhalation,
tidal volume, and external flow resistance [201]. Although this initially may act in favor of the patient,
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by reducing the resistive work of breathing, the thorax and lungs increase in volume, length–tension
relationships of the respiratory muscles shorten and the strength of contraction eventually diminishes.
As the severe exacerbation remains unresponsive, expiratory and accessory muscles become active,
the work of breathing increases and fatigue is a serious and potentially fatal possibility, as it further
compromises respiratory function and deteriorates respiratory failure. Bronchospasm and increased
resistance, mucous and compression of the peripheral airways from auto-PEEP, lead to significant
heterogeneity of the lung. Normal lung units coexist with pathological lung units creating a variety of
many different time constants across the lung.
Figure 5. Dynamic hyperinflation during exacerbation.
Hemodynamic compromise is another important feature of a severe asthma attack that leads
to significant dynamic hyperinflation. The development of positive intrathoracic pressures lead to
decrease of the right heart output by decreasing right heart preload (venous return and end–diastolic
volume of the right heart) and increasing right heart afterload (vascular pulmonary resistance).
The decreased right heart output in parallel with the diastolic dysfunction of the left heart (caused
by shifting the intraventricular septum towards the left ventricle) and its incomplete filling, lead to a
significant reduction of the arterial systolic pressure in inspiration and the presence of pulsus paradoxus
sign [202] (Figure 6).
Figure 6. Pathophysiological changes due to dynamic hyperinflation.
Thus, due to uncontrolled or difficult to treat dynamic hyperinflation, a patient with asthma can
be drowsy, confused or agitated, or may present with paradoxical thoracic-abdominal movement,
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with absent of wheeze in lung auscultation, bradycardia or with pulsus paradoxus. This patient is near
respiratory arrest status and endotracheal intubation. Mechanical ventilation and admission to an ICU
may be imminent [203].
10. Clinical Assessment
Identification of severe asthma exacerbations is of outmost importance, as they are related with
worse outcomes and require close observation and aggressive management. A brief interview with
the patient is necessary to determine certain features in the patient’s history that need to be looked
into closely, because current literature identifies them as factors that increase asthma-related death.
Hospital and Intensive Care Unit (ICU) admission, as well as mechanical ventilation due to an asthma
exacerbation has been shown to significantly increase the risk for a new episode of near fatal and fatal
asthma [204]. It is also very important to obtain a detailed description of the patient’s medication history.
Medications that play a significant role in the prediction of asthma related morbidities and death are
inhaled and systematic corticosteroids, as well as the use of beta agonists. In this context, not currently
using inhaled corticosteroids (ICS), currently using or having recently discontinued treatment with oral
corticosteroids (OCS), as well as documented overuse of short acting β agonists (SABAs) are all factors
related with an increased risk for asthma associated morbidity and mortality [205,206]. Elements from
the medication history may also conceal clues that may suggest inadequate treatment, or even poor
adherence to a prescribed treatment plan. The lack of a written asthma plan and socioeconomic factors
are also associated with a greater risk for a severe exacerbation [207].
Patients suffering from an asthma exacerbation may present with a variety of signs and
symptoms [208] (Figure 7). Dyspnea, chest tightness, cough and wheezing are few of those, but there
is wide heterogeneity in the asthmatic patient presentation. Features that characterize acute severe
asthma are agitation, drowsiness or signs of confusion, significant breathlessness at rest, with the
patient talking in words, tachypnea of more than 30 breaths per minute, use of accessory respiratory
muscles, tachycardia of >120 beats per minute and pulsus paradoxus. Moreover, it is crucial to
identify signs that indicate an imminent respiratory arrest, such as paradoxical thoraco-abdominal
movement, silent chest with absence of wheeze, bradycardia, while the absence of pulsus paradoxus
might imply muscle fatigue [208]. Upon examining the patient with acute severe asthma, apart from
recognizing the signs that indicate severity, it is imperative to diagnose any pathology that might
attenuate the exacerbation and requires specific treatment. Such entities are pneumothorax and
pneumo-mediastinum, and pneumonia. At the same time, the clinician needs to exclude conditions
that may mimic the symptoms of an asthma attack, such as cardiogenic pulmonary edema, exacerbation
of chronic obstructive disease, airway obstruction caused by a foreign body or an intraluminal mass,
pulmonary embolism, hyperventilation syndrome and vocal cord dysfunction [209–211].
Although lung function measurements are less sensitive than the history of symptoms, during an
asthma exacerbation, serial PEF and FEV1 measurements are more objective and reliable indicators
of severity and should remain part of the initial assessment of an asthma patient presenting to the
emergency department according to current guidelines [1,2]. Regarding PEF, the cut-off value of 50%
of the patient’s best or predicted value is within the definition of an acute severe asthma episode,
and requires greater attention and action. Moreover, a value of less than 33% of their best or predicted
value is an indicator of life-threatening asthma. Serial monitoring of PEF may also assist the decision
of either discharging the patient, should this be accompanied with a clinical improvement, or for ICU
referral if the values are continuously deteriorating despite initial appropriate treatment. There is
certainly a concern regarding the safety of this test in the setting of an acute exacerbation in the
emergency department, and it should be performed with caution and continuous observation of
the patient.
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Figure 7. Global Initiative for Asthma (GINA) recommendations for the management of asthma
exacerbations in acute care facility. PEF: Peak expiratory flow; FEV1: Forced expiratory volume in one
second; SABA, short acting beta 2 agonists; ICU, Intensive Care Unit.
Further laboratory testing is not necessary for every patient that presents to the emergency
department with an exacerbation. Chest radiographs are advised when the clinician needs to exclude
conditions such as pneumonia, pneumothorax or atelectasis, but not for all patients. Arterial blood gas
analysis should be performed on all patients that are critically ill, and/or are desaturating less than
92% despite treatment [212]. By performing arterial blood gas analysis, the clinician will be able to
assess not only hypoxemia and the trend of PaCO2, but also acid base disturbances, such as respiratory
acidosis and lactic acidosis which are common on acute severe asthma [213]. Further investigations
may include total white blood cell count, to evaluate the potential of infection, levels of brain natriuretic
peptide to exclude the presence of congestive heart failure and electrolyte level measurement.
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11. Pharmacological and Non-Pharmacological Management
Most current guidelines regarding asthma exacerbations highlight the necessity of supplying the
asthma patient with a written plan of action appropriate for their level of control, which will lead to
early recognition and management of their exacerbations [1,2]. It is of outmost importance that the
patients become educated on when to seek help, during the event of an acute exacerbation. In primary
care and further in the emergency department or the hospital ward, a severe asthma attack needs to be
identified within a short time period in order for the correct action to be taken. A severe exacerbation
of asthma is a life-threatening medical emergency, thus being crucial to transfer the patient to an acute
care facility, once such a condition is identified, ensuring the patient’s safety. During the transfer, it is
required to provide controlled oxygen therapy, inhaled SABA, ipratropium bromide, and systemic
corticosteroids. In the emergency department the pharmacological therapy of acute severe asthma
should consist of SABA, ipratropium bromide, systemic corticosteroids (oral or iv), controlled oxygen
therapy, and the clinician should consider the use of iv magnesium sulfate and high dose ICS [1].
(Figure 7, Table 2)
11.1. β2-Adrenergic Receptor Agonists
The cornerstones of acute asthma medication are bronchodilators and especially short acting beta
agonists (SABA). It is recommended that in acute severe asthma SABAs are administered repetitively
or continuously. These substances activate the β2 adrenoreceptors (β2ARs), which are located mainly
on the smooth airway muscle cells, but are also found on other airway cells even on the inflammatory
cells. Their very important characteristic is that they have a rapid onset of action, while at the same
time being well tolerated, despite high doses. Although the β2 AR agonists are substances known
for centuries, the great challenge remains improving their selectivity, in order to benefit from their
desired effect, while at the same time reducing their adverse effects. All current asthma guidelines
introduce short acting β2 agonists (SABAs), as the first line treatment for acute severe asthma. In the
first steps of escalating therapy during an exacerbation, the patient is advised to increase their use “as
needed”. That is also the recommendation for the primary care setting, as well as for the emergency
department, where repeated inhaled administration of SABA is advised. Studies on the efficacy of
nebulizers vs. metered dose inhalers (MDIs) have not proven superiority of nebulized administration.
In a recent review, nebulized delivery did not improve hospital admission, length of stay in the
emergency department or pulmonary function [214]. According to GINA 2018, the preferred method
of administration is with strong evidence (Evidence A) pMDI with a spacer [1]. This evidence becomes
less strong when referring to severe and near fatal asthma. Although continuous nebulization of SABAs
was initially a very promising perspective, several studies and meta-analyses have failed to clearly
demonstrate strong evidence on favor of continuous nebulized SABAs for acute asthma. Rodrigo et al.
in 2002 performed a systematic review and meta-analysis that showed no difference in respiratory
function measured in the first hours of administration or on the rate of hospital admissions [215].
A Cochrane systematic review on the subject, including few more studies, showed significant difference
on both respiratory function and hospital admissions, in favor of the continuous use of SABA, while at
the same time demonstrating a good tolerance from the patients who did not present more adverse
effects with this method of administration [216]. The most commonly used SABA is salbutamol or
albuterol as named in the United States, which has an onset of action of less than 10 min and duration
of approximately 6 h. Lebalbuterol is a recent addition to the choices of SABAs, with its benefit of a
lower than salbutamol dose that provides similar effect. There is currently evidence about its efficacy in
acute severe asthma as an intermittent regimen, but not as a continuous nebulization strategy [217,218].
Continuous intravenous infusion of β2 agonists has also been proposed as a therapy, especially in
patients who did not respond to intensive bronchodilation. There is no evidence to support the
use of intravenous β2 agonists [219,220] or the method of continuous, subcutaneous infusions of
terbutaline [221]. Epinephrine has been studied, as a nebulized, subcutaneous, intramuscular and
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intravenous administration, but, in current guidelines, its use is restricted for acute asthma related
with anaphylaxis and angioedema [1,222,223].
11.2. Anticholinergics
Anticholinergic agents act as inhibitors of acetylcholine at the muscarinic cholinergic receptor.
Therefore, they inhibit parasympathetic nerve impulses and they produce a beneficial effect in acute
asthma, by causing airway smooth muscle relaxation. Furthermore, they enhance β2-agonist-induced
bronchodilation via intracellular processes and they prolong their bronchodilator effect [61,224].
The anticholinergic agent used primarily is ipratropium bromide due to its selectivity for airway
smooth muscle receptors, which reduces the systemic adverse effects. Their use is included in current
guidelines for moderate to severe acute and life-threatening asthma, as well as for patients who show
poor response to initial SABA therapy [1,2]. It is not recommended to use anticholinergics as a single
therapy for acute asthma. It has been demonstrated that the addition of inhaled ipratropium bromide to
therapy with SABAs improve hospitalization rates, relapse rates and are associated with lung function
improvement [62–64]. This combination therapy benefit is greater for the patients who present with
acute severe asthma and are at a higher risk of hospitalization. There is an increased rate of adverse
effects, which are of mild nature, such as mouth dryness and tremor.
11.3. Corticosteroids
Within the asthma setting, it has been well established that inhaled corticosteroids reduce the rates
of hospitalization and mortality for patients with asthma [65,225]. In the event of acute exacerbation,
there is a different approach of their use. Current recommendations suggest that high dose ICS given
within the first hour of the patient’s presentation in the emergency department, reduce the rate of
hospital admissions, for patients who are not on systemic corticosteroid therapy [1]. Recent evidence
however seems to be conflicting regarding their performance without the use of systemic corticosteroids,
when rate of hospital admissions or changes in lung function has been studied [226,227].
Systemic corticosteroids, due to their significant anti-inflammatory properties, have a fundamental
role in the management of acute asthma, and particularly for patients who present with exacerbation
while receiving oral corticosteroids (OCS), or have previous history of exacerbation that required use
of OCS. They are also recommended for patients who did not respond to initial SABA therapy with a
prolonged effect. Apart from their role against asthma associated inflammation, they seem to increase
the number and sensitivity of β-adrenergic receptors, and also restrain the migration and function
of eosinophils and other inflammatory cells. On the other hand, their lack of bronchodilatory effects
prohibits their use for acute asthma as a monotherapy [74]. A recent multi-center study showed that
there is a significant percentage of patients who get admitted to hospital with acute asthma and do not
receive systemic corticosteroids, despite the clear suggestion of current guidelines [228]. With regards
to the root of administration, intravenous administration seems to not provide additional efficacy to
the use of oral therapy [229,230]. Intramuscular regimens seem to be as effective as oral in reducing
the risk for relapse [231]. The oral route is better tolerated and preferred, because it is quicker and less
expensive. Identifying groups of patients where intravenous administration could be more beneficial
is a recent field of study, and guidelines support that they should be considered for patients who
may be unable to swallow due to breathlessness, or may not absorb efficiently the medication due
to gastro-enteral disturbances, such as vomiting [1]. There is a lack of robust evidence to clarify the
superiority of longer or higher dose OCS, thus the literature suggests a 5–7-day regimen of 50 mg
prednisolone as a single dose, or 200 mg hydrocortisone in divided doses [1,2,232].
11.4. Magnesium Sulfate
Magnesium has been proven to be an important co-factor in enzymatic reactions and changes of its
concentrations may result in different response from the smooth muscles. Hypomagnesemia may cause
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contraction, whereas hypermagnesemia causes relaxation of the smooth muscles and bronchodilation,
possibly through inhibition of calcium influx into the muscles.
Recent recommendations include magnesium sulfate, at dose of 2 g infused over 20 min, as a second
line intervention for acute severe asthma exacerbation [1,233]. It has been shown to reduce the rate of
hospitalization in adults with FEV1 of 25–30% at presentation and those who are unresponsive to initial
treatment, and have persistent hypoxemia, and correlates with improvement in lung function [234,235].
Its infusion has not been correlated with severe adverse events; it is however contra-indicated for
patients with renal insufficiency, hypermagnesemia and myasthenia Gravis. Magnesium has also
been tried in its nebulized form for asthma exacerbation, with very few data to support it. A recent
systematic review, which examined the efficacy and safety of inhaled administration of magnesium,
concluded that, although safe, it has not shown significant benefits when compared with the first line
inhaled agents, thus it is not routinely recommended [236]. The current literature is reluctant to fully
support the use of magnesium, mainly because of the heterogeneity of the severity of asthma attacks it
has been used on in trials, especially in the context of optimized first line treatment with β2-agonists
and corticosteroids [237]. A 2014 randomized controlled trial failed to show any evidence of clear
benefit in the use of either intravenous or inhaled magnesium [238]. Further prospective trials are
necessary to provide accurate evidence on this treatment option.
11.5. Methylxanthines
On the ground of their anti-inflammatory properties, methylxanthines (aminophylline and
theophylline) used to be included in the primary treatment for acute asthma. Their poor safety
profile, which includes significant side effects, in combination with the inability to provide evidence of
improved outcomes, such as improved pulmonary function or rate of hospitalization when given for
severe acute asthma, has excluded them from current guidelines [1,239]. A more recent review and
meta-analysis, however, has supplied some evidence of aminophylline’s efficacy, when combined with
other bronchodilators, but more data are needed on this direction [240].
11.6. Leukotriene Modulators
Although leukotriene receptor antagonists (LTRAs) are included as a controller agent in the
asthma management, there are limited data on the efficacy of intravenous or oral antileukotriene
drugs in acute asthma. Montelukast and zafirlukast were studied on patients with acute asthma and
demonstrated some evidence of lung function improvement [241,242]. A review of the literature,
however failed to provide robust evidence of the effectiveness of this medication category on lung
function or on the outcomes of the patients [243].
11.7. Oxygen Supply
Although asthma exacerbations are not usually accompanied with severe hypoxemia, acute severe
asthma often presents with arterial PO2 derangements, due to extensive V/Q mismatch as explained
above. Oxygen should be administered via nasal cannula or mask, with a target of arterial oxygen
saturation of 93–95%, or to those patients where saturation monitoring is not available [1]. Although
not all guidelines agree on the level of the desirable target saturation, studies have shown that, in severe
acute asthma, oxygen therapy with controlled low flow administration, with a target SpO2, is correlated
with better outcomes than the use of per se high flow 100% oxygen delivery, as it has been shown to
correlate with increases in PaCO2, as well as with decreased values of PEF [244,245]. There is also
some evidence about the use of oxygen driven nebulization with SABAs, because of the pulmonary
vasodilation caused by the β2-agonist, which results in increasing perfusion of poorly ventilated areas,
thus resulting in deterioration of the V/Q abnormalities [246].
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Table 2. Pharmacological management of patients with acute severe exacerbation in the
emergency department.
Medication Dosing References
Salbutamol (albuterol) solution for
nebulization: single dose
2.5 mg/2.5 mL
Continuous nebulization for an hour and
re-assess clinical response [214–221,223]
Ipratropium bromide Nebulization of 0.5 mg/2.5 mL/4–6 h incombination with salbutamol (same nebulizer) [61–63,224]
Corticosteroids
Methylprednisolone iv infusion of 40 mg or
hydrocortisone iv, 200 mg or oral prednisone
40 mg
[65,225–232]
Magnesium sulfate Single iv infusion of 2 gr/20 min [233–238]
Methylxanthines Not recommended as first line; poor responseand potential serious adverse events [239,240]
Leukotriene receptor antagonists Single iv infusion of 7–14 mg over 5 min [241–243]
Epinephrine (adrenaline) 0.3–0.4 mL sc of a 1:1000 (1 mg/mL)solution/20 min for 3 doses in case of no response [222]
Terbutaline (1 mg/mL) 0.25 mg sc/20 min for 3 doses in case of noresponse (preferred in pregnancy) [221,223]
Heliox Helium/oxygen mixture in a 80:20 or 70:30 ratio [247–249]
iv, intravenous; sc, subcutaneous.
11.8. Heliox
Heliox is a mixture of helium (70–80%) with oxygen (20–30%). Heliox can be used for severe
asthma exacerbations that are unresponsive to standard therapy or in patients having an upper
airway obstruction component. Heliox, with density less than air, leads to lower Reynolds number,
thus decreasing resistance to airflow under conditions of turbulent flow, as are prominent in the central
airways and at the branch points. This effect can potentially decrease the work of breathing and
improve ventilation. On the contrary, airflow in smaller airways, which are mainly affected during
an asthma exacerbation, will not improve with heliox, as it is typically laminar, depending on gas
viscosity rather than density.
Despite the theoretical benefits of heliox, and while a few case series have suggested a beneficial
effect in acute asthma, no studies in adults have demonstrated an advantage of heliox above and
beyond standard oxygen therapy. In asthma exacerbation either without or with intubation, heliox has
not demonstrated consistent benefit [247,248].
Heliox has demonstrated greatest benefit for improving symptoms when used as a nebulizing
gas for a beta-2 agonist medication. Benefit is generally seen within minutes after the initiation of
therapy [247]. Another study has shown that using heliox as a carrier gas increase gas delivery up to
50% in a mechanical model for both MDIs and nebulizers [249]. Given that its effect is based on the
percentage of helium, it should not be administrated to patients requiring FiO2 > 40%.
11.9. Ketamine
Ketamine is well known drug that has been in use since circa 1960. It is a dissociative anesthetic
drug that has the potential to have different actions, depending on the dose used. It may work as a
potent analgesic and as an anesthetic agent, but may also have secondary effects as a bronchodilator,
while at the same time preserving airway reflexes and sympathetic nervous system tone, with no
effects on the cardiovascular system. A dose of 1–2 mg/kg dose has been described as an inductive
agent in rapid sequence intubation (RSI) of asthma patients [250]. In doses lower than this it does not
have sedative effects, whereas in higher doses it can cause laryngospasm and apnea. Its psychoactive
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effects make it even less popular for use. In the context of asthma, there are no large randomized
trials to examine its effect. There is some evidence of its bronchodilatory effect, especially in mild and
moderate asthma exacerbations, and in doses lower than 1 mg/kg, but larger trials would be necessary
to establish its role for asthma [251,252].
11.10. Antibiotics
There is no evidence supporting the use of antibiotics per se for severe acute asthma, unless the
patient’s history and clinical assessment indicate the presence of infection. In a recent retrospective
cohort study, it has been demonstrated that, in patients hospitalized with acute asthma and receiving
OCS, antibiotic use was associated with longer hospital length of stay and hospital cost, whereas it
held similar risk of treatment failure [253]. In a previous study in the US, 60% of the patients who
were admitted to hospital with asthma exacerbation, received antibiotics, with no clear indication
accompanying this decision [254]. Current guidelines suggest against their use and that they should be
considered after optimizing other treatment options and when there is clear evidence of infection [1].
11.11. Non-Invasive Mechanical Ventilation
Although the benefits of non-invasive mechanical ventilation (NIMV) are well recognized in
the acute exacerbation of chronic obstructive pulmonary disease and pulmonary edema, its usage
for asthma exacerbation remains controversial. Despite the lack of supporting evidence, NIMV is
commonly used in patients with severe asthma exacerbation as a mean to obviate the need for intubation
and mechanical ventilation and its detrimental effects.
In the absence of clinical guidelines that recommend the use of NIMV for the management of
acute asthma, evidence suggests that a trial of NIMV (for one or two hours) may be beneficial for a low
risk group of patients [255], particularly those unresponsive to medical therapy. Prolonged trials of
NIMV are not recommended. Suggested criteria for an NIMV trial include RR > 25 breaths per minute,
heart rate > 110 beats per minute, hypoxemia with PaO2/FiO2 ratio greater than 200, hypercapnia
with PaCO2 < 60 mmHg, FEV1 < 50% less than predicted and use of accessory respiratory muscles.
A trial of NIMV should not be undertaken if there is any absolute criterion for endotracheal intubation
(respiratory arrest, hemodynamic instability or shock, GSC < 8), excessive respiratory secretions and
risk of aspiration, severe agitation and poor patient collaboration and any cause that precludes the
right mask fitting (facial surgery) [256].
In a trial of 30 patients who presented to the emergency department with a severe asthma
exacerbation that was not responding to inhaled bronchodilator therapy, NIMV was associated with
reduction in the rate of hospitalization and increased lung function. Improvements in respiratory
rate and dyspnea appear to be influenced by the amount of pressure support above expiratory
positive airway pressure (EPAP) provided. The use of NIMV has been associated with reduction
in endotracheal intubation, improvement in oxygenation, decrease in carbon dioxide retention,
and improvement in airflow obstruction. Studies are controversial regarding the mortality and ICU
length stay [86]. NIMV can also be used in the asthmatic patients who are at risk for intubation,
following extubation [257].
11.12. Invasive Mechanical Ventilation
The decision to intubate and mechanically ventilate a near-fatal asthma patient is considered a
challenging task and should be based primary on a series of clinical evaluations. Major indications
for initiation of invasive mechanical ventilation (IMV) are: (1) cardiac arrest; (2) respiratory arrest or
bradypnea; (3) respiratory insufficiency with PaO2 < 60 mmHg on 100% FiO2 and PaCO2 > 50 mmHg;
(4) physical exhaustion; and (5) compromised level of consciousness. Relative indications for IMV are:
(1) hypercapnia PaCO2 > 50 mmHg or PaCO2 increased by 5 mmHg per hour; (2) worsening respiratory
acidosis;, (3) inability to treat patient appropriately; (4) failure to improve with proper therapy; and (5)
clinical signs of deterioration and respiratory fatigue such as tachypnoea of >40 breaths per minute,
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severe hypoxemic respiratory insufficiency, hemodynamic instability, paradoxical thoracic movement,
and silent chest [258].
The decision to intubate and mechanically ventilate a patient with acute asthma exacerbation is a
clinical one and may be made urgently. When the clinician decides that respiratory failure is progressing,
and is unlikely to be reversed by further pharmacologic therapy, intubation should be performed
as quickly as possible by a skilled intensivist or anesthesiologist, who has extensive experience in
intubation and airway management, using rapid sequence intubation (RSI) protocol suitable for
asthmatic patients (good preparation, sufficient pre-oxygenation, suitable induction to anesthesia
agents suitable for asthma, and placement of the endotracheal tube) [259]. Regarding the preferred
method of intubation, oral endotracheal intubation is preferred, although the literature also includes
awake nasotracheal intubation, which may be complicated by the fact that many asthmatic patients also
have nasal polyps [203]. Additionally, oral intubation allows the use of an endotracheal tube of a larger
diameter, facilitating secretion removal and bronchoscopy, if needed, while at the same time decreasing
inspiratory airway resistance. It should be noted that unlike other conditions in which intubation and
mechanical ventilation can solve problems, the dynamic hyperinflation that mechanical ventilation can
create or even exacerbate can have devastating consequences for a severe asthmatic patient, such as
cardiovascular collapse and/or barotrauma and ventilator induced lung injury. Therefore, there are
certain considerations to be made before and during RSI. During RSI in such patients one should
anticipate rapid oxygen desaturation despite maximal effort at pre-oxygenation especially in those
patients who do not achieve a SpO2 above 93%, so adequate pre-oxygenation is advised. Bag mask
ventilation should be done using small tidal volume and high inspiratory flow rate with a prolonged
expiratory phase, attempting with this way to mimic the approach used during mechanical ventilation.
Excessive mag mask ventilation should be avoided because of the risk of pneumothorax [260,261].
Manipulation of the airway can cause laryngospasm and worsening of bronchoconstriction, so one
could consider the use of atropine to attenuate vagal reflexes [203]. The literature suggests the bolus use
of intravenous ketamine for RSI taking advantage of its bronchodilatory effect, while propofol is also
considered a safe approach. Opiates and barbiturates should be avoided due to the risk of histamine
release that can exacerbate bronchoconstriction [262]. If muscle relaxants are needed, non-depolarizing
muscle relaxants (except maybe atracurium and mivacurium) and succinylcholine are suitable in
asthmatic patients [263].
11.13. Goals of Mechanical Ventilation
Near fatal asthma is characterized by severe dynamic hyperinflation of the lung with severe
respiratory and circulatory consequences. The aim of mechanical ventilation is to maintain adequate
oxygenation, to reduce the work of breathing and to prevent and confront further hyperinflation
without any circulatory compromise or ventilator induced lung injury [264]. The intubation and
post-intubation period is often complicated with severe cardio-respiratory derangement. Hypotension,
the most common post-intubation complication, may be caused due to dynamic hyperinflation and
auto-PEEP, and can be aggravated by dehydration, sedatives and neuromuscular blocking agents.
Arrhythmias, barotraumas, laryngospasm or even seizures have also characterized the post-intubation
period [265,266]. Phenomena such as hypercapnia, hypoxemia and acidemia, as well as ventilatory
lung injury and life threatening pneumotrauma (pneumothorax and pneumo-mediastinum), may also
complicate the post-intubation period. Reasons for the aforementioned may be the severity and
non-responsiveness of the disease, but may also be the result of inadequate sedation or patient–ventilator
desynchrony. Wrong and harmful initial ventilator settings may also result in providing too little or too
excessive minute ventilation, potentially deteriorating the already very fragile asthmatic patient [267].
Management of the asthmatic patient post intubation starts with ensuring adequate sedation in
order to achieve the desirable patient–ventilator synchronization. Sedation and analgesia will also
decrease the metabolic rate, oxygen consumption and carbon dioxide production. Dexmedetominide,
propofol and remifentanyl are the appropriate drugs for sedation and analgesia. Their usage has been
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associated with shorter length of ICU stay, shorter duration of mechanical ventilation and improved
long term neurocognitive outcomes when compared to benzodiazepines [266,268]. It is important to
use agents that accomplish deep sedation, while at the same time allow rapid awakening, should the
patient improve quickly, which is common in the asthma cases (Table 3).
Table 3. Sedation, analgesia and paralysis in patients with acute severe asthma exacerbation
requiring intubation.
Medication Dosing Side Effects References
Midazolam 0.03–0.1 mg/kg bolus iv infusion,followed by an infusion of 3–10 mg/h Hypotension [268,269]
Propofol
Infusion of 60–80 mg/min initially,
up to 2 mg/kg. Continue with iv
infusion of 5–10 mg/kg/h as needed,








Initial dose of 1 μg/kg iv infusion,
followed by an infusion of





1 mg/mL bolus iv infusion, followed





Initial loading dose of 1 μg/kg, iv over
10–30 min, followed by a maintenance




0.1–0.2 mg/kg bolus iv infusion,
followed by infusion in a rate of
3 μg/kg/min (up to 10 μg/mL/min)
Bronchospasm [269,270]
Patients with severe asthma with persistently dangerous levels of hypercapnia and arterial
hypoxemia, and extreme patient–ventilatory asynchrony may require paralysis in addition to sedation.
The preferred paralytic, non-depolarizing agent is cis-atracurium, as it is eliminated by esterase
degradation and spontaneous breakdown in the serum. Paralytic agents can be administered either
intermittently through bolus injections, or by continuous intravascular infusion. Its duration must be as
short as possible, because concomitant use of intravascular corticosteroids and paralytic neuromuscular
agents increases the incidence of critical illness myopathy [269,270].
To avoid the hemodynamic effects of dynamic hyperinflation, once the patient is intubated, it is
advised to perform a brief discontinuation (60–90 s) from the ventilation (apnea test), a slowly bagged
ventilation and to administer fluids (1–2 L or more) and vasopressors. Although there is no clear
evidence to support the volume-preset over the pressure-preset modes, the preferred ventilator modes
for the asthmatic patient are the volume-limited ones [263]. Barotrauma seems to occur regardless of
the mode of ventilation. Volume-limited modes of ventilation are usually used for near death asthmatic
patients at their entrance in the ICU. It is essential to closely monitor the Peak inspiratory and Plateau
pressures, to early detect any change in resistance and compliance, and this is easily achievable when
using volume modes (Figure 8). Although high inspiratory flow rates of 80 L/min up to 100 L/min and
square waveforms shorten inspiratory time and increase expiration time, thus reducing hyperinflation,
it has been shown that this may not have a significant impact to the degree of hyperinflation once
the minute ventilation has been limited by high peak inspiratory pressure [271]. Minute ventilation
should be set at a level of less than 115 mL/kg/min (less than 10 L/min) with a respiratory rate of
10–12 breaths/min and a prolonged expiratory time by decreasing I:E ratio (1:3 or 1:4 up to 1:5) [263,266].
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Tuxen and Lane showed a remarkable increase in hyperinflation when using higher levels of minute
ventilation [120]. The fraction of inspired oxygen (FIO2) should be titrated to maintain the pulse
oxygen saturation (SpO2) above 90% (up to 94%) or the arterial oxygen tension (PaO2) above 60 mmHg.
One should avoid SpO2 > 96% due to oxygen toxicity (Table 4).
Figure 8. Flow time tracing of a patient with persistence of flow at the end of expiration which indicates
dynamic hyperinflation and pressure time tracing with a slope increase indicative of over-distension.
Table 4. Initial ventilator settings in intubated patients with acute severe asthma exacerbation.
Mode Settings
Tidal volume 6 mL/kg ideal bodyweight
Respiratory rate 8–10/min
Minute ventilation <10 L/min
Inspiratory flow rate 60–80 L/min
Inspiratory to expiratory ratio >1:3
Inspiratory wave form Decelerated waveform
Expiratory time 4–5 s
Plateau pressure <30 cm H2O
PEEP 0 cm H2O
FiO2 100% initially and titrate to maintain SaO2 > 90%
SaO2: Oxygen saturation; Peep: positive end expiratory pressure.
Limited data exist about the use of external PEEP when ventilating a patient with severe asthma.
The use of progressively higher external PEEP from 5 to 15 cmH2O has been shown to have a
deteriorating effect both in respiratory (deterioration of the end-inspiratory volume, the functional
residual capacity and plateau pressure) and circulatory system (decrease of systolic arterial pressure
and cardiac output) [271]. In one prospective study of patients undergoing control mode of ventilation,
external PEEP worsened hyperinflation and had serious hemodynamic effects by worsening gas
trapping [272]. On the other hand, other studies have shown that the application of external PEEP,
may produce a paradoxical lung deflation by reducing lung volumes and airway pressures and
increasing lung homogeneity [273]. In the case of assist mode of mechanical ventilation, the application
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of external PEEP at a value less than 80% of the intrinsic PEEP, or 5 cm H2O if intrinsic PEEP is
<10 cm H2O can counterbalance the endogenous peep and reduce the work of breathing [274]. A trial
of stepwise increase in PEEP can be used and terminated when indications of worsening of dynamic
hyperinflation it is shown.
11.14. Permissive Hypercapnia
Hypercapnia is a common fact during mechanical ventilation of asthmatic patients. PaCO2 levels
up to 60 mmHg and pH values less than 7.20 are common on the first day of mechanical ventilation
even with increased minute ventilation. The term permissive hypercapnia is a ventilating strategy that
can be applied to mechanically ventilated asthma patients, that emphasizes on giving priority to the
reduction of hyperinflation rather than normal minute ventilation. The reduction of minute ventilation
through reduction of tidal volume and respiratory rate is used to decrease pulmonary hyperinflation.
PaCO2 levels should rise gradually during mechanical ventilation rather than rapidly, preferably at a
rate of <10 mmHg per hour or even slower if the PaCO2 exceeds 80 mmHg. Generally, a pH level of
7.20–7.25 is accepted, but the literature has failed to demonstrate a benefit from using alcalotic agents,
such as bicarbonate infusion to accomplish that [274].
11.15. Additional and Unconventional Therapies for Acute Severe Asthma
11.15.1. Oxygen Delivery by High Flow Nasal Canula
Oxygen delivery via high flow nasal canula (HFNC) can be used to hypoxemic patients who
are not expected to respond to conventional therapies. HFNC with flow up to 60 L/min of warmed
and humidified oxygen, decreases inspiratory resistance, as well as the work of breathing, can wash
out carbon dioxide, thus decreasing the anatomic dead space and may also produce a positive end
expiratory pressure (up to 5 mmHg) by increasing the end expiratory lung volume. The role of HFNC
in asthmatic adults is unknown. Studies in children have shown that its use reduces respiratory distress
in moderate and severe asthma exacerbations and also reduces the need for intubation [275,276].
11.15.2. Extracorporeal Life Support (ECLS)
Extracorporeal membrane oxygenation (ECMO) is an invasive therapy, in which oxygenation and
carbon dioxide removal are performed through an artificial membrane. Although evidence based on
clinical trials for the use of ECMO in asthmatic patients is lacking [277,278], there is growing evidence
on the subject, supporting the use of ECLS for patients receiving mechanical ventilation due to an
asthmatic exacerbation. A 2009 review by Mikkelsen et al. has demonstrated that, when ECLS is used
for status asthmaticus, it correlates with better outcomes in comparison to its use for other causes
of respiratory failure [279]. In this study, they used data from the multicenter Extracorporeal Life
Support Organization (ELSO), but included only a small number of patients. In 2017, there was another
review of the same database, confirming that the use of ECMO is an acceptable option, and resulted
in acceptable survival rates, although it is necessary to understand and reduce the ECMO related
complications [280]. Di Lascio et al., using ECMO for asthmatic patients receiving IMV, showed
that it could provide adjunctive pulmonary support for patients who remain severely acidotic and
hypercapnic despite aggressive conventional therapy [281]. The writers conclude that ECMO should
be considered as an early treatment in patients with status asthmaticus whose gas exchange is not
satisfactory despite using conventional therapy, aiming to provide adequate gas change and to prevent
ventilator induced lung injury.
A modified ECMO technique such as extracorporeal carbon dioxide removal (ECCO2R) may also
play an important role in severe asthmatic patient in mechanical ventilation. In a difficult to safely
ventilate asthmatic patient, due to extremely high airway pressures, hypoventilation and persistent
severe respiratory acidemia are common issues. The usage of ECCO2R, considering the reversibility of
the pathophysiology of asthma, provide the opportunity for more protective ventilation and more
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time for the bronchodilator agents to act and reverse inflammation and hyperinflation. There is no
sufficient evidence to support a clear role of this technique in asthmatic patients, but there seems to be
a growing interest on the subject [282,283]. Schneider et al. even presented a case where ECCO2R was
used in an “awake” patient with a near fatal asthma attack, refractory to the use of pharmacological
intervention and NIMV, resulting in avoidance of intubation [284]. However, more data are needed to
establish an indication for this intervention in the context of an acute severe asthma exacerbation.
11.15.3. Anesthetic Agents
Some inhalational anesthetic agents such as halothane, isoflurane and sevoflurane act as
bronchodilators, probably not only through a direct relaxation effect on airway smooth muscles
but also by attenuating cholinergic tone [285,286]. This characteristic may have favorable effects in
patients with refractory to conventional and optimized bronchodilatory therapy. Case report studies
have indicated a positive effectiveness with halothane, but also with isoflurane and sevoflurane but with
several limitations. Hypotension, myocardial depression, increased ventricular irritability especially in
the presence of acidosis, beta-agonists and theophylline have been reported [287–289]. In addition,
factors such as the expense of inhalational treatment, the need of a bedside anesthesiologist, the practical
issues concerning the equipment for delivering the inhalational agents, the short time of duration
of bronchodilation (immediate return of bronchoconstriction after discontinuation), and, finally,
the absence of randomized trials to evaluate and confirm their efficacy in near-death adult asthmatic
patients make the usage of anesthetic agents a last resort as a non- conventional bronchodilatory
therapy for refractory near death asthma exacerbations [290,291].
11.15.4. Enoximone
Enoximone is an intravenous bronchodilatory agent that can be used in severe asthma exacerbation
in adults. Enoximone, a selective phosphodiasterase inhibitor III, was tested in a study by
Beute et al. on eight patients with status asthmaticus, six of whom had a respiratory arrest or
hypercapnia [292]. The bronchodilatory effect was immediate. Even if the intravenous administration
bypasses inhalation incapability in severe asthma, and no side-effects were observed in this study,
phosphodiesterase inhibitors in general are associated with ventricular and atrial arrhythmias,
hypotension, and hepatotoxicity. Further studies are needed to confirm enoximone efficacy and
safety in patients with acute exacerbations of asthma that are refractory to conventional therapies.
12. Prognosis
Asthmatic patients who require mechanical ventilation, not only have increased hospital mortality
(7%), but also long-term mortality [40,293]. Most of the long-term mortality is attributed to recurrent
asthma [294]. Psychological disturbances such as depression and denial are also common features of
asthmatic patients who survived a near fatal episode. Anxiety seems to be more common among close
family members than the patients themselves [295]. Smoking cessation is one of the recognized factors
that improves survival [151].
13. Prevention and Risk Reduction
GINA recommends that all adults and adolescents with asthma should receive ICS-containing
controller treatment, either as-needed (in mild asthma) or daily, in order to reduce their risk of serious
exacerbations and to control symptoms, [1] (Figure 9). Asthma treatment should be optimized in
patients continuing having poor symptom control and/or exacerbations, even though Step 4 and Step 5
treatments and contributing factors should be assessed, in order to treat modifiable risk factors that
compromise disease stability (smoking, environmental exposures, allergen exposure (if sensitized
on skin prick testing or specific IgE), and medications such as beta-blockers and NSAIDs) (Table 5).
It is imperative to optimize the inhaler technique and adherence to treatment, as well as overuse of
SABAs, and medication side effects. Furthermore, comorbidities should be assessed including obesity,
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GERD, chronic rhinosinusitis, obstructive sleep apnea, anxiety, depression, and social difficulties.
Non-pharmacological interventions (e.g., smoking cessation, exercise, weight loss, mucus clearance,
and influenza vaccination) should also be recommended where indicated.
If the problems continue after having optimized all the above parameters, patients should refer to
a specialist center for phenotypic assessment and consideration of add-on therapy including biologics
(Figure 10). The prevalence of severe, refractory asthma is generally estimated to be 5–10% of the
total asthma population [77,151]. It is important to distinguish between asthma that is difficult to
control and asthma that is truly severe. Severe asthma is defined by the joint European Respiratory
Society/American Thoracic Society (ERS/ATS) guidelines according to the following criteria [151]:
• Requirement for treatment with high-dose inhaled corticosteroids (ICS) and a second controller
(and/or systemic corticosteroids) to maintain control.
• Refractory to the treatment mentioned above.
• Incomplete management of comorbidities such as severe sinus disease or obesity.
The GINA 2019 guidelines for adolescents and adults with difficult-to-treat and severe asthma [77]
recommend that assessment of the severe asthma phenotype should be done during high dose ICS
treatment (or lowest possible dose of OCS), and biological treatment should be chosen accordingly
(Figure 8). Where relevant, test for parasitic infection should precede and be treated if present, before
commencing Type 2 targeted treatment. The currently approved add-on biological treatments for
severe asthma include anti-IgE treatment for severe allergic asthma (omalizumab), anti-IL5 or anti-IL5R
for severe eosinophilic (mepolizumab, benralizumab, and reslizumab), and anti-IL4R for severe
eosinophilic/Type 2 asthma or patients requiring maintenance OCS asthma (dupilumab) (Table 6).
Figure 9. Personalized management for adults and adolescents to control symptoms and minimize
future risk [1].
251
J. Clin. Med. 2019, 8, 1283
Table 5. Modifiable risk factors that have to be treated in order to reduce exacerbations.
Risk Factor Treatment Strategy Evidence
Any patient with 1 risk
factor for exacerbations
(including poor symptom control)
• Ensure patient is prescribed an ICS-containing controller A
• Ensure patient has a written action plan appropriate for their
health literacy A
• Review patient more frequently than low-risk patients A
• Check inhaler technique and adherence frequently A
≥1 severe exacerbation
in last year
• Consider alternative controller regimens to reduce
exacerbation risk, e.g., ICS-formoterol maintenance and
reliever regimen
A
• Consider stepping up treatment if no modifiable risk factors A
• Identify any avoidable triggers for exacerbations C
Exposure to tobacco
smoke
• Encourage smoking cessation by patient/family; provide
advice and resources A
• Consider higher dose of ICS if asthma poorly-controlled B
Low FEV1, especially
if <60% predicted
• Consider trial of 3 months of treatment with high-dose ICS
and/or 2 weeks of OCS B
• Exclude other lung disease, e.g., COPD D
• Refer for expert advice if no improvement D
Obesity
• Strategies for weight reduction B
• Distinguish asthma symptoms from symptoms due to
deconditioning, mechanical restriction, and/or sleep apnoea D
Major psychological
problems
• Arrange mental health assessment D
• Help patient to distinguish between symptoms of anxiety





• Identify most cost-effective ICS-based regimen D
Confirmed food allergy • Appropriate food avoidance; injectable epinephrine A
Allergen exposure if
sensitized
• Consider trial of simple avoidance strategies; consider cost C
• Consider step up of controller treatment D
• Consider adding SLIT in symptomatic adult HDM-sensitive





• Increase ICS dose independent of level of symptom control A
FEV1, forced expiratory volume in 1 s; HDM, house dust mite; ICS, inhaled corticosteroids; OCS, oral corticosteroids;
SLIT, sublingual immunotherapy.
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Figure 10. Criteria for the choice of biologic as add on treatment in Th2 driven severe asthma.
Table 6. Currently available biologics: indications and adverse effects.
Medication Use Adverse Effects
Anti-IgE
(omalizumab, SC, ≥6 years)
An add-on option for patients with severe allergic
asthma uncontrolled on high dose ICS-LABA.
elf-administration may be permitted
Reactions at the site of injection are
common but minor. Anaphylaxis
is rare.
Anti-IL5/anti-IL5R
(anti-IL5 mepolizumab (SC, ≥12 or
≥6 years), reslizumab (IV, ≥18
years) or anti-IL5 receptor
benralizumab (SC, ≥12 years))
Add-on options for patients with severe
eosinophilic asthma uncontrolled on high dose
ICS-LABA
Headache and reactions at injection
site are common but minor.
Anti-IL4R
(dupilumab, SC, ≥12 years)
An add-on option for patients with severe
eosinophilic/Type 2 asthma uncontrolled on high
dose ICS-LABA, or requiring maintenance OCS.
It is also approved for treatment of
moderate-severe atopic dermatitis.
Self-administration may be permitted
Reactions at injection site are common
but minor. Blood eosinophilia occurs
in 4–13% of patients.
14. Conclusions
Severe asthma exacerbations are a major cause of disease morbidity, functional impairment,
increased healthcare costs, and increased risk of mortality. Asthma patients experience exacerbations
irrespective of underlying disease severity, phenotype, or despite optimal guideline-directed treatment,
as a result of the ongoing inflammatory processes and loss of the disease control. Patients with
frequent emergency department visits, patients requiring hospitalization, and, more importantly,
patients intubated for an asthma exacerbation are at significantly increased risk for future severe
exacerbations. It is evident that prevention of exacerbations remains a major unmet need in asthma
management. The identification of patients at risk to have severe exacerbations is of paramount
importance. Patient education and written plans of management, control of triggering/risk factors
and co-morbid conditions, monitoring of asthma control and pulmonary function as well as optimal
pharmacotherapy are needed to prevent and/or decrease exacerbations. A better understanding of the
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pathogenesis of asthma exacerbations will ultimately lead to better strategies and the development of
novel treatments in the pursuit of preventing and treating severe asthma exacerbations.
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